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Coronary computed tomography angiography
Coronary computed tomography angiography (CCTA) is considered the non-invasive gold standard for 
detection of coronary atherosclerosis. To categorize extent and severity of coronary artery disease 
(CAD), the first single- and multicenter CCTA diagnostic performance studies concentrated on the 
ability of interpreting physicians to effectively visualize obstructive coronary stenoses, as defined by a 
50% or 70% luminal stenosis threshold, when compared to invasive quantitative coronary angiography 
(QCA). These studies reported high sensitivities (95-100%) and moderate specificities (64-84%) for 
detection and exclusion of obstructive CAD in patients with generally low-to-intermediate pretest 
likelihood of CAD (1,2,3). There is only a limited relationship between lesion severity and myocardial 
ischemia, especially for intermediate coronary lesions with 50 to 70% luminal narrowing (4,5). 
Nonetheless, the absence of significant lesions (i.e. > 50% stenosis) on CCTA practically rules out 
hemodynamic relevance of a stenosis (1,2,3). CCTA is therefore an excellent diagnostic tool to exclude 
hemodynamically significant CAD in patients with low to intermediate pretest likelihood of obstructive 
CAD. Consequently, the European Society of Cardiology guidelines advocate the use of CCTA in patients 
with low or intermediate pretest likelihood for CAD to judiciously guide subsequent referral for invasive 
evaluation (6). Beyond luminal stenosis severity, current generation CT technologies possess sufficient 
spatial and temporal resolution to enable quantitative assessment of plaque volume, morphology, 
composition and remodeling with reasonable accuracy and reproducibility (figure 1) (7,8). These 
findings have proven clinically relevant, as plaque morphology, total plaque volume, and plaque 
progression have been identified as independent factors that predispose individuals to incident 
unheralded coronary events (4,9). Moreover, the presence of high-risk vulnerable coronary plaques 
on CCTA could guide medical therapy and may even be predictive for myocardial ischemia. Vulnerable 
plaques are prone to rupture and may induce myocardial infarction, with potentially irreversible 
myocardial damage and subsequent loss of functional capacity of the myocardium. Nonetheless, some 
limitations of CCTA for stenosis- and plaque (volume) assessment should be recognized. Although 
spatial resolution has significantly improved over the last decades, real-life preciseness of quantitative 
stenosis and plaque density detection has not yet been accomplished. Recent introduction of dual-
energy CT may aid in improving accuracy of plaque type characterization. Furthermore, coronary CTA 
is associated with exposure to radiation, although tremendous reductions in radiation burden have 
already been established.
Panel A shows an intermediate proximal LAD stenosis with 49% luminal narrowing as assessed by QCA 
(B). Coronary CTA (C) revealed a comparable visual estimation of stenosis on cMPR imaging. Panel D 
represents a cross-sectional view of a non-diseased vessel area, suitable as reference for CTA quan-
11 
Figure 1. Invasive coronary angiography, QCA, and coronary CTA of a patient with an intermediate proximal 
LAD stenosis. 
titative stenosis calculation. The yellow line on the straightened MPR (G) indicates the location of 
the reference cross-section (D). The stenotic cross-section (E-F) coincides with the red line on the 
straightened MPR (G). There is an evident variance in plaque attenuation (E), which was detected 
by plaque composition analysis (F). Coronary plaque was graded as low attenuation (≤30 HU), 
intermediate attenuation (31-129 HU), or calcified (≥130 HU). Quantitative plaque volume and stenosis 
grading revealed a diameter stenosis of 40% and total plaque volume of 122.5 ± 11.2 mm3, which 
was predominantly non-calcified. QCA, quantitative coronary angiography; coronary CTA, coronary 
computed tomography angiography; cMPR, curved multiplanar reformatted; HU, Hounsfield units
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Myocardial perfusion
The primary task of the heart is to provide sufficient circulation through the human body to maintain 
individual organs functional. Perfusion and oxygenation of the heart muscle itself is essential for a 
good contractile myocardial function. There are multiple non-invasive diagnostic tests available 
to determine the extent of myocardial perfusion as equivalent of the coronary (patho)physiology. 
In general, stable CAD starts as a subclinical process of atherosclerosis potentially evolving in flow 
limiting focal or diffuse lesions or even a chronic total coronary occlusion (CTO). The purpose of a 
diagnostic test is to identify patients who have indeed flow limiting lesions, since those patients 
are most likely to benefit from revascularization. The optimal diagnostic test to detect flow-limiting 
lesions is determined by the pre-test likelihood of CAD as well as the specific properties of the utilized 
diagnostic tool.
Noninvasive myocardial perfusion imaging
The most important distinction between CCTA and myocardial perfusion imaging (MPI) is that MPI 
evaluates the consequences of a potential coronary stenosis on myocardial perfusion rather than 
identifying coronary atherosclerosis itself. Therefore, MPI is an appropriate technique to diagnose 
hemodynamically significant CAD and guide referral to the catheterization laboratory for percutaneous 
coronary intervention (PCI). However, a normal scan result does not exclude the presence of coronary 
atherosclerosis in general. Nowadays, guidelines for stable CAD recommend treating flow-limiting 
lesions with PCI. This recommendation is based on invasive studies (5,10) which have shown that 
a pressure drop over a stenosis ≥ 20-25% (i.e fractional flow reserve (FFR) ≤ 0.80-0.75) was related 
with clinical benefit from revascularization, whilst for lesions with relatively preserved blood flow 
the risk of implantation of a coronary stent may outweigh the benefit of coronary intervention. 
Therefore, accurate non-invasive identification of patients with flow limiting coronary lesions is of 
importance to avoid unnecessary referral for invasive procedures. Current widely accepted modalities 
to assess myocardial perfusion are single photon emission computed tomography (SPECT), positron 
emission tomography (PET), and cardiac magnetic resonance imaging (CMR) (11). Multiple studies 
trying to identify the most accurate technique showed varying results. The most recent head-to-
head comparison between PET and SPECT identified that PET was superior in especially sensitivity 
as compared to SPECT (12). Over the last decade, ongoing developments in technology have enabled 
CCTA derived fractional flow reserve (CT-FFR), which is based on complex computational fluid 
dynamics. As FFR-CT may be a very promising technique, its current shortcomings such as artifacts 
due cardiac movement and/or severe coronary calcifications are currently hampering broad clinical 
adoption. A meta-analysis, comparing the diagnostic performance of CMR, SPECT, CCTA, FFR-CT, 
stress echocardiography and invasive coronary angiography (ICA) stenosis severity in comparison with 
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FFR, identified that CMR had the highest performance for diagnosis of ischemia-causing CAD (11). 
Noteworthy, PET perfusion imaging was lacking in this meta-analysis. The current guidelines therefore 
advice to choose the imaging modality based on pretest likelihood, costs as well as local expertise (13).
Percutaneous coronary intervention
More than three decades ago, plain old balloon angioplasty (POBA) was introduced to restore 
myocardial perfusion in the presence of an obstructive epicardial coronary stenosis. POBA consisted 
solely of balloon dilatation of a specific stenosis. Although considered quite effective, POBA was 
accompanied by a high rate of complications such as dissection and local hematoma (14). The 
introduction of implantable bare metal stents reduced the rate of complications seen with POBA. 
(15). However, short-term proliferation of neointima resulted in a considerably high occurrence of 
in-stent restenosis. As a third revolution within the interventional cardiology, cytostatic drug eluting 
stents (DES) were developed to antagonize overgrowth of short-term neointima and thereby reducing 
the rate of in-stent restenosis  (16). Still, long-term restenosis is a frequently seen complication 
with need for subsequent revascularization and irreversible myocardial cell death when presented 
as an acute myocardial infarction. A potential solution for the long term risk of in-stent restenosis 
are bioabsorbable vascular scaffolds (BVS) (17). A BVS gradually dissolves after implantation while 
supporting the vessel wall during the first 6 to 12 months after implantation. Due to the resorption of 
the scaffold, there is a renewed exposure of the natural vessel wall to the pulsatile blood flow, shear 
stress, and cyclic strain patterns, potentially reinstalling a normal physiology and vasomotor function. 
The BVS has been largely investigated with initially very promising results, however, recent large 
multicenter trials have identified an increased risk of acute scaffold thrombosis within the first three 
years after implantation. Subsequently the Food and Drug Administration has communicated a safety 
concern and the BVS is no longer commercially available. Still, little evidence is available regarding the 
effect of scaffold absorption on coronary physiology.
Alongside recent developments in PCI materials and techniques over the last decades, the interest 
for more complex percutaneous revascularization has been growing. Among these, chronic total 
occlusion (CTO) PCI has been rapidly evolved with introduction of dissection- and re-entry and 
retrograde techniques (18,19). This so-called ‘’hybrid approach’’ has resulted in high success rates 
for CTO PCI (20). However, patient benefit regarding CTO PCI has been questioned due to lack of data 
showing a clear clinical benefit with regard to reduced major adverse cardiac events after CTO PCI (21). 
However, randomized studies investigating the effect of CTO PCI have been poorly performed with 
slow inclusion and high rates of crossover between conservative and CTO PCI arms. 
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OUTLINE OF THE THESIS
Aim of this thesis
(1) Further optimize and improve the detection of hemodynamically significant CAD with CCTA as well 
as MPI.
(2) Examine the effect of resorption of the BVS regarding coronary physiology as measured by absolute 
perfusion with cardiac PET.
(3) Investigate the effect of dedicated CTO PCI on myocardial perfusion and function.
Thesis outline
The introduction introduces the utilized imaging modalities within this thesis for assessment of 
significant CAD or as an outcome tool for evaluation of the effect of coronary implantation of the BVS 
and CTO PCI.
Part I Detection of significant coronary artery disease
In chapter 1 the additional value of transluminal contrast attenuation gradient over and above luminal 
stenosis with CCTA was investigated. The goal was to improve specificity of CCTA for predicting flow-
limiting lesions, as luminal stenosis generally demonstrates high sensitivity but low specificity. In 
chapter 2 the diagnostic accuracy of relative reduction of myocardial blood flow with quantitative PET 
was compared with absolute myocardial blood flow with invasive FFR being the gold standard.
In chapter 3 the influence of plaque characteristics, assessed with CCTA, on myocardial blood flow 
and FFR was assessed. The main results of the Computed Tomographic Evaluation of Atherosclerotic 
Determinants of Myocardial Ischemia (CREDENCE) Trial, a prospective, multicenter diagnostic 
derivation-validation controlled clinical trial recruiting 612 stable patients, are presented in chapter 
4. All patients were assessed with CCTA as well as perfusion imaging and ICA with FFR measurements 
as reference standard. The aim of this trial was to derive, validate, and compare an optimized CCTA 
with MPI assessment for the prediction of functionally significant CAD, determined as vessel-specific 
ischemia by invasive FFR.
Part II Bioresorbable vascular scaffold
In chapter 5 and 6 the interim and final results of the Impact of Vascular Reparative Therapy on 
Vasomotor Function and Myocardial Perfusion: A Randomized [15O]2O PET/CT Study (VANISH) are 
presented. The randomized clinical VANISH-trial was conducted to assess myocardial blood flow and 
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coronary flow reserve during stress and cold pressor testing with quantitative PET perfusion imaging 
after implantation of a metal DES vs. BVS during 3-year follow-up.
Part III Chronic total occlusion percutaneous coronary intervention
In chapter 7 through 11, the diagnostic work-up, interventional strategies and effects of CTO PCI are 
discussed. These chapters provide a detailed description what to do, when and how to treat, and what 
to expect as a result of treatment for patients with stable CAD and a CTO. 
General summary and future perspectives
The general conclusions and future perspectives of this thesis are discussed in this paragraph.
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CONDENSED ABSTRACT
The transluminal attenuation gradient (TAG) in coronary computed tomography angiography (CCTA), 
defined as the coronary contrast opacification gradient, has recently been introduced as a noninvasive 
functional imaging tool for coronary artery disease. The current study evaluated the diagnostic value of 
TAG over anatomical assessment alone in a prospective patient population on a 256-slice CT scanner, 
using FFR as reference. TAG with correction models for multiple heartbeat acquisition of 256-slice CCTA 
and dense mural calcifications did not establish a clinical relevant incremental value over CCTA alone.
ABSTRACT
Objectives: The current study evaluates the incremental value of TAG, TAG-CCO, and TAG-ExC over CCTA 
alone using fractional flow reserve (FFR) as gold standard.
Background: The transluminal attenuation gradient (TAG) is defined as the contrast opacification 
gradient along the length of a coronary artery on a coronary computed tomography angiogram (CCTA). 
Preliminary data suggest that TAG provides additional functional information. Interpretation of TAG is 
hampered due to multiple heartbeat acquisition algorithms and  coronary calcifications. Two correction 
models have been proposed based on either dephasing of contrast delivery by relating coronary density 
to corresponding descending aortic opacification (TAG-CCO) or exclusion of calcified coronary segments 
(TAG-ExC). 
Methods: Eighty-five patients with intermediate probability of coronary artery disease (CAD) were 
prospectively included. All patients underwent step-and-shoot 256-slice CCTA . TAG, TAG-CCO, and 
TAG-ExC analysis were performed followed by invasive coronary angiography in conjunction with FFR 
measurements of all major coronary branches. 
Results: Thirty-four (40%) patients were diagnosed with hemodynamically significant CAD (i.e. FFR≤0.80). 
On a per vessel basis (n=253), 59 lesions (23%) were graded hemodynamically significant and diagnostic 
accuracy of CCTA (diameter stenosis ≥ 50%) was 95, 75, 98, and 54% for sensitivity, specificity, NPV, and 
PPV, respectively. TAG and TAG-ExC did not discriminate between vessels with or without hemodynamically 
significant lesions (-13.5 ± 17.1 vs. -11.6 ± 13.3, p=0.36, and 13.1 ± 15.9 vs. -11.4 ± 11.7 HU ∙ 10 mm-1, 
p=0.77, respectively). TAG-CCO was lower in vessels with a hemodynamically significant lesion  (-0.050 ± 
0.051 vs. -0.036 ± 0.034, p=0.03) and TAG-ExC resulted in a slight improvement of the net reclassification 
index (0.021, p<0.05).
Conclusions: TAG did not provide incremental diagnostic value over 256-slice CCTA alone in assessing the 
hemodynamic consequences of a coronary stenosis. Correction for temporal non-uniformity of contrast 




Coronary computed tomography angiography (CCTA) is increasingly utilized as a non-invasive diagnostic 
imaging tool for detection and exclusion of coronary artery disease (CAD) (1-3). A well-recognized 
limitation of CCTA, similarly to the anatomical evaluation during invasive coronary angiography 
(ICA), is its moderate ability to assess the hemodynamic significance of a given coronary stenosis 
(4-6) Therefore, functional evaluation of CCTA deemed significant coronary lesions is warranted in 
order to avoid excess referral for ICA and guide revascularization therapy in a judicious manner (6, 
7). Although CT stress perfusion and CCTA derived estimation of fractional flow reserve (FFRCT) based 
on computational fluid dynamics have been developed for this purpose, these methods require 
additional contrast/radiation exposure or extremely complex off-line analysis, respectively, hampering 
their implementation in routine clinical practice (8-11). Alternatively, linear regression analysis of 
the attenuation gradient along the course of a coronary artery has been proposed to evaluate the 
functional relevance of a coronary lesion. The rationale behind the transluminal attenuation gradient 
(TAG) is that contrast opacification should fall off more rapidly in the presence of a functionally 
significant stenosis (12). Preliminary data, utilizing 320-row CT, has shown incremental value of TAG 
over CCTA assessment alone (13). However, TAG interpretation is complicated by multiple heartbeat 
acquisitions (64 - 256 slice CT) resulting in lack of temporal uniformity. In addition, distortions due to 
highly calcified coronary plaques may influence results. Two correction models have been proposed 
based on either dephasing of contrast delivery by relating coronary density to corresponding 
descending aortic opacification (TAG-CCO), and exclusion of non-linear values provoked by coronary 
calcifications (TAG-ExC) (14, 15). Studies that have evaluated these models are scarce and results are 
conflicting (14-17). The current study aims to explore the diagnostic potential of TAG, including its 
correction models, obtained with a 256-slice CT scanner. Imaging results were prospectively compared 
with ICA in conjunction with invasive FFR.
METHODS
Patient population
Ninety-one patients with an intermediate probability of CAD, determined according to the criteria of 
Diamond and Forrester (18), were prospectively enrolled. Exclusion criteria were prior percutaneous 
coronary intervention, coronary artery bypass graft surgery, a previous myocardial infarction, atrial 
fibrillation, second- or third-degree atrioventricular block, impaired renal function, symptomatic 
asthma, or pregnancy. Electrocardiography and echocardiography confirmed normal global left 
ventricular systolic function and the absence of prior myocardial infarction or regional wall motion 
abnormalities in all patients. The protocol consisted of cardiac CT with coronary artery calcium score 
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and CCTA, followed by ICA in conjunction with FFR measurements of all major coronary branches 
within five days. CCTA was not performed in case of persistent elevated heart rate above 65 bpm 
despite pre-treatment with betablocking agents (n=4). Two patients refused ICA after CCTA. The study 
population therefore comprised 85 patients. No cardiac events were documented between CCTA and 
ICA in these patients. The study was approved by the ethics committee and written informed consent 
was obtained from all patients. 
Cardiac CT
Patients underwent coronary artery calcium scoring and CCTA on a 256-slice CT scanner (Philips 
Brilliance iCT, Philips Healthcare, Best, the Netherlands). A stable low heart rate below 65 min-1 was 
achieved prior to the scanning protocol, either spontaneous or after administration of oral and/or 
intravenous metoprolol. A standard scanning protocol was applied, with a section collimation of 2 x 
128 × 0.625 mm, a gantry rotation time of 270 ms, a tube voltage of 120 kV, and a tube current of 
55-150 mA (for coronary artery calcium scoring) or 200mA (for CCTA). All scans were performed with 
prospective ECG-gating (Step & Shoot Cardiac, Philips Healthcare, Best, The Netherlands) at 75% of the 
R-R interval. Coronary calcification was defined as a plaque with an area of 1.03 mm2 and a density 
≥ 130 HU. The CAC score was calculated according to the method described by Agatston et al. (19). 
After CAC scoring, CCTA was performed immediately after administration of sublingual nitroglycerine. 
For visualization of the coronary artery lumen a bolus of 100 ml iobitidol (Xenetix 350) was injected 
intravenously (5.7 mL ∙ s-1) followed by a 50 ml saline chaser. The scan was triggered, using an 
automatic bolus tracking technique with a region of interest placed in the descending thoracic aorta, 
at a threshold of 150 HU. All CT scans were analyzed on a 3-D workstation (Brilliance; Philips Medical 
Systems, Best, The Netherlands) by an experienced radiologist and cardiologist. The coronary tree was 
evaluated according to a 16-segment coronary artery model modified from that of the American Heart 
Association (20), a ≥ 50% diameter stenosis was deemed significant. Image quality was determined 
on a 3-point scale: poor, moderate, or good. The mean radiation effective dose during CAC-score and 
CCTA was estimated by using the dose-length product multiplied by 0.014 as conversion factor (21).
Transluminal attenuation gradient
TAG was determined on a Philips IntelliSpace Portal workstation Version 5.0.0.20030. For all major 
coronary branches on CCTA the luminal centreline was determined. Perpendicular cross-sectional 
images were constructed and a circular region of interest of 1.0 mm2 was manually positioned 
in the luminal center. The mean Hounsfield units were determined within the region of interest. 
Measurements were obtained at 5 mm intervals from the coronary ostium to the distal segment (till a 
cross sectional area of 2.0 mm2 as described previously (13)). TAG, expressed in Hounsfield units ∙ 10 
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mm-1, was measured in the three major coronary branches matching the arteries interrogated by FFR. 
Besides standard TAG analysis, two correction models were applied: 1) TAG-ExC, excluding excessive 
calcified coronary segments in order to maintain linearity of the gradient (14, 17); 2) TAG-CCO, 
corrected for timing dependent perturbation of coronary contrast delivery associated with multiple 
heartbeat imaging of 256-slice CCTA. Each luminal attenuation measurement was normalised to the 
descending aortic attenuation of the corresponding scanning cycle by dividing the mean coronary 
HU to the mean aortic HU (13, 15, 17). TAG-CCO is defined as gradient of the quotient of the mean 
coronary HU and mean aortic HU per 10 mm.
Invasive coronary angiography and fractional flow reserve
ICA imaging was performed with a biplane or monoplane cardiovascular X-ray system (Allura Xper FD 
10/10, Philips Healthcare, Best, The Netherlands) in at least two orthogonal directions per evaluated 
coronary artery segment. Prior to the contrast injection, 0.2 mL of nitroglycerin was administered 
intracoronary to induce epicardial coronary vasodilation. Each major coronary artery territory was 
routinely interrogated by FFR except for occluded or subtotal lesions. The operator refrained from 
FFR measurements in these tight lesions due to the potential risk of inflicting a coronary dissection 
by the pressure wire. The FFR was measured using a 0.014-inch sensor tipped guide wire (Volcano 
Corporation, Rancho Cordova, California), which was introduced through a 5- or 6-F guiding 
catheter, calibrated and advanced into the coronary artery. Adenosine was infused intracoronary (150 
µg) in the right and left coronary artery, to induce maximal coronary hyperemia (22). The FFR was 
calculated as the ratio of the mean distal intracoronary pressure, measured by the pressure wire, 
to the mean arterial pressure (MAP) measured by the coronary catheter (23). A stenosis with > 90% 
luminal diameter reduction or with a FFR ≤ 0.80 was considered hemodynamically significant (6). The 
coronary tree was divided into a 16-segment coronary artery model modified from the American Heart 
Association (20). Quantitative coronary angiography was performed on all coronary segments > 1.5 
mm in diameter (Xcelera, Philips Healthcare, Best, The Netherlands). Two experienced interventional 
cardiologists blinded to the CCTA results interpreted all images and FFR signals. Thrombolysis In 
Myocardial Infarction (TIMI) flow grade was assessed in each major coronary artery. 
Statistical analyses
Continuous variables are presented as mean values ± standard deviation (SD), whereas categorical 
variables are expressed as actual numbers. TAG, TAG-ExC, and TAG-CCO were determined as a linear 
regression coefficient from the coronary ostium to the most distally measured value per 10 mm. There 
were no corrections performed for the interdependency of the coronary data within one patient. 
Continuous variables of TAG, TAG-ExC, and TAG-CCO between groups were compared with the Mann 
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Whitney U test because of not normal distribution. A receiver-operator characteristic curve analysis 
was used to define optimal cut-off values based on the maximal sum of specificity and sensitivity 
(Youden Index) to obtain the highest discriminatory value for TAG, TAG-ExC, and TAG-CCO. Diagnostic 
performance of CCTA, TAG, TAG-ExC, and TAG-CCO for the diagnosis of obstructive CAD compared 
with FFR was determined with sensitivity, specificity, negative predictive value, and positive predictive 
value, including their related 95% confidence intervals, on per vessel and per patient basis. Incremental 
value of TAG, TAG-ExC, and TAG-CCO to CCTA was determined with area under the receiver operator 
characteristic curve analysis based on a combination of parameters in the logistic regression model 
and the net reclassification index (NRI) (24). The relation between the three TAG-modalities was 
analysed using linear regression analysis. Intra- and interobserver variability of TAG was determined 
with the intraclass correlation coefficient using a two way random effects model. A p value < 0.05 was 
considered statistically significant. All statistical analyses were performed using IBM SPSS software 
package (IBM SPSS Statistics 20.0, Chicago, IL).
RESULTS
Baseline characteristics of the 85 included patients are shown in table 1. 
Table 1. Baseline patient characteristics (n = 85)
Characteristic N (%) or mean ± SD
Age (years) 57.3 ± 9.7 
Male 51 (60%)




Current or history smoking 38 (45%)




ACE inhibitors 16 (19%)
Beta-blockers 54 (64%)
Statins 72 (85%)
Angiotensin-II-receptor blockers 12 (14%)
Calcium channel blockers 31 (25%)
Long acting nitrates 10 (12%)




Coronary Computed Tomography Angiography
Prior to CCTA, 14 (16%) patients received additional oral metoprolol (range 50-150 mg), and in 30 
(35%) patients metoprolol was administered intravenously (range 5-30 mg). Sublingual nitroglycerin 
was given in 83 (98%) of patients. All patients were in sinus rhythm with an average heart rate of 57 ± 
7 min-1, CCTA characteristics are shown in table 2. Fifty-two out of 85 patients (61%) were diagnosed 
with obstructive CAD (i.e. >50% diameter stenosis in at least one coronary artery) based on CCTA 
results.
Table 2. Coronary Computed Tomography Angiography
Characteristics N (%), mean ± SD
Heart rate (min-1) 57 ± 7





CCTA DS ≥ 50%
Per patiënt (n=85) 52 (61%)
Per vessel (n=253) 104 (41%)
CAC score
Median 141 (IQR 0-818)
Age and gender corrected percentile (%) 66 ± 37
CCTA, coronary computed tomography angiography; DS, diameter stenosis;  
CAC, coronary artery calcium; IQR, inter quartile range
Invasive coronary angiography 
All procedures and FFR measurements were conducted without any complications. Of the 255 
vessels in 85 patients, two vessels with an intermediate stenosis were excluded due to the inability to 
interrogate the artery with FFR owing to tortuosity, resulting in a total of 253 evaluated vessels. FFR 
measurements were obtained in 230 (91%) out of these 253 vessels. The operator refrained from FFR 
interrogation in 19 (8%) arteries due to the presence of a subtotal lesion, 3 (1%) lesions were chronic 
total occlusions with collateral circulation from a native donor artery. These 22 (sub-)total lesions were 
considered hemodynamically significant (6). All patent arteries displayed TIMI 3 flow. In one vessel 
without an apparent lesion, FFR was not obtained due to technical reasons. This vessel was allocated 
to the non-significant group. On a per patient basis 34 (40%) displayed at least one vessel with a FFR ≤ 
28
0.80, whereas on a per vessel basis 59 (23%) lesions were hemodynamically significant. Quantitative 
coronary angiography diameter stenosis per vessel analysis is shown in table 3. 
Table 3. QCA diameter stenosis at invasive coronary angiography (n=253)
QCA Diameter Stenosis N (%)
< 30% 137 (54%)
30 – 50% 57   (23%)
50 – 70% 22   (9%)
> 70% 37   (15%)
QCA, quantitative coronary angiography
Transluminal Attenuation Gradient
TAG, TAG-ExC, and TAG-CCO were measured in all 253 vessels, regardless of the presence of CAD 
or image quality (good to moderate in 98%, see table 2, figure 1, and figure 2) Subgroup analysis 
was performed in vessels with a CCTA based DS ≥ 50%. Table 4 lists mean TAG parameters and 
differentiation between vessels with or without CCTA graded significant lesions. Although all three 
TAG analyses showed on average a slightly lower value for the vessels containing a hemodynamically 
significant stenosis, statistical significance was only achieved for TAG-CCO (p=0.03). When subgroup 
analysis of vessels with a CCTA based DS ≥ 50% was performed TAG-CCO was no longer significant 
(n=104, p=0.07). Figure 3 shows the correlation between different TAG parameters. All correlations 
were highly significant (p < 0.001).
CCTA (A,C) and cross sectional images with the region of interest indicated by the green circle (D), 
invasive coronary angiography with FFR (B) and results of three TAG analyses (E). Note the decrease 
of contrast density along the coronary artery, compatible with the presence of an obstructive lesion 
in the left anterior descending coronary artery with a non-calcified hemodynamic significant stenosis 
(FFR = 0.43). CCTA, coronary computed tomography angiography; TAG, transluminal attenuation 
gradient; FFR, fractional flow reserve; HU, Hounsfield units; HUa, aortic Hounsfield units; HUc, 
coronary Hounsfield units; mm, millimeter.
CCTA (A,C) and cross sectional images with the region of interest indicated by the green circle (D), 
invasive coronary angiography with FFR (B), and TAG analyses (E) of a normal left anterior descending 
coronary artery without stenosis (FFR = 0.93). Note that TAG values are in the same order of magnitude 
as the patient with an ischemic lesion as depicted in figure 1. Abbreviations as figure 1.
1
29 
Figure 1. Example of TAG analysis of a left anterior descending coronary artery with a hemodynamically 
significant stenosis.
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Figure 2. Example of TAG analysis of a left anterior descending coronary artery without stenosis.
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Figure 3. Scatt er plot showing the relati on between TAG, TAG-CCO, and TAG-ExC. Correlati ons of TAG, TAG-CCO, 
and TAG-ExC were highly signifi cant (p < 0.001 for all correlati ons)
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Table 4. Transluminal attenuation gradient analyses on a per vessel basis, and subgroup analysis for CCTA 
significant (DS ≥ 50%) vessels
Average FFR > 0.80 FFR ≤ 0.80 Between 
FFR-groups*
All vessels n = 253 n = 194 n = 59
TAG (HU ∙ 10 mm-1) -11.6 ± 13.3 -11.1 ± 11.8 -13.5 ± 17.1 p = 0.36
TAG-ExC (HU ∙ 10 mm-1) -11.8 ± 12.8 -11.4 ± 11.7 -13.1 ± 15.9 p = 0.77  
TAG-CCO (10 mm-1) -0.039 ± 0.039 -0.036 ± 0.034 -0.050 ± 0.051 p = 0.03
CCTA DS ≥ 50% n = 104 n = 48  n = 56
TAG (HU ∙ 10 mm-1) -11.3 ± 15.3 -9.0 ± 12.3 -13.3 ± 17.3 p = 0.17
TAG-ExC (HU ∙ 10 mm-1) -11.6 ± 14.2 -10.1 ± 11.7 -12.9 ± 16.0 p = 0.36
TAG-CCO (10 mm-1) -0.042 ± 0.045 -0.034 ± 0.037 -0.049 ± 0.051 p = 0.07
CCTA, coronary computed tomography angiography; DS, diameter stenosis; FFR, fractional flow reserve; TAG, 
transluminal attenuation gradient; HU, Hounsfield units; mm, millimeter; *Mann Whitney U test
Diagnostic accuracy of CCTA diameter stenosis and TAG 
Table 5 summarizes the diagnostic accuracy of CT parameters. A DS of ≥ 50% was utilized as cut-
off value for CCTA, whereas optimal thresholds for TAG, TAG-ExC, and TAG-CCO were derived from 
receiver operator characteristic curve analyses. Diagnostic accuracy of CCTA was distinctly superior to 
any TAG-modality. The area under the curve  at receiver operator characteristic analyses for TAG, TAG-
ExC, and TAG-CCO did not significantly differ from the line of identity (p>0.05 for all).
Table 5. Diagnostic accuracy (and 0.95% confidence intervals) of CCTA, TAG, TAG-ExC, and TAG-CCO for 
predicting FFR ≤ 0.80 on a per patient and vessel basis (both for all and CCTA positive vessels only)






Per vessel basis (n=253) DS ≥ 50 % ≤ -7,51 ≤ -7,36 ≤ -0,035 
Sensitivity (%) 95 (86 - 99) 69 (56 - 81) 64 (51 - 76) 63 (49 - 75)
Specificity (%) 75 (69 - 81) 44 (37 - 52) 44 (37 - 51) 54 (46 - 61)
NPV (%) 98 (94 - 100) 83 (74 - 90) 80 (71 - 87) 83 (75 - 89)
PPV (%) 54 (44 - 64) 27 (21 - 35) 26 (19 - 34) 29 (22 - 38)
Per patient basis (n=85) DS ≥ 50 % ≤ -7,51 ≤ -7,36 ≤ -0,035 
Sensitivity (%) 100 (100) 91 (76 - 98) 91 (76 - 98) 91 (76 - 98)
Specificity (%) 65 (50 - 78) 16 (7 - 29) 14 (6 - 26) 20 (10 - 33)
NPV (%) 100 (100) 73 (39 - 94) 70 (35 - 93) 77 (46 - 95)
PPV (%) 65 (50 - 78) 42 (31 - 54) 41 (30 - 53) 43 (31 - 55)
CCTA significant vessels (n=104) ≤ -7,51 ≤ -3,29 ≤ -0,025 
Sensitivity (%) NA 70 (56 - 81) 84 (72 - 92) 77 (64  -87)
Specificity (%) NA 52 (37 - 67) 33 (20 - 48) 44 (30 - 59)
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NPV (%) NA 60 (43 - 74) 64 (43 - 82) 62 (44 - 78)
PPV (%) NA 62 (50 - 75) 59 (48 - 70) 61 (49 - 73)
CCTA, coronary computed tomography angiography; TAG, transluminal attenuation gradient; FFR, fractional 
flow reserve; HU, Hounsfield units; mm, millimeter; DS, diameter stenosis; NPV, negative predictive value; PPV, 
positive predictive value; NA, not applicable
Incremental value of TAG in addition to CCTA DS for predicting FFR ≤ 0.80
Figure 4 illustrates the incremental value of the TAG parameters to the diagnostic value of CCTA 
DS alone. None of the added TAG parameters raised the area under the curve of CCTA DS analysis. 
Table 6 lists the diagnostic accuracy of CCTA in conjunction with each of the TAG-modalities and net 
reclassification indices. Although differences were minute, TAG-ExC had significant impact on CCTA 
alone and resulted in four (1.6%) correct reclassifications from false positive to true negative (net 
reclassification improvement index = 0.021, p =0.046). Net reclassification indices were not significant 
for TAG and TAG-CCO.
Figure 4. Diagnostic performance of CCTA alone and TAG, TAG-ExC, and TAG-CCO in addition to CCTA.
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ROC curve analysis with corresponding AUCs and 95 % Confidence Interval displaying the diagnostic 
performance of CCTA, CCTA and TAG, CCTA and TAG-ExC, and CCTA and TAG-CCO for the detection 
of hemodynamically significant CAD as indicated by FFR. CCTA, coronary computed tomography 
angiography; TAG, transluminal attenuation gradient; ROC, receiver operator characteristic; AUC, area 
under the curve; CAD, coronary artery disease; FFR, fractional flow reserve
Table 6. Incremental diagnostic value (and 0.95 confidence interval) of TAG in addition to CCTA for predicting 
FFR ≤ 0.80 on a per vessel basis (n=253)
CCTA + TAG CCTA + TAG-ExC CCTA + TAG-CCO
Sensitivity (%) 95 (86 - 99) 95 (86 - 99) 95 (86 - 99)
Specificity (%) 76 (69 - 82) 77 (71 - 83) 76 (69 - 82)
NPV (%) 98 (94 - 100) 98 (94 - 100) 98 (94 - 100)
PPV (%) 54 (44 - 64) 56 (46 - 66) 54 (44 - 64)
NRI 0.005 0.021 0.005
P-value NRI 0.32 0.046 0.32
TAG, transluminal attenuation gradient; CCTA, coronary computed tomography angiography; FFR, fractional flow 
reserve; NPV, negative predictive value; PPV, positive predictive value; NRI, net reclassification improvement 
index
Impact of plaque composition on TAG
Figure 5 displays an example of a patient with heavily calcified coronary plaques, potentially hampering 
reliable TAG analysis. Subgroup analysis according to the presence and severity of plaque calcification 
is summarized in table 7 (calcified vs. non / partially calcified), with additional subgroups analyses for 
CCTA positive and negative vessels. Eighty-six out of 253 vessels were defined as calcified whereas 
167 vessels were defined as non-calcified or partially calcified. There was no significant difference of 
TAG, TAG-ExC, or TAG-CCO between vessels with severely calcified plaques and no or partially calcified 
plaques.
CCTA (A,C) and cross sectional images with the region of interest indicated by the green circle (D), 
invasive coronary angiography with FFR (B) and TAG analyses (E) of a highly calcified right coronary 
artery with a hemodynamically significant stenosis (FFR = 0.27). Note that TAG analyses were 
comparable and omission of calcified segments did not alter results. In this patient, TAG did not show a 
decline in contrast density along the artery despite a severely compromised hyperemic distal pressure. 
Abbreviations as figure 1.
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Figure 5. Example of TAG analysis of a highly calcified right coronary artery.
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Table 7. Influence of plaque composition on TAG
CCTA Plaque composition 
All (n=253)
TAG 
(HU ∙ 10 mm-1)
TAG-ExC 
(HU ∙ 10 mm-1)
TAG-CCO 
(10 mm-1)
Calcified (n=86) -10.8 ± 14.6 -10.9 ± 13.0 -0.040 ± 0.043
Non/Partially-calcified (n=167) -12.1 ± 12.6 -12.2 ± 12.7 -0.039 ± 0.037
p-value* 0.68 0.40 0.44
CCTA DS ≥ 50% (n=104) -11.4 ± 15.3 -11.6 ± 14.2 -0.042 ± 0.046
Calcified (n= 52) -10.7 ± 17.6 -11.0 ± 15.5 -0.042 ± 0.051
Non/Partially-calcified (n=52) -12.0 ± 12.7 -12.3 ± 12.9 -0.042 ± 0.039
p-value* 0.70 0.43 0.76
CCTA DS ≤ 50% (n = 149) -11.8 ± 11.7 -11.9 ± 11.7 -0.038 ± 0.034
Calcified (n=34) -10.9 ± 8.0 -10.9 ± 8.0 -0.037 ± 0.025
Non/Partially–calcified (n=115) -12.1 ± 12.6 -12.2 ± 12.6 -0.038 ± 0.036
p-value* 0.95 0.87 0.64
TAG, transluminal attenuation gradient; CCTA, coronary computed tomography angiography; HU, Hounsfield 
units; mm, millimeter; DS, diameter stenosis; *Mann U Whitney test between calcified and non/partially calcified 
groups
Intra and inter observer variability for TAG
TAG-measurements were stable and reproducible within and between observers in twenty-five 
randomly selected vessels. Corresponding intraclass correlation coefficients for single measures were 
0.91 (p < 0.001) and 0.85 (p < 0.001) for intra and inter observer variability, respectively.
DISCUSSION
The current study was conducted to evaluate the potential of TAG to assess the hemodynamic 
consequences of coronary stenoses diagnosed by CCTA. The results demonstrate that TAG does not 
evidently improve the diagnostic accuracy over 256-slice CCTA alone to diagnose hemodynamically 
significant lesions by ICA/FFR. Exclusion of calcified coronary plaques or correction for arterial phase 
dependent contrast density levels between heartbeats during image acquisition did influence TAG 
results, however, it did not enhance its diagnostic performance on a clinical relevant basis. 
Coronary Computed Tomography Angiography
Using a diameter stenosis threshold of 50%, CCTA displayed an excellent sensitivity and negative 
predictive value on a per vessel and patient basis whereas specificity and positive predictive value 
were moderate at best to diagnose functionally CAD. Although numerous studies have evaluated the 
diagnostic accuracy of CCTA (1-3, 25), this is one of the few investigations that have systematically 
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utilized FFR as a reference technique in a prospective manner (9, 26). In line with these studies, 35% 
of patients with a significant angiographic stenosis at CCTA did not exhibit functionally CAD when 
evaluated with invasive FFR, whereas not a single patient with a negative CCTA displayed functionally 
CAD on ICA. These data confirm the widely regarded notion that CCTA can accurately rule out CAD but 
requires additional functional testing in case of an equivocal or abnormal result.
Transluminal Attenuation Gradient
In an effort to retrieve functional information from a routine CCTA, TAG has been suggested as a method 
to evaluate the hemodynamic consequences of a coronary lesion and to enhance the diagnostic 
performance of CCTA alone (13, 14). The current data, however, did not reveal any differences in 
TAG values between FFR positive and negative lesions. On average, linear regression analysis of the 
contrast density along a functionally significant coronary stenosis did display a decline of 13.5 ± 17.1 
HU ∙ 10 mm-1, yet a physiological density drop in nearly the same order of magnitude was observed 
in not functionally affected vessels (11.1 ± 11.8 HU ∙ 10 mm-1). Such a fall in contrast density along 
the length of a non-obstructed coronary has previously been documented by initial work of Steigner 
et al, although an exacerbated decline of TAG was observed in patients with a single significant 
lesion in the left anterior descending coronary artery (27). As in the current study, reproducibility of 
measurements was proven to be high and relatively independent of heart rate, body mass index, or 
cardiac phase. The relative steep diminution of contrast density distal to a coronary lesion has been 
linked to a reduction in basal coronary flow (28). To validate this concept, utilizing a 64-slice device, 
Choi et al. retrospectively selected 126 patients with a chronic total coronary occlusion in at least one 
vessel (14). The authors observed a gradual decline in TAG with decreasing TIMI flow rate as observed 
during ICA, although large overlap between groups existed. In general, however, such angiographic 
findings are infrequent in a prospective patient population without a prior cardiac history and an 
intermediate likelihood for CAD for whom CCTA is considered to be most appropriate (29). Thus, such 
a study design may be suitable to act as proof-of-principle but yields results that are not applicable 
to a clinical relevant cohort of patients. Indeed, in the current study population only three chronic 
total occlusions with collateral flow were visualized during ICA and all the patent arteries displayed 
TIMI 3 flow. Subsequently, two 64-row CT studies have compared TAG with FFR, and similar to the 
present study, used a FFR cut-off of 0.80 as a reference standard. Yoon et al. selected 53 patients and, 
upon exclusion of non-evaluable segments, identified 82 arteries of which 32 had a positive FFR (17). 
Although statistically significant, the area under the curve for TAG was only 0.63 with an optimal cut-
off value of -6.5 HU ∙ 10 mm-1. In another study, Choi et al. retrospectively selected 65 patients with 
a positive CCTA with matching ICA and FFR measurements where appropriate (16). In line with Yoon 
et al, diagnostic accuracy of TAG was moderate at best with an area under the curve of 0.70 and an 
optimal threshold of again -6.5 HU ∙ 10 mm-1. Nonetheless, there was some incremental value of TAG 
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over CCTA alone. These studies, however, were retrospective in nature, biased in patient selection, 
and excluded non-diagnostic segments. The current is the first prospective 256-row CT study with an 
intention to evaluate all segments, irrespective of imaging quality or lesion characteristics. Comparable 
with the aforementioned studies, optimal TAG cut-off was -7.51 HU ∙ 10 mm-1, yet the area under the 
curve did not appreciably diverge from the line of identity. Moreover, TAG did not add incremental 
value to the diagnostic accuracy of CCTA alone. It therefore appears that the previously demonstrated 
limited value of TAG as observed in retrospective analysis is no longer present in a prospective study 
design. 
Correction Temporal Non-uniformity of Contrast Delivery and for 
Coronary Calcification
A limitation of the current and the aforementioned studies is that images were obtained using CT 
equipment that require multiple heartbeats to cover the entire heart. During post-processing, these 
images of successive beats are stitched together. Consequently, different segments of the artery from 
proximal to distal lack temporal uniformity of contrast opacification. To resolve this issue, Chow et 
al. proposed the corrected coronary opacification (CCO) whereby intracoronary contrast density is 
divided by the density level of the descending aorta in the same axial plain (15). CCO is then defined 
as the quotient of this value obtained proximal and distal of a coronary lesion. Chow and colleagues 
performed a proof-of-concept study utilizing a 64-slice CT in 52 patients selected on the basis of an 
abnormal CCTA. CCO was significantly lower in arteries with impaired resting flow (TIMI flow grade < 
3 at ICA), but could not distinguish significantly stenosed from non-significantly stenosed vessels in 
case of TIMI 3 flow. Choi et al. were subsequently unable to establish an enhanced diagnostic accuracy 
of CCO over conventional TAG, both of which added no surplus value to CCTA (16). In an effort to 
optimize results, in the current study CCO was calculated using linear regression of CCO values along 
the coronary as employed with TAG (TAG-CCO). Although, TAG-CCO was lower in arteries with a 
positive FFR (-0.036 ± 0.034 vs. -0.050 ± 0.051, p=0.03), there was large overlap between FFR groups 
and TAG-CCO did not increase diagnostic accuracy of CCTA alone. To circumvent the issue of temporal 
uniformity, Wong et al. recently utilized TAG with a single beat acquisition of a 320-row CT system in a 
retrospective cohort of patients (13). They reported a potential incremental value of TAG; clearly more 
TAG studies on such devices that acquire the entire heart volume within a single beat are warranted.
It has been suggested that omission of heavily calcified segments that disrupt the linear regression 
analysis upon which TAG is based may improve results (14). Therefore, TAG analysis excluding these 
calcified segments was additionally performed. This analysis, however, did not alter results. In 
fact, and as depicted in figure 3, TAG correlated highly with both TAG-ExC and TAG-CCO and these 
parameters appeared to be interchangeable. Finally, given the high sensitivity and negative predictive 
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value of CCTA, TAG may only be useful in obstructive vessels to enhance the low specificity and 
positive predictive value. Some of the aforementioned retrospective studies may in fact have more 
accurately identified these patients who might benefit from this approach. Subgroup analysis in CT 
based abnormal arteries in the current study, however, did not alter the results and TAG remained 
unable to discriminate hemodynamic significant from non-flow limiting stenoses.
From a theoretical point of view these observations are not entirely unanticipated. A fall in contrast 
opacification beyond a stenosis reflects impaired resting flow (27) whereas multiple studies have 
clearly demonstrated that resting flow remains stable till the point of subtotal coronary occlusion (30-
32). Therefore, TAG appears to be most suitable to detect subtotal occlusions with TIMI flow rates < 3 
or total occlusions with a collateral circulation. 
Limitations
It must be acknowledged that comparison between the current and previous studies on the value 
of TAG is hampered by differences in scan technology and acquisition. Most studies have utilized 64-
row devices with helical acquisition mode, whereas the current study has utilized step-and-shoot 
with a 256-slice CT. Moreover, initiation of the CT acquisition was triggered by bolus tracking of the 
descending aorta whereas previous studies based acquisition timing after test bolus tracking. These 
factors may result in discrepancies of coronary contrast concentrations, which may affect the TAG 
results. Furthermore, signal magnitude is dependent on tube voltage and mA. Different scan settings 
between studies may have been on influence. 
The sample size of the current study was relatively small and therefore does not provide definite 
evidence of the limited additional valued of TAG over CCTA. Larger studies are needed to provide a 
more insight into this matter. The utilization of 320-slice or high-pitch dual source CT equipment will 
also be pivotal in these studies, overcoming the shortcomings of temporal non-uniformity of contrast 
delivery by single-beat acquisitions.
With respect to missing FFR values some assumptions were made. A stenosis of > 90% was considered 
hemodynamically significant although no FFR was provided. The operator refrained from FFR-
measurements due to a potential risk of causing pressure wire related complications. Anatomical 
lesion severity is known of its inability to provide accurate functional information, however Tonino et 
al. showed FFR to be ≤ 0.80 in 96% of all lesions with a severity of 91-99% (6).
Intracoronary adenosine administration was used in the current study protocol to achieve vasodilation 
during FFR measurements, whereas intravenous administration of 140 μg/kg/min is generally 
considered to be the reference standard (33). Although the utilized dosage of 150 μg intracoronary 
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agrees well with intravenous administration (22), some studies have reported more potent vasodilation 
with higher dosages ranging from 300 - 600 μg and therefore may have yielded different results (34, 
35).
CONCLUSION
In the current prospective cohort of  patients with an intermediate likelihood for CAD, TAG did not 
provide incremental diagnostic value over 256-slice CCTA alone in assessing the hemodynamic 
consequences of a coronary stenosis. Correction for temporal non-uniformity of contrast delivery or 
exclusion of calcified coronary segments slightly enhanced the results, although the clinical impact of 
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ABSTRACT
Background: Quantitative myocardial perfusion imaging is increasingly utilized for the diagnosis of 
coronary artery disease (CAD). Quantitative perfusion imaging allows to noninvasively calculate FFR. 
This so called relative flow reserve (RFR) is defined as the ratio of hyperemic MBF in a stenotic area to 
hyperemic MBF in a normal perfused area. The aim of the present study was to assess the value of RFR 
in the detection of significant CAD. 
Methods and Results: From a clinical population of patients with suspected CAD who underwent 
H2
15O cardiac PET and invasive coronary angiography, 92 patients with single or two vessel disease 
were included. Intermediate lesions (diameter stenosis 30 - 90%, n = 75) were interrogated by FFR. 
Thirty-eight (41%) vessels were deemed hemodynamically significant (> 90% stenosis or FFR ≤ 0.80). 
Hyperemic MBF, CFR, and RFR were lower for vessels with a hemodynamically significant lesion (2.01 ± 
0.78 vs. 2.90 ± 1.16 mL∙min-1∙g-1, p<0.001, 2.27 ± 1.03 vs. 3.10 ± 1.29, p<0.001, and 0.67 ± 0.23 vs. 0.93 
± 0.15, p<0.001, respectively). The correlation between RFR and FFR was moderate (r = 0.54, p<0.01). 
ROC curve analysis showed an area under the curve of 0.82 for RFR, which was not significantly higher 
compared to hyperemic MBF and CFR (0.76, p=0.32 and 0.72, p=0.08, respectively). 
Conclusions: Noninvasive estimation of FFR with quantitative perfusion PET by calculating RFR is 
feasible, yet only a trend toward a slight improvement of diagnostic accuracy over hyperemic MBF 




Quantitative myocardial perfusion imaging with positron emission tomography (PET) is gaining interest 
in clinical practice for the non-invasive diagnosis of coronary artery disease (CAD)1-3. Studies that have 
attempted to define optimal thresholds for identifying hemodynamic relevant CAD, however, lack 
uniformity and predominantly have utilized angiographic lesion severity as a reference4, 5. Fractional 
flow reserve (FFR) evaluates the hemodynamic consequences of an epicardial coronary stenosis and 
helps to guide revascularization decision making in a more judicious manner6. Recently, Danad et al. 
proposed cut-off values for hyperemic myocardial blood flow (MBF) and coronary flow reserve (CFR) 
to diagnose CAD, with FFR as reference, in a large cohort of patients using oxygen-15-labeled water 
([15O]H2O) PET
7. Although, hyperemic MBF outperformed CFR, and showed  a high agreement with 
FFR, these parameters cannot be considered interchangeable. 
FFR reflects the hyperemic pressure gradient across a specific epicardial lesion. It has to be noted, 
however, that the pressure gradient is dependent on the hyperemic response of the vessel distal to 
a stenosis. In vessels with a more pronounced response to an adenosine challenge, the pressure will 
drop more at the level of the stenosis than in the vessel in which the hyperemic response is blunted. 
Therefore, in patients with poor microvascular response, even angiographically severe stenosis cannot 
cause significant pressure gradients. On the other hand, in case of a very good microvascular response, 
even a mild stenosis can cause a pressure gradient, whilst the absolute stress MBF may remain above 
the level of ischemia.
Hyperemic MBF is a composite measurement of an entire single coronary vascular bed affected by an 
epicardial stenosis as well as microvascular resistance. Thus, MBF cannot separate effects of a specific 
lesion from those of microvascular dysfunction. In case of poor microvascular function, MBF becomes 
abnormal even without obstructive epicardial disease. Consequently, disconcordance between FFR 
and hyperemic perfusion can frequently be observed due to differences in underlying physiological 
processes8.
From quantitative MBF measurements relative flow reserve (RFR), defined as the ratio of hyperemic 
MBF in a stenotic area to hyperemic MBF in a normally perfused area can be calculated9. Small scale 
studies have demonstrated good agreement between FFR and RFR9-11. Data on diagnostic performance 





Ninety-two patients with documented single or two-vessel disease based on invasive coronary 
angiography (ICA) and at least a single reference vessel without a diameter stenosis > 30% were 
included. These selection criteria were applied as RFR calculations require a normal vascular reference 
area as previously described by de Bruyne et al9. Both schematic illustration and rationale of RFR 
calculation are shown in Figure 1. In case of two diseased vessels within a patient one vessel was 
randomly selected for the current analysis. The patients included in the current analysis were derived 
from a recently published larger cohort of subjects suspected of CAD, who were referred for ICA in 
conjunction with FFR measurements and underwent [15O]H2O PET imaging prior to ICA
7 . Exclusion 
criteria were prior percutaneous coronary intervention, coronary artery bypass graft surgery, a previous 
myocardial infarction, atrial fibrillation, second- or third-degree atrioventricular block, impaired 
renal function, symptomatic asthma, or pregnancy. Electrocardiography and echocardiography 
were used to confirm normal global left ventricular systolic function and absence of regional wall 
motion abnormalities in all patients. Vessels with an intermediate stenosis (30 – 90%) without FFR 
interrogation were excluded from analysis because of the inability to determine functional relevance 
of the lesion. The study was approved by the Ethics Committee of the VU University Medical Center.
PET imaging
PET studies using oxygen-15 labelled water were performed as described previously7 . In short, patients 
were scanned on a PET/CT device according to a site specific scanning protocol. All patients were 
informed to refrain from any caffeine or xanthine containing products for 24 hours prior to scanning. 
A dynamic emission scan was performed at rest followed by an identical scan during intravenous 
adenosine induced hyperemia. Low dose CT scans were used to correct for scatter and attenuation12. 
Parametric MBF images were generated and analysed quantitatively using Cardiac VUer or Carimas13, 
14. MBF was expressed in mL∙min-1∙g-1 of perfusable tissue. MBF and CFR were calculated for each of 
the three vascular territories left anterior descending (LAD), circumflex (Cx), and right coronary artery 
(RCA) according to standard segmentation procedures15. CFR was calculated as the ratio of hyperemic 
MBF to baseline MBF for each of the vascular territories.
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figure 1. Schematic illustration displaying the rationale of relative flow reserve (RFR) and fractional flow reserve 
(FFR) as comparable physiological parameters to evaluate the functional significance of a coronary stenosis. FFR 
is the ratio of hyperemic flow in the vascular territory subtended by the affected artery (A) to hyperemic flow in 
that same region in the hypothetical case of a normal artery (A`), which corresponds to the ratio of mean arterial 
pressure distal and proximal (A’’) of the stenosis during hyperemia. RFR is the ratio of hyperemic myocardial 
blood flow in the affected vascular territory (A) to flow in a normal reference area (B), which can be calculated 
in patients with single or two-vessel disease in whom quantitative perfusion measurements have been obtained 
by [15O]H2O PET. This concept relies on two assumptions. First, hyperemic minimal microvascular resistance is 
homogenous throughout the myocardium independent of the presence of epicardial coronary lesions. Two, the 
normal reference vessel is free from atherosclerosis without hyperemic pressure decline of the conduit epicardial 
segment. The latter assumption, however, is debatable as a non-significant hyperemic pressure decline (and thus 
FFR) can frequently be observed in coronary arteries without apparent obstructive lesions. FFR, fractional flow 
reserve; p, pressure; RFR, relative flow reserve; CAD, coronary artery disease; hMBF, hyperemic MBF.
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Invasive coronary angiography
ICA imaging was obtained in at least two orthogonal directions for each coronary artery using 
intracoronary administration of 0.2 mL of nitroglycerin prior to contrast injection to induce epicardial 
coronary vasodilation. Intermediate coronary lesions (diameter stenosis 30 – 90%) were interrogated 
by FFR. The operator refrained from FFR measurements in (sub-) total (90 – 100%) lesions to minimize 
the risk of provoking pressure wire related complications. For study purposes, 64 (53 %) of the non-
stenotic (i.e. <30% diameter stenosis) RFR reference vessels were also interrogated by FFR. All patients 
exposed to additional FFR measurements provided written informed consent. FFR was measured 
using a 0.014 inch sensor tipped guide wire, calibrated and advanced into the coronary artery. The 
use of intracoronary (150 µg, n = 54) or intravenous (140 μg∙kg-1∙min-1, n = 38) adenosine, to induce 
maximal coronary hyperemia during FFR interrogation, was left to the discretion of the operator7, 16. 
FFR was calculated as the ratio of the mean distal intracoronary pressure, measured by the pressure 
wire, to the mean arterial pressure (MAP) measured by the coronary catheter17. A stenosis with ≥ 90% 
luminal diameter reduction or with an FFR ≤ 0.80 was considered hemodynamically significant18. A 
coronary artery with less than 30% luminal narrowing was considered normal and served as reference 
for PET calculations19, 20. The coronary tree was divided into a 16-segment coronary artery model 
modified from the American Heart Association15. QCA was performed on all coronary segments > 2.0 
mm in diameter (Xcelera, Philips Healthcare, Best, The Netherlands).
Calculation of relative flow reserve
RFR was calculated as the ratio of hyperemic MBF of a stenotic myocardial area to hyperemic MBF 
of a non-stenotic reference vascular territory. Parametric hyperemic MBF polar maps were visually 
assessed to delineate defect areas, and quantitative MBF values of stenotic vessels were obtained for 
the ischemic segments only as opposed to entire vascular territories.
RFR = stenotic hyperemic MBF / reference hyperemic MBF 
Statistical analysis
Continuous variables are presented as mean values ± standard deviation (SD), whereas categorical 
variables are expressed as actual numbers. Continuous variables of paired data were compared 
with the paired sample t-test whereas comparisons between groups were performed using the two 
independent sample t-test, unless stated otherwise. Paired non-normal data were analysed with the 
Wilcoxon signed rank test where appropriate. Comparison of differences in myocardial perfusion, 
RFR and FFR between groups with different CAD severities was performed using one-way analysis of 
variance (ANOVA) and a posthoc Bonferroni for localizing the source of the difference. The association 
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between FFR and RFR was evaluated using Spearman’s correlation analysis, since both variables are 
non-normal data. Both receiver operator characteristics (ROC) curve analysis and Youden Index were 
used to define optimal cut-off values for hyperemic MBF. The areas under the curves of hyperemic MBF 
and RFR were compared with the method of DeLong et al.21. Incremental value of RFR over hyperemic 
MBF alone was determined with area under the ROC curve (AUC) analysis based on a combination 
of parameters in the logistic regression model, and the net reclassification index (NRI)22. Diagnostic 
performance of hyperemic MBF, RFR and RFR in addition to hyperemic MBF for the diagnosis of 
significant CAD was determined with sensitivity, specificity, negative predictive value (NPV), positive 
predictive value (PPV), and accuracy including their related 95% confidence intervals, on a per vessel 
basis. No corrections were necessary for the site the data came from because a linear mixed model 
did not expose any significant impact of the site on the results. Additionally, intra-class correlations 
confirmed no strong relationship between the data and the site the data came from. Based on ROC 
curve analysis of previously published data7, the sample size of the current study was 87 to detect a 
10% difference in AUC with an alpha of 0.05 and power of 0.80 in a population with a prevalence of 
disease of 40%. Statistical analyses were performed using IBM SPSS software (IBM SPSS Statistics 20.0, 
Chicago, IL) or MedCalc software (MedCalc Software 12.5.0.0, Ostend, Belgium).
RESULTS
Baseline patient characteristics are shown in table 1. Ninety-two patients, from the VU University 
Medical Center (n = 60), Turku University Hospital (n = 28), and Uppsala University Hospital (n = 
4,) who underwent both [15O]H2O PET imaging and ICA/FFR were included for analysis. No cardiac 
events or procedural related complications were documented between PET and ICA. A total of 
92coronary lesions were used for analysis of RFR. All intermediate stenotic vessels (30 - 90% diameter 
stenosis) were interrogated by FFR (n = 75, 82%), 17 (18%) vessels displayed a subtotal stenosis of 
at least 90% and were deemed hemodynamically significant. Thirty-eight (41%) lesions were graded 
hemodynamically significant determined by an FFR ≤ 0.80 (n = 21) or diameter stenosis of ≥ 90% (n 
= 17). In addition, 43 (47%) reference vessels were also interrogated by FFR with an average value of 
0.94 ± 0.06. Table 2 lists the characteristics of the coronary arteries analysed. 
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Table 1. Baseline patient characteristics (n = 92)
Characteristic N (%) or mean ± SD
Age (years) 61.0 ± 9.6
Male 57 (62%)




Current or history of smoking 30 (32%)




ACE inhibitors 15 (16%)
Beta-blockers 55 (60%)
Statins 67 (73%)
Angiotensin-II-receptor blockers 16 (17%)
Calcium channel blockers 16 (17%)
Long acting nitrates 8    (9%)
SD, standard deviation; CAD, coronary artery disease; ACE, angiotensin converting enzyme
Table 2. Description of coronary arteries analysed (n=92)
Coronary artery N (%) FFR  ≤ 0.80
LAD 52 (57%) 23 (44%)*
RCA 19 (21%)   7 (37%)*
CX 21 (23%)   8 (38%)*
Stenosis severity (QCA)
30 - 50 % 42 (46%) 6 (14%)
50 - 70 % 23 (25%) 7 (30%)
70 - 90 % 10 (11%) 8 (80%)
> 90% 17 (19%) NA
Reference artery (DS < 30%)
LAD 18 (20%) NA
RCA 36 (39%) NA
CX 38 (41%) NA
FFR, fractional flow reserve; LAD, left anterior descending; RCA, right coronary artery; Cx, circumflex; QCA, 




Hemodynamic conditions during PET
The hemodynamic conditions during rest and vasodilator PET are summarized in table 3. Heart rate and 
rate pressure product increased from rest to stress imaging (both p < 0.001). There were no significant 
differences in heart rate, blood pressure, or rate pressure product for rest and stress imaging between 
patients with or without hemodynamically significant CAD.
Table 3. Hemodynamic conditions during PET at baseline and hyperemia










Baseline 60 ± 9 61 ± 8 59 ± 11 0.34
Hyperemia
P-value
  79 ± 13
< 0.001
  81 ± 14 
 < 0.001
78 ± 12 
< 0.001
0.23
Systolic blood pressure (mmHg)










Diastolic blood pressure (mmHg)










Mean arterial pressure (mmHg)


















9969 ± 2254 
< 0.001
0.37
FFR, fractional flow reserve; bpm, beats per minute. 
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Myocardial blood flow
All patients successfully underwent imaging of adenosine induced hyperemic perfusion. Due to 
technical issues, imaging at rest could not be performed in a single patient. Global MBF on a per 
patient level was 0.97 ± 0.22 mL∙min-1∙g-1 at rest and 2.71 ± 1.04 mL∙min-1∙g-1 during adenosine induced 
hyperemia (p < 0.001). Baseline MBF of reference and angiographic stenotic coronary arteries at rest 
were 0.97 ± 0.23 and 0.98 ± 0.25 mL∙min-1∙g-1, p = 0.41, respectively. During hyperemia, MBF was higher 
for reference than for stenotic coronary arteries (3.07 ± 1.01 and 2.53 ± 1.11 mL∙min-1∙g-1, p < 0.001 
, respectively). Table 4 shows MBF in relation to anatomical lesion severity for the stenotic vessels. 
Hyperemic MBF was significantly lower for vessels with a hemodynamically relevant lesion (FFR ≤ 0.80 
or > 90% diameter stenosis) than for intermediate stenotic vessels with an FFR > 0.80 (2.01 ± 0.78 
vs. 2.90 ± 1.16 mL∙min-1∙g-1, p < 0.001, table 5). Baseline MBF was not affected by hemodynamically 
significant CAD (figure 2).
Table 4. Baseline MBF, hyperemic MBF, FFR, and RFR for all vessels as function of lesion severity
Baseline MBF 
(mL ∙ min-1 ∙ g-1)
Hyperemic MBF 
(mL ∙ min-1 ∙ g-1)
FFR RFR P - value 
(between FFR and RFR1)
All vessels 0.98 ± 0.25 2.53 ± 1.11   0.85 ± 0.14*   0.88 ± 0.19* 0.12
QCA DS%
30 - 50% (n = 42) 0.98 ± 0.25 2.98 ± 1.22§,   0.90 ± 0.09µ 0.95 ± 0.16 µ , 0.19
50 - 70% (n = 23) 0.99 ± 0.21 2.62 ± 0.88‡  0.85 ± 0.09µ 0.86 ± 0.15§, 0.72
70 - 90% (n = 10) 0.99 ± 0.33 1.92 ± 0.76 0.62 ± 0.21 0.67 ± 0.22 0.51
> 90% (n = 17) 0.96 ± 0.27 1.70 ± 0.49 NA 0.57 ± 0.18 NA
ANOVA p –value 0.84 < 0.001 < 0.001 < 0.001
*DS < 90% (n = 75); µ p < 0.001 vs. 70-90%;  p < 0.001 vs. > 90%; ‡ p = 0.03 vs. > 90%; § p < 0.02 vs. 70-90%; 
Intergroup significance was determined with ANOVA and a posthoc Bonferroni for localizing the source of the 
difference. 1Wilcoxon signed rank test, myocardial blood flow; FFR, fractional flow reserve; RFR, relative fractional 
flow; QCA, quantitative coronary angiography; DS, diameter stenosis; NA, not applicable
Table 5. Baseline MBF, hyperemic MBF, RFR, and CFR as function of FFR
FFR  > 0.80 FFR  ≤ 0.80 p-value
bMBF (mL ∙ min-1 ∙ g-1) 0.98 ± 0.25 0.98 ± 0.25    0.99
hMBF (mL ∙ min-1 ∙ g-1) 2.90 ± 1.16 2.01 ± 0.78 < 0.001
RFR 0.93 ± 0.15 0.67 ± 0.23 < 0.001
CFR 3.10 ± 1.29 2.27 ± 1.03 < 0.001
FFR; fractional flow reserve; bMBF, baseline myocardial blood flow; hMBF, hyperemic myocardial blood flow; RFR, 
relative flow reserve; CFR, coronary flow reserve
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Figure 2. Baseline MBF, hyperemic MBF and RFR in relation to hemodynamically significant CAD as indicated by 
FFR. MBF, myocardial blood flow (mL∙min-1∙g-1); CAD, coronary artery disease. 
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Coronary flow reserve
Mean CFR of stenotic vessels was significantly lower compared to the CFR of the reference vessels 
(2.76 ± 1.25 vs. 3.32 ± 1.24, p < 0.001, respectively). Within stenotic vessels, the CFR was lower for 
vessels with a hemodynamically significant lesion than for vessels with an FFR > 0.80 (2.27 ± 1.03 vs. 
3.10 ± 1.29, p = 0.001, respectively, table 5).
Relative flow reserve
RFR was calculated for all stenotic vessels (n = 92). FFR measurements were performed in stenotic 
vessels with intermediate lesions (diameter stenosis 30 – 90%, n = 75). Average RFR was 0.83 ± 0.22 for 
all vessels. The RFR for vessels with an intermediate stenosis was 0.88 ± 0.19 and was not significantly 
different compared to the average FFR of these arteries (0.85 ± 0.14, p = 0.12, n = 98). The mean 
difference between FFR and RFR was 0.04 ± 0.16.  RFR in relation to lesion severity and in comparison 
with FFR is shown in table 4. RFR was lower for vessels with a hemodynamically significant lesion than 
for vessels with an FFR > 0.80 (0.67 ± 0.23 vs. 0.93 ± 0.15, p < 0.001; table 5, figure 2). The correlation 
between FFR and RFR, and its corresponding Bland-Altman plot, is given in figure 3.
Diagnostic accuracy of hyperemic MBF, CFR, and RFR
ROC analysis revealed an AUC of 0.76 for hyperemic MBF, 0.72 for CFR, and 0.82 for RFR (p = 0.32 for 
RFR vs. hyperemic MBF, p = 0.08 for RFR vs. CFR, and p = 0.18 for hyperemic MBF vs. CFR, figure 4, table 
6). The optimal cut-off values for hyperemic MBF, CFR, and RFR were 2.35 mL∙min-1∙g-1, 2.58, and 0.69, 
respectively. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), 
and accuracy of hyperemic MBF, CFR, RFR, and RFR in combination with hyperemic MBF for predicting 
abnormal FFR are shown in table 7. The agreement of RFR with FFR is shown in figure 3. The AUC of 
RFR in addition to MBF (0.82) was not significantly different compared to the AUC of hyperemic MBF 
or RFR alone (p = 0.20 vs. hyperemic MBF, and p = 0.85 vs. RFR). Consequently, reclassifications based 
on RFR in addition to hyperemic MBF did not result in a better prediction model (net reclassification 
improvement index of -0.002 ± 0.076 (p = 0.98)).
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Correlation of FFR and RFR
























Figure 3. Relationship of RFR with FFR. The corresponding Bland-Altman plot shows the mean difference of FFR 
and RFR (bold line). RFR, relative flow reserve; FFR, fractional flow reserve
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ROC curves



















Figure 4. ROC curves of hyperemic MBF, RFR, RFR in addition to hyperemic MBF, and CFR with corresponding AUC 
and 95% confidence intervals. All ROC-curves were significant different form the line of identity. MBF, myocardial 
blood flow (mL∙min-1∙g-1); RFR, relative flow reserve; CFR, coronary flow reserve; AUC, area under the curve; ROC, 
receiver operator characteristics
Table 6. Area under the receiver operating characteristics curve
AUC 95% CI p - value* 
hMBF 0.76 0.66 – 0.86 < 0.001
RFR 0.82 0.72 – 0.91 < 0.001
hMBF and RFR 0.82 0.73 – 0.91 < 0.001
CFR 0.72 0. 61 – 0.83 < 0.001
AUC, area under curve; CI, confidence interval; hMBF, hyperemic myocardial blood flow; RFR, relative flow 
reserve; CFR, coronary flow reserve; *compared to the line of identity
Table 7. Diagnostic accuracy of hyperemic MBF, RFR, RFR in addition to hyperemic MBF, and CFR for predicting 
hemodynamically significant CAD
hMBF  
(2.35 mL ∙ min-1∙g-1)
RFR  
(0.69)




Sensitivity (%) 79 (66 – 92) 58 (42 – 74) 66 (51 – 81) 66 (51 – 81)
Specificity (%) 70 (60 – 81) 98 (95 – 100) 91 (83 – 98) 69 (56 – 81)
NPV (%) 83 (72 –94) 77 (67 – 87) 79 (69 – 89) 74 (62 – 86)
PPV (%) 65 (51 – 79) 96 (87 – 100) 83 (70 – 97) 60 (45 – 74)
Accuracy 74 (65 – 83) 82 (74 – 89) 80 (72 – 89) 67 (58 – 77)
hMBF, hyperemic myocardial blood flow; RFR, relative flow reserve; CFR; coronary flow reserve; CAD, coronary 




The present study was conducted to evaluate the agreement between RFR and FFR, and to determine 
the diagnostic accuracy of RFR in assessing significant CAD in patients with single or two vessel 
coronary artery disease. Results indicate that RFR values were not significantly different compared 
to FFR, however, the correlation between these parameters is only moderate. In addition, diagnostic 
accuracy of RFR for detecting functionally CAD was not evidently better than that of hyperemic MBF 
and CFR in the current analysis.
RFR vs. FFR
For intermediate stenotic lesions, PET derived RFR correlated only moderate with FFR. These results 
are in contrast to previous RFR validation studies, which yielded a high agreement9, 11. The differences 
with these studies, which used the same PET and FFR technology, are likely due to patient selection. 
These earlier studies carefully identified patients with single coronary artery disease together with 
isolated discrete lesions in the absence of any atherosclerotic features of the reference vessels. In 
contrast, in the present study, patients were selected from a consecutive cohort of patients who 
underwent PET and FFR, and displayed single or two vessel coronary artery disease. In each of these 
patients a reference vessel was identified based on a stenosis diameter of less than 30%. Nevertheless, 
frequently diffuse atherosclerosis without a focal lesion was observed in these arteries, questioning 
whether they can be used as reference. In fact, in the subgroup of patients in whom FFR was measured 
in the reference artery, an FFR of 0.94 was obtained, indicating a hyperemic pressure decline across 
the course of the artery even in the absence of apparent stenosis. Previously, this phenomenon has 
been documented by de Bruyne et al23. As opposed to FFR, RFR depends on the validity of a true 
normal reference area and the slight decrease in hyperemic MBF due to diffuse atherosclerosis results 
in overestimation of RFR relative to FFR. This overestimation does not indicate a limited correlation 
since the correlation between two parameters can be very high if a fixed offset is apparent. However, 
the correlation between FFR and RFR was limited which indicates that in a consecutive, clinical patient 
population with single or two vessel disease, RFR does not appear to robustly mimic invasive FFR. 
Additionally, a relevant number of vessels with FFR > 0.80 display abnormal hemodynamics due to 
microvascular dysfunction24. Identification of microvascular dysfunction, in addition to FFR, is essential 
to guide clinical management in a judicious manner25-27.  Furthermore, impaired vasomotor function 
is a significant prognostic predictor, suggesting that myocardial perfusion is relevant despite the value 
of FFR28, 29.
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Diagnostic accuracy of hyperemic MBF and RFR
Recently, an optimal cut-off value of absolute hyperemic MBF (for [15O]H2O) has been established in 
a multicentre cohort of 330 patients with an intermediate pretest probability of CAD7. Danad et al. 
presented 2.3 mL∙min-1∙g-1 as optimal cut-off value to detect hemodynamically significant CAD based 
on a FFR cut-off value of 0.80. The corresponding diagnostic accuracy was 84% on a per vessel basis 
and 85% on a per patient basis, which was in line with previous studies30-33. In the present study, using 
a selection of patients from the same dataset, a lower diagnostic accuracy of hyperemic MBF on a per 
vessel basis (74%) was obtained for the same cut-off value. This lower diagnostic accuracy is the result 
of selection bias whereby the classification agreement between measurements will decrease when 
continuous values are studied close to an established cut-off value (FFR 0.80), which is the case due 
to studying diseased vessels only in the current study. Adding unaffected scans with homogeneous 
perfusion will provide very low incidence of false-negative test results, and would improve the 
specificity of hyperemic MBF and RFR.
Hyperemic MBF and FFR display a physiological disconcordancy in approximately ~25% of cases7, 8, 
34. This is due to the variability in coronary microvascular resistance, whereby for a given FFR (of an 
epicardial lesion) hyperemic MBF is blunted or preserved in case of augmented or low microvascular 
resistance, respectively8. Non-invasive PET derived FFR estimation by RFR has similar dependency to 
variations of coronary microvascular resistance and should therefore, on a theoretical basis, display a 
higher concordancy with FFR than hyperemic MBF. Yet, the diagnostic accuracy and C-statistic at ROC 
analysis of RFR (82% and 0.82, respectively) were not significantly higher compared to hyperemic MBF 
(74% and 0.76, respectively), when taking FFR of 0.80 as a reference. As already alluded to, reference 
arteries sometimes display diffuse subclinical atherosclerosis, which hampers the accuracy of RFR by 
lack of normally perfused myocardium. In addition, RFR is a ratio whereby fluctuations in each of the 
two parameters utilized will induce noise and larger variability as compared with single measurements 
alone. A similar phenomenon has previously been documented with the ratio of coronary flow reserve, 
which yields a lower diagnostic accuracy to diagnose CAD, as confirmed in the current, compared to 
hyperemic MBF alone7, 31, 33, 35.
Clinical implication of RFR
The current aimed to evaluate whether the theoretical benefit of noninvasive assessment of FFR by 
means of PET derived RFR would translate into a higher diagnostic accuracy than hyperemic MBF 
alone. The data trends toward a higher diagnostic value, however no significant improvement was 
found compared to that of hyperemic MBF alone. This parameter is further limited by the fact that 
it can only be utilized in patients with single or two vessel disease as a normal reference territory is 
required for its assessment. It can thus only be calculated in combination with anatomical imaging 
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either by invasive or CT based coronary angiography. As RFR did not add significant incremental value 
over hyperemic MBF, the application  in clinical practice cannot be established yet. This is in line with 
the results obtained by Hajjiri et al., who demonstrated that the relative uptake ratio of impaired 
perfusion in relation to a normal reference area using [13N]NH3 PET was inferior to hyperemic perfusion 
in diagnosing obstructive CAD36.
Coronary flow reserve
Consistent with previously published data, CFR does not seem to level with absolute hyperemic MBF 
when it comes to diagnostic accuracy for predicting hemodynamically significant CAD as reflected 
by FFR ≤ 0.80, in the current study7, 31, 33, 35. However, Johnson et. al. showed an useful approach 
combining both hyperemic MBF and CFR to account for diffuse low perfusion due to risk factors or 
clinical circumstances8, which is essential due to its prognostic value28, 29.
Cut-off values
Cut-off values for hyperemic MBF and CFR in the current seem rather high compared with previously 
reported cut-off values37, 38. However, the lack of this uniformity may be attributed to study design and 
the use of different PET tracers. Due to individual kinetic properties, different PET tracers will provide 
various cut-off values.
Study limitations
Intravenous administration of adenosine at a dose of 140 μg∙kg∙min-1 is considered to be the gold 
standard for FFR assessment6. The current study used either intravenous or intracoronary adenosine 
to achieve hyperemia during FFR interrogation. Based on matching FFR-values between 140 μg∙kg-
1∙min-1 iv and 150 μg intracoronary as demonstrated by Casella et al., 150 μg adenosine was used as 
intracoronary dosage in the present study16.
Furthermore, with regard to grading of hemodynamically significant CAD the assumption was 
made that a lesion of > 90% diameter stenosis was hemodynamically significant, despite missing 
FFR measurements. Tonino et al. provided evidence that vessels with a stenosis of 90-99% were 
hemodynamically significant, graded by an FFR ≤ 0.80, in 96% of the cases18. Due to these lacking FFR 
values correlation of FFR and RFR could only be provided for vessels with intermediate lesion severity.
Although site-specific differences in scanning protocol and software packages exists in the current 
analysis, MBF extraction with Cardiac VUer and Carimas is similarly retrieved with highly comparable 
quantitative global and regional MBF values13, 39, 40. However, influence on the results cannot be 
entirely excluded due to the possible existence of significant offsets between different models, scan 
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techniques, and reconstruction parameters. Furthermore, ratio-measures such as RFR might be more 
robust to potential heterogeneity of these analyses in contrast to MBF. Consequently, caution must be 
maintained in interpreting the negativity of these results.
The current sample size was insufficient to detect a significant improvement of the AUC for RFR, 
although a trend towards a higher diagnostic accuracy for RFR was found. This could indicate the 
current study was hampered by limited statistic power. Given te preliminary nature of the findings 
further investigation with a larger sample size is warranted.
The current investigated the diagnostic accuracy of RFR with FFR as reference standard, whilst initially 
FFR was validated against PET and other functional tests9-11, 17, 41. This circularity of literature should be 
taken into account when drawing conclusions to the results. However, RFR might compensate for the 
disconcordancy between FFR and hyperemic perfusion which is frequently observed in patients with 
microvascular dysfunction and data on the diagnostic performance of RFR is lacking. 
CONCLUSION
Non-invasive estimation of FFR with quantitative perfusion PET by calculating RFR is feasible, yet only 
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CONDENSED ABSTRACT
Next to coronary stenosis severity, atherosclerotic plaque burden and morphology may also affect 
myocardial perfusion. The present study explores the impact of CT derived atherosclerotic plaque 
characteristics on both myocardial perfusion as assessed with PET as well as invasive FFR. Independent 
of luminal stenosis, also positive remodeling and a large noncalcified plaque volume revealed to predict 
a lower myocardial blood flow and lower FFR. Although statistically significant, the additional value 
of these adverse plaque characteristics over luminal stenosis as predictors of ischemia was limited.
ABSTRACT
Background: Next to coronary lesion severity, atherosclerotic plaque characteristics may also affect 
downstream myocardial perfusion. 
Objectives: The purpose of the present study was to evaluate the association between quantitative 
plaque burden and plaque morphology obtained using coronary computed tomography angiography 
(CCTA) and quantitative myocardial perfusion obtained using [15O]H2O positron emission tomography 
(PET) as well as fractional flow reserve (FFR) derived invasively.  
Methods: 208 patients (63% men, age 58 ± 8.7 years) with suspected coronary artery disease 
were prospectively included. All patients underwent 256-slice CCTA, [15O]H2O PET, and invasive FFR 
measurements. CCTA derived plaque burden and morphology were assessed using commercially 
available software and compared with PET perfusion and FFR.
Results: Atherosclerotic plaques were present in 179 (86%) patients and 415 of 610 (68%) evaluable 
coronary arteries. On a per-vessel basis, traditional coronary plaque burden indices, such as plaque 
length and volume, minimal lumen area, and stenosis percentage, were significantly associated with 
impaired hyperemic myocardial blood flow (MBF) and FFR. In addition, morphological features, such as 
partially calcified plaques, positive remodeling (PR), and low attenuation plaque (LAP), also displayed 
a negative impact on hyperemic MBF and FFR. Multivariable analysis revealed that the morphological 
feature of PR was independently related to impaired hyperemic MBF as well as an unfavorable FFR (p = 
0.004 and p = 0.007, respectively), next to stenosis percentage (p = 0.001 and p < 0.001, respectively), 
and noncalcified plaque volume (p < 0.001 and p = 0.010, respectively).
Conclusions: Positive remodeling and noncalcified plaque volume are associated with detrimental 




Coronary computed tomography angiography (CCTA) is an established tool for the noninvasive 
assessment of coronary artery stenosis.(1-4) However, the relationship between anatomical coronary 
stenosis severity and myocardial ischemia is complex. Whereas roughly one fifth of ≥ 70% stenotic 
lesions do not cause ischemia, attenuation of flow can occur even in apparent nonobstructive coronary 
arteries due to diffuse atherosclerosis.(5-9) Based on an increasing awareness of this discrepancy, 
other atherosclerotic factors are under investigation in order to improve the prediction of ischemia. 
In line with the search beyond traditional stenosis severity, CCTA also allows for noninvasive evaluation 
of quantitative atherosclerotic plaque burden and plaque morphology, which closely matches results 
obtained using invasive intravascular ultrasound and optical coherence tomography.(4, 10-14) Although 
adverse plaque characteristics (APCs) such as positive remodeling (PR) and low attenuation are linked 
to plaque rupture and acute coronary syndromes (15), plaque morphology has also been associated 
with hemodynamic consequences of those lesions. (16-19) Consequently, the additive value of CCTA 
derived atherosclerotic plaque burden and morphology might be beneficial for both diagnostic and 
prognostic purposes. Therefore, the aim of this study was to investigate the associations of CCTA 
derived plaque burden and morphology, and myocardial perfusion as assessed with [15O]H2O PET, as 
well as the clinical reference standard for coronary revascularization being FFR.
METHODS
Patient Population
This was a post hoc substudy comprising all patients from the PACIFIC (Prospective Comparison of 
Cardiac PET/CT, SPECT/CT Perfusion Imaging and CT Coronary Angiography With Invasive Coronary 
Angiography) trial involving 208 patients suspected of CAD, who underwent CCTA and PET with 
interrogation by FFR of all coronary arteries (NCT01521468).(20) Patients suspected of stable coronary 
artery disease (CAD) with an intermediate pre-test likelihood of CAD and normal left ventricular 
function were included. Exclusion criteria incorporated a documented history of CAD, signs of prior 
myocardial infarction, atrial fibrillation, renal failure, second- or third-degree atrioventricular block, 
symptomatic asthma, or pregnancy. The study complied with the Declaration of Helsinki and the study 
protocol was approved by the VUmc Medical Ethics Review Committee. All patients provided written 
informed consent.
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Coronary computed tomography angiography
All patients underwent CCTA on a 256-slice CT scanner (Philips Brilliance iCT, Philips Healthcare, Best, 
the Netherlands). Sublingual nitroglycerine was administered to all patients prior to the scanning 
protocol. Metoprolol was administered only if necessary, aiming for a heart rate of < 65 beats∙min-1. 
CT scans were performed using a standard scanning protocol, with a section collimation of 2 × 128 × 
0.625 mm, a gantry rotation time of 270 ms, and tube current between 200 and 360 mAs at 120 kV, 
primarily adjusting mAs based on body habitus. The scan was triggered, using an automatic bolus-
tracking technique with a region of interest placed in the descending thoracic aorta, at a threshold 
of 150 Hounsfield units (HU). Prospective electrocardiogram-gating (Step & Shoot Cardiac, Philips 
Healthcare, Best, The Netherlands) was used at 75% of the R-R interval. Due to a persistent heart rate 
> 65 beats∙min-1, 4 scans were performed using a retrospective helical protocol. An intravenous bolus 
of 100 mL of iodinated contrast agent (XenetiX 350, Guerbet, Brussels, Belgium) was injected at a flow 
rate of 5.7 mL∙s-1 directly followed by a 50 mL saline flush.
Assessment of coronary plaques
Using dedicated semi-automated software (Comprehensive Cardiac Analysis, Philips Healthcare, Best, 
The Netherlands), all coronary segments with a diameter ≥2 mm were assessed by an experienced 
reader blinded to both PET and FFR results. The coronary tree was evaluated according to a 17-segment 
coronary artery model using axial, multiplanar reformation, maximum intensity projection, and cross-
sectional images (slice thickness 0.9mm, increment 0.50mm). Manual corrections to centerline and 
vessel contours by the reader were allowed. Stenosis severity was graded as 0, 1-50, 50-70, and ≥ 70%. 
Quantitative coronary atherosclerotic burden was assessed automatically within manually designated 
regions. Total plaque lengths and volumes were calculated per vessel by summing the lengths and 
volumes of separate plaques along each coronary artery. A scanner specific threshold of 150 HU was 
used for distinguishing noncalcified from calcified plaque components, which subsequently was used 
to determine noncalcified and calcified plaque volumes. At the site of maximal stenosis, lumen area, 
wall area, and maximal plaque burden (plaque area divided by vessel area 100%) were assessed in 
the short-axis of the vessel. Coronary lesions were also analyzed for qualitative atherosclerotic plaque 
characteristics. The remodeling index was computed as the ratio of vessel area at the site of the 
maximal lesion to that of a proximal reference point, with an index > 1.1 representing PR.(17) Low 
attenuation plaque (LAP) was defined as a plaque containing any voxel < 30 HU.(17) Spotty calcification 
(SC) was characterized by a calcified plaque comprising <90° of the vessel circumference and <3 mm 
in length (17). Napkin ring sign was defined by a plaque core with low CT attenuation surrounded by a 




Patients were scanned using a hybrid PET-CT device (Philips Gemini TF 64, Philips Healthcare, Best, 
The Netherlands). The scanning protocol has been described in detail previously.(22) In summary, a 
dynamic PET perfusion scan was performed during resting conditions using 370 MBq of [15O]H2O. A 
6 min emission scan was started simultaneously with the administration of [15O]H2O. This dynamic 
scan sequence was followed immediately by a low dose CT scan for attenuation correction. After a 
10 min interval to allow for decay of radioactivity, an identical PET sequence was performed during 
hyperemic conditions induced by an i.v. adenosine infusion (140 µg∙kg-1∙min-1), initiated 2 min before 
the stress scan for maximal vasodilation. Images were reconstructed using the 3D row action maximum 
likelihood algorithm and applying all appropriate corrections. Parametric MBF images were generated 
and quantitatively analyzed using software developed in-house (Cardiac VUer) (23). Myocardial blood 
flow was expressed in mL∙min-1∙g-1 of perfusable tissue. In addition to calculating both resting and 
hyperemic MBF for the left ventricle as a whole, MBF was also calculated for each of the three vascular 
territories derived from standard segmentation: left anterior descending (LAD), left circumflex (LCX), 
and right coronary artery (RCA). Coronary flow reserve (CFR) was defined as the ratio between 
hyperemic and resting MBF.  For comparison with CT characteristics, predominantly hyperemic MBF 
was used, because of its greater ability to identify ischemia as compared with resting MBF or coronary 
flow reserve using [15O]H2O as a tracer (22,24).
Invasive coronary angiography and fractional flow reserve measurements
Selective invasive coronary angiography (ICA) was performed by standard catheterization in accordance 
with the American College of Cardiology guidelines for coronary angiography (25). Intracoronary 
nitroglycerin was administered prior to contrast injection, inducing epicardial coronary vasodilation. 
All major coronary arteries and side branches >2.0 mm were interrogated with FFR. Operators 
refrained from FFR measurement in tight lesions > 90% to avoid the risk of a coronary dissection by the 
pressure wire. FFR was measured using a 0.014-inch sensor-tipped guidewire, introduced through a 
5- or 6-F guiding catheter. To induce maximal coronary hyperemia, adenosine was infused using either 
intravenous or intracoronary administration at a dose of 140 μg∙kg-1∙min-1 or 150 μg, respectively. FFR 
was calculated as the ratio of the mean distal intracoronary pressure, measured by the pressure wire 




Continuous variables are represented as mean ± standard deviation (SD) and categorical variables as 
numbers and percentages. Mixed effects models and Generalized Estimating Equations (GEEs) were 
used in SPSS to identify factors associated with a reduced hyperemic MBF, CFR and an FFR ≤ 0.80, 
respectively. Mixed effects models and GEEs were used rather than standard linear regression and 
logistic regression in order to account for correlation of outcomes between multiple vessels within 
the same patient. Mixed effects models included a random effect for patient and the GEEs assumed 
an exchangeable correlation matrix to account for within-patient correlation. Predicted values for the 
outcomes based on the fixed parts of the obtained models were exported to MedCalc in order to 
perform the ROC analyses. MBF and CFR data were logarithmically transformed to correct for rightward 
skew. All candidate predictors were first tested for association in univariable analyses. Additional 
analyses were performed with a correction for luminal stenosis severity based on 4 predefined 
categories (i.e. no stenosis, 0-50% stenosis, 50-70% stenosis, and >70% stenosis). Subsequently, a 
forward selection procedure was to find sets of independent predictors for MBF and FFR values. 
Only predictors with a p < 0.10 in univariable analyses were considered in the multivariable analysis. 
Forward selection was used rather than backward elimination as the latter required the estimation of 
a model containing all predictors which was hampered by multi-collinearity. Regression coefficients 
and odds ratios (OR) with their 95% confidence intervals were reported as effect sizes for mixed effects 
models and GEEs, respectively. One-way analysis of variance with Bonferroni’s correction for multiple 
pair-wise comparisons were used to compare differences in MBF between particular numbers of APCs 
as well as plaque features between subgroups of combined MBF, CFR, and FFR. In addition, areas 
under the receiver-operating characteristic curves (AUCs) were used to evaluate the additive value 
of plaque characteristics next to stenosis severity in predicting ischemia (FFR ≤ 0.80). Correlations 
of both reference standards and plaque features were compared using William’s test. Interobserver 
reproducibility of plaque characteristics was quantified using intra-class correlation coefficient (ICC). 
A two-sided p value < 0.05 was considered statistically significant. Statistical analyses were performed 
using SPSS (version 20.0,  IBM Corporation, Armonk, NY, USA) and Medcalc (version 11.0, MedCalc 
Software, Ostend, Belgium) software.
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Central Illustration: In this study, various atherosclerotic plaque characteristics were derived from CCTA and 
related to MBF as assessed with [15O]H2O PET imaging and invasive FFR. Among these plaque features, luminal 
stenosis severity showed to be the strongest predictor of both a detrimental myocardial blood flow and FFR. 
Interestingly, also positive remodeling and noncalcified plaque volume revealed an independent and negative 
impact on myocardial perfusion and FFR. In addition, while spotty calcification and low attenuation plaque 
were independent predictors of low FFR values, this did not account for PET MBF. CCTA = coronary computed 




The final study population comprised 204 patients and 610 evaluable coronary arteries, after excluding 
14 vessels due to non-evaluable CCTA scans. The median number of evaluable arteries per patient was 
3 (range of 2 – 3). A total of 596 of these coronaries were interrogated by FFR or showed (sub)total 
occlusion on ICA. Vascular territories could be related to PET derived MBF in 203 patients. Baseline 
characteristics are listed in Table 1. Overall, 303 (50%) vessels were found to be obstructive with a 
coronary stenosis ≥ 50% on CCTA, whereas invasive FFR was ≤ 0.80 in only 158 (26%) coronaries. Table 
2 provides an overview of CT findings in the total population.
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Table 1 . Patient baseline characteristics (n = 204)
Demographics
Age, years 58.1 ± 8.7
Male 129 (64%)
Body mass index (kg/m2) 27.0 ± 3.8





Current smoker 41 (20%)
Smoking history 100 (49%)





ACE inhibitor 39 (19%)
ARB 36 (18%)
Calcium-channel blocker 59 (29%)
Long acting nitrate 21 (10%)
Type of chest pain
Typical angina 71 (35%)
Atypical angina 80 (39%)
Nonspecific chest discomfort 53 (26%)
Values are mean ± SD or n (%)
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; 




Table 2 . CT plaque characteristics
CT characteristics Total CT evaluable 
coronaries  
(n = 610)
Vessels with FFR  
 
> 0.80 (n = 437)
Vessels with FFR 




Stenosis - - - <0.001 for trend
   No stenosis 195 (32) 188 (43) 1 (1) <0.001
   0 – 50% stenosis 112 (18) 99 (23) 10 (6) <0.001
   50 – 70% stenosis 149 (24) 99 (23) 45 (28) 0.154
   > 70% stenosis 154 (25) 51 (12) 103 (65) <0.001
Plaque length [mm] 26 ± 28 17 ± 23 52 ± 27 <0.001
Plaque volume [mm3] 162 ± 224 97 ± 155 350 ± 276 <0.001
Noncalcified plaque volume [mm3] 52 ± 118 25 ± 48 131 ± 196 <0.001
Calcified plaque volume [mm3] 110 ± 152 72 ± 123 218 ± 168 <0.001
Lumen area [mm2] 3.2 ± 2.4 4.0 ± 2.3 1.3 ± 1.1 <0.001
Wall area [mm2] 5.3 ± 5.1 4.0 ± 4.4 8.8 ± 5.1 <0.001
Plaque burden [%] 55 ± 40 42 ± 39 90 ± 16 <0.001
Noncalcified plaque 113 (19) 60 (14) 51 (32) <0.001
Partically calcified plaque 272 (45) 139 (32) 132 (83) <0.001
Calcified plaque 266 (44) 161 (37) 101 (64) <0.001
Low attenuation plaque 75 (13) 19 (4) 56 (35) <0.001
Positive remodeling 67 (11) 17 (4) 50 (31) <0.001
Spotty calcification 35 (6) 10 (2) 25 (16) <0.001
Napkin ring sign 22 (4) 5 (1) 17 (11) <0.001
Values are mean ± SD or n (%)
CAD = coronary artery disease; CT = computed tomography; FFR = fractional flow reserve; ICA = invasive coronary 
angiography
Quantitative plaque burden and morphology related to hyperemic MBF
The association between plaque characteristics and hyperemic MBF is shown in table 3. Using 
univariable regression analysis, all quantitative plaque parameters showed a significant association 
with reduced hyperemic MBF. With respect to plaque morphology, only the presence of noncalcified 
plaques and calcified plaques were not significantly related to MBF. After adjusting for luminal 
stenosis, all quantitative plaque parameters, except lumen area, still predicted a significantly lower 
MBF. Likewise, the morphological features LAP, PR, and SC remained significantly related. When 
subsequently using multivariable regression analysis with forward selection, only noncalcified plaque 
volume (NCPV) and PR persisted to be significantly associated with impaired hyperemic MBF, next 
to stenosis severity. A multivariable analysis to predict PET derived CFR also revealed NCPV and PR 
as independent predictors next to stenosis severity (supplemental table 1). Figure 1 illustrates the 
gradual reduction in hyperemic myocardial blood flow in relation to the number of adverse plaque 
characteristics.
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Table 3. Univariable and multivariable analysis of plaque characteristics for hyperemic myocardial blood flow 
using [15O]H2O PET
Univariable analysis Analysis adjusted for 
luminal stenosis
Multivariable analysis using 
forward selection
Plaque characteristics Coefficient (95% 
CI)
 P-value Coefficient  
(95% CI)




Luminal stenosis - <0.001* 
(overall)
- - - 0.001* 
(overall)
   No stenosis 0 
(reference)
- - - 0 
(reference)
-
   0 – 50% stenosis 0.015 
(-0.037, 0.067)
0.571 - - 0.027 
(-0.024, 0.078)
0.303
   50 – 70% stenosis -0.049 
(-0.102, 0.004)
0.072 - - -0.018 
(-0.070, 0.035)
0.504
   > 70% stenosis -0.157 
(-0.213, -0.102)
<0.001* - - -0.087 
(-0.146, -0.029)
0.003*

























































<0.001* -0.044  
(-0.089, 0.001)
0.056 - -





























CI = confidence interval; * indicate significant coefficients for P < 0.05
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Figure 1: Number of adverse plaque characteristics related to blood flow. Distribution of hyperemic myocardial 
blood flow values derived from [15O]H2O positron emission tomography, categorized by the number of APCs. 
Blood flow gradually declining with increasing number of APCs. All categories were only significantly different 
from the group without APCs. APC = adverse plaque characteristic.
Table 4 displays the results of regression analysis between plaque characteristics and FFR. Univariable 
analysis showed that all quantitative and qualitative plaque characteristics had a significant 
relationship with FFR. Applying an adjustment for luminal stenosis excluded calcified plaque volume, 
wall area, noncalcified and calcified plaques along with NRS as significant predictors. Multivariable 
analysis yielded inverse relationships with FFR for noncalcified plaque volume, LAP, PR, and SC next to 
luminal stenosis severity.
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Table 4. Univariable and multivariable analysis of plaque characteristics for fractional flow reserve




Plaque characteristics OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Quantitative plaque characteristics
Luminal stenosis - <0.001* 
(overall)
- - - <0.001* 
(overall)
   No stenosis 0 
(reference)
- - - 0 
(reference)
-
   0 – 50% stenosis 5.3 
(1.7, 15.9)
0.003* - - 3.9 
(1.2, 12.3)
0.021*
   50 – 70% stenosis 22.0 
(8.1, 59.2)
<0.001* - - 12.2 
(4.3, 34.3)
<0.001*
   > 70% stenosis 82.3 
(30.0, 226.3)
<0.001* - - 35.4 
(12.4, 101.2)
<0.001*



















































































CI = confidence interval; OR = odds ratio; * indicate significant OR for P < 0.05
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Additive value of plaque characteristics next to stenosis severity in 
identifying ischemia
Next to stenosis severity, the only plaque characteristics which independently predicted both 
an impaired hyperemic MBF and FFR were noncalcified plaque volume and PR. While LAP and SC 
remained significantly related to FFR, this was not the case for the comparison with hyperemic 
MBF. Noncalcified plaque volume affected perfusion impairment and a significant reduction in FFR 
comparably (p = 0.29 for difference in correlation). Positive remodeling and luminal stenosis, however, 
had a greater impact on a significant hyperemic pressure drop than on impaired perfusion (p < 0.001 
and p = 0.005, respectively).
Figure 2 shows quantitative relation between MBF and FFR, whereas Online Figure 1 shows the 
relationship for PET CFR and FFR. Most plaque features were significantly detrimental for concordant 
abnormal MBF and FFR results as compared with concordant negative MBF and FFR results 
(supplemental table 2). Among discrepancy subgroups, an impaired FFR in combination with normal 
MBF was characterized by higher grade stenosis severity, smaller lumen areas, and more severe 
maximal plaque burden in comparison to the group of a preserved FFR in the presence of impaired 
MBF. Conversely, the latter group displayed smaller plaque lengths and similar plaque volumes. Plaque 
characteristics, however, did not significantly differ between the subgroups with discrepant hyperemic 
MBF and CFR results (Online Figure 2 and Online Table 3).
Figure 3 shows receiver-operating characteristic (ROC) analyses for identifying a positive FFR (≤ 0.80). 
Compared to luminal stenosis alone, the addition of noncalcified plaque volume and, subsequently, 
PR, improved the predictive value for FFR ≤ 0.80. Accordingly, area under the curve (AUC) increased 
from 0.86 to 0.89 and 0.90, respectively. Figure 4 illustrates an example of an ischemia causing lesion 
without being obstructive, yet showing multiple plaque characteristics (noncalcified plaque with LAP 
and PR).
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Figure 2: Hyperemic myocardial blood fl ow related to FFR. Quanti tati ve relati onship between PET derived 
hyperemic MBF and FFR when available. Colored quadrants delineate subgroups with concordant and discordant 
hyperemic MBF and FFR results. Among these cases 77.4% were concordant, whereas 6.4% of cases showed 
normal MBF but abnormal FFR and 16.2% of cases showed abnormal MBF despite normal FFR. FFR = fracti onal 
fl ow
Figure 3: AUC for predicti on of FFR ≤ 0.80. ROC curves for the discriminati on of a FFR ≤ 0.80. AUCs signifi cantly 
improved by adding NCPV and PR to stenosis severity alone. 
AUC = area under the curve; FFR = fracti onal fl ow reserve; NCPV = noncalcifi ed plaque volume; PR = positi ve 
remodeling; ROC = receiver-operati ng characteristi c.
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Figure 4: Nonobstructive lesion with adverse plaque characteristics causing ischemia. Representative example 
of a nonobstructive lesion in the left circumflex artery with multiple plaque characteristics causing ischemia. (A) 
Multiplanar reconstruction demonstrating small calcified plaques in the proximal left anterior descending and 
circumflex artery as well as 50% luminal stenosis caused by a noncalcified plaque (green border) with positive 
remodeling (red line) compared to the reference segment (yellow line). (B) Corresponding cross sections at the 
site of the reference segment (B-I) and the plaque (B-II), whereby the red line indicates the luminal border and 
the blue line the outer border of the vessel containing plaque. (B-II) Automatic assessment of plaque content 
revealed a noncalcified plaque (HU < 150, purple) with parts of low attenuation (HU < 30, light green). (C-I and 
II) Short axis images of hyperemic [15O]H2O PET showing a inferolateral perfusion defect (arrows). (D-I and II) PET 
perfusion at rest was normal. (E) Using invasive coronary angiography, a nonobstructive stenosis (arrow head) 
was found corresponding with the stenosis seen on coronary CT angiography. An unfavorably low FFR of 0.41 was 
measured. FFR
Reproducibility
A total number of 21 patients and 63 vessels (10% of study population) were re-analyzed to test 
interobserver variability. For stenosis severity the interobserver reproducibility expressed as ICC 
was 0.78. Agreement was also good for plaque features NCPV and PR with an ICC of 0.81 and 0.66, 
respectively.
DISCUSSION
The present substudy of the PACIFIC trial was conducted in order to explore whether and, if so, 
to which extent quantitative plaque burden and morphology are related to hyperemic myocardial 
blood flow in patients undergoing CCTA. Various traditional lesion severity indices such as plaque 
length and volume showed an inverse relationship with hyperemic MBF, even after adjustment for 
luminal stenosis. Morphological features like noncalcified plaque volume and positive remodeling also 
attenuated flow independent of stenosis severity.
Although CCTA displays good agreement with invasive coronary angiography, the relatively poor 
predictive value for ischemia using stenosis severity alone derived from either invasive or noninvasive 
angiography is well established.(5-8) Apparently, hemodynamics are not only affected by luminal 
stenosis, but also by other geometric variables such as plaque length and volume.(27, 28) Recent 
studies have suggested that plaque morphology also may affect blood flow.(16-18, 29) Since recent 
technological developments have advanced the ability of CCTA to quantify plaque burden and evaluate 
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plaque characteristics, a comprehensive assessment could potentially improve the discrimination 
between ischemic and nonischemic coronary artery disease.
In line with the majority of prior studies, the present study showed an association between multiple 
atherosclerotic plaque characteristics and ischemia. Some of the prior studies used myocardial 
perfusion imaging as the reference method, such as Naya et al (16), who reported only a modest 
effect of plaque geometry and morphology on coronary flow reserve using 82Rb PET. Interestingly, 
positive remodeling was not correlated with myocardial perfusion when a multivariable model was 
used, which is in contrast with the present study. Partially calcified plaques, however, were associated 
with impaired myocardial flow reserve. A study by Shmilovich et al.(29) described that the presence of 
low attenuation plaque and positive remodeling in severely stenotic plaques on CCTA was predictive 
of myocardial hypoperfusion. Their finding of PR as an independent predictor of hypoperfusion is in 
agreement with the current study using [15O]H2O PET. The reason why this doesn’t completely account 
for LAP could be that NCPV is a more robust feature and an even stronger predictor containing both 
quantitative and morphologic features. Furthermore, the fact that total plaque volume was not 
incorporated in the present multivariable models, which could at least partially be explained by 
collinearity with NCPV, does not detract from its intuitively important role in causing ischemia and 
cardiac events.
In addition to the assessment of myocardial perfusion using PET, the present study also included FFR 
measurements. The latter parameter is considered a more clinical useful tool to guide revascularization 
decision making, which has been shown to improve outcome.(30) NCPV, LAP, PR, and SC appeared to 
be independently associated with a significant reduction in FFR. A few other studies have investigated 
the relationship between plaque morphology and FFR. Nakazato et al (27) found that aggregated 
plaque volume demonstrated incremental discriminatory power over luminal stenosis for lesions 
with FFR ≤ 0.80. This is in agreement with the present findings, especially for the noncalcified part 
of the plaque volume. Other plaque characteristics, however, were not evaluated. Park et al reported 
that PR, LAP, percentage aggregated plaque volume, and the number of APCs were independent 
predictors of ischemia using FFR as a reference (17). In contrast to these two studies, in the current 
paper spotty calcification also appeared to be significantly associated with adverse FFR. While the 
analysis from Nakazato and Park did not include specific plaque composition volumes (i.e. calcified and 
noncalcified), a recently published substudy of the NXT trial did differentiate calcified and noncalcified 
plaque volumes (18). Roughly similar predictors of ischemia were found as compared to the present 
paper: NCPV, plaque length and in particular low density NCPV (18).
Although several studies, including the present one, have observed interactions between multiple 
plaque characteristics and ischemia, the underlying mechanisms have not been clarified yet. A number 
of potential pathophysiological causes might, at least in part, explain the connection between certain 
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plaque characteristics and reduced MBF. Firstly, the presence of (compensatory) positive remodeling 
might represent a stage of atheroma development wherein the atherosclerotic burden exceeds a certain 
threshold that is associated with ischemia. This is supported by findings of De Bruyne et al (9), who 
reported that early-stage coronary atherosclerosis is often associated with abnormal resistance of the 
coronary arteries, even before angiography reveals a focal high-grade stenosis. PR together with LAP 
and SC may be anatomical markers of focal or systemic pathophysiological processes. These processes 
include vascular inflammation, endothelial dysfunction, and altered shear stress patterns, which are 
associated with the inability of coronary arteries to vasodilate and consequently cause ischemia.(31, 
32) Previous studies have reported an association between coronary endothelial dysfunction and 
necrotic core plaques,(33) which can be recognized as LAP and PR using CCTA. PR had a greater impact 
on a reduction in FFR than in hyperemic MBF. It could imply that this adverse plaque morphology has 
a closer agreement specifically with epicardial pathology, than overall downstream consequences, as 
FFR tends to evaluate the epicardial lesion specific hemodynamics, whereas MBF using quantitative 
PET reflects both the epicardial and microvascular bed. From the results of supplemental table 2, 
however, it could be postulated that microvascular disease, as defined by abnormal PET despite a 
normal FFR, cannot be fully determined by these CCTA abnormalities.
Combining both endpoints of hyperemic MBF and FFR revealed that noncalcified plaque volume and 
positive remodeling affected both parameters in an independent manner. ROC curve analysis indicated 
that adding these morphological features to diameter stenosis alone, improved diagnostic accuracy 
for obstructive coronary artery disease taking FFR as a reference. Although statistically significant, the 
incremental value appeared to be only modest starting from a high baseline AUC value (AUC increased 
from 0.86 to 0.90, p < 0.001). As can be derived from the ROC analysis, with a fixed sensitivity of 
88.2%, specificity increased from 64.9% for stenosis severity alone, to 72.1% when adding NCPV and 
PR. Using a second fixed sensitivity of 65.2%, specificity merely increased from 92.2% to 93.5% with 
the addition of the aforementioned plaque features. The increase in diagnostic accuracy in absolute 
values may therefore appear modest, but could be considered of clinical significance. This is further 
highlighted in figure 1, which displays great overlap between blood flow in arteries with and without 
adverse plaque characteristics. In other words, although addition of adverse plaque characteristics 
may hold prognostic value and enhance diagnostic accuracy for identifying myocardial ischemia, at 
present the clinical relevance remains limited.
Study limitations
In the present study, stenosis severity was graded categorical as commonly used in clinical practice. 
The use of stenosis severity as a continuous variable, however, could have provided additional 
information and possibly altered current findings. Similarly, dichotomized FFR was used in present 
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models, according to an established threshold with proven prognostic value.(30) For statistical and 
methodological reasons, continuous FFR values could not be used in current analysis, even though it 
might have provided additional insides in the relationship between plaque and FFR. As a consequence, 
the difference in association of plaque features with dichotomized FFR and continuous MBF should be 
interpreted with caution given the slightly different statistical approach. Furthermore, some predictors, 
such as lumen area and maximal plaque burden, were found to be associated with perfusion in 
univariable analyses, but were also strongly associated with stenosis severity. Therefore, they were 
not included in the final multivariable model because their predictive value when added to stenosis 
severity was only small. Another limitation involves standard segmentation for vascular territories 
which was utilized to derive MBF data from the PET scans. Individual variation of coronary anatomy 
and analysis of atherosclerotic major sidebranches by FFR and CCTA may therefore not exactly coincide 
with the assigned PET segments and may have diluted the potential influence of coronary lesions on 
flow parameters. Finally, it should be noted that reproducibility of the semi-automated plaque analysis 
remains suboptimal with modest ICCs of 0.66 to 0.81.
CONCLUSION
CCTA derived morphological adverse plaque characteristics are associated with detrimental hyperemic 
myocardial perfusion and invasive FFR values, independent from lesion severity. Including these 
atherosclerotic plaque characteristics in a comprehensive CCTA evaluation, modestly improves the 
prediction of ischemic coronary artery disease compared with luminal stenosis assessment alone.
CORE CLINICAL COMPETENCIES
The present study explores the impact of atherosclerotic plaque burden and morphology on 
myocardial perfusion and FFR. Independent of luminal stenosis, also positive remodeling and a large 
noncalcified plaque volume revealed to predict both a lower myocardial blood flow and lower FFR. 
Although statistically significant, the additional value of these adverse plaque characteristics over 
luminal stenosis as predictors of ischemia was limited.
TRANSLATIONAL OUTLOOK
Additional studies are required to elucidate the underlying mechanism of the associations between 
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KEY POINTS
Question: Are atherosclerotic plaque measurements associated with physiologic measures of invasive 
fractional flow reserve? 
Findings: Results from the CREDENCE controlled clinical trial reveal that nonobstructive and obstructive 
measures of atherosclerotic plaque are significantly associated with invasive fractional flow reserve. 
A comprehensive set of atherosclerotic plaque features improved the accuracy of classifying vessel-
specific reduced fractional flow reserve over and above rest/stress myocardial perfusion imaging 
measurements. 
Meaning: Using CCTA for detection of atherosclerotic plaque features associated with coronary 
phsiology may improve diagnostic certainty and guide clinical management of symptomatic patients. 
ABSTRACT
Importance: Stress imaging has been the standard for diagnosing functionally significant coronary 
artery disease. It is unknown whether novel, atherosclerotic plaque measures improve accuracy 
beyond coronary stenosis for diagnosing invasive fractional flow reserve (FFR) measurement. 
Objective: In a derivation-validation trial, we compared the diagnostic accuracy of comprehensive 
anatomic (obstructive and nonobstructive atherosclerotic plaque) versus functional imaging measures 
for estimating vessel-specific FFR. 
Design: Controlled clinical trial of diagnostic accuracy
Setting: Multicenter derivation-validation cohort of patients referred for nonemergent invasive 
coronary angiography. 
Participants: A total of 612 stable patients (64±10 years, 30% women) with signs and symptoms 
suggestive of myocardial ischemia from 23 sites. 
Intervention: Patients underwent invasive coronary angiography with measurement of invasive FFR, 
coronary computed tomographic angiography (CCTA) quantification of atherosclerotic plaque and 
FFR by CT (FFR-CT), and semi-quantitative scoring of rest/stress myocardial perfusion imaging (MPI 
by magnetic resonance, positron emission tomography, or single photon emission CT). Multivariable 
generalized linear mixed models were derived and validated calculating the area under the receiver-
operating characteristics curve (AUC). 
Main Outcome Measure: The primary endpoint was invasive FFR ≤0.80. 
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Results: An invasive FFR ≤0.80 was measured in 26.5% of 1,727 vessels. In the derivation cohort, CCTA 
vessel-specific predictors of FFR ≤0.80 were stenosis severity, percent noncalcified atheroma volume, 
lumen volume, the number of lesions with high-risk plaque (≥2 of low attenuation plaque, positive 
remodeling, or spotty calcification), and the number of lesions with stenosis >30%. FFR-CT was not 
additive to this model including stenosis and atherosclerotic plaque. Significant MPI predictors were 
the summed rest and difference scores. In the validation cohort, the AUCs were 0.81 for CCTA versus 
0.67 for MPI (p<0.001). 
Conclusion: A comprehensive anatomic interpretation with CCTA, including quantification of 
obstructive and nonobstructive atherosclerotic plaque, was superior to functional imaging in the 
diagnosis of invasive FFR. Comprehensive CCTA measures improve prediction of vessel-specific 
coronary physiology more so than stress-induced alterations in myocardial perfusion.
Funding:  This trial was supported by a grant from the National Institutes of Health - National Heart, 
Lung, and Blood Institute (R01HL118019). 
Trial Registration: Registered as NCT02173275 on ClinicalTrials.gov (June 23, 2014).
WORD COUNT: 311
Key words:  Coronary Computed Tomography Angiography, Myocardial Perfusion Imaging, Fractional 
Flow Reserve, Diagnostic Accuracy
92
INTRODUCTION
For decades, the diagnostic evaluation of patients with stable chest pain has largely relied on stress 
myocardial perfusion imaging (MPI) and other functional tests for assessment of inducible ischemia. 
The presence and severity of inducible abnormalities are the basis for decisions on ischemia-guided 
management including invasive coronary angiography (ICA) and coronary revascularization.1-3 
Among noninvasive imaging tests, MPI, including single photon emission computed tomography 
(SPECT), positron emission tomography (PET), and cardiac magnetic resonance imaging (CMR), are 
commonly used to determine functionally-significant coronary artery disease (CAD) based on the 
extent and severity of inducible myocardial ischemia.4,5 Recent evidence has emerged to support the 
role of coronary computed tomography angiography (CCTA) as an alternative noninvasive, anatomic 
diagnostic imaging modality.6-8 
Discerning the physiologic significance of a stenosis is a major goal of stress testing and is fundamental 
to guide management of ischemic heart disease. Anatomic approaches focusing on the detection 
of a stenosis are often considered incomplete without incorporation of physiologic parameters. To 
date, comparative diagnostic accuracy evidence does not uniformly reveal superiority of functional 
versus anatomic testing when estimating invasive fractional flow reserve (FFR) measurement.5,9 
Moreover, comparative findings from prior diagnostic accuracy trials generally focus on the accuracy 
of stenosis severity and did not include the entirety of anatomic data available, namely volumetric 
and compositional atherosclerotic plaque.5-7,10,11 A comparison of comprehensive noninvasive 
anatomic, including quantification of nonobstructive and obstructive atherosclerotic plaque, 
versus functional imaging has not been performed as it relates to predicting invasive FFR. The aim 
of the Computed Tomographic Evaluation of Atherosclerotic Determinants of Myocardial Ischemia 
(CREDENCE) trial was to derive, validate, and compare an optimized CCTA with MPI assessment for the 
prediction of functionally significant CAD, determined as vessel-specific invasive FFR.
METHODS
Study Design
The CREDENCE trial (clinicaltrials.gov NCT02173275) is a prospective, multicenter diagnostic 
derivation-validation, controlled clinical trial recruiting patients from 2014-2017. A detailed design 
manuscript is available.12 Enrolled patients underwent CCTA and MPI followed by ICA with FFR 
measurements (≤60 days). Eligibility criteria (Appendix A) included referral to nonemergent ICA. All 
index tests were interpreted blindly by core laboratories. Local sites were not blinded to test data. 




Derivation and Validation Cohorts
The study population comprised 612 patients with stable symptoms and without a prior diagnosis 
of CAD referred for nonemergent ICA (Figure 1 and Appendix D). Patients were recruited across 23 
centers (Appendix E-F). Trial participants were assigned to 2 subsets with the first half of enrollees 
at each site assigned to the derivation (n=307) and the second half to the validation (n=305) dataset.
Endpoint of Invasive Vessel-Specific FFR
The primary aim was to compare the area under the receiver-operating characteristics curve (AUC) of 
an integrated CCTA versus MPI assessment for the discrimination of vessel-specific FFR ≤0.80 by ICA. 
Imaging Protocols
CCTA was performed using a single or dual source CT scanner with at least 64-detector rows and a 
detector row width of ≤75 mm. Sites were instructed to perform CCTA in accordance with guidelines 
from the Society of Cardiovascular Computed Tomography (SCCT).13 Image quality for CCTA was 
acceptable in 99% of patients. 
Rest/stress MPI was performed using SPECT, PET, or CMR in accordance with guidelines of the American 
Society of Nuclear Cardiology or Society of CMR.14,15 Six MPI patients had missing or corrupted scan 
data. Image quality for MPI was acceptable in 95% of patients. 
Imaging protocols and Core Laboratories methods are in Appendices G-I. 
Invasive Coronary Angiography and Measurement of FFR
ICA was performed in agreement with clinical indications and imaging standards. All major coronary 
arteries or branches (≥2.0 mm) containing a lesion between 40-90% were interrogated by FFR during 
intracoronary (150μg) or intravenous (140μg∙kg-1∙min-1) adenosine infusion to achieve maximal 
hyperemia. 
Noninvasive Imaging Interpretation and Candidate Variables
All noninvasive imaging was interpreted at a core laboratory by physicians blinded to clinical and 
test results. CCTA images were interpreted on per lesion and per segment basis for lumen and vessel 
volume, diameter stenosis, plaque composition and volume, number of lesions, and the presence of 
high-risk plaque features using semi-automated plaque analysis software (QAngioCT Research Edition, 
version 3.1.4.1; Medis Medical Imaging, Leiden, the Netherlands). The percent atheroma volume 
was calculated by dividing plaque volume/vessel volume*100%; with compositional subgroups. The 
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lumen volume was divided by vessel length. High-risk plaque was defined by ≥2 of the following: 
positive remodeling (≥1.1), spotty calcification (<3.0 mm), napkin ring sign, or low attenuation plaque 
(Hounsfield unit [HU] density <30).16 Segmental results were summed to per vessel and per patient 
values.13 Six patients had missing plaque measurements. FFR by CT (FFR-CT) was measured by 
HeartflowTM (Redwood City, California). In the setting of >25% focal stenosis, FFR-CT was co-registered 
to the segment of maximal diameter stenosis by readers blinded to the other test findings.17 An 
FFR-CT ≤0.80 was considered abnormal. FFR-CT was non-evaluable in 135 patients; commonly due to 
significant calcification, arterial motion, missing segment, image misalignment or noise. 
Rest/stress MPI scans were scored by segments and expressed as summed rest score (SRS) and 
summed difference scores (SDS) using the % myocardium.14,18,19 Segmental scores were aggregated 
per patient and vascular territory. Measurements of left ventricular ejection fraction (LVEF) and 
electrocardiographic ST segment changes with stress were available. Rest and stress LVEF was missing 
in 28 and 57 patients.
Reference Standard Measurement
All lesions with a diameter stenosis ≥30% on visual estimation were measured with quantitative 
coronary angiography (QCA) by a core laboratory, blinded to clinical and test results. Vessels with QCA 
<40 or ≥90% diameter stenosis without FFR interrogation were deemed normal or ischemic. An FFR 
≤0.80 was graded as abnormal. 
Statistical Methods
Analysis was performed on an intention-to-diagnose basis. In the derivation set, the best overall 
prediction model for vessel-specific abnormal FFR was fit using a generalized linear mixed model 
with logistic link function to estimate the probability of an abnormal, invasive FFR. For CCTA, model 
building was performed first including diameter stenosis severity; second, adding atherosclerotic 
plaque characteristics (volumetric measurements – total and compositional); and third, adding FFR-
CT. Data unavailable due to clinical reasons or artifact were coded as missing not at random. FFR-CT 
data was coded using a separate category for missing measurements. Similar approaches were used 
for the LVEF data.  For MPI, model building initially included rest/stress MPI; second, adding rest/stress 
LVEF; and third, adding exercise ECG findings. The selection procedure (with Akaike’s information 
criterion as a stopping rule) and clinical domain expertise was used for variable selection and model 
development. Interactions were assessed by clinical plausibility and statistical significance using a 
likelihood ratio test. Marginal risk20 was calculated from the optimal models and receiver operating 
characteristics (ROC) curves derived from marginal risk were utilized to compare diagnostic accuracy. 
The area under the ROC curve (AUC) and 95% confidence intervals were summarized. The primary 
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analysis included estimation of  invasive FFR using CCTA vessel and MPI vascular territory data. Based 
on variables included in the multivariable model for CCTA and MPI, predicted probabilities of invasive 
FFR were calculated. A per patient analysis was also performed.  
A necessary sample size of 868 vessels (or 305 patients) was calculated with 90% power (α=0.05) to 
detect 5% superiority in the AUC of CCTA versus MPI. A p-value <0.05 was considered statistically 
significant. Analyses were performed using R (version 3.5.2, Vienna, Austria) and SAS (version 9.4, 
Cary, NC).
RESULTS
Descriptive Characteristics of the Trial Patients
Of the eligible patients, 11 patients withdrew before any index test was performed and 6 patients did 
not undergo ICA (Figure 1). The final enrollment included 612 patients (307 in the derivation and 305 
in the validation set).
Patients were on average 64±10 years of age and mostly male (69.6%). A comparison of the clinical 
characteristics of age, sex, race, and risk factor prevalence were largely similar between the derivation 
and validation subgroups (Table 1 and eTable 1); except, dyslipidemia and atypical chest pain were 
more prevalent in the validation cohort.
Table 1. CCTA Findings in the Derivation and Validation Subgroups from the CREDENCE Trial. All measures are 









Age, years (mean±SD) 64±10 64±10 0.685
Female Sex (%) 29% 31% 0.561
Stenosis severity (%)
    0%
    1-24%
    25-49%
    50-69%
    70-99*%














≥50% Stenosis in Proximal Left Anterior Descending 
Artery (%)
23% 28% 0.149
≥50% Stenosis in Left Main Artery (%) 7% 9% 0.638
Number of Vessels with ≥50% Stenosis
    1 Vessel CAD


















    0%
    1-24%
    25-49%
    50-69%
    70-99%














Number of Lesions with >30% stenosis (mean±SD) 0.6±0.7 0.6±0.8 0.144
Lumen Volume, per mm (mean±SD) 5.2±1.9 5.2±1.8 0.819
Percent Atheroma Volume, % (mean±SD) 14.0±13 13.1±12 0.115
Percent Noncalcified Atheroma Volume, % 
(mean±SD)
7.5±8.1 7.2±8.2 0.026
High Risk Plaque (%)
    Low Attenuation Plaque <30 HU 15% 13% 0.219
    Positive Remodelling ≥1.1 71% 70% 0.677
    Spotty Calcification <3.0 mm 14% 16% 0.588
  Number of Features
    0
    1
    2










FFR-CT ≤0.80 (%)** 16% 22% 0.009
*Stenosis severity is based on the qualitative interpretation. **FFR-CT was non-evaluable in 135 patients due to 
significant coronary calcification, arterial motion, a missing segment, or image misalignment or noise. 
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Figure 1: Standards for Reporti ng of Diagnosti c Accuracy Studies Diagram for the CREDENCE Trial.
Invasive Coronary Angiography Measures of Coronary Stenosis and FFR
Among 1,727 epicardial coronary arteries, 26.5% exhibited ischemia by FFR ≤0.80. On ICA, 
approximately half of pati ents had an obstructi ve stenosis ≥50%. The eTable 2 reports the angiographic 
fi ndings across the major epicardial vessels. On a per-vessel basis, the mean diameter stenosis was 
28.8±29.6%. The prevalence of an abnormal FFR was highest in the left  anterior descending coronary 
artery. 
CCTA Findings of Obstructi ve CAD, Atheroscleroti c Plaque, and FFR-CT
On CCTA, the prevalence of CAD stenosis ≥50% on a per pati ent basis was 58%; with nearly half of these 
stenoses having an abnormal FFR-CT. Table 1 summarizes per pati ent and per vessel CCTA fi ndings in 
the derivati on and validati on cohort. On a per vessel basis, the prevalence of CCTA-observed stenosis 
was higher in the validati on cohort at the 50% and 70% threshold (p=0.001). High risk plaque features, 
especially positi ve remodeling, were commonly observed. Positi ve remodeling ≥1.1 was identi fi ed 
in 70.2% of pati ents. Low att enuati on plaque was identi fi ed in 14.1% of pati ents. Spott y calcifi cati on 
was identi fi ed in 15.4% of pati ents.  The concordance between invasive FFR and FFR-CT was moderate 
(kappa=0.45); 91% of normal FFR-CT also had a normal invasive FFR while only 51% of abnormal FFR-
CT had an abnormal invasive FFR. 
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Rest and Stress MPI Findings
On MPI, nearly one-third of patients had at least mild ischemia encumbering ≥5% of the myocardium; 
with most having a preserved LVEF. Table 2 summarizes per patient and per vessel MPI findings 
according to the derivation and validation cohort. Pharmacologic stress MPI SPECT imaging was 
commonly performed. Exertional ST-segment depression ≥1.0 mm occurred in 27% of patients. 
Overall, nearly 1 in 5 patients had moderate-severe ischemia encumbering ≥10% of the myocardium. 
On a per vessel basis, the mean SRS and SDS within derivation and validation was 0.8±2.6 and 0.7±2.0% 
(p=0.379) and 1.5±3.9 and 1.7±3.6% (p=0.001) of the myocardium. The negative predictive value of an 
SDS <5% of the myocardium to exclude obstructive CAD stenosis (≥50%) was high (93%). Conversely, 
the positive predictive value to detect an obstructive stenosis ≥50% using a threshold of ≥5% ischemic 
myocardium was low (22%). Similar values were reported for the anterior, inferior, and lateral vascular 
territories, respectively (negative predictive value ranges: 92-94% and positive predictive value ranges: 
18-25%). The positive and negative predictive value was also similar by type of MPI imaging modality. 
Table 2. Rest and Stress MPI Findings in the Derivation and Validation Subgroups from the CREDENCE Trial. All 
measures are calculated as mean±standard deviation (SD) or %, as noted. 




Type of MPI Performed (%)
    CMR
    PET








Type of Stress Performed for Nuclear (%)
    Exercise Stress






Exercise Duration, in minutes (mean±SD) 9.6±11.0 7.6±6.9 0.573
Exercise-Induced ST Segment Depression ≥1.0 mm (%) 33% 23% 0.304
Heart Rate (beats/minute), (mean±SD)
   Rest
   Peak Stress
      Peak Exercise










Blood Pressure (mmHg), (mean Systolic / Diastolic)
   Rest
   Peak Stress
      Peak Exercise










Limiting or Non-Limiting Chest Pain, (%) 10% 10% 1.0
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≥5% Ischemic Myocardium (%)
    Anterior Vascular Territory
    Inferior Vascular Territory










≥10% Ischemic Myocardium (%) 18% 19% 0.938
LVEF <50%,* (%)
    Rest











MPI - % Myocardium
    SRS (mean±SD)






    SSS (mean±SD)






    SDS (mean±SD)






*LVEF was missing in 57 patients (n=28 for rest and n=57 for stress).
Model Building For Vessel-Specific Measurements Within the Derivation 
Cohort
The ROC curve analysis for prediction of invasive FFR for derivation models MPI and CCTA are plotted 
in Figure 2. The AUC for CCTA stenosis severity was 0.82. Significant atherosclerotic plaque predictors 
included percent non-calcified atheroma volume, lumen volume, the number of lesions with high-risk 
plaque, and the number of lesions with ≥30% diameter stenosis (Table 3). Adding atherosclerotic plaque 
significantly improved the AUC to 0.88 (p<0.001). Subsequent addition of FFR-CT to atherosclerotic 
plaque and stenosis severity did not improve discrimination within ROC curve analysis (AUC=0.88). 
In the subgroup with ≥50% stenosis (n=162), only 68.1% of the abnormal FFR-CT were concordant 
with invasive FFR; however, FFR-CT had a high negative predictive value (85.1% of 612 vessels) among 
patients with <50% stenosis. The AUC for stress MPI, including the SRS and SDS within specific vascular 
territories, was 0.69 (Figure 2). The AUC did not change by stepwise addition of LVEF (AUC: 0.69) or 
with exercise ECG findings (AUC: 0.70). In the final model, significant predictors of invasive vessel-
specific ischemia for MPI included the vessel-specific summed rest score and summed difference score 
(eTable 3). Based on these findings, for every 5% of the myocardium that was ischemic in a specific 























































































































































































































































































































































































































































































Table 3. Multivariable Generalized Linear Mixed Model Based on CCTA Vessel Measurements of Stenosis 
Severity and Atherosclerotic Plaque Estimating Invasive FFR from the CREDENCE Trial. This final model was 
based on variables included in the final CCTA model from Figure 2.* For ease of presentation, we also present 
a second model that includes stenosis severity subgroups and quartile measures for percent atheroma volume, 
noncalcified plaque volume, and lumen volume.** 
Model Parameters for Per-Vessel Odds Ratio
(95% Confidence Interval) Χ2 p value
Stenosis Severity,*** %
    0%
    1-24%
    25-49%
    50-69%







Percent Atheroma Volume, % 
Quartile Measurement*
   0.00-3.60%
   3.61-10.93%
   10.94-21.16%







Noncalcified Atheroma Volume, %
Quartile Measurement*
   ≤1.67%
   1.68-5.51%
   5.52-10.96%







Lumen volume, per mm
Quartile Measurement*
      ≥5.97 per mm 
      4.74-5.96 per mm
      3.93-4.73 per mm







Number of Lesions with High Risk Plaque 1.99 (1.26-3.14) 8.9 0.003
Number of Lesions with >30% Stenosis 1.81 (1.25-2.62) 9.8 0.002
Number of Lesions at a Bifurcation 1.34 (0.99-1.81) 3.7 0.055
*FFR-CT was not statistically significant and not entered into the final multivariable model.
**Quartile measurements are presented for descriptive purposes. 
***Stenosis severity was based on a qualitative interpretation. 
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Model Comparison in the Validation Cohort
With regard to the primary objective comparing the AUC by modality, the results revealed that an 
optimized CCTA model was superior to the overall MPI model for the diagnosis of abnormal FFR (AUC 
0.81 (95% Confidence Intervals [CI]: 0.78-0.84) vs. 0.67 (95% CI: 0.63-0.71), p<0.001, Figure 2). The 
AUC results were comparable when analyzed on a per patient basis (eFigure 1). Subgroup analyses 
revealed similarly higher AUC for CCTA when compared with MPI in subgroups of women, men, and 
for those age <65 and ≥65 years (all p<0.001, eTable 4). Similar results were also observed when 
the MPI analysis was limited to patients undergoing SPECT imaging (p<0.001, eTable 4). Plots of 
the predicted probability of invasive FFR ≤0.80 for each of the variables in the CCTA (Table 3) and 
MPI (e-Table 3) multivariable models are reported in e-Figures 2 and 3. Predicted probabilities for 
CCTA variables had a generally wider range of measurements than MPI variables. A comparison of 
the predicted probabilities for CCTA and MPI for each of the presented models is plotted in e-Figure 
4, revealing that many patients categorized with a lower predicted probability by MPI are in higher 
probability tertiles by CCTA. 
DISCUSSION
In this first derivation-validation trial, an anatomic approach using CCTA including multiple 
atherosclerotic plaque measures, demonstrated improved diagnostic accuracy as compared with 
functional assessment using rest/stress MPI for the prediction of invasive FFR. We extend prior results 
revealing that various qualitative and quantitative CCTA-derived atherosclerotic plaque characteristics 
were highly predictive of invasive FFR.21,22 From the CREDENCE trial, we report a strong relationship 
between volumetric measures of atherosclerotic plaque, especially that which is noncalcified, and 
lumen size as highly predictive of invasive FFR. These findings capture the instability thought to be 
associated with more lipid-rich, atherosclerotic plaque23 and reveal the importance of vessel size 
as an important marker of FFR abnormality. Our findings of the relationship between atherosclerotic 
plaque and invasive FFR were similar in the derivation and validation cohorts. 
Importance of Atherosclerotic Plaque to Guide Clinical Decision Making
Clinical guidelines support ischemia-guided management of a focal coronary stenosis, based on evidence 
from several trials supporting FFR-guided revascularization.1,2 The evidence that functional testing is 
the basis for evaluation and management of patients with stable chest pain is longstanding.24,25 Prior 
evidence, however, did not examine detailed quantification of atherosclerotic plaque in the estimation 
of vessel-specific FFR on ICA. Given this, identification of CCTA atherosclerotic plaque features with 
coronary stenosis may provide sufficient evidence to guide preventive treatment and reduce the need 
for confirmatory functional testing or even use of invasive FFR. 
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We validated the well-known correlation between significant luminal stenosis and reduced FFR. 
However, our findings also provide unique insight and potentially a working model as to nonobstructive 
atherosclerotic disease factors influencing epicardial coronary artery ischemia. A smaller lumen volume 
may reflect diffuse atherosclerosis and/or impaired hyperemia. This is similarly noted in the number of 
>30% stenoses which was a strong predictor of invasive FFR. Both factors combined with the percent 
atheroma volume and noncalcified plaque volume provide further evidence as to the importance 
of quantifying atherosclerotic plaque for detection of at-risk patients. This supports the intriguing 
findings of atherosclerotic plaque precursors of symptoms or ischemia in the setting of nonobstructive 
CAD.21,22 In combination with the characteristic features of high risk plaque, previously shown to 
predict acute coronary syndromes and major CAD events,16,26 we have identified factors which 
define vessel instability and, potentially, identify patients who may benefit from intensive preventive 
care resulting in improved outcome as compared with standard care approaches.27-29
MPI Abnormalities as Predictive of Invasive FFR
Functional imaging has been the cornerstone of ischemia-guided management for decades. Our 
findings revealed that the extent and severity of MPI ischemia exhibited a moderate association with 
invasive vessel-specific ischemia, reflecting the variable findings noted in the literature.5,10,11,30,31 
Although the AUC values were not as high as with CCTA, significant MPI predictors included the extent 
and severity of myocardial perfusion defects measured at rest and stress. Resting perfusion deficits 
represent the extent of scarred myocardium and a correlation with more severe coronary stenosis is 
expected. Moreover, invasive FFR would also correlate with the subtended myocardial vascular beds 
and thereby relate to the extent and severity of MPI ischemia. However, when MPI was compared 
with CCTA findings, the CREDENCE trial data support that the underlying burden of anatomically-
defined CAD, including atherosclerotic plaque and stenosis, had a stronger link to invasive FFR than 
the physiologic consequences of myocardial perfusion. 
We propose several reasons for the reduced concordance between invasive FFR and MPI ischemia. 
First, variability likely is greatest when comparing ischemic myocardium versus vessel-specific FFR 
measurements, whereby invasive FFR is a solely epicardial measurement while perfusion reflects 
myocardial uptake from both epicardial arteries, microvasculature, and collateral vessels. Second, the 
proportion of patients with more extensive and severe myocardial ischemia was likely insufficient to 
improve the strength of this relationship. As well, there are notable challenges with attenuation and 
other artifacts, especially with SPECT, that contributed to the reduced accuracy of MPI. The diminished 
concordance between myocardial ischemia and invasive FFR is multifactorial but a reduced sensitivity 
(e.g., 57%) of SPECT was reported in recent trials.10,11 
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Atherosclerotic Plaque and Invasive FFR
Although prior studies have not provided a comprehensive comparative analysis between CCTA and 
stress MPI, the relationship between plaque characteristics, such as plaque burden and morphology, 
with reduced FFR has been explored. Gaur et al. investigated 254 patients using CCTA and reported 
that noncalcified plaque volume predicted FFR ≤0.80, independent of other plaque and stenosis 
characteristics.23 Park et al. demonstrated that high-risk plaque features (i.e., positive remodeling and 
low attenuation plaque) and aggregated plaque volume were independently related to invasive FFR.32 
These results were confirmed by a recent post-hoc analysis from the PACIFIC trial whereby positive 
remodeling and noncalcified atherosclerotic plaque volume reduced both absolute myocardial blood 
flow with H215O PET and invasive FFR; independent of luminal stenosis.33 These prior findings align 
with the CREDENCE analyses which observed noncalcified plaque volume, presence of high-risk 
plaque, and vessel size as independent predictors of invasive FFR; independent of stenosis severity. 
The use of an integrated plaque assessment of CCTA, and not just luminal stenosis, contributes to an 
important difference between our results and other research findings. 
FFR-CT did not significantly improve discrimination of normal versus abnormal invasive FFR; supporting 
the concept that a reduced pressure difference is a response to specific underlying atherosclerotic 
plaque characteristics. In the subgroup with ≥50% stenosis (n=162), only 68.1% of the abnormal FFR-
CT were concordant with invasive FFR. These findings emphasize the complex, multifaceted nature of 
coronary ischemia, which is influenced by more than coronary artery lumen features that are analyzed 
during the derivation of FFR-CT. 
Study Limitations
All clinical investigations enrolling large samples of patients from diverse institutions and healthcare 
settings have limitations. Although all subjects underwent multiple procedures, the test strategy was 
not randomized and selection bias cannot be excluded. Also, follow-up therapeutic care and ensuing 
prognostic data was not collected. Lastly, quantitative CCTA measurements are, at present, time-
consuming.
CONCLUSION
In this multicenter, controlled clinical trial, comprehensive CCTA interpretation was superior to MPI for 
the diagnosis of vessel-specific FFR. Combined with measures of stenosis severity, quantification and 
characterization of atherosclerotic plaque prove optimal for detection of invasive vessel-specific FFR. 
The incorporation of whole vessel quantification of epicardial coronary atherosclerosis provides a more 
comprehensive view of the underlying disease burden and vessel FFR as compared to examination of 
4
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a given focal stenosis alone. Future explorations including assimilation of the CREDENCE findings into 
clinical practice should support a broader inclusion of atherosclerotic plaque findings as meaningful 
to assess coronary physiology.
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The present interim report of the ongoing randomised clinical trial of bioresorbable vascular scaffold 
(BVS) vs. metal drug eluting stent (DES) showed that neither BVS- nor DES-implantation leads to 
reduced myocardial perfusion as quantified by cardiac PET, however,  a slightly attenuated coronary 
flow reserve was observed one month after BVS implantation in comparison to DES. 
ABSTRACT
Aims: A randomised clinical trial of bioresorbable vascular scaffold (BVS) vs. metal drug-eluting stent 
(DES) was initiated, using positron emission tomography (PET) perfusion imaging to assess the effects 
of both treatments on (hyperaemic) myocardial blood flow (MBF) and coronary flow reserve (CFR) 
over a three-year period (VANISH trial). In the present study, early, i.e., after one month, MBF and CFR 
are reported.
Methods and results: Sixty patients (45 men [75%], 55±7 years) with a documented single-vessel type 
A or B1 lesion were included in this single-blind randomised clinical trial. Patients were randomised to 
implantation of a BVS or DES in a one-to-one fashion. Approximately one month after percutaneous 
coronary intervention, patients underwent [15O]H2O PET to assess (hyperaemic) MBF, cold pressor 
test MBF, and CFR. One patient refused PET perfusion at one-month follow-up (in the DES arm). 
MBF of the treated myocardial territory during rest, CPT, and hyperaemia were not different in BVS-
treated patients as compared to DES-treated patients (1.02±0.28 vs. 0.96±0.24 mL∙min–1∙g–1, p=0.38, 
1.20±0.38 vs. 1.08±0.23 mL∙min–1∙g–1, p=0.16, and 3.04±0.80 vs. 3.33±0.77 mL∙min–1∙g–1, p=0.16, 
respectively). CFR of the treated myocardial territory was significantly lower in the BVS-treated 
patients (3.09±0.94 vs. 3.57±0.85, p<0.05).
Conclusions: No differences in PET-derived absolute myocardial perfusion were observed between 
BVS-treated patients as compared to DES-treated patients at one-month follow-up. CFR was attenuated 




The bioresorbable vascular scaffold (BVS) has been developed as a novel approach for the percutaneous 
treatment of coronary artery disease (CAD). After implantation, a BVS provides six to 12 months 
support to the vessel wall before gradually dissolving in the following two-year period. Regression 
of the scaffold stimulates remodelling of the natural vessel wall as a result of renewed exposure to 
pulsatile flow, shear stress, and cyclic strain patterns, potentially circumventing some of the long-term 
hazards of permanent metal coronary drug-eluting stents (DES)1-4. Released from the metal “cage”, 
the originally stented coronary segment may become responsive to physiological stimuli with revival 
of normal vasomotor functions5,6. Furthermore, a recent interim report of the randomised ABSORB 
II trial described a reduction of cumulative rates of new or worsening angina from up to 30 days 
after treatment with BVS in comparison with metal stents7. Although additional research is warranted 
to clarify and substantiate this observation, it is hypothesised that restoration of normal coronary 
physiology and enhanced conformability of the BVS contribute to improved clinical outcome7,8. 
Compared with DES, however, a relatively diminished acute lumen gain and increased midterm 
(six months) lumen loss have been documented after BVS implantation in the ABSORB trials7,9-12. 
Therefore, a randomised clinical trial of BVS vs. metal DES was initiated, utilising positron emission 
tomography (PET) perfusion imaging to assess (hyperaemic) myocardial blood flow (MBF), MBF during 
a cold pressor test (CPT), and coronary flow reserve (CFR) over a three-year period (VANISH trial, 
NCT01876589)13. In the present report, results of the ongoing VANISH trial at one-month follow-up 
are presented, investigating whether lower cumulative rates of angina after BVS can be explained by 
enhanced MBF and CFR.
METHODS
Study design and participants
The VANISH trial is a prospective, single-blind, randomised, two-group, single-centre clinical trial. 
Eligible participants were 18-66 years old with de novo flow-limiting single-vessel CAD (type A or B1 
lesions) without biochemical signs of myocardial infarction and with a normal left ventricular function 
(≥50%). Exclusion criteria were prior cardiac history, poor kidney function (eGFR <30 ml∙min–1), 
asthma, other than sinus rhythm, or pregnancy. Patients were randomised to implantation of a BVS 
or metal DES using Absorb or XIENCE PRIME® (Abbott Vascular, Santa Clara, CA, USA), in a one-to-one 
fashion. Patients were blinded as to the implanted study device. Study investigators and operators 
were instructed not to disclose treatment assignment to patients and referring physicians. Follow-
up using [15O]H2O PET to assess baseline MBF, CPT MBF, hyperaemic MBF, and CFR was planned 
approximately one month, one year, and three years after percutaneous coronary intervention (PCI). 
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Furthermore, re-invasive coronary angiography (ICA) with optical coherence tomography (OCT) of the 
treated coronary segment will be performed at three-year follow-up. The primary study design aimed 
to include 60 participants in order to provide 90% power to detect a 10% difference in hyperaemic 
MBF, assuming completed study protocols in at least 50 subjects. The study was approved by the 
ethics committee of the VU University Center and written informed consent was obtained from all 
patients.
Percutaneous Coronary intervention and optical coherence tomography
ICA and PCI were performed on a biplane or monoplane cardiovascular X-ray system (Allura Xper 
FD 10/10; Philips Healthcare, Best, The Netherlands). Selection of device dimensions was guided 
by OCT or quantitative coronary angiography (QCA). Implantation of DES and BVS was performed 
according to standard procedural guidelines and choice of post-dilatation was left to the discretion 
of the operator. The study device had to cover at least 2 mm of non-diseased tissue on either side 
of the target lesion. Post-dilatation was allowed with a balloon shorter than the implanted device. 
When additional bail-out stenting was required, an additional investigational device was implanted. 
Intravascular OCT was performed prior to and immediately after device implantation with automated 
injection of three or four ml∙sec–1 contrast agent. Automated pullback was set at 20 mm/sec–1 and 
was manually initiated. OCT image quality was instantly interpreted and OCT was repeated according 
to the judgement of the operator until sufficient image quality was obtained. All patients will receive 
at least 80 mg of aspirin daily for the study duration and 75 mg of clopidogrel daily for a minimum of 
12 months after PCI.
Optical coherence tomography
Measurements were analysed by an analyst blinded to the PET perfusion results with patented offline 
software (ILUMIEN™ OPTIS™; LightLab Imaging/St. Jude Medical, St. Paul, MN, USA). Analyses of 
continuous cross-sections were performed at each longitudinal frame within the treated segment. 
Mean and minimal luminal areas, and mean and minimal luminal diameters were calculated using 
semi-automated endoluminal contour detection, and were manually adjusted if necessary12. By using 
the endoluminal vessel wall contour, the device struts of both BVS and DES were included in the 
luminal dimensions in case of good apposition or malappostion. However, delineation within the strut 
area was performed in case of vessel wall prolapse protruding through the device struts12.
PET imaging
PET studies using oxygen-15 labelled water were performed as described previously14. Briefly, patients 
were scanned on an Ingenuity TF 128 PET/CT scanner (Philips Healthcare). All patients were asked to 
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refrain from any caff eine or xanthine containing products for 24 hours prior to scanning. Vasoacti ve 
medicati on was ceased temporarily at least fi ve pharmacological half-lifes prior to the scan. Aft er a 
scout CT for pati ent positi oning, a dynamic emission scan was performed at rest followed by two 
identi cal scans during CPT and intravenous adenosine (140 µ∙kg–1∙min–1) induced hyperaemia (Figure 
1). CPT was performed by immersing the right hand of the pati ent into melti ng ice water, starti ng at 
least 90 seconds prior to the start of the scan, and was conti nued for at least 7.5 minutes15. Aft er 60 
to 90 seconds, pati ents were asked to provide a level of pain according to a 10-point scale. Low-dose 
CT scans were used to correct for scatt er and att enuati on16. Parametric MBF images were generated 
and analysed quanti tati vely by an experienced analyst using Cardiac VUer17. The analyst was blinded 
for all other study results. MBF was expressed in mL∙min–1∙g–1 of perfusable ti ssue. MBF during 
rest, CPT, and hyperaemia was calculated for each of the following three vascular territories, left  
anterior descending (LAD), circumfl ex (Cx), and right coronary artery (RCA), according to standard 
segmentati on procedures18. CFR was calculated as the rati o of hyperaemic MBF to baseline MBF 
whereas CPT reserve was calculated as the rati o of CPT MBF to baseline MBF for each of the vascular 
territories. To account for changes in CFR caused by cardiac workload at baseline, baseline MBF values 
were corrected for the rate pressure product. Corrected baseline MBF was calculated by multi plying 
10,000 by the rati o of baseline MBF and rate pressure product. The corrected CFR was defi ned as the 
rati o of hyperaemic MBF and the corrected baseline MBF. Target area was defi ned as the myocardial 
territory of a treated vessel, whilst remote myocardium was defi ned as the myocardial territory of the 
remaining non-treated vessels.
Figure 1. PET perfusion protocol. Schemati c illustrati on of the PET protocol at one month aft er BVS and DES 
implantati on. PET perfusion imaging was performed during resti ng conditi ons (baseline), followed by two 
identi cal PET sequences during CPT and intravenously administered adenosine (hyperaemia). BVS: bioresorbable 
vascular scaff old; CPT: cold pressor test; CT: computed tomography; DES: drug-eluti ng stent; LD: low-dose; [15O]
H2O: oxygen labelled water; PET: positron emission tomography
Stati sti cal analysis
Conti nuous variables are presented as mean values±standard deviati on (SD), whereas categorical 
variables are expressed as actual numbers. Conti nuous variables of paired data were compared with 
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the paired samples t-test, whereas comparisons between groups were performed using the two 
independent samples t-test, unless stated otherwise. Differences in proportions between groups were 
assessed with the Pearson chi-square or Fisher’s exact test, depending on the expected frequency of 
categories. Statistical analyses were performed using SPSS software, Version 20.0 (IBM Corp., Armonk, 
NY, USA)
RESULTS
From August 2013 to December 2014, 60 patients were enrolled successfully and randomised to 
implantation of BVS versus DES in a one-to-one ratio. Baseline characteristics are listed in Table 1. In 
both the BVS and DES arms, all devices were implanted successfully. BVS was implanted with lower 
driving pressure and post balloon dilatation was performed more often to achieve appropriate device 
apposition. Culprit lesions were predominantly located in the LAD (n=36, 60%) and less frequently 
in the RCA (n=14, 23%), or Cx (n=10, 17%). Bail-out stenting was required in three culprit lesions (all 
DES arm), either to seal a proximal (n=1) or distal (n=1) edge dissection or because of initial lesion 
length underestimation (n=1). The average device length was comparable between both treatment 
arms. Due to a small side branch occlusion, one patient (BVS arm) suffered from a periprocedural 
myocardial infarction without Q-wave occurrence and minimal cardiac enzyme release (CKMB max of 
32.4 U/l–1). Procedural characteristics are shown in Table 2. One patient from the DES arm declined 
PET perfusion at one-month follow-up and was excluded for PET perfusion analysis. Apart from the 
single aforementioned periprocedural myocardial infarction, no major adverse cardiac events were 
registered during the first month of follow-up.
Table 1. Baseline patient characteristics (n = 60)
Characteristic All 
N (%) or mean ± SD
BVS 
N (%) or mean ± SD
DES 
N (%) or mean ± SD
p-value
BVS vs. DES
Age (years) 55 ± 7 55 ± 7 55 ± 7 0.78
Male 45 (75%) 23 (77%) 22 (73%) 0.77
Body Mass Index (kg ∙ m-2) 27.2 ± 4.7 26.7 ±4.9 27.7 ± 4.5 0.43
CAD risk factors
Hypertension 30 (50%) 15 (50%) 15 (50%) 1.00
Hypercholesterolemia 16 (27%) 8 (27%) 8 (27%) 1.00
Current smoking 29 (48%) 18 (60%) 11 (37%) 0.12
History of smoking 12 (20%) 3 (10%) 9 (30%) 0.10
Family history CAD 34 (57%) 17 (57%) 17 (57%) 1.00




N (%) or mean ± SD
BVS 
N (%) or mean ± SD
DES 




Aspirin 57 (95%) 28 (93%) 29 (97%) 1.00
ACE inhibitors 24 (40%) 12 (40%) 12 (40%) 1.00
Beta-blockers 54 (90%) 27 (90%) 27 (90%) 1.00
Statins 54 (90%) 27 (90%) 27 (90%) 1.00
Dual anti-platelets 32 (53%) 16 (53%) 16 (53%) 1.00
Long-acting nitrates 6  (10%) 2 (7%) 4 (13%) 0.67
Indication
Stable angina 42 (70%) 18 (60%) 24 (80%) 0.16
Silent ischemia 1 (2%) - 1 (3%) 1.00
Unstable angina 17 (28%) 12 (40%) 5 (17%) 0.08
Culprit arteries
LAD 36 (60%) 16 (53%) 20 (67%) 0.43
RCA 14 (23%) 6 (20%) 8 (27%) 0.76
CX 10 (17%) 8 (27%) 2 (7%) 0.08
SD, standard deviation; DES, drug eluting stent; BVS, bioresorbable vascular scaffold; CAD, coronary artery 
disease; ACE, angiotensin converting enzyme; LAD, left anterior descending; RCA, right coronary artery; Cx, 
circumflex
Table 2. Percutaneous coronary intervention characteristics
All (n=60) BVS (n=30) DES (n=30) p-value
Post-dilatation (n (%)) 33 (55%) 21 (70%) 12 (40%) 0.02
Implantation pressure (atm) 13.4 ± 3.3 12.5 ± 3.3 14.3 ± 3.0 0.03
Maximal dilatation pressure (atm) 16.1 ± 4.0 16.2 ± 4.6 15.9 ± 3.3 0.82
Maximal diameter (mm) 3.61 ± 0.39   3.59 ± 0.34   3.63 ± 0.44 0.69
Unforeseen addition device implantation (n (%)) 3 (5%) 0 (0%) 3 (10%) na
Average device length (mm) 24.2 ± 6.1 24.3 ± 4.9 24.1 ± 7.2 0.90
DES, drug eluting stent; BVS, bioresorbable vascular scaffold; atm, atmosphere; mm, millimeter; na, not 
applicable
Optical coherence tomography
Representative OCT images prior to and immediately after BVS and DES implantation are shown in 
Figure 2. In one patient OCT was not obtained due to the inability to provide an injection with sufficient 
contrast through a 5 Fr guiding catheter (the initial 6 Fr radial access procedure was converted to a 
5 Fr guide due to radial artery spasm and patient discomfort). In four patients OCT image quality 
was considered insufficient to perform proper luminal analyses. This was mainly due to inadequate 
positioning of the guiding catheter resulting in insufficient contrast. In the remaining 55 patients OCT 
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was performed successfully immediately aft er device implantati on. Mean and minimal luminal areas, 
and mean and minimal luminal diameters post device implantati on were comparable between both 
treatment arms (Table 3).
Figure 2. ICA and OCT of BVS and DES. Representati ve ICA and OCT images prior to and aft er BVS and DES 
implantati on. A) A severely stenosed proximal LAD on ICA (arrow), and OCT of the most aff ected segment. This lesion 
was successfully treated with a BVS, as shown on ICA (arrow) and OCT immediately aft er implantati on (B). C) ICA and 
OCT of a high-grade distal RCA stenosis (arrow), with a good angiographic and OCT result aft er DES implantati on (D, 
arrow). BVS: bioresorbable vascular scaff old; DES: drug-eluti ng stent; ICA: invasive coronary angiography; LAD: left  
anterior descending coronary artery; OCT: opti cal coherence tomography; RCA: right coronary artery









Mean luminal area (mm2) 7.91 ± 1.88 7.71 ± 1.68 8.10 ± 2.06 0.45
Minimal luminal area (mm2) 5.79 ± 1.76 5.64 ± 1.50 5.94 ± 2.00 0.55
Mean luminal diameter (mm) 3.14 ± 0.37 3.10 ± 0.35 3.18 ± 0.40 0.43
Minimal luminal diameter (mm) 2.69 ± 0.39 2.65 ± 0.35 2.73 ± 0.43 0.45
PCI, percutaneous coronary interventi on; BVS, bioresorbable scaff old; DES, drug eluti ng stent; mm, millimeter
Heamodynamic conditi ons during PET
Haemodynamic conditi ons during baseline, CPT, and hyperaemic PET scans are summarised in Table 4. 
Blood pressure increased signifi cantly during CPT in comparison with baseline, whilst heart rate was 
signifi cantly higher during hyperaemia PET. There were no diff erences in heart rate, blood pressure, or 
rate pressure product between treatment arms (all p>0.05).
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PET, positron emission tomography; CPT, cold pressor test; BVS, bioresorbable vascular scaffold; DES, drug eluting 
stent; bpm, beats per minute.
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Baseline myocardial blood flow
PET perfusion measurements were performed successfully in 59 patients at 35±9 days post PCI. Table 
5 summarises quantitative perfusion values of global, target, and remote areas in both treatment 
arms. Global MBF at baseline was 0.99±0.27 mL∙min–1∙g–1 (BVS vs. DES; 1.02±0.29 vs. 0.96±0.24 
mL∙min–1∙g–1, p=0.37). Target and remote baseline MBF were comparable between BVS and DES 
arms (p≥0.05 for both).










MBF baseline (mL∙min-1∙g-1) 0.99 ± 0.27 1.02 ± 0.29 0.96 ± 0.24 0.37
CPT (mL∙min-1∙g-1) 1.11 ± 0.29 1.16 ± 0.34 1.06 ± 0.23 0.20
CPT reserve 1.13 ± 0.16 1.14 ± 0.16 1.12 ± 0.16 0.60
MBF hyperemia (mL∙min-1∙g-1) 3.12 ± 0.78 3.00 ± 0.78 3.25 ± 0.78 0.22
CFR 3.26 ± 0.90 3.04 ± 0.86 3.49 ± 0.90 0.06
RPP corrected CFR 2.63 ± 0.66 2.41 ± 0.62 2.87 ± 0.64 <0.01
Target area
MBF baseline  (mL∙min-1∙g-1) 0.99 ± 0.26 1.02 ± 0.28 0.96 ± 0.24 0.38
CPT (mL∙min-1∙g-1) 1.14 ± 0.32 1.20 ± 0.38 1.08 ± 0.23 0.16
CPT reserve 1.16 ± 0.23 1.18 ± 0.20 1.15 ± 0.26 0.69
MBF hyperemia (mL∙min-1∙g-1) 3.18 ± 0.79 3.04 ± 0.80 3.33 ± 0.77 0.16
CFR 3.32 ± 0.92 3.09 ± 0.94 3.57 ± 0.85 <0.05
RPP corrected CFR 2.68 ± 0.69 2.44 ± 0.67 2.93 ± 0.63 <0.01
Remote area
MBF baseline (mL∙min-1∙g-1) 1.00 ± 0.29 1.03 ± 0.32 0.96 ± 0.25 0.35
CPT (mL∙min-1∙g-1) 1.11 ± 0.30 1.15 ± 0.34 1.06 ± 0.24 0.22
CPT reserve 1.13 ± 0.17 1.14 ± 0.18 1.12 ± 0.17 0.38
MBF hyperemia (mL∙min-1∙g-1) 3.11 ± 0.80 2.99 ± 0.78 3.22 ± 0.81 0.25
CFR 3.25 ± 0.93 3.03 ± 0.86 3.48 ± 0.96 0.06
RPP corrected CFR 2.61 ± 0.69 2.39 ± 0.62 2.84 ± 0.68 <0.01
CFR target vs. remote ratio 1.03 ± 0.13 1.02 ± 0.13 1.04 ± 0.13 0.62
BVS, bioresorbable vascular scaffold; DES, drug eluting stent; MBF, myocardial blood flow; CFR, coronary flow 
reserve; CPT, cold pressor test; RPP, rate pressure product
Cold pressor test myocardial blood flow
The reported 10-point-scaled pain score during CPT was 6.2±1.4. Quantitative perfusion of the target 
area increased significantly from baseline to CPT (p<0.001) (Table 5). There were no significant 
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diff erences in CPT quanti tati ve perfusion or CPT reserve between treatment arms of the target (BVS 
vs. DES; p=0.16 and p=0.69, respecti vely) (Figure 3) and remote area (p=0.22 and p=0.38, respecti vely).
Figure 3. Myocardial blood fl ow response to cold pressor testi ng. MBF of the target area increased signifi cantly 
(p<0.01) from baseline to CPT in both the BVS and DES arms. No diff erences in CPT reserve were observed 
between both treatment groups. CPT: cold pressor test; BVS: bioresorbable vascular scaff old; DES: drug-eluti ng 
stent; MBF: myocardial blood fl ow
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Hypereamic myocardial blood fl ow
Global MBF during hyperaemia was 3.12±0.78 mL∙min–1∙g–1 (BVS vs. DES; p=0.22) (Table 5). Target 
(Figure 4) and remote hyperaemic MBF were comparable between BVS and DES arms (p=0.16 and 
p=0.25, respecti vely).
Figure 4. Baseline MBF, hyperaemic MBF, and CFR of both the BVS and DES treatment arms. Baseline and 
hyperaemic MBF were comparable between BVS and DES-treated vessels; however, CFR of the target area was 
signifi cantly lower in the BVS arm. BVS: bioresorbable vascular scaff old; CFR: coronary fl ow reserve; DES: drug-
eluti ng stent; MBF: myocardial blood fl ow
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Coronary fl ow reserve
A typical example of PET CFR in a case of BVS and one of DES can be seen in Figure 5. A trend for a 
globally att enuated CFR was observed (p=0.06) in the BVS treatment arm, whilst CFR of the target area 
was signifi cantly lower in the BVS arm than in the DES arm (3.09±0.94 vs. 3.57±0.85, p<0.05) (Table 
5, Figure 4). In additi on, a trend towards a lower CFR was observed in remote areas of the BVS arm 
(p=0.06). Target area CFR in relati on to remote area CFR (CFR target/CFR remote) was comparable 
between both treatment arms (p=0.62) (Table 5). Correcti on for baseline rate pressure product (RPP) 
increased the signifi cance levels of CFR diff erences between the BVS and DES arms for global, target, 
and remote areas (all p<0.01) (Table 5).
Figure 5. PET results of two pati ents aft er BVS or DES implantati on. Completely normal baseline MBF, hyperaemic 
MBF, and CFR one month aft er implantati on of BVS (upper row) and DES (lower row) of a proximal LAD with an 
excellent angiographic result (white arrows). Although both CFR results are well above clinical cut-off  values (2.5), 
this example illustrates the att enuated CFR aft er BVS in comparison with DES treatment. BVS: bioresorbable 
vascular scaff old; DES: drug-eluti ng stent; MBF: myocardial blood fl ow; PET: positron emission tomography
DISCUSSION
The present interim analysis of the VANISH trial was conducted to evaluate myocardial perfusion 
at one month aft er BVS and DES implantati on. The results indicate that myocardial perfusion of the 
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treated vascular territory and remote area at baseline, CPT, and hyperaemia are comparable between 
the BVS and DES arms. Only CFR was significantly lower in the target area after BVS implantation. 
In addition, a trend towards lower CFR was also observed in remote areas in BVS-treated patients. 
Nevertheless, the ratio of target CFR to remote CFR was comparable between both treatment arms.
Procedural characteristics
The vulnerable BVS design mandates careful implantation instructions19. BVS was employed with 
lower driving pressure and post-dilatation was performed more frequently in comparison with 
DES. Although polymeric scaffold disruption due to overexpansion by post-dilation of BVS has been 
described, no scaffold fractures were observed in the present study20,21. This is in line with recent 
evidence that post-dilatation in order to achieve scaffold optimisation does not result in (major) adverse 
cardiac events22. In contrast to some prior BVS studies7,9,11,12, OCT analysis revealed comparable 
acute luminal areas post implantation between BVS and DES, which can be assigned to the higher rate 
of post-dilatation in the BVS group23. Apart from one small side branch occlusion, no complications 
during BVS implantation were registered. However, despite the common occurrence of side branch 
occlusion during conventional stent implantation, the increased strut dimensions (150 μm vs. 80 μm 
for XIENCE) cannot be excluded as a contributing factor. Bail-out stenting for edge dissections was only 
required after DES implantation in two patients. Although this study was not powered to analyse BVS 
implantation characteristics and adverse cardiac events, these results confirm that BVS is safe and 
adequately implantable in type A or B1 coronary lesions if the prescribed implantation instructions 
are strictly respected.
Cold pressor test
CPT is considered the gold standard to assess coronary artery vasomotor function in response to 
sympathetic stimulation24-26. An impaired response to this test is related to abnormal coronary 
endothelial and vascular smooth muscle cell function, and is associated with a risk of developing 
cardiovascular events24,27. The purpose of including CPT MBF measurements in the present trial 
design was to evaluate the potential restoration of endothelial and vasomotor function upon final 
resorption of the scaffold. Compared with baseline, MBF of the treated vascular territory increased 
by 0.15±0.21 mL∙min–1∙g–1 during CPT, which is in line with previously reported values of patients 
with traditional CAD risk factors (i.e., hypertension, hypercholesterolaemia, or smoking) without flow-
limiting CAD15,28. At one-month follow-up, CPT MBF and CPT reserve were comparable between 
both treatment arms. This result was anticipated, as BVS retains its integrity for up to 12 months after 
implantation. The final results of the ongoing VANISH trial are awaited in order to assess the effects 
on CPT MBF of previously reported long-term vasomotor function restoration after BVS treatment.
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Hyperaemic myocardial perfusion and coronary flow reserve
The primary goal of PCI is not to relieve anatomical blockage per se but to restore downstream 
myocardial perfusion. The present interim analysis has shown that hyperaemic MBF was comparable 
between both treatment arms, although CFR was significantly lower in the BVS treatment arm. 
CFR decreases if baseline perfusion is increased, as seen with a higher RPP. However, the level of 
significance increased when CFR was adjusted for the RPP of the baseline scan. Interestingly, the ratio 
of target CFR to remote CFR did not differ between both treatment arms, indicating a homogeneously 
attenuated global CFR. If anything, this would indicate a global effect of BVS on attenuating CFR and 
is therefore not explained by the previously observed smaller luminal area of BVS-treated coronary 
segments7,9,11,12. In fact, as already alluded to, luminal dimensions were similar between BVS and 
DES as documented by OCT immediately after implantation. The hypothesised global effect of BVS on 
CFR in the present study is so far unexplained and requires further research. Although speculative, it 
could be hypothesised that in the early phase of BVS implantation global myocardial effects are exerted 
due to local vessel wall inflammation29. The process of enhanced inflammation could theoretically be 
elicited by the degradation of the scaffold characterised by phagocytosis to assimilate small particles 
into lactate and finally pyruvate1. It is likely that these inflammatory processes will dissipate over time 
as a porcine coronary artery model has demonstrated only minimal inflammation at two years after 
BVS implantation30. Alternatively, the increased BVS strut dimensions result in low endothelial shear 
stress at the base of the struts, theoretically increasing neointimal growth and hampering normal 
coronary physiology, which possibly interferes with the vasoactive reactivity31,32. Nevertheless, 
all these processes seem to appear locally and are unlikely to explain reduced global reactivity to 
hyperaemia satisfactorily. Although the treatment strategy was randomised, the possibility of a priori 
variation in baseline characteristics between treatment groups should be considered as a contributing 
factor.
Limitations
The specific device characteristics of BVS potentially increase the risk of periprocedural complications. 
Serruys et al previously demonstrated a slight increase of myocardial enzyme release after BVS 
implantation as compared to DES (5 vs. 2%, respectively)7. The present study design did not 
include periprocedural cardiac biomarker assessment, although periprocedural myocardial damage 
would be relevant with regard to the expected normalisation of myocardial perfusion and potential 
microvascular dysfunction.
Results of a globally attenuated CFR in the BVS treatment group suggest some degree of global 
microcirculatory impairment. However, without pre-interventional MBF and CFR data, these 
differences could be pre-existing, and no definite conclusions about an unequivocal relation between 
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BVS and attenuated global CFR should be drawn based on these data. The purpose of this study is to 
contribute to the understanding of the physiological processes during BVS resorption.
CONCLUSIONS
The present study shows that CFR is attenuated in BVS-treated patients, but neither BVS nor DES 
implantation leads to reduced myocardial perfusion. The comparable perfusion levels in both 
treatment arms, one month after implantation, do not offer an explanation for the recently reported 
lower cumulative rates of new or worsening angina in BVS-treated patients. Long-term results are 
awaited to determine whether vasomotor function will further improve after BVS resorption.
IMPACT ON DAILY PRACTICE
Although CFR is attenuated in BVS-treated patients, implantation of a BVS seems safe without major 
consequences on short-term results with regard to myocardial perfusion.
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Long-term resorption of the bioresorbable everolimus-eluting scaffold (BVS) reinstates normal 
vessel geometry allowing for natural regeneration of the newly formed endothelium with revival 
of vasomotor functions. The randomized clinical VANISH-trial was conducted to assess absolute 
myocardial blood flow (MBF) during resting, hyperemia, and cold pressor testing with quantitative 
positron emission tomography perfusion imaging after implantation of a metallic drug eluting stent as 
compared with BVS during 3-year follow-up. The hypothesized beneficial effects of scaffold resorption 
did not translate in improved MBF during hyperemia or endothelium-dependent vasodilation by cold 
pressor testing. 
ABSTRACT
Background: Long-term resorption of the bioresorbable everolimus-eluting scaffold (BVS) reinstates 
normal vessel geometry allowing for natural regeneration of the newly formed endothelium with 
revival of vasomotor functions.
Objective: The randomized clinical VANISH-trial was conducted to assess quantitative myocardial 
blood flow (MBF) during resting, hyperemia, and cold pressor testing (CPT) with positron emission 
tomography (PET) perfusion imaging after implantation of a bioresorbable everolimus-eluting scaffold 
(BVS) as compared with. drug eluting stent (DES).
Methods: Sixty patients (age 18-65) with single vessel disease and a type A or B1 lesion were 
randomized in a one-to-one fashion. Approximately one month, one year, and three years after device 
implantation, patients underwent [15O]H2O cardiac PET. The primary endpoint was the interaction of 
used device type and evolution over time of hyperemic MBF, coronary flow reserve (CFR), or CPT-
reserve. At three-year follow-up, a control invasive coronary angiogram with optical coherence 
tomography (OCT) was performed.
Results: Fifty-nine (98%), 56 (93%), and 51 (85%) patients successfully completed one-month, year-
year, and three-year follow-up PET imaging, respectively, and no culprit vessel events were registered 
during follow-up time. The primary study endpoint (i.e. interaction between device type and time) was 
nonsignificant for hyperemic MBF, CPT-reserve, and CFR (all p>0.05). In all patients, hyperemic MBF 
decreased from one to three years (p=0.02), whilst CFR was lower at three-year follow-up compared 
with one-month and one-year follow-up (both p=0.03). After three years, percentage area stenosis 
measured with OCT was higher within the BVS stent as compared to DES (p=0.03).
Conclusion: The hypothesized beneficial effects of scaffold resorption did not translate in improved 




The completely bioresorbable everolimus-eluting scaffold (ABSORB BVS) has been developed to 
improve long-term outcomes for percutaneous coronary intervention (PCI). The long-term resorption 
of the BVS restores normal vessel geometry allowing for natural regeneration of the endothelium due 
to preferential shear stress, blood flow, and cyclic strain patterns.(1-3) Moreover, favorable epicardial 
blood flow and flow mediated coronary dilatation after BVS resorption could significantly aid in 
restoration of vasoactivity and long-term myocardial perfusion, which is one of the most important 
independent prognostic predictors for adverse events and death in ischemic heart disease.(4, 5) After 
resorption of the BVS, the treated coronary artery may regain its responsiveness to sympathetic stimuli 
inducing endothelial-dependent vasodilation. Cold pressor testing is considered the gold standard 
for the evaluation of sympathetic function, and an impaired response to a cold pressor test (CPT) is 
associated with the risk of developing cardiovascular events.(6) Data to substantiate these postulated 
effects after BVS implantation are, however, lacking. Therefore, a randomized clinical trial of BVS vs. 
metallic DES was performed, utilizing positron emission tomography (PET) perfusion imaging to assess 
(hyperemic) myocardial blood flow (MBF), MBF during a CPT, and coronary flow reserve (CFR) over a 
three-year period (VANISH-trial, NCT01876589).
METHODS
Study design and participants
A detailed study design of the ‘’Impact of Vascular Reparative Therapy on Vasomotor Function 
and Myocardial Perfusion: a randomized H2
15O PET/CT Study (VANISH-trial)’’ has been described 
previously.(7) The VANISH trial is a prospective, single blind, randomized, two group, single center 
clinical trial. Patients with de novo single vessel coronary artery disease (CAD) (type A or B1 lesions) 
resulting in myocardial ischemia without biochemical signs of myocardial infarction and with a normal 
left ventricular function (≥ 50%) were eligible for inclusion. Exclusion criteria were age >65 years, 
prior cardiac history, poor kidney function (eGFR < 30ml∙min-1), asthma, other than sinus rhythm, or 
pregnancy. After inclusion, randomization between implantation of BVS or metallic DES using Absorb 
or Xience Prime (Abbott Vascular, Santa Clara, CA, USA) was performed in a one-to-one fashion. 
Patients were blinded for the implanted study device during the complete study follow up. Study 
investigators and operators were instructed not to disclose treatment assignment to patients and 
referring physicians. Follow-up visits were planned approximately one month, one year, and three 
years after PCI. At every time point, [15O]H2O PET was performed to assess resting MBF, CPT MBF, 
hyperemic MBF, CPT-reserve and CFR. Additionally, re-invasive coronary angiography (ICA) with optical 
coherence tomography (OCT) of the treated coronary segment was included in the study protocol at 
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three-year follow-up. The primary endpoint of the study was the difference in the evolution of MBF 
during hyperemia, CFR, and CPT-reserve over time between the two treatment arms. Written informed 
consent was obtained from all patients and the ethics committee of the VU University Medical Center 
approved the study.
Percutaneous coronary intervention and optical coherence tomography
Invasive coronary angiography and PCI were performed on a monoplane cardiovascular X-ray system 
(Allura Xper FD 10/10, Philips Healthcare, Best, The Netherlands). Device dimensions were based 
on OCT measurements or quantitative coronary angiography (QCA). All device implantations were 
performed according to standard procedural guidelines. Lesion length had to allow for complete 
coverage of the lesion including at least 2 mm of non-diseased tissue on either side of the target 
lesion. Post dilatation was performed with a balloon shorter than the implanted device and was 
left at the discretion of the operator. Intravascular OCT was performed prior and immediately after 
device implantation with automated injection of three or four ml∙sec-1 contrast agent and automated 
pullback set at 20mm∙sec-1. All patients received at least 80 mg of aspirin daily for the study duration 
and 75 mg of clopidogrel daily for a minimum of 12 months after device implantation. Control ICA, 
including OCT of the originally stented segment, was performed at three-year follow-up.
Quantitative coronary angiography analysis
In all patients, QCA analyses were performed off-line, by an analyst blinded to all other test results, with 
an automated contour analysis system (CAAS II, Pie Medical, Maastricht, the Netherlands). The small 
radiopaque markers at each end of the Absorb scaffold aided for localization of the non-radiopaque 
scaffold. Lesion length, reference vessel diameter, in-device minimal lumen diameter (MLD), and 
percent diameter stenosis (%DS), were calculated using an automated contour analysis with manual 
correction when required. In-device binary restenosis at three-year follow up was defined as a ≥50 
percent diameter stenosis. 
Optical coherence tomography
Baseline and three-year follow-up in-device cross-sections were analyzed with 1 mm interval by an 
analyst blinded to all other test results with patented offline software (ILUMIEN™ OPTIS™; LightLab 
Imaging/St. Jude Medical, St. Paul, MN, USA). Lumen areas and diameters were calculated with semi-
automated lumen contour detection and manually adjusted if necessary. Strut areas in both BVS 
and DES lying within the lumen contour were included in the luminal dimensions in case of good 
apposition or mal-apposition. Reference lumen area was defined as the average of the proximal and 
distal reference area, both selected as the frame with the largest lumen area within 5 mm distance 
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of the device.(8) Percent area stenosis (%AS) was the ratio between minimal lumen area (MLA) and 
reference lumen area. Post-PCI scaffold/stent areas were measured at the endoluminal reflective edge 
of metallic struts, whereas in polymeric struts the endoluminal bright border was used. At three-year 
follow-up the endoluminal edge of the black core of polymeric struts was considered as the endoluminal 
surface(9). The asymmetry index was post-PCI calculated per lesion (1 – (lowest of crossectional in-
device minimum device diameter / highest of crossectional maximum device diameter). A lesion with 
asymmetry index > 0.3 was considered an asymmetric lesion.(10) The circularity of each in-device 
cross section was post-PCI evaluated through the eccentricity index: the minimum device diameter 
divided by the maximum device diameter. The cross section with the lowest eccentricity index was 
used for the analysis per lesion, with an eccentricity index <0.7 indicating an eccentric lesion.(10) The 
scaffold/stent expansion index was post-PCI calculated by the ratio of minimal endoluminal scaffold/
stent area to the average reference lumen area. Optimal scaffold/stent expansion was present in case 
the expansion index was ≥90% or exceeded the luminal area of the reference segment with the lowest 
luminal area. If minimal endoluminal device area was  ≥9 mm2, optimal scaffold/stent expansion was 
defined as an expansion index of ≥80%.(10) At three-year follow-up, recognizable (former) polymeric 
struts with a black box and clear endoluminal and abluminal borders were used for analyses.(11) 
Neointimal area was defined as the difference between endoluminal stent area and lumen area, 
corrected for extra-stent lumen when present.(9, 12) Neointimal strut coverage was defined as the 
distance between the midpoint of the endoluminal strut surface and the lumen contour. Struts were 
classified as uncovered in case of strut coverage <30 μm and 0 μm for (former) polymeric and metallic 
struts respectively. A strut was considered malapposed when the distance between the endoluminal 
strut surface and the lumen contour was more than the strut thickness (90 μm and 150 μm for metallic 
and (former) polymeric struts, respectively).(9) 
PET imaging
PET studies using oxygen-15 labelled water were performed as described previously.(13) The Ingenuity 
TF 128 PET/CT scanner (Philips Healthcare, Best, The Netherlands) was used for all PET studies. 
Patients were instructed to temporarily cease all vasoactive medication at least 5 pharmacological 
half-lifes prior to the scan. First, a scout-CT was performed for patient positioning, followed by a 
dynamic emission scan at rest, during CPT, and during intravenous adenosine (140µ∙kg-1∙min-1) induced 
hyperemia. CPT was performed by immersing the left or right hand of the patient into melting ice 
water (0° degree Celsius (°C).). A plastic tube of 30x15 centimeters, containing half ice cubes and half 
water, was used for CPT. The tube was concealed by exploration of an expanded plastic glove within 
the ice water and on top of the open end of the plastic tube. the hand of the patient was introduced 
into the explored glove, which was surrounded by melting ice water, starting at least 90 seconds prior 
to the start of the scan, and was continued during the complete scan acquisition.(14) Parametric MBF 
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images were generated and analyzed quantitatively by an experienced analyst using Cardiac VUer.(15) 
The analyst was blinded to all other study results. Myocardial blood flow was expressed in mL∙min-
1∙g-1 of perfusable tissue. Myocardial blood flow during rest, CPT, and hyperemia was calculated for 
each of the three coronary territories, according to standard segmentation procedures.(16) Coronary 
flow reserve was calculated as the ratio of hyperemic MBF to resting MBF whereas CPT-reserve 
was calculated as the ratio of CPT MBF to resting MBF. Target area was defined as the myocardial 
territory of a treated vessel, whilst remote myocardium was defined as the myocardial territory of the 
remaining non-treated vessels. To account for changes in resting MBF caused by cardiac workload, 
additional resting MBF values were obtained by correcting for rate-pressure product (RPP), an index 
of myocardial oxygen consumption, using the following equation: corrected MBF = (MBF/RPP) × 104. 
Subsequently, corrected CPT-reserve (CPT-reservecor) and CFR (CFRcor) values were calculated using 
resting MBFcor.
Statistical analyses
Continuous variables are presented as mean values ± standard deviation (SD), whereas categorical 
variables are expressed as actual numbers. Continuous variables were analyzed using the Independent-
Samples T Test, or Mann-Whitney U test in case data was not normally distributed, unless otherwise 
stated. Categorical variables were analyzed using the Fisher’s Exact Test. A mixed model analysis was 
used to analyze PET perfusion results with a Bonferroni correction for multiple pairwise comparisons 
for localizing the source of the difference.  Based on a total sample size of 25 per group this study 
will have 80% power to detect differences in mean changes in outcomes between devices of at least 
0.8 times the standard deviation of the outcome. This calculation was based on a test for a non-zero 
difference in mean change score between two groups between two time points, assuming a within-
subject correlation of 0.5 and two-sided testing at a significance level of 5%. Statistical analyses were 
performed using SPSS software (IBM SPSS Statistics 20.0, Chicago, IL) 
RESULTS
From August 2013 to December 2014, 60 patients were enrolled and successfully randomized 
between BVS and DES.  Table 1 lists the baseline characteristics of both treatment arms. Procedural- 
and device implantation characteristics have been described previously.(7) In the DES arm, three 
patients required an additional device implantation due to significant edge dissection (n=2) or lesion 
length underestimation (n=1). Procedural non-Q-wave myocardial infarction (CKMB max of 32.4 
U∙l-1) occurred in one patient due to small side branch occlusion after BVS implantation. Non-target 
vessel revascularization during follow-up was performed in two patients in the DES arm, of which one 
was driven by stable angina and one was due to non-target vessel myocardial infarction. Five (17%) 
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patients in the DES arm and 4 (13%) patients in the BVS arm had withdrawn during follow-up, resulting 
in 25 (83%) and 26 (87%) patients with complete PET follow-up data in both treatment arms. Of these, 
1 (4%) and 3 (12%) patients refused ICA at three-year follow-up, respectively. At three-year follow-up, 
there was one significant lesion in the originally treated coronary segment in both treatment arms 
requiring percutaneous intervention after completion of complete follow-up.
Table 1. Baseline patient characteristics (n = 60)
Characteristic BVS
N (%) or mean ± SD
n=30
DES
N (%) or mean ± SD
n=30
p-value
Age (years) 55 ± 7 55 ± 7 0.78
Male 23 (77%) 22 (73%) 0.77
Body Mass Index (kg ∙ m-2) 26.7 ±4.9 27.7 ± 4.5 0.43
CAD risk factors
Hypertension 15 (50%) 15 (50%) 1.00
Hypercholesterolemia 8 (27%) 8 (27%) 1.00
Current smoking 18 (60%) 11 (37%) 0.12
History of smoking 3 (10%) 9 (30%) 0.10
Family history CAD 17 (57%) 17 (57%) 1.00
Diabetes 2 (7%) 4 (13%) 0.67
Medication
Anti- platelet therapy 28 (93%) 29 (97%) 1.00
ACE inhibitors 12 (40%) 12 (40%) 1.00
Beta-blockers 27 (90%) 27 (90%) 1.00
Statins 27 (90%) 27 (90%) 1.00
Dual anti-platelets 16 (53%) 16 (53%) 1.00
Long-acting nitrates 2 (7%) 4 (13%) 0.67
Indication
Stable angina 18 (60%) 24 (80%) 0.16
Silent ischemia - 1 (3%) NA
Unstable angina 12 (40%) 5 (17%) 0.08
Target arteries
LAD 16 (53%) 20 (67%) 0.43
RCA 6 (20%) 8 (27%) 0.76
CX 8 (27%) 2 (7%) 0.08
ACE, angiotensin converting enzyme; BVS, bioresorbable vascular scaffold; CAD, coronary artery disease; Cx, 
circumflex; DES, drug eluting stent; LAD, left anterior descending; RCA, right coronary artery; SD, standard 
deviation; NA, not applicable
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Myocardial perfusion
PET perfusion results for resting MBF, CPT, hyperemic MBF, CPT-reserve, and CFR, including the 
absolute changes from 1 month to 1 year and 3 years follow-up respectively, are presented in table 
2. The primary study endpoint; interaction between device type and time was non-significant for 
hyperemic MBF, CPT-reserve, and CFR (Central illustration, all p>0.05), meaning that the used device 
type and the time from implantation were not of influence on each other. Bonferroni post-hoc testing 
revealed that within the total cohort of patients, hyperemic MBF significantly decreased from one to 
three years (p=0.02), whilst CFR was lower at three-year follow-up compared with one month and 
one-year follow-up (both p=0.03). There was a trend (p=0.06) for an increase in CPT MBF from one 
year to three years within the whole patient population. There were no significant differences for 
resting MBF, CPT MBF, hyperemic MBF, CPT-reserve, or CFR between the two treatment arms (all 
p>0.05). After correction for resting RPP, CFRcor was significantly lower for BVS over all time points 
together as compared with DES (table 3, p=0.03). Representative ICA (baseline and three-year follow-
up) and PET perfusion (three-year follow-up) images of a patient with BVS and a patient with DES are 
depicted in figure 1. 
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Central illustrati on. Interacti on between Device and Time for hyperemic MBF, coronary fl ow reserve, 
and cold pressor test reserve. Per pati ent absolute myocardial perfusion results are displayed, 
comparing BVS and DES, measured with [15O]H2O PET one month, one year and three years aft er 
device implantati on respecti vely. The red horizontal lines represent the means. P-values show the 
nonsignifi cant interacti on between device type and ti me for each absolute myocardial perfusion 
outcome. MBF is expressed in mL∙min-1∙g-1. BVS, bioresorbable vascular scaff old; DES, drug-eluti ng 
stent; MBF, myocardial blood fl ow; PET, positron emission tomography.
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Table 2. Positron emission tomography perfusion results






month to 1 
year
Delta 1 
month to 3 
years
Resting MBF BVS 1.02±0.28 0.99±0.24 1.05±0.25 DT:  p=0.70
TP:  p=0.20
-0.05±0.15 0.01±0.22
DES 0.96±0.24 1.00±0.23 1.03±0.26 p=0.30 0.03±0.22 0.06±0.17
All 0.99±0.26 0.99±0.23 1.04±0.26 -0.01±0.19 0.03±0.20
CPT BVS 1.20±0.38 1.07±0.30 1.17±0.32 DT:  p=0.47
TP:  p<0.05
-0.12±0.22 -0.02±0.34
DES 1.08±0.23 1.08±0.25 1.15±0.26 p=0.14 0.00±0.23 0.06±0.20
All 1.14±0.32 1.08±0.27 1.16±0.29Δ -0.06±0.23 0.02±0.28
Hyperemic MBF BVS 3.04±0.80 3.20±1.17 2.96±0.92 DT:  p=0.46
TP:  p<0.05
0.16±0.85 -0.03±0.58
DES 3.33±0.77 3.38±0.83 3.02±0.67 p=0.21 0.05±0.83 -0.41±0.88
All 3.18±0.79 3.29±1.01 2.99±0.80* 0.11±0.83 -0.21±0.76
CPT-reserve BVS 1.16±0.21 1.09±0.14 1.13±0.16 DT:  p=0.92
TP:  p=0.27
-0.05±0.19 -0.02±0.21
DES 1.15±0.23 1.12±0.20 1.14±0.17 p=0.86 -0.03±0.26 -0.01±0.25
All 1.16±0.21 1.10±0.17 1.13±0.16 -0.04±0.23 -0.01±0.23
CFR BVS 3.09±0.94 3.17±0.99 2.87±0.86 DT:  p=0.19
TP:  p<0.05
0.18±0.99 -0.05±0.94
DES 3.57±0.85 3.45±0.97 3.07±0.84 p=0.18 -0.10±0.76 -0.57±0.89
All 3.33±0.92 3.31±0.98 2.97±0.85*† 0.04±0.89 -0.31±0.95
Values are mean ± SD. Influence of device type and time respectively on absolute myocardial perfusion 
was calculated using a mixed model analysis including two main effects (device type; time point) and 
a Bonferroni post hoc analysis when appropriate. Note that the values for the delta of the perfusion 
indices are displaying the change in patients who reached 1-year and 3-year follow-up respectively. 
BVS, bioresorbable vascular scaffold; CFR, coronary flow reserve; CPT, cold pressor test; DES, drug-
eluting stent; DT, device type; MBF, myocardial blood flow (in mL∙min-1∙g-1), TP, time point; Δp=0.06 
versus 1 year; *p=0.02 versus 1 year; †p=0.03 versus 1 month and 1 year.
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Table 3. Positron emission tomography results corrected for resting rate-pressure product






month to 1 
year
Delta 1 
month to 3 
years
Resting MBFcor BVS 1.27±0.24 1.21±0.19 1.28±0.24 DT: p=0.19
TP: p=0.71
-0.07±0.24 -0.01±0.21
DES 1.16±0.24 1.19±0.32 1.17±0.30 p=0.38 0.02±0.20 0.02±0.26
All 1.22±0.24 1.20±0.26 1.23±0.27 -0.02±0.22 0.00±0.23
CPT-Reservecor BVS 0.95±0.25 0.89±0.22 0.94±0.26 DT: p=0.38
TP: p=0.32
-0.05±0.20 0.01±0.23
DES 0.97±0.29 0.99±0.34 1.04±0.34 p=0.59 0.01±0.25 0.06±0.31
All 0.96±0.27 0.94±0.29 0.99±0.30 -0.02±0.22 0.03±0.27
CFRcor BVS 2.44±0.67 2.57±0.95 2.29±0.65 DT: p=0.03
TP: p=0.03
0.20±0.89 -0.04±0.67
DES† 2.93±0.63 3.01±1.01 2.70±0.83 p=0.51 0.08±0.88 -0.30±0.78
All 2.68±0.69 2.79±1.00 2.50±0.76* 0.14±0.87 -0.17±0.73
Values are mean ± SD. Influence of device type and time respectively on absolute myocardial perfusion 
was calculated using a mixed model analysis including two main effects (device type; time point) and 
a Bonferroni post hoc analysis when appropriate. Note that the values for the delta of the perfusion 
indices are displaying the change in patients who reached 1-year and 3-year follow-up respectively. 
Resting MBFcor, corrected resting MBF; BVS, bioresorbable vascular scaffold; CFRcor, corrected coronary 
flow reserve; CPTcor, corrected cold pressor test; DES, drug-eluting stent; DT, device type; MBF, 
myocardial blood flow (in mL∙min-1∙g-1), TP, time point; †p=0.03 versus BVS measured over all time 
points together; *p=0.02 versus 1 year. 
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Figure 1. Representative ICA and PET perfusion for BVS and DES. A) ICA showed a good angiographic result from 
two different angles (arrows) immediately after successful BVS implantation in the mid LAD. At three-year follow-
up, the scaffold was patent on ICA (B, arrows), and PET (C) showed normal rest MBF that slightly increased during 
a CPT, as well as normal MBF during hyperemia. D) ICA demonstrated the immediate result after successful DES 
implantation in the mid LAD (arrows). At three-year follow-up, the stent remained patent (E, arrows), and PET 
(F) showed normal MBF during rest with a small increase during a CPT, alongside normal MBF during hyperemia. 
MBF is expressed in mL∙min-1∙g-1. CPT, cold pressor test; ICA, invasive coronary angiography; LAD, left anterior 




Table 4 illustrates the QCA results of both treatment arms. Lesion length was 10.21 ± 4.69 and 10.08 
± 3.82 for BVS and DES, respectively (p=0.91). Minimal lumen diameter was not significantly different 
between both treatment arms prior to intervention (p=0.48). The acute luminal gain due to device 
implantation was lower within the BVS treatment arm (p=0.02), which resulted in a lower MLD and 
increased %DS post-PCI (p<0.01 and p<0.01, respectively). A difference in MLD and %DS was no longer 
observed at three-year follow-up (p=0.33).
Table 4. Quantitative coronary angiography
BVS DES p-value
Lesion length (mm) 10.21 ± 4.69 10.08 ± 3.82 0.91
Reference vessel diameter (mm)
       Pre-procedure 2.69 ± 0.42 2.66 ± 0.47 0.81
       Post-procedure 2.72 ± 0.40 2.83 ± 0.51 0.36
       Three-year follow up 2.66 ± 0.31 2.77 ± 0.45 0.32
Minimal lumen diameter (mm)
       Pre-procedure 0.80 ± 0.29 0.86 ± 0.32 0.48
       Post-procedure 2.23 ± 0.35 2.59 ± 0.50 <0.01
       Three-year follow up 2.03 ± 0.38 2.23 ± 0.49 0.13
       Acute gain 1.42 ± 0.51 1.73 ± 0.52 0.02
       Late loss 0.16 ± 0.38 0.37 ± 0.45 0.10
       Net gain 1.25 ± 0.51 1.41 ± 0.48 0.29
Percent diameter stenosis 
       Pre-procedure 68.72 ± 13.62 67.78 ± 9.92 0.76
       Post-procedure 18.10 ± 9.75 9.22 ± 7.03 <0.01
       Three-year follow up 23.19 ± 11.92 19.80 ± 11.34 0.33
Binary restenosis at three-year follow-up 1 (3.3) 1 (3.3) 1.00
Values are mean ± SD and n (%). BVS, bioresorbable vascular scaffold; DES, drug-eluting stent.
Optical coherence tomography
Optical coherence tomography was successfully performed in 29 (out of 30) patients in both treatment 
arms at baseline and 24 and 21 patients at three-year follow-up in the BVS and DES arm, respectively 
(table 5 and 6). Figure 2 shows an example of ICA and OCT for BVS and DES prior to PCI, immediately 
post-PCI, and at three-year follow-up. Immediately after device implantation and post dilatation if 
indicated, MLA and %AS were not significantly different between both treatment arms (p=0.71 and 
p= 0.78, respectively). Post-PCI expansion index was significantly lower within the BVS treatment arm, 
whereas asymmetry index and eccentricity index ware comparable between BVS and DES treatment 
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arm. Percentage malapposed struts (%) was comparable at baseline and three-year follow-up between 
BVS and DES (p=0.08 and p=0.51 respectively). The percentage of uncovered struts at three-year 
follow-up was higher with the DES group (p<0.01). Figure 3 illustrates that there was a significant 
decrease in MLA and increase in %AS from baseline (post-PCI) to three-year follow-up within the BVS 
arm, whilst no difference over time was observed within the DES arm. In BVS at three-year follow-up, 
%AS was significantly higher in comparison with DES (p=0.03), and a trend was observed for lower 
MLA (p=0.08).
Table 5. Optical coherence tomography post-PCI and at 3-year follow up.
n BVS n DES p-value
Reference lumen area (mm2)
Post-PCI 29 7.89 ± 1.82 29 8.20 ± 2.30 0.58
Three-year follow-up 24 7.51 ± 1.80 21 7.97 ± 2.84 0.52
Minimal lumen area (mm2)
Post-PCI 29 5.84 ± 1.49 29 6.01 ± 1.94 0.71
Three-year follow-up 24 4.27 ± 1.59 21 5.33 ± 2.35 0.08
Percent area stenosis (%)
Post-PCI 29 24.90 ± 13.55 29 25.93 ± 14.38 0.78
Three-year follow-up 24 44.05 ± 14.83 21 33.45 ± 16.90 0.03
Percent malapposed struts (%)
Post-PCI 29 0.00 (0.00-1.50) 29 0.85 (0.00-3.37) 0.08
Three-year follow-up 24 0.00 (0.00-0.00) 21 0.00 (0.00-0.00) 0.51
Minimal endoluminal scaffold/stent 
area (mm2)
Post-PCI 29 5.39 ± 1.58 29 6.27 ± 1.99 0.07
Three-year follow-up 24 5.20 ± 2.22 21 6.74 ± 2.13 0.02
Scaffold/stent-based percent area 
stenosis (%)
Post-PCI 29 31.26 ± 13.21 29 22.96 ± 14.14 0.02
Three-year follow-up 24 26.05 (13.53-37.54)) 21 12.28 (-1.85-27.55) <0.01
Post-PCI implantation results
Asymmetry index (AI) 29 0.38±0.08 29 0.38±0.08 0.90
Asymmetric lesion (n, %) 29 25 (86) 29 24 (83) 1.00
Eccentricity index (EI) 29 0.72±0.08 29 0.72±0.06 0.88
Eccentric lesion (n, %) 29 10 (34) 29 11 (38) 1.00
Expansion index (%) 29 68.74±13.21 29 77.04±14.14 0.02
Optimal stent/scaffold expansion (n, %) 29 9 (31) 29 12 (41) 0.59
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n BVS n DES p-value
Three-year follow-up
Mean neointimal area (mm2) 24 1.32 ± 0.46 21 1.14 ± 0.48 0.23
Maximum neointimal area (mm2) 24 2.15 ± 0.73 21 2.43 ± 1.28 0.39
Percent uncovered struts (%) 24 0.00 (0.00-0.00) 21 0.00 (0.00-1.02) <0.01
Neointimal strut coverage (mm) 24 0.16 ± 0.04 21 0.13 ± 0.06 0.12
Presented data is unpaired due to differences in number of patients at post-PCI and three-year follow-
up. The changes between post-PCI and 3-year follow-up measurements presented in this table should 
therefore be interpreted with caution, and may be induced by differences in included patients at timing 
of evaluations. Values are mean ± SD, median (interquartile range) and n (%). BVS, bioresorbable 
vascular scaffold; DES, drug-eluting stent; PCI, percutaneous coronary intervention
Table 6. OCT not performed or insufficient quality
BVS DES
Post-PCI
Insufficient contrast delivery (n, %) 1 (3.3%) 1 (3.3%)
Three-year follow-up
Insufficient contrast delivery (n, %) 1 (3.3%) 1 (3.3%)
Withdrew from study (n, %) 4 (13.3%) 5 (16.7%)
Refused ICA (n, %) 1 (3.3%) 3 (10.0%)
BVS, bioresorbable vascular scaffold; DES, drug eluting stent; ICA, invasive coronary angiography ; OCT, optical 
coherence tomography; PCI, percutaneous coronary intervention.
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Figure 2. Representative ICA and OCT images prior to, immediate after, and at three-year follow-up after BVS and 
DES implantation. A severe stenosis (arrow) in the mid LCX (A) and a severe stenosis (arrow) in the proximal LAD 
(B), with OCT showing the most affected sides. Both lesions were successfully treated with a BVS (C, arrow) and 
DES (D, arrow), as is shown with ICA and OCT immediately after implantation. At three-year follow-up after BVS 
implantation (E) and DES implantation (F), ICA showed a good angiographic result with a patent device (arrows), 
while OCT showed a small layer of neointimal tissue and limited loss of lumen area within the device. LCX, left 
circumflex artery; OCT, optical coherence tomography; Other abbreviations as in central illustration and figure 1.
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Figure 3. Changes in minimal lumen area (A) and percentage area stenosis (B) over ti me, measured by OCT at 
baseline (post-PCI) and three-year follow-up, are shown for the BVS and the DES treatment arm respecti vely. The 
circle and error bars represent the mean and standard deviati on, and are given for the measurements at baseline 
and at follow-up in both the BVS and DES treatment arm. %AS, percentage area stenosis, MLA, minimal lumen 
area. Other abbreviati ons as in central illustrati on and fi gure 2.
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DISCUSSION
The present study was conducted to assess the evolution of quantitative MBF during endothelium-
dependent vasodilation by cold pressor testing and maximal hyperemia by intravenous administration 
of adenosine after BVS implantation as compared to conventional metallic DES over a three-year 
period. The main results indicate that there was no significant difference in evolution of CPT reserve, 
hyperemic MBF, and CFR over time after BVS versus metallic DES implantation. After correction for 
resting RPP, CFR was significantly lower within the BVS treatment arm. Additionally, QCA illustrated 
that implantation of BVS resulted in less acute luminal gain, which caused a lower MLD and increased 
%DS immediately post-PCI. Furthermore, OCT analyses revealed a significant decrease in MLA and 
increase in %AS from baseline (post-PCI) to three-year follow-up within the BVS arm, whilst no 
apparent change was observed within the DES arm. This resulted in a significantly higher %AS within 
the BVS compared to DES at three years after implantation.
Myocardial perfusion during cold pressure testing
Metabolically mediated increase in blood flow after acute cold exposure is an important determinant 
of coronary vasomotor response to sympathetic activation. Sympathetic activation provokes 
endothelium-dependent vasodilation of the coronary arteries in case of normal coronary circulation. 
In the presence of endothelial dysfunction, the metabolically mediated increase of flow is offset by the 
α-adrenergically stimulated vasoconstriction.(14) An impaired response to CPT is, therefore, related 
to vascular dysfunction and occurrence of adverse cardiac events.(6) Previous pioneering preclinical 
and clinical studies have shown that alongside resorption of the BVS, coronary segments regained 
the ability to respond to administration of intracoronary acetylcholine, an endothelium-dependent 
vasodilator.(17, 18) More recently, contradicting evidence has become available. The randomized 
ABSORB II trial found no superiority in vasomotor reaction to pharmacologic stimuli for BVS with 
respect to the metallic stent at three-year follow-up.(19) Dudek and colleagues, who demonstrated 
that the degree of vasomotor response of the originally stented segment with BVS remained lower 
in comparison with adjacent segments, further substantiated these findings.(20) However no studies 
have been performed utilizing CPT, which is the gold standard for evaluation of endothelial function 
by sympathetic stimulation. Within the present study, there were no differences observed in the 
responsiveness to CPT between BVS and DES. This may imply that vasomotor function is not largely 
restored or minor changes in responsiveness to CPT may be antagonized by diffuse CAD.(3) Moreover, 
responsiveness to sympathetic stimuli is highly affected by age and traditional CAD risk factors (i.e. 
hypertension, hypercholesterolemia, or smoking), even in the absence of flow limiting CAD.(21) 
Although falling short in statistical significance, there were numerically more current smokers within 
the BVS group, which may have neutralized the postulated favouring effect of scaffold resorption on 
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vasomotor function.(21) Consequently, we cannot genuinely conclude that there is no recovery of 
epicardial vasomotor function based on the results of the present study, however any substantial 
magnitude on myocardial perfusion after cold pressor testing was not observed. 
Impact of BVS resorption on hyperemic myocardial perfusion and 
coronary flow reserve
It has been shown that even in the absence of a coronary lesion, a reduction in MBF is associated with 
the occurrence of major adverse cardiac events.(4, 5) Data regarding the effect of scaffold resorption 
on absolute MBF in stable patients is lacking. The present study showed that there was no significant 
interaction between device type and follow-up time for resting and hyperemic MBF or CFR. These 
findings denote that resorption of BVS did not alter the vessels’ ability to increase hyperemic MBF or 
CFR as compared with metallic DES up to three years after implantation. Notwithstanding, a comparable 
efficacy of BVS and DES in terms of absolute perfusion during hyperemia in patients with stable CAD 
was observed. These findings are in line with the ABSORB TROFI II trial, a randomized clinical trial of 
BVS versus metallic DES for treatment of infarct-related lesions, demonstrating adequate and similar 
invasively measured functional microcirculatory parameters between both treatment arms at three-
year follow-up. Moreover, absolute flow by intracoronary thermodilution was similar between both 
treatment arms.(22) Myocardial perfusion is the composite effect of focal, diffuse, and microvascular 
disease.(23) Hypothetically, restoration of epicardial vessel physiology due to scaffold resorption may 
not translate into an apparent increase in perfusion on the myocardial level due to a transcending 
and counterweighting effect of diffuse and microvascular disease in patients with established CAD. 
Results for hyperemic MBF and CFR were similar in the myocardial areas of non-treated vessels within 
the same patient (data not shown), supporting the limited effects of vessel ‘’caging’’ on hyperemic 
myocardial perfusion and CFR. In addition, a decrease in hyperemic MBF and CFR was observed within 
the complete study population together at three-year follow-up, which may further support the effect 
of atherosclerotic progression on myocardial perfusion in patients with CAD. 
QCA and OCT
Acute luminal gain due to device implantation, as measured with QCA, was lower within the BVS 
treatment arm, which resulted in a lower MLD and increased %DS post-PCI. This difference in MLD and 
%DS was not observed at three-year follow-up. Sotomi et al. previously showed that in-device luminal 
dimension measurements after BVS implantation are underestimated using QCA probably due to 
polymer strut protrusion in the coronary lumen and this could have induced a unfavorable difference 
in MLD and acute luminal gain post-PCI for BVS.(24) Moreover, after three-year follow-up, OCT analyses 
showed a higher %AS and a trend for lower MLA within the BVS compared to DES. These results were 
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consistent when using the scaffold/stent area as reference to calculate area stenosis, an analysis that 
was performed to limit bias potentially introduced by reference vessel diameter. In line with present 
study results, the randomized China ABSORB trial observed that within device the post-PCI MLD and 
acute gain were lower with BVS compared with metallic DES, and the %DS was slightly greater.(25) In 
addition, the ABSORB II trial observed a difference in MLA by intravascular ultrasound assessment at 
three-year follow-up (BVS vs. DES: 4.32 mm2 [SD 1.48] vs. 5.38 mm2 [SD 1.51]; p<0.0001).(19) These 
results are essentially similar with the OCT observations at three-year follow-up in the present study 
(BVS vs. DES: 4.27 mm2 [SD 1.59] vs 5.33 mm2 [SD 2.35]; p=0.08). Interestingly, this difference did not 
evidently translate into lower myocardial perfusion during CPT and hyperemia. Yet, after correction 
for resting RPP (i.e. cardiac workload), CFR was significantly lower for BVS when comparing over all 
time points together, which may be explained by an increase in %AS. There were 2 patients (1 DES 
and 1 BVS) with a significant restenosis in the originally stented segment and in 1 patient (DES) a 
significant stenosis was observed distally form the stented segment at three year follow-up. A clear 
perfusion decrease between 1-month and 3-years was observed in only in 1 out of these 3 patients 
within the DES-arm. During inclusion of the present study the instructions for BVS implantation 
developed and accurate predilation, scaffold sizing, and post-dilation (PSP technique) have been 
strongly advised to minimize scaffold-related hard events. Although the PSP technique has not been 
performed systematically within the present study, all stent- and scaffold implantations were OCT-
guided performed, which is documented to optimize PCI outcomes acutely and long-term(26). Stent/
scaffold sizing was based on dimensions measured by OCT and additional post-dilation was performed 
in case of suboptimal scaffold/stent employment. Rates of optimal stent/scaffold deployment were 
not significantly different between the groups (Table 5).
Limitations
Although blinded randomization was performed, the BVS group comprised numerically more left 
circumflex arteries. These incidental differences in targeted coronary arteries between both treatment 
arms may have affected the results. Moreover, the downstream extent of myocardial area is generally 
smaller for left circumflex arteries, which may has interfered with the potential benefit of BVS 
implantation. Furthermore, the BVS group involved non-significant but numerically more patients 
with unstable angina as compared with the DES treatment arm. Since, the extent of atherosclerotic 
inflammation, as seen in patients with unstable plaques, may decrease the ability of coronary vessels 
to respond to cold pressor testing and pharmacologic stimuli, beneficial effects of scaffold resorption 
could have been diminished within the BVS population.
The sample size was calculated to detect differences in mean changes in outcomes between devices 
using 0.8 times the standard deviation of the outcome. This cutoff was chosen based on the inter-
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scan difference, however smaller differences between both treatment arms may not have been found 
significant due to the wide confidence interval and relatively small sample size.
Perfusion imaging prior to inclusion was not performed by design of the study. Therefore, differences 
in recovery of myocardial perfusion due to implantation of BVS versus metallic DES were not assessed. 
Implantation of both BVS and DES reinstate vessel patency, however, it could be hypothesized that 
larger strut dimensions of BVS compromise side branch patency. 
Although patients were instructed to continue statin therapy according to current international 
guidelines, adherence to statin therapy during follow-up visits was not documented and could have 
induced differences in atherosclerotic progression between both treatment arms. 
OCT and QCA data should be considered hypothesize generating only since the study was not 
sufficiently powered to investigate difference in disease progression.
CONCLUSIONS
Up to 3 years, implantation of the BVS did not result in a favorable evolution of hyperemic MBF, CFR 
or CPT-reserve as compared to the metallic DES implantation in patients with de novo single vessel 
CAD. Angiographic characteristics after BVS implantation seem to be slightly inferior compared with 
metallic DES. 
CLINICAL PERSPECTIVES
Long-term resorption of the BVS restores normal vessel geometry allowing for natural regeneration 
of the endothelium. The randomized clinical VANISH-trial showed that restoration of normal vessel 
geometry did not translate in improved absolute myocardial blood flow (MBF) during 3-year follow-
up. These results do not support the use of BVS over DES until benefit with regard to long-term major 
adverse cardiac events has been shown.
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ABSTRACT
Chronic total coronary occlusions (CTO) are documented in approximately in one fifth of diagnostic 
invasive coronary angiographies (ICA). Percutaneous coronary interventions (PCI) of CTO are 
challenging and are accompanied by higher complication and lower success rates in comparison with 
non-CTO PCI. Scrutinous evaluation of ischemia and viability to justify percutaneous revascularization 
is therefore of importance to select eligible patients for such a procedure. Furthermore, knowledge 
of the anatomical features of the occlusion may predict the chances of success of CTO PCI and could 
even guide the procedural strategy to augment the likelihood of recanalization. Positron emission 
tomography (PET) is unequivocally accepted as the reference standard for ischemia and viability 
testing, whereas coronary computed tomography angiography (CCTA) currently allows for non-invasive 
detailed three-dimensional imaging of the coronary anatomy that adds morphological information 
over two-dimensional ICA. Hybrid PET/CT could therefore be useful for optimal patient selection as 




Coronary artery disease (CAD) is the leading cause of death in the western world. In 18-35% of 
patients with known or suspected CAD a chronic total coronary occlusion (CTO) is involved(1-4). A 
CTO is defined as native coronary artery with absent or minimal antegrade blood flow for > 12 weeks 
duration (5, 6). Patients with CTOs are treated differently from non-occlusive CAD and are less likely 
to undergo revascularization, either percutaneously or surgically. For CTO patients who are offered 
revascularization, coronary artery bypass grafting surgery (CABG) is the mainstay with a 3:1 ratio(1). 
The reluctance of physicians to refer patients for revascularization is based on the false assumption 
that symptoms are easily controlled by optimal medical therapy (OMT) and that the myocardium 
subtended by the CTO artery is often non-viable and / or non-ischemic that would not benefit from 
revascularization. Owing to the traditionally low success rate of about 50-70% and relatively high 
complication rate, percutaneous coronary intervention (PCI) of CTO is empirically attempted in less 
than 15% of eligible patients(1, 7-12). However, successful recanalization of a CTO is accompanied by 
symptom relief, recovery of left ventricular (LV) function, and improved survival as opposed to patients 
in whom the procedure was unsuccessful(3, 7, 13-21).
In recent years, advances in guide wire technology and implementation of dissection and re-entry 
techniques have resulted in augmented success rates exceeding 90% in the hands of experienced CTO 
centers(22-24). Nonetheless, these procedures are still accompanied by slightly higher complication 
rates, contrast and radiation burden, and costs in comparison with non-CTO PCI (5, 25-27). Scrutinous 
evaluation of ischemia and viability to justify percutaneous revascularization is therefore of importance 
to select eligible patients for such a procedure. Furthermore, knowledge of the anatomical features 
of the occlusion may predict the chances of success and could even guide the procedural strategy to 
augment the likelihood of recanalization in an efficient manner(* 28, ** 29). 
The combination of hybrid positron emission tomography (PET) and coronary computed tomography 
angiography (CCTA) nowadays allows for the accurate detection and quantification of myocardial 
ischemia and viability in conjunction with coronary anatomy and morphology near simultaneously. As 
such, hybrid PET/CT could prove useful in the clinical work-up of CTO patients to determine eligibility 
and plan procedural strategy. This review discusses the potential value of PET/CT to guide CTO PCI.
SELECTION OF ELIGIBLE PATIENTS FOR REVASCULARIZATION 
OF CTO
The decision scheme on the diagnostic work-up for CTO patients to evaluate eligibility for revascularization 
is depicted in Figure 1. Please note, that this algorithm is based on current international guidelines and 
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is not specifically targeted to CTO patients but to obstructive CAD in general. Once the diagnosis of a 
CTO has been established, usually through a diagnostic invasive coronary angiogram (ICA), information 
pertaining LV function is mandatory. Normal regional LV function of myocardium subtended by the 
CTO by definition excludes non-viability. The decision to proceed to a revascularization procedure 
is then merely based on the presence and extent of ischemia. Without documented ischemia, such 
a procedure is futile and even hazardous(30) as the patient is subjected to potential procedural 
complications without a clear benefit and OMT suffices. In the majority of cases, however, ischemia is 
observed. Even the presence of well-developed collaterals does generally not protect the myocardium 
against ischemia. An increase in collateral flow reserve during pharmacological stress has been shown 
to occur in only 7% of patients, while coronary steal can be documented in a third (31, 32). When 
the jeopardized myocardium comprises more than 10% of the LV, revascularization on top of OMT is 
considered appropriate irrespective of symptoms(33). Retrospective analysis of myocardial perfusion 
studies in large registries have revealed that such an ischemic burden holds prognostic relevance 
and revascularization is associated with improved outcome(34). When the extent of ischemia is less 
pronounced (i.e. < 10%), an initial treatment strategy of OMT is justified and revascularization only 
contemplated after inadequate response to medical therapy.
Conversely, when patients exhibit extensive regional wall motion abnormalities in the affected 
vascular territory, we recommend that the diagnostic work-up focus on myocardial viability rather than 
ischemia. Without signs of myocardial viability (i.e. previous (near) transmural myocardial infarction), 
similar to lack of ischemia, revascularization is considered inappropriate as no recovery of function is 
anticipated(35, 36). Although it must be noted that revascularization of non-viable myocardium might 
halt the process of progressive LV remodelling (37). The presence of substantial viability warrants 
revascularization and is accompanied by recovery of LV function and improved outcome as observed 
in both retrospective and prospective studies (35, 38, 39). The extent of viability deemed necessary 
for a clinically relevant improvement in LV ejection fraction (i.e. >5 percentage points) is uncertain, but 
generally ranges from 10-25% jeopardized myocardium (40, 41). Small quantities of viability are not 
associated with recovery of function, but revascularization could be considered to reduce symptoms 
not controlled by medical therapy.
Although the presented literature supports the utilization of the proposed treatment algorithm, 
randomized trials on imaging guided revascularization are scarce. The PET and Recovery Following 
Revascularization (PARR-2) (42) and a substudy of the Surgical Treatment for Ischemic Heart Failure 
(STICH) (43) trial have evaluated the impact of viability assessment on clinical outcomes after CABG, 
and were both negative. A nuclear substudy of the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) trial suggests that an appreciable reduction of ischemia is 
accompanied by a favourable outcome after PCI (44). These results were corroborated for CTO patients 
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Figure 1. Proposed diagnosti c and treatment algorithm in pati ents with a documented chronic total coronary 
occlusion (CTO). LV, left  ventricular; OMT, opti mal medical therapy.   
who underwent PCI, whereby a baseline ischemic burden > 12.5% in combinati on with a reducti on >
5% yielded the most favourable clinical outcomes(45). A randomized imaging study on the merits of 
ischemia-guided revascularizati on is, however, lacking altogether. The ongoing Internati onal Study of 
Comparati ve Health Eff ecti veness With Medical and Invasive Approaches (ISCHEMIA) trial is att empti ng 
to establish the value of revascularizati on in pati ents with a large ischemic burden in a randomized 
fashion. More specifi cally tailored to CTO PCI, large observati onal studies have shown that a successful 
percutaneous recanalizati on results in improved all-cause mortality, lower MACE rates (relati ve risk: 
0.70), and reduced need for CABG as opposed to unsuccessful att empts (13, 18, 19, 46). Nonetheless, 
these studies are all observati onal in nature and thus prone to confounding. Currently, the Drug-
Eluti ng Stent Implantati on Versus Opti mal Medical Treatment in Pati ents With Chronic Total Occlusion 
(DECISION-CTO) and the Randomized Multi centre Trial to Evaluate the Uti lizati on of Revascularizati on 
or Opti mal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions (EURO-CTO) trials 
are the fi rst studies to more accurately assess the surplus clinical value of CTO PCI over OMT alone in 
a randomized fashion. The results of the aforementi oned studies are eagerly awaited. 
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POSITRON EMMISION TOMOGRAPHY
Although a large armamentarium of imaging modalities is available to evaluate myocardial perfusion 
and viability, PET is unequivocally accepted as the reference standard for this task. The following 
section will place the value of PET within the context of alternative imaging techniques.
Myocardial Perfusion Imaging
Four tracers in particular have been well validated for myocardial perfusion imaging (MPI) with PET(* 
47). Of the available tracers, 82Rb, 13NH3, and H2
15O are the most commonly used. 18F-flurpiridaz is an 
emerging perfusion tracer not yet available for clinical use, but holds great potential and is currently 
being tested in phase 3 trials(48-50). Each of these tracers possesses unique characteristics with 
their individual pros and cons pertaining (costs of) radionuclide production, physical half-life, image 
quality, radiation exposure, and compatibility with exercise acquisition protocols (Table 1). None of 
the perfusion tracers excels on all of these features. Choice of tracer is therefore multifactorial and 
frequently depends on practical and logistical considerations.
Table 1. PET tracers characteristics
H215O 13NH3 82Rb 18F-flurpiridaz
Half-life 123 sec 9.97 min 76 sec 110 min
Production Cyclotron Cyclotron Generator Cyclotron










Mean positron range 
in tissue
1.1 mm 0.4 mm 2.8 mm 0.2 mm
Scan duration









Radiation dose (3D) 
according to protocol 
in references
~ 0.4 mSv / 370 MBq ~ 1 mSv / 550 MBq ~ 0.7 mSv / 555 
MBq
(2D: ~ 2.3 mSv  / 
1850 MBq) 
~ 2.1 mSv / 111 MBq 
(rest)




- - - +
Quantification Excellent Good Moderate Very good
Image quality Good (parametric 
images)
Very good Good Excellent
PET, positron emission tomography; H2
15O, oxygen-15-labeled water,   13NH3, 13N-labeled ammonia; 82Rb, 
82rubidium;  mSv, millisievert; MBq, megabecquerel
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Figure 2 shows an example of perfusion PET in a patient with a CTO of the LAD with collateral filling 
through a right ventricular branch. A large perfusion defect can be observed during hyperemia 
whereas resting perfusion is normal. These images justify an attempt to recanalize the artery for 
prognostic benefit as already alluded to. In the previous section diagnostic accuracy for MPI with PET 
to diagnose obstructive CAD has proven to be excellent. Pooled analysis of diagnostic studies display 
weighted sensitivity, specificity, NPV, and PPV of 91, 86, 81, and 93%, respectively(* 47). Moreover, 
diagnostic performance of PET is superior to the more commonly utilized single photon emission 
computed tomography (SPECT) MPI. Increased tracer extraction and higher spatial resolution of PET 
allows detection of subtle perfusion defects that may go undetected with SPECT. In addition, routine 
attenuation correction of PET significantly reduces false positive results that are frequently observed 
with SPECT(51). Figure 3 shows examples of this phenomenon. In recent years, cardiovascular 
magnetic resonance imaging (CMR) has emerged as an alternative imaging tool for MPI. CMR has the 
advantage of superior spatial resolution and perfusion can be visually assessed by first pass imaging of 
gadolinium based contrast agents. Nonetheless, a meta-analysis by Jaarsma et al. has demonstrated 
that PET is the imaging modality of choice to evaluate the functional consequences of CAD with higher 
performance over SPECT and CMR(* 52). Another distinct advantage of PET is the fact that, next to 
visual assessment of regional perfusion defects, myocardial blood flow is routine quantified in absolute 
terms (i.e. in units of mL∙min-1∙g-1) and allows to calculate coronary flow reserve (CFR)(53-57). 
Quantification of perfusion unmasks conditions of balanced ischemia whereby visual interpretation 
of perfusion images (regardless of the utilized technique like PET, SPECT, or CMR) can be completely 
normal and yield false negative results in multi-vessel disease. As patients with CTO frequently exhibit 
multi-vessel CAD, routine quantification of perfusion with PET aids in the interpretation of a seemingly 
normal scan (Figure 4). Furthermore, PET/CT allows for near simultaneous cardiac PET and CCTA to 
assess perfusion defects in relation to the coronary anatomy (figure 5).  
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Figure 2. Extensive myocardial ischemia induced by a CTO LAD.
Pati ent with a known CTO LAD for over 7 years with NYHA class II was analysed with PET to assess the 
extent of myocardial ischemia before reconsidering (percutaneous) revascularisati on. Panel A shows 
the proximal total occlusion of the LAD (white arrow). To appreciate collateralisati on, length, and 
course (white arrow) of the occlusion a bilateral injecti on was performed during a diagnosti c invasive 
coronary angiogram (B). PET perfusion shows the extensive (C and D) perfusion defect in presence 
of a proximal occlusion of the LAD. CTO, chronic total occlusion; LAD, left  anterior descending artery, 
NYHA, New York Heart Associati on; PET, positron emission tomography
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Figure 3. Representati ve cases of a false negati ve and false positi ve SPECT result due to limited tracer 
extracti on or att enuati on, respecti vely.
False negati ve SPECT result (A) in case of an unmistakable perfusion defect of the inferior wall on PET 
(B) of a pati ent with a chronic total occlusion of the RCA on ICA (C). False positi ve SPECT result (D) 
(perfusion defect of the inferior wall) of a pati ent with normal perfusion on PET (E) and no obstructi ve 
coronary artery disease on ICA (F). SPECT, single photon emission computed tomography; RCA, right 
coronary artery; ICA, invasive coronary angiography; other abbreviati ons as in fi gure 2.
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Figure 4. Balanced ischemia on SPECT
Example of a (nearly) normal SPECT (A) and severely reduced perfusion on positron emission 
tomography (PET) (B and C) in case of a signifi cant left  main stenosis (white arrow) and a chronic 
total occlusion of the RCA (black arrow) on invasive coronary angiography. SPECT is hampered by 
the relati ve nature of the images, whereas quanti fi cati on with PET allows for detecti on of diff usely 
balanced ischemia. Abbreviati ons as in fi gure 2 and 3.
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Figure 5. State-of-the-art illustrati on of fused CCTA and PET of a CTO RCA
Relati ve and absolute (normal value > 2.3 mL∙min-1∙g-1(79)) perfusion defect on H2
15O PET perfusion 
(A   B) fused with CCTA (C) shows the perfusion defect of the left  ventricle in relati on to the occluded 
segment of the RCA. ICA confi rmed the precise locati on of the coronary occlusion with bilateral 
contrast injecti on (D) CCTA, coronary computed tomography angiography; other abbreviati ons as in 
Figure 2 and 3.
Myocardial Viability Imaging
In approximately half of CTO pati ents, wall moti on abnormaliti es are observed with electrocardiographic 
evidence of myocardial infarcti on in a third of pati ents (1).  It is of interest to note that the presence 
or absence of collaterals does not signify or excludes viability, respecti vely (58-60). In such conditi ons, 
170
viability imaging is advocated. Normal resti ng perfusion basically indicates intact capillary and 
sarcolemmal membranes and is thus confi rmatory of viable myocardium. An irreversible (“fi xed”) 
perfusion defect, however, does not mean that the myocardium is not viable as it may represent 
either myocardial scarring (nonviable myocardium) or hibernati ng myocardium, a conditi on 
characterized by resti ng hypoperfusion with preserved or even augmented metabolism. The 
disti ncti on between these two conditi ons can be made by metabolic imaging. The most experience 
for myocardial substrate metabolism has been obtained with the glucose analogue 18F-deoxyglucose 
(18F-FDG)(61). Figure 6 shows the imaging patt erns of resti ng MBF and glucose metabolism 
in a pati ent with (mismatch) and without myocardial viability (match). Although nowadays 
there are many alternati ves for myocardial viability testi ng (e.g. 99mTechneti um SPECT, low dose 
dobutamine echocardiography, and delayed contrast enhanced CMR) the combinati on of cardiac 
perfusion / metabolism PET is sti ll considered the gold standard with the highest diagnosti c 
accuracy. PET/CT off ers the additi onal advantage to fuse the metabolic with the anatomical images to 
more comprehensively evaluate regional viability in relati on to the coronary tree (Figure 7).
Figure 6. Myocardial viability imaging with PET
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Illustrati on showing a mismatch of resti ng MBF and glucose metabolism of the inferolateral wall 
indicati ng viable myocardium (top). A matched resti ng perfusion and glucose metabolism defect of 
the inferior wall, indicati ng non-viable myocardium is shown in the bott om image. 82Rb, 82rubidium; 
FDG, 18F-deoxyglucose; SA, short axis; HLA, horizontal long axis; VLA, verti cal long axis; reprint with 
permission (80).
Figure 7. Viability assessment with combined PET perfusion and metabolism
Illustrati on of simultaneous mapping of coronary anatomy, myocardial perfusion and metabolism. 
Due to fused images it becomes possible to precisely disti nguish ischemic viable form non-viable 
myocardium. 13NH3, 13N-labeled ammonia; HU, Hounsfi eld units; other abbreviati ons as in fi gure 6; 
reprint with permission (81).
CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY 
(CCTA)
Over the last decade, CCTA has developed as a valuable non-invasive alternati ve for the visualizati on of 
coronary anatomy. Current multi slice CT scanners in combinati on with modern acquisiti on protocols 
enable robust and reproducible assessment of coronary artery morphology with relati vely high 
temporal and spati al resoluti on accomplished at an acceptable radiati on dose(62-65). CCTA allows to 
visualize the characteristi cs of a CTO, which is not only useful for diagnosti c purposes but also to plan 
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a potenti al interventi onal strategy. CCTA even has some advantages over invasive angiography with 
3-dimensional reconstructi ons of the aff ected segment to fully appreciate the course and length of 
the occlusion (Figure 8).
Figure 8. Example of precise occlusion length esti mati on with CCTA.
Three-dimensional reconstructi on (A), maximum intensity projecti ons (B), center line extracti on (C), 
and multi planar reconstructi ons (D) of CCTA accurately assesses coronary course, epicardial collaterals, 
plaque morphology, and occlusion length in case of a long LAD occlusion. The occlusion length was 
confi rmed with bilateral contrast injecti on during ICA (E). Abbreviati ons as in fi gure 2, 3, and 5.
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Definition of CTO on CCTA
A CTO on CCTA is diagnosed if there is complete discontinuity of contrast opacification of the coronary 
artery lumen in the cross-sectional views, multiplanar reconstructions (MPR) and maximum intensity 
projections (MIP). The time-lapse between the intravenous contrast injection and the contrast bolus 
tracking set-off results in less dense and reverse contrast opacification distal to the occlusion due to 
collateral flow (66, 67). Suspicion of a more recent occluded vessel should rise if there is no distal 
contrast opacification (68, 69). Von Erffa et al. showed that an occlusion length of ≥ 9 mm on CCTA 
predicted a total occlusion on ICA with 100% specificity in a group of 40 consecutive patients with 
a lesion demonstrating complete contrast discontinuity on CCTA. Figure 8 shows the accuracy of 
occlusion length on CCTA in comparison with ICA. Nevertheless, differentiation between high-grade 
stenosis and total occlusion remains unreliable due to the relatively limited spatial resolution of CCTA 
(70), while the presence of true lumen antegrade flow is of clinically importance since it significantly 
influences the success rate of PCI. 
Angiographic predictors of succecc of CTO PCI
Historically, the success rate of CTO PCI ranged between 50-70%, which has resulted in the reluctance 
to attempt percutaneous revascularization(1, 7, 12). To more adequately predict the chances of 
successful antegrade wire crossing (within thirty minutes) for appropriate case selection, the Japanese 
Multicenter CTO Registry (J-CTO) score was developed(* 28). The J-CTO score has identified several 
independent angiographic predictors of failure being heavy calcification, bending within the occluded 
segment, blunt proximal stump, and occlusion length > 20 mm. An additional point in this scoring 
system is given for a previous failed attempt. Low J-CTO scores are thus easily crossed, while high 
scores are characterized by high likelihood of failure. One of the issues in the full assessment of the 
J-CTO score is the frequent necessity of simultaneous double arterial injection of the right and left 
coronary artery (see Figure 2, 7, 8, 9). These images are generally not produced during a diagnostic 
invasive angiogram. These angiographic features, however, can also be visualized by CCTA and could 
therefore similarly aid in the prediction of procedural success (Table 2). Several small scaled studies 
have indeed identified very comparable angiographic CTO characteristics obtained with CCTA that 
were associated with CTO PCI failure as those observed in the J-CTO registry(71-75). It has even been 
suggested that pre-procedural knowledge of the 3D-anatomy of the occlusion may aid in antegrade 
wire escalation and crossing of the lesion and thus improve procedural outcome (76). Figure 9 
illustrates that CCTA can be quite helpful to appreciate the coronary course of an occluded segment. 
More recently, Opolski et al.(** 77) reported a CCTA based scoring system in 240 CTO patients to 
predict success of percutaneous antegrade wire crossing in the Computed Tomography Registry 
of Chronic Total Occlusion Revascularization (CT-RECTOR). Very much like the J-CTO, independent 
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angiographic predictors were occlusion length > 20 mm, multiple occlusions, blunt stump, bending, 
and severe calcification. Clinical predictors were previously failed attempt and CTO duration > 12 
months or unknown duration. The predictive value of the CT-RECTOR proved to be superior over 
the J-CTO score to predict antegrade wire crossing < 30 min (AUC 0.83 vs. 0.71). Figure 10 shows 
an example of a low and high CTO difficulty score on CCTA and ICA. These data suggest that CCTA 
could be utilized in clinical practice for case selection and perhaps even for pre-procedural planning 
to improve success. There is, however, an important caveat in the interpretation of these data. All of 
these studies have merely investigated the likelihood of antegrade wire crossing. Even though this 
type of approach is still the mainstay in attempts to percutaneously tackle CTOs, its success rate is 
low (62% in the CT-RECTOR Registry). Dedicated CTO centers that have adopted the ‘hybrid’ approach 
(i.e. next to antegrade wire escalation implementing retrograde wire escalation and dissection re-
entry techniques) nowadays achieve success rates over 90% with very acceptable complication rates. 
This approach (as depicted in Figure 11) lets coronary anatomy define the procedural strategy, but 
anatomical features and lesion complexity are not used to select cases(** 29). As such, CCTA is hardly 
utilized by hybrid operators. Nonetheless, pre-procedural CCTA could be useful for antegrade wire 
operators. Based on non-invasive CT imaging, lesion complexity and thus chances of success can be 
accurately assessed and this information employed to select cases or refer to expert centers(78).
Table 2. Assessable angiographic features of a CTO
Invasive CCTA
Lesion length ++ +++
Tortuosity ++ +++
Calcification + +++
Proximal cap morphology ++ +
Proximal side branch +++ ++
Bridging collaterals +++ +
True lumen flow ++ +
Vessel course + +++
Landing zone ++ ++
Plaque characteristics + +++
Interventional collaterals ++ +
CTO, chronic total occlusion; CCTA, coronary computed tomography angiography
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Figure 9. CCTA coronary course tracking
ICA of the RCA during bilateral contrast injection (A) and corresponding CCTA coronary course tracking 
images (B) shows that the course of the occluded segment is superiorly illustrated with CCTA in 
comparison with ICA. Abbreviations as in figure 2, 3, and 5.
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Figure 10. CTO wire crossing diffi  culty score appreciated from CCTA and ICA.
The top CCTA (A) and ICA (B) images display a short occlusion (<20mm), tapered proximal stump, no 
calcifi cati on, and no bending of the occluded segment (low CT-RECTOR score). This occlusion should be 
approached and probably successfully crossed with antegrade wire escalati on technique. The bott om 
CCTA (C) and ICA (D) images clearly demonstrates a long (>20mm) calcifi ed occlusion (high CT-RECTOR 
score) suggesti ng that the operator should be able to use dissecti on and re-entry techniques before 
trying to cross this occlusion because anatomy dictates which approach should be used. Abbreviati ons 
as in fi gure 2 and 3. 
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Figure 11. Algorithm for crossing CTOs 
Hybrid approach dictated by anatomical features of a chronic total occlusion of a nati ve coronary 
artery. LaST, limited antegrade subinti mal tracking; other abbreviati ons as in fi gure 2; reprint with 
permission(** 29). 
CONCLUSIONS
Percutaneous revascularizati on of CTOs is less frequently performed as non-occlusive CAD due to 
technical procedural challenges, lower likelihood of recanalizati on, and increased complicati on rate. 
PET/CT allows for non-invasive imaging of myocardial perfusion and metabolism to objecti fy the extent 
of ischemia and viability. The hybrid images of coronary anatomy with CT and functi onal consequences 
of the CTO with PET allows for appropriate selecti on of pati ents who are likely to benefi t from CTO PCI 
and facilitate procedural planning.
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Chronic coronary total occlusions (CTO) are diagnosed in up to 20% of patients with coronary artery 
disease and have a detrimental effect on patients’ quality of life and long-term prognosis. The 
exponential developments in CTO percutaneous coronary intervention (PCI) equipment, recanalization 
techniques, and operator expertise have been merged into the hybrid approach that represents a 
percutaneous revascularization algorithm for treating CTOs and has led to technical success over 90% 
at experienced centers. Therefore, patient selection for CTO PCI should be focused on anticipated 
patient benefit in terms of health status and long-term prognosis rather than coronary anatomic 
complexity. 
CONTENTS
This review will provide an overview of the clinical presentation and characteristics of patients with 
a CTO and will discuss the essential needs toward judicious patient selection for percutaneous CTO 
revascularization according to contemporary knowledge. Furthermore, the current high standard 




Chronic coronary total occlusions (CTO) can be considered the final stage of obstructive coronary artery 
disease (CAD) and are associated with a negative impact on long-term prognosis [1]. A CTO is defined 
as complete luminal obstruction of a native coronary artery for a duration of ≥3 months. The minimal 
duration of a CTO is preferably determined by previous coronary angiography or, if unavailable, 
estimated based on clinical grounds [2]. CTOs are classified by the Thrombolysis in Myocardial 
Infarction (TIMI) flow grade on invasive coronary angiography as a ‘‘true’’ or ‘‘functional’’ CTO (TIMI 
flow grade 0 and 1, respectively). In large clinical registries, a CTO has been diagnosed in 16-18,4% 
of patients with CAD [3, 4]. These large registries showed that the current mainstay in the treatment 
of patients presenting with a CTO is optimal medical therapy (OMT), and only a minority of these 
individuals receive additional surgical (22-26%) or percutaneous (10-22%) revascularization [3, 4]. The 
general preference for OMT in patients with a CTO originates from the concerns regarding clinical and 
prognostic patient benefit of revascularization, complexity of CTO percutaneous coronary intervention 
(PCI) with historically low technical success and high complication rates, high contrast and radiation 
use, and doubts about the presence of ischemia or viability in the myocardial territory subtended 
by the occluded artery [5, 6]. However, the availability of specialized CTO PCI equipment has been 
increasingly expanding along with an ongoing progress in percutaneous revascularization techniques 
and operator expertise [7, 8]. This has resulted in enhanced technical success rates from 50-70% to 
over 90% achieved by high-volume operators [5, 8-10]. Therefore, CTO PCI has emerged as a feasible 
and valuable treatment option warranting new perceptions regarding the traditionally conservative 
era in CTO treatment. The present review provides an overview of the clinical characteristics and 
management of patients with a CTO, next to updated perspectives and technical standards in CTO PCI. 
CLINICAL PRESENTATION OF PATIENTS WITH A CHRONIC 
TOTAL OCCLUSION
In general, patients with a CTO are older, more frequently male, and have a relatively unfavorable 
cardiac risk factor profile as compared with patients with non-occlusive CAD [3, 4]. A higher prevalence 
of diabetes mellitus (34 vs. 26%), hypertension (75 vs. 68%), hyperlipidemia (82 vs. 78%), current 
smoking (33 vs. 24%), peripheral vascular disease (8 vs. 4%) and prior myocardial infarction (MI) (40% 
vs. 23%) is observed among patients with a CTO as compared to patients with non-occlusive CAD [3]. 
This observation illustrates that pronounced CAD, as depicted by a CTO, is accompanied by severe 
comorbidity. 
An undiagnosed or untreated acute thrombotic event is regularly the origin of CTO development, 
which is supported by electrocardiographic evidence of pathological Q-waves corresponding to the 
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myocardial territory subtended by an occluded artery in a quarter of patients [3]. However, the majority 
of patients (60%) with a CTO did not suffer from previous MI [3]. In these patients, the occlusion 
seems to be the result of long-term gradual luminal narrowing allowing for recruitment of collaterals 
to the occluded vessel. The recruitment of collaterals has a protective role by supplying myocardial 
blood flow to the CTO territory and thereby preventing acute myocardial ischemia. Preserved viable 
myocardium subtended by the occluded artery and absence of cardiac symptoms are therefore 
common observations [11]. The development of a CTO, either after a thrombotic event or by long-term 
gradual luminal narrowing, is not reserved to the natural vessel wall only and can occur in a previously 
implanted stent in patients treated with PCI earlier on [12]. Approximately one out of four patients with 
a CTO does not experience symptoms [13]. Chest pain is a fairly late expression in the ischemic cascade 
and symptoms can even be absent in the presence of intermittent moderate-to-severe ischemia [14]. 
The lack of symptoms may be amplified due to autonomic neuropathy in diabetic patients, whom are 
strongly represented in the CTO patient population [3]. In symptomatic CTO patients, typical cardiac 
chest pain may be less prominent than shortness of breath or atypical symptoms including physical 
activity limitation, extensive fatigue, or palpitations due to ventricular arrhythmias [4, 6]. Patients with 
a CTO and an implantable cardioverter defibrillator for primary or secondary prevention of sudden 
cardiac death have a higher incidence of appropriate delivered therapies and shocks as compared to 
patients with ischemic cardiomyopathy without a CTO [15]. A CTO in an infarct-related artery (IRA) has 
been identified as an independent predictor for the occurrence of ventricular arrhythmias, resulting 
in a two to three-fold higher recurrence rate, even after ventricular tachycardia ablation [15, 16]. It 
could be hypothesized that an IRA-CTO with additional residual ischemia around the necrotic area and 
the potentially negative influence on long-term remodeling of myocardial scar acts as an initiator for 
ventricular arrhythmias [15, 16]. 
HAZARDS OF CHRONIC TOTAL OCCLUSIONS IN PATIENTS 
WITH AN ACUTE CORONARY EVENT
Chronic total occlusions in a non-IRA are present in 10% of patients presenting with ST elevation 
myocardial infarction (STEMI) [3]. The presence of a concomitant CTO in patients with STEMI is 
responsible for a worsened 30-day event rate and long-term prognosis [17]. Prognosis especially 
deteriorates in case the CTO vessel receives collateral flow from the IRA [18]. This so called ‘’double 
jeopardy’’ phenomenon results from an amplified ischemic myocardial territory subtended by the 
occluded artery due to its dependence on blood flow through the IRA (figure 1). 
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Figure 1. The risk of a non-IRA CTO in a patient with ACS. A STEMI patient with an acute thrombotic occlusion 
(arrow) of the proximal LAD (A) and a CTO RCA (arrow: proximal cap) (B). After primary PCI of the LAD a very 
well-developed collateral over the apex (arrowhead) appeared to be the predominant source of collateral flow to 
the CTO territory (arrow) (C). After successful recanalization of the CTO RCA in a second procedure (D), antegrade 
flow to the CTO territory (arrow) eliminated dependency on the donor artery. ACS, acute coronary syndrome; 
CTO, chronic coronary total occlusion; IRA, infarct-related artery; LAD, left anterior descending artery; PCI, 
percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST elevation myocardial infarction.
The recently published randomized EXPLORE-trial investigated potential gain in left ventricular 
function (LVF) due to non-IRA CTO revascularization within one week after the occurrence of STEMI. 
The hypothesis of this trial was that early CTO revascularization in STEMI patients restores LVF and 
improves healing of the infarct border zone, yet no additional benefit on LVF was observed in patients 
with additional CTO PCI compared to OMT alone [19]. Later on a substudy of the EXPLORE-trial 
demonstrated a greater recovery in regional systolic function in the CTO territory after CTO PCI [20]. 
However, there is currently insufficient evidence supporting CTO PCI in an acute patient. 
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BENEFIT OF CHRONIC TOTAL OCCLUSION 
REVASCULARIZATION IN STABLE PATIENTS
Multiple observational studies have demonstrated the association of successful CTO revascularization 
with improved clinical outcomes compared to non-successful CTO revascularization. These studies 
showed in symptomatic patients a significant symptom relief and improved self-reported quality of 
life and exercise tolerance [21-23]. Successful CTO revascularization significantly reduces myocardial 
ischemic burden (figure 2) and a modest positive effect on LVF and left ventricular remodeling has 
been suggested [24-27]. 
Figure 2. Myocardial ischemia induced by a CTO RCA and recovery of myocardial perfusion after successful 
PCI. The distal vascular bed of the RCA (white arrow) prior to PCI receives collateral flow through septal and 
epicardial collaterals from the LAD and LCX respectively. (A) Re-established antegrade flow to the distal vascular 
bed of the RCA (white arrow) after CTO PCI (B). PET perfusion shows myocardial ischemia (C) with recovery after 




Furthermore, successful CTO PCI has been associated with a reduced need for coronary artery bypass 
graft surgery (CABG), and may provide a long-term survival benefit compared to non-successful 
revascularization [21, 24]. The beneficial effect of successful CTO PCI on long-term survival is, despite 
more major comorbidities, maintained in the elderly (≥75 years) [28]. Importantly, the observational 
nature of the aforementioned studies cannot exclude the impact of confounding and selection bias on 
clinical outcomes. Recently, the results from the DECISION-CTO trial (NCT01078051) and the EURO-CTO 
trial, as the first randomized studies to elucidate the surplus clinical value of CTO PCI over OMT alone 
in terms of health status and safety outcomes, were revealed (table 1) [29]. In the DECISION-CTO trial, 
the three-year rate of the composite endpoint of all-cause death, MI, stroke, and any revascularization 
in the intention-to-treat analysis was similar between the PCI and OMT groups (20.6% vs 19.6%) [30, 
abstract only]. It remains challenging to draw definite conclusions within this trial due to delayed and 
incomplete recruitment of patients, the revascularization of other non-occlusive lesions in addition to 
CTO PCI after randomization and baseline health status assessment, the high crossover rate to the PCI 
group (15-20%), and inclusion of periprocedural MI in the primary outcome. Interim analysis of the 
EURO-CTO trial revealed a significantly improved one-year health status in the PCI group compared to 
the OMT alone arm, whilst the major adverse cardiovascular events rate was comparable [29]. Study 
completion including the results of the three-year composite endpoint of all-cause death and non-
fatal MI is expected in 2018. The SHINE-CTO trial (NCT02784418) is designed to determine whether 
CTO PCI improves patients’ symptoms by randomizing to CTO PCI or a sham procedure. The results 
of the SHINE-CTO trial are expected to be available in 2018. Although these first trials pave the way 
toward appropriate treatment decision-making for stable patients with a CTO, more well-designed 
randomized trials will be needed to provide the necessary evidence to guide treatment.
Table 1. Three randomized trials concerning the additional clinical value of CTO PCI over OMT alone.
DECISION-CTO trial EURO-CTO trial SHINE-CTO trial




Recruited patients 834 (enrollment stopped) 407 (enrollment stopped) Ongoing 
Major inclusion & 
exclusion criteria
CTO in a major artery ≥2.5mm
Stable angina, ACS or ischemia 
Non-CTO PCI before 
randomization
No LVEF <30%
CTO in a major artery ≥2.5mm
Symptoms/ischemia and 
viability
Non-CTO PCI before 
randomization 
No previous MI < 1 month 
Clinically-indicated CTO PCI
Symptoms related to the 
CTO
Already treated with OMT
 
No previous MI <7 days
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DECISION-CTO trial EURO-CTO trial SHINE-CTO trial
Primary 
endpoint(s)
Three year composite of
    - Death from any cause
    - MI
    - Stroke
    - Any revascularization
1) Health status at 1 year
    - SAQ
2) Three year composite of:
    - All-cause death
    - Non-fatal MI
Health status at 1 month
    - SAQ
Primary results 
[29, 30 (abstract 
only)]
PCI + OMT 20.6% vs OMT only 
19.6% (p=0.54)
OMT non-inferior to PCI + OMT 
in intention-to-treat analysis
OMT not non-inferior to PCI + 
OMT in per-protocol and as-
treated analyses
1) More improvement after 
PCI in:
    - Quality of life 
    - Anginal frequency 
    Equal between groups:
    - Physical limitation 
    - Anginal stability 
    - Treatment satisfaction 
2) Results are awaited
Results are awaited
ACS, acute coronary syndrome; CTO, chronic coronary total occlusion; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; SAQ, Seattle 
Angina Questionnaire.
DIAGNOSTIC WORK UP
Once the diagnosis of a CTO in a patient is established, the indication for revascularization of a CTO can 
be determined similar to CAD in general, by the presence of symptoms and/or the extent of ischemia 
and viability (figure 3) [31]. 
Normal wall motions or hypokinesia of the myocardium subtended by the occluded artery per 
definition excludes non-viability. In the presence of myocardial viability, CTO revascularization is 
considered beneficial if there are persisting invalidating symptoms despite OMT [31, 32]. According 
to the European guidelines, CTO revascularization is also indicated if myocardial ischemia comprises 
>10% of the left ventricle irrespective of symptoms [31]. The latter is based on observational studies 
that hint towards a prognostic benefit of revascularization in the presence of CAD in general (not CTO 
specific) and a large ischemic burden [33]. Randomized trials are lacking to support this hypothesis 
although the ongoing ISCHEMIA trial (NCT01471522) is addressing this issue. The American guidelines 
include additional clinical and angiographic characteristics to determine the appropriate use of myo 
cardial revascularization in asymptomatic patients, including CTO lesions  [32]. In case of one- or two- 
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Figure 3. Diagnostic and treatment algorithm in patients presenting with a chronic coronary total occlusion.
vessel disease and intermediate- or high-risk findings on (non)invasive testing, revascularization 
may be appropriate, and in a few subsets of these asymptomatic patients revascularization can be 
considered appropriate when there is proximal LAD or left dominant left circumflex involvement 
[32]. In asymptomatic patients with three-vessel disease and low-risk findings on noninvasive testing, 
revascularization in general may be appropriate, and can be considered appropriate in some cases in 
the presence of diabetes and intermediate or high anatomical disease complexity. In asymptomatic 
patients with three-vessel disease and intermediate- or high-risk findings on noninvasive testing, 
revascularization (preferably CABG) is considered appropriate regardless of anatomical disease 
complexity [32].
Angiographically well-developed collaterals to the occluded artery are often assumed to be sufficient to 
prevent ischemia. Non-invasive and invasive studies have clearly demonstrated the limited functional 
capacity of collaterals to provide sufficient myocardial perfusion in the vast majority of patients (figure 
4) [14, 34]. Therefore, the existence of well-developed collaterals should not guide the indication for 
revascularization. Marked ischemia holds prognostic relevance, whilst a significant benefit in ischemia 
reduction can be established with CTO PCI [25, 35]. In case of significant wall motion abnormalities 
of the myocardium subtended by the occluded artery, the diagnostic work-up should be primarily 
focused on the detection of myocardial viability. Without signs of myocardial viability, no recovery of 
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LVF can be anticipated and CTO revascularization is considered inappropriate [25, 26]. Conversely, the 
presence of substantial myocardial viability prior to revascularization is a predictor for improvement 
of regional and global LVF [25, 26]. Myocardial ischemia and viability can be assessed using an array of 
non-invasive imaging tests [36]. The choice of non-invasive imaging for CTO patients should be based 
on local availability and expertise.
Figure 4. Extensive myocardial ischemia despite angiographically well-developed collaterals. A Epicardial 
(arrow) and septal collaterals supplying retrograde flow to the distal vascular bed of a CTO in the proximal LAD 
(arrowhead). PET perfusion shows extensive myocardial ischemia in the LAD territory despite the angiographically 
well-developed collaterals (B and C). Abbreviations as in figure 1 and 2.
NEW CONSIDERATIONS CONCERNING CTO PCI AS CHOICE 
OF TREATMENT
While CTOs are diagnosed in 16-18.4% of patients with CAD, a national report stated that CTO PCI 
represented only 4.8% of the total PCI volume in 2013 in the United States [3-5]. In addition, national 
reports from the Swedish Coronary Angiography and Angioplasty Registry (average in 2005-2012), 
the United Kingdom (in 2012) and a Japanese multicenter registry (average of all elective procedures 
in 2008-2013) reported that CTO PCI comprised 5.8%, 5% and 10.1% of the total PCI volume, 
respectively [4, 37, 38]. CTO PCI has traditionally been considered as a less appropriate treatment 
strategy relative to non-CTO PCI and surgical revascularization, and OMT is currently the most 
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frequently applied treatment option [3, 4, 6]. In every patient with a CTO, especially in the presence 
of multivessel disease, the international guidelines advocate an individualized risk-benefit analysis by 
the Heart team encompassing clinical and angiographic considerations to guide treatment decision 
making [31, 32, 39]. A recent analysis showed that incomplete revascularization following CTO PCI 
has a detrimental effect on long-term clinical outcomes [40]. The SYNTAX II study demonstrated in 
addition the incremental value of several new developments in the field of complex PCI in patients 
with triple-vessel disease, leading to improved clinical outcomes compared to the PCI performed in 
similar patients in the original SYNTAX-I trial [41, 42]. Of note, the implementation of contemporary 
revascularization techniques in CTO PCI by experienced operators led to a 87% success rate that was 
achieved overall in 22 participating centers [41]. These technical developments and increasing success 
rates in CTO PCI leading to complete revascularization should play a role in the interpretation of current 
rather conservative recommendations for percutaneous CTO revascularization [8, 31]. Randomized 
trials are warranted to be able to accurately appreciate the potential advances of these developments 
in CTO PCI. In 2012, a hybrid percutaneous treatment algorithm focusing on percutaneous CTO 
revascularization in a most safe, effective, and efficient manner was introduced [7]. Current standards 
and considerations within the framework of this so called ‘‘hybrid approach’’ in CTO PCI will be further 
discussed.
PERCUTANEOUS REVASCULARIZATION OF CHRONIC TOTAL 
OCCLUSIONS: PREPARATION IS KEY
Once a clinical indication for CTO PCI has been established, planning and preparation of the procedure 
will be a major factor for revascularization success. Double arterial access is strongly recommended 
since it facilitates dual contrast injection and a potential retrograde approach [43]. Such access can 
be femoral-radial, bifemoral, or biradial. The latter however is limited by use of ≤7 French guiding 
catheters. An 8-French guiding catheter for the CTO vessel enables the utilization of the full range 
of dedicated CTO PCI materials and is preferred in complex CTO PCI cases over ≤7 French guiding 
catheters only [44]. In general, more aggressive support guiding catheters are preferred to provide 
the required penetrative power to deal with the often resilient proximal cap and adequate support to 
maneuver a microcatheter through the retrograde channel. However, access site and guiding catheter 
selection always depends on patient and angiographic suitability as well as the preference of the CTO 
operator [43]. 
Careful assessment of the target CTO lesion and other angiographic characteristics is essential for 
adequate procedural planning. It is recommended to start virtually all CTO procedures with dual 
contrast injection, with the exception of sole ipsilateral collaterals, as it ensures optimal visualization of 
the CTO body and collateral filling. Dual injection is performed by contrast injection in the donor vessel 
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followed by a slightly delayed simultaneous injection in the CTO vessel. Prolonged image acquisition 
at low magnification without table panning from multiple angles allows adequate appreciation of the 
angiographic information needed to determine an adequate treatment strategy. 
In the hybrid approach, four angiographic characteristics (figure 5) guide initial strategy selection 
(table 2) [7]:
1) The proximal cap: location and morphology. Proximal cap morphology is distributed over three 
classifications with increasing difficulty to approach: tapered, blunt, or ambiguous. Proximal cap 
ambiguity indicates the inability to define its location and can be due to the origin of a side-branch 
near the proximal cap.
2) CTO lesion length. Based on the Japanese CTO registry, a cut-off of 20mm is used to dichotomize 
with <20mm more suitable for a wire escalation technique and ≥20mm for a dissection and re-entry 
technique as initial approach [7, 45]. Noteworthy, lesion length does not guide preference for an 
antegrade or retrograde approach.
3) Distal landing zone. The distal landing zone refers to the part of the CTO vessel beyond the occlusion. 
Evaluation of the distal landing zone includes vessel size, angiographic health, and its presence near 
a bifurcation or side branch. A proper distal landing zone would favor an antegrade (dissection and 
re-entry) approach, whereas in case of a poor distal target an initial retrograde approach may be more 
suitable. 
4) The interventional suitability of collaterals. Favorable aspects of an interventional collateral are a 
suitable angle to engage the collateral from the donor vessel, minimal tortuosity, a visible connection, 
and an adequate entry of sufficient length to penetrate the distal body of the CTO. The presence of 
multiple collaterals to the CTO vessel reduces the risk of intra-procedural ischemia due to mechanical 
obstruction during collateral engagement with a microcatheter. All potential retrograde pathways, 
including septal and epicardial collaterals and (occluded) bypass grafts, should be evaluated for 
interventional suitability.
Table 2. Favorable angiographic characteristics for each of the percutaneous revascularization techniques in 
CTO PCI.
AWE ADR RWE RDR
Clear proximal cap + + - -
Lesion length ≥20mm - + - +
Good distal landing zone + + - -
Interventional collaterals - - + +
ADR, antegrade dissection and re-entry;  AWE, antegrade wire escalation; CTO, chronic coronary total occlusion; 




Figure 5. Examples of the four main angiographic characteristics guiding strategical planning in CTO PCI. 1a CTO 
RCA with a tapered proximal cap, 1b CTO LAD with a blunt proximal cap, 1c CTO LAD with an ambiguous proximal 
cap (tapered line), the distal cap is also shown (arrow), 2a CTO LAD with a short lesion length (<20mm), 2b CTO 
RCA with a long lesion length (>20mm), 2c a functional CTO RCA with TIMI grade flow I, 3a CTO RCA with a good 
distal landing zone, 3b CTO RCA with a diseased distal landing zone, 3c CTO RCA with significant side branches 
near the distal cap, 4a CTO RCA and multiple potentially interventional septal collaterals, 4b CTO RCA and a 
potentially interventional epicardial collateral arising from the LCX, 4c CTO RCA and a vein graft (arrow) with 
an anastomosis to the distal RCA (arrowhead) serving as a potential retrograde pathway. TIMI, thrombolysis in 
myocardial infarction. Other abbreviations as in figure 1 and 2
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Antegrade wire escalation
Favorable angiographic findings for antegrade wire escalation (AWE) are: an unambiguous (preferably 
tapered) proximal cap, <20mm occlusion length, and a good distal target. In AWE (figure 6), usually the 
initial wire choice is a (non-traumatic) polymer-jacketed wire with low-gram tip load (≤ 1 gr.) for loose 
tissue tracking. Penetration force and maneuverability of the wire can be supported by advancing 
a microcatheter near to the tip. With lack of progress, stepwise escalation to wires with increasing 
tip-load should be used until successful CTO crossing is achieved or strategy is altered (vide infra for 
other strategies). The subsequent wire in AWE is determined by lesion characteristics. In unclear, long 
or tortuous pathways, a non-tapered polymer-jacketed wire with moderately high-gram tip load is 
preferred, while in case of a short and clear path and target a stiff tapered wire with high-gram tip load 
will be more efficient for direct penetration of tissue.
The Japanese CTO score (J-CTO score) can be applied when considering AWE. The J-CTO score is 
an angiographic model predicting the probability of successful CTO crossing within 30 minutes 
performing AWE only, using 5 independent predictors for failure [45]. A previous failed attempt, a 
blunt proximal cap, presence of any calcification, >45 degrees bending within the CTO segment, and 
≥20mm occlusion length each adds 1 point to the J-CTO score. With every increase in J-CTO score the 
probability of successful AWE within 30 minutes decreases [45]. While maintaining its predictive value 
for complexity of CTO recanalization, the J-CTO has limited value in predicting final success rate in case 
of an experienced operator using the hybrid approach (including antegrade dissection and re-entry 
(ADR) and retrograde techniques) [9]. 




Retrograde approaches are complementary techniques to AWE and have allowed for a significant 
increase in technical success rates [46, 47]. Generally retrograde approaches result in longer 
procedural times and higher radiation and contrast requirements [46]. However, they are often used 
for CTO lesions of higher anatomic complexity and are regularly the key to successful CTO crossing 
after a failed antegrade approach [46, 47]. Periprocedural complications occur more frequently in 
retrograde approaches compared to antegrade approaches, mainly because of the higher occurrence 
of periprocedural MI and the possibility of donor vessel- or collateral injury [46, 48]. A retrograde 
approach may be favorable over an antegrade approach in case there is an ostial or ambiguous 
proximal cap or a poor distal landing zone, and a suitable interventional collateral. Crossing an 
available bypass graft in post-CABG patients is safe and generally successful [49]. Septal collaterals are 
also commonly suitable and safe pathways to reach the CTO vessel [46, 47, 49]. A major advantage 
of the septal collateral is its tolerability for channel perforations, as it practically never leads to 
cardiac tamponade since the perforation would leak to one of the ventricular cavities or results in 
a (usually) self-limiting intraseptal hematoma. Successful septal crossing depends predominantly on 
tortuosity rather than size, and septal collaterals can be crossed using a tip injection facilitated or blind 
septal surfing technique [50]. The tip injection technique includes sequential distal microcatheter tip 
injections within the septal collateral in order to visualize a distal connection to the occluded artery. 
Septal surfing involves probing of septal channels by trial and error in a more blinded fashion in search 
of a path of low resistance. By using this technique, visualization of septal channels on the coronary 
angiogram is of less importance. The course of an epicardial collateral can be contralateral or ipsilateral 
including bridging collaterals. Epicardial collateral crossing is associated with a higher incidence of 
non-Q-wave MI and channel injury requiring treatment as compared with septal collaterals and is 
therefore more challenging [49]. Over-the-wire balloons are contraindicated in epicardial collaterals 
due to the risk of epicardial channel injury. Dedicated low-profile microcatheters allow a more safe 
and effective crossing of these collaterals [51]. 
Most operators report that the distal cap is easier to cross compared to the proximal cap [52]. The 
occlusion can be crossed using the retrograde wire escalation (RWE) technique, similar to AWE. If the 
guidewire enters the subintimal space or CTO characteristics are unfavorable for RWE, a retrograde 
dissection and re-entry (RDR) technique can be initiated. In RDR, a guidewire will be navigated into 
the subintimal space distal or within the occlusion to cross the CTO through the subintimal space. The 
most common used RDR technique is the reverse controlled antegrade and retrograde subintimal 
tracking (CART) technique [46, 51]. In this technique adjacent subintimal dissection planes around or 
proximal to the CTO are created with an antegrade as well as a retrograde guidewire. Of paramount 
importance before applying re-entry into the vessel lumen is the determination of a proper re-entry 
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zone. Subintimal passing of bridging collaterals and side branches can lead to their loss after coronary 
angioplasty, which can potentially result in MI. In reverse CART, a connection between both subintimal 
spaces is created by inflating a balloon over the antegrade guidewire. Subsequently, the retrograde 
guidewire passes through the subintimal track created by the antegrade guidewire before making 
re-entry into the vessel true lumen [7]. Once successful retrograde crossing of a CTO is realized, the 
final step should be wire externalization. After the retrograde guidewire and microcatheter have been 
directed into the antegrade guiding catheter, the retrograde wire can be changed for an externalization 
guidewire (>3.30 m), which can be advanced until it exits the Y-connector of the antegrade guiding 
catheter. This wire externalization technique creates a closed system enabling antegrade coronary 
angioplasty. The crossed collateral endures high forces while maintaining this externalized wire and 
should be protected by the retrograde microcatheter at all times. If the conventional externalization 
method does not succeed, snaring the wire, the tip-in technique and the rendezvous technique offer 
an alternative to succeed the retrograde approach. In snaring, the antegrade guiding catheter should 
be pulled back, and subsequently the retrograde externalization wire has to be directed into the aorta 
through one of the loops of the antegrade snare. Once the externalization wire has been ‘’snared’’, 
it will be pulled back into the antegrade guiding catheter to allow for externalization [52]. The tip-in 
technique involves the advancement of an antegrade microcatheter over a retrograde wire, and can 
usually be accomplished in the aortic arch, where the retrograde wire and antegrade microcatheter 
can meet in the outer curve of the antegrade guiding catheter [53]. Once the tip-in technique has 
been successful, the antegrade microcatheter can be advanced over the retrograde wire to the distal 
vessel, allowing for antegrade coronary angioplasty. The tip-in technique shows similarities with the 
rendezvous technique, that uses the aligment of an antegrade and retrograde microcatheter to direct 
the antegrade wire into the retrograde microcatheter. After progressing the antegrade wire through 
the retrograde microcatheter further down beyond the occlusion, the operator can proceed with 
antegrade coronary angioplasty [54].
Antegrade dissection and re-entry
The ADR technique is the subintimal passage of a CTO in an antegrade fashion with re-entry into the 
distal vessel lumen [8]. This technique is especially useful for crossing of long lesions (≥20mm) with 
a clear proximal cap and a good distal landing zone. ADR should be considered complementary to 
other techniques enabling higher procedural success rates and several studies reported comparable 
complication rates after the use of ADR and intraplaque crossing techniques [55-57]. Subintimal 
tracking can be achieved with the knuckle wire technique or device-assisted using a CrossBoss 
catheter (Boston Scientific, Maple Grove, MN, USA). The knuckle technique is used to achieve blunt 
cleavage of the subintimal space across the CTO by pushing a looped polymer-jacketed wire (‘’the 
knuckle’’) toward the distal landing zone. The CrossBoss catheter is an over-the-wire catheter and 
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its blunt, low-profile tip minimizes vessel trauma during subintimal tracking and preserves relatively 
more side-branches. Due to its higher crossing profile, the CrossBoss catheter also allows in some 
patients for effective intraplaque crossing, especially in case of in-stent CTOs [12]. The first introduced 
re-entry technique was the wire-based subintimal tracking and re-entry (STAR) technique in which a 
forward push of the knuckle results in spontaneously re-entry to the vessel lumen [8]. The wire-based 
limited antegrade subintimal tracking (LAST) technique uses a straight-tip guidewire with high tip load 
for re-entry. LAST preserves relatively more side branches and has a higher success rate compared 
to the STAR-technique [58]. An alternative for these wire-based re-entry techniques is the Stingray 
Balloon Catheter (Boston Scientific, Maple Grove, MN, USA), designed to deploy in the subintimal 
space. The exit ports on either side of the balloon can be selectively engaged to provide re-entry in the 
vessel lumen [59]. The CrossBoss/Stingray combination facilitates a more controlled dissection plane 
as well as re-entry compared to the LAST- and STAR-techniques with relatively high success rates and 
improved long-term clinical outcomes [58]. 
The hybrid approach
The hybrid algorithm provides a consistent and reproducible format enabling flexible change to other 
techniques when one fails (figure 7). The PROGRESS CTO score and the RECHARGE score are 2 novel 
easy-to-use predictive tools to assess the risk for technical failure in CTO PCI. Both scores are based 
on the presence or absence of several CTO-related angiographic characteristics and are validated in a 
cohort of hybrid approach based CTO PCI [60, 61]. Previous studies indicated more complications in CTO 
PCI compared to non-CTO PCI including a higher rate of major adverse cardiac events and perforations 
along with higher contrast- and radiation use (with the potential for radiation-related dermal injury 
and contrast-induced renal dysfunction) [5, 62]. Failed attempts to open a CTO compared to successful 
CTO procedures are associated with a higher incidence of periprocedural complications [63]. On the 
contrary, the application of the hybrid approach in high-volume CTO PCI centers has led to technical 
and procedural success rates up to 90-95% with acceptable periprocedural complication rates [8-
10]. A recent European multicenter study including 17 high and lower experienced CTO PCI centers 
using the hybrid approach showed an overall low complication rate [8]. Of note, the abovementioned 
proposed techniques and considerations within the framework of the hybrid approach apply for 
trained hybrid CTO operators only.  Before using the hybrid algorithm in CTO PCI, the CTO operator 
needs to be familiar with the full range of techniques and dedicated CTO equipment. Experience with 
a variety of tools to deal with the potential acute periprocedural complications, such as perforations 
or tamponade requiring pericardiocentesis is necessary. PCI operators whom have no experience with 
the technical standards used in the hybrid approach could master the antegrade true-to-true approach 
for less complex CTO lesions such as the lesions with a J-CTO score of 0 or 1, however, should refer 
cases of higher anatomic complexity to more experienced CTO centers [64]. It is advised  for starting 
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CTO operators to attend to CTO focused meetings and to be assisted by more experienced operators 
through a proper proctorship to develop stepwise the dedicated skills for performing CTO PCI. 
Figure 7. The hybrid algorithm for crossing CTOs, dictated by anatomical features of a CTO in a native coronary 
artery. LaST, limited antegrade subintimal tracking; STAR, subintimal tracking and re-entry.  
CURRENT PERSPECTIVES
CTOs are commonly diagnosed in patients with CAD and have a negative impact on quality of life 
and long-term prognosis. Observational studies point toward additional benefits of CTO PCI over 
OMT alone, however, randomized clinical trials with hard outcomes are eagerly awaited for further 
exploration. With nowadays high success and acceptable complication rates, patient selection for 
percutaneous revascularization should be focused on anticipated patient benefits instead of coronary 
anatomic complexity. With judicious patient selection and a dedicated operator with the appropriate 
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Aims: Previous studies on invasive assessment of collateral function in CTO patients have displayed 
only a limited increase in collateral flow and high occurrence of coronary steal during pharmacological 
stress. This could question the necessity for ischemia testing prior to revascularization of CTOs in the 
presence of myocardial viability. The purpose of the present study was to determine the prevalence of 
perfusion impairments in patients with a CTO as assessed by [15O]H2O positron emission tomography 
(PET).
Methods and Results: Seventy-six consecutive patients (60 men, 62±10 years) with a documented 
CTO and preserved left ventricular ejection fraction (LVEF) were included. All patients underwent 
PET to assess (hyperemic) myocardial blood flow (MBF) and coronary flow reserve (CFR). Collateral 
connection score was zero in 7 (9%), 1 in 13 (17%), and 2 in 56 (74%) of the cases, with predominantly 
a high Rentrop grade (96%≥2). MBF of the target area during hyperemia was significantly lower as 
compared to the remote area (1.37±0.37 vs. 2.63±0.71 mL∙min-1∙g-1, p<0.001). Target to remote ratio 
during hyperemia was on average 0.54±0.13, and 73 (96%) patients demonstrated a significantly 
impaired target to remote ratio (≤0.75). Only 7 (9%) patients displayed a preserved CFR of≥2.50, 
whereas coronary steal (CFR<1.0) was observed in 10 (13%) patients.
Conclusions: Even in the presence of angiographically well-developed collateral arteries, the vast 
majority of CTO patients with a preserved LVEF showed significantly impaired perfusion. These 





Chronic coronary total occlusions (CTO) are encountered in up to one third of patients with known 
or suspected coronary artery disease (CAD).(1-3) A CTO is defined as a native coronary artery with 
complete discontinuity of contrast opacification and TIMI flow grade zero or 1 for ≥ 3 months.(4-
6) Successful percutaneous coronary intervention (PCI) of a CTO is associated with symptom relief, 
recovery of left ventricular function, and improved survival as opposed to patients in whom the 
procedure was unsuccessful(3;5;7;8). Still, patients with a CTO are less likely to be treated with 
percutaneous revascularization.(1) The reluctance of physicians to refer patients for PCI of a CTO is 
based on lower procedural success, traditionally higher complication rates, contrast and radiation 
burden, and potentially the assumption that angiographically well-developed collateral arteries 
(Rentrop grade 2-3) prevent myocardial ischemia.(5;9) Consequently, non-invasive evaluation of 
myocardial ischemia and viability has been proposed to justify percutaneous revascularization of a 
documented CTO.(10;11) An ischemic burden of ≥ 10% has been considered of prognostic value and 
has been incorporated in those decision schemes.(12) However, these decision schemes are mainly 
based on the uncertainty of the hemodynamic significance of non-occlusive CAD, whereas CTOs are 
purely dependent on collateral flow.(13;14) Previous invasive flow investigations have demonstrated 
the inability of collateral arteries to comply with the demand during exercise.(15;16) This could 
question the necessity for ischemia testing prior to revascularization of CTOs in the presence of 
myocardial viability. The present study was designed to evaluate the prevalence and extent of absolute 
myocardial perfusion impairment using cardiac positron emision tomography (PET) in patients with a 
documented CTO and a preserved left ventricular ejection fraction (LVEF).
METHODS
Study design and participants
All CTO-patients considered for percutaneous revascularization at the VU University Medical Center are 
analyzed in a dedicated program with two experienced CTO operators. Invasive coronary angiograms, 
myocardial viability, ischemia, and cardiac symptoms of all patients were analyzed to determine 
indication for revascularization and a prospective database of all patients is maintained. Symptomatic 
as well as asymptomatic patients are included in this database. Patients with a documented CTO 
referred for [15O]H2O PET to assess myocardial blood flow (MBF) were included in the present study. 
Inclusion criteria were a documented CTO of a native coronary artery and a preserved LVEF (≥ 50%) on 
echocardiography or magnetic resonance imaging to guarantee viable myocardium of the downstream 
myocardial territory of the CTO. Exclusion criteria were symptomatic asthma, pregnancy, high degree 
AV-block, and three-vessel disease. The study was approved by the institutional ethics committee. 
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Angiographic CTO characteristics
Pre-interventional invasive coronary angiograms (ICA) were evaluated by two experienced CTO 
operators (PK & AN) during a consensus meeting to determine angiographic CTO characteristics. A 
CTO was defined as an occlusion on ICA with no or minimal antegrade filling of the distal vessel (TIMI 
0-I).(5) Collateral connection score was graded as no visible connection (CC0), thread-like connection 
(CC1), or small branch like connection (CC2).(15) Collateral flow was scored based on contra-lateral 
filling of the occluded artery consistent with the Rentrop and Cohen classification.(17) Angiographic 
CTO morphology was assessed according to the J-CTO score.(18)
Positron emission tomography
PET studies using [15O]H2O were performed as described previously.(19) Briefly, patients were scanned 
on an Ingenuity TF 128 PET/CT scanner (Philips Healthcare, Best, The Netherlands). All patients were 
asked to refrain from any caffeine or xanthine containing products for 24 hours prior to scanning. 
After a scout-CT for patient positioning, a dynamic emission scan was performed at rest followed by 
an identical scan during intravenous adenosine (140 µ∙kg-1∙min-1) induced hyperemia. Parametric MBF 
images were generated and analyzed quantitatively by an experienced analyst using Cardiac VUer.(20) 
MBF during baseline and hyperemia was calculated according to standard segmentation procedures 
for each of the following three vascular territories, left anterior descending (LAD), circumflex (Cx), 
and right coronary artery (RCA).(21) CFR was calculated as the ratio of hyperemic MBF to baseline 
MBF and relative flow reserve (RFR) was calculated as the ratio of hyperemic MBF of the downstream 
myocardial area of a CTO (target) to hyperemic MBF of a normal reference vascular territory (remote). 
Remote area was defined as four adjacent segments supplied by a non-obstructive vessel with the 
highest hyperemic perfusion values. Parametric hyperemic MBF polar maps were visually assessed to 
delineate defect areas. Quantitative MBF values of CTO vessels were obtained for the perfusion defect 
only as opposed to entire vascular territories.
Statistical analyses
Continuous variables are presented as mean values ± standard deviation (SD), whereas categorical 
variables are expressed as actual numbers. Continuous variables of paired data were compared 
with the paired sample t-test. Intergroup differences were determined with ANOVA and a posthoc 
Bonferroni for localizing the source of the difference. Differences in MBF and CFR predicted by given 
variables were estimated by linear regression analysis. Each variable was first modeled separately. All 
variables that were significant with univariate analyses were entered simultaneously in a multivariate 
regression analyses model using backward elimination. A level of p < 0.05 was considered significant. 





Seventy-six consecutive patients with a documented CTO and preserved LVEF who underwent 
[15O]H2O cardiac PET to determine indication for revascularization were included. Baseline patient 
characteristics are shown in table 1. Seventeen patients (22%) were asymptomatic at time of cardiac 
PET, whilst the majority of patients were analyzed for stable angina (n=43, 57%), dyspnea (n=13, 
17%), or unstable angina (n=3, 4%).  Asymptomatic patients were analyzed to determine indication 
for CTO PCI after PCI for (Non-)ST-elevated myocardial infarction (n=12), staged PCI for stable angina 
(n=3), cardiovascular screening (n=1), or an episode of ventricular arrhythmia (n=1). CTOs were 
predominantly located in the RCA (n=52, 68%) and less frequently in the LAD (n=15, 20%), or Cx (n=9, 
12%). The majority of the included patients had single vessel disease (CTO), whilst seventeen patients 
(22%) had an additional obstructive lesion in a non-CTO vessel. Medical history exposed 34 (45%) 
patients with prior myocardial infarction, 53 (70%) patients with previous PCI, and in 5 (7%) patients 
coronary artery bypass grafting was performed previously. In 6 (8%) patients, with prior myocardial 
infarction, pathologic Q-waves of the downstream CTO-territory were observed on electrocardiogram. 
In all these six patients myocardial viability of the CTO territory was confirmed with late gadolinium 
enhanced magnetic resonance imaging (<50% transmurality). CTO characteristics are listed in table 2.
Table 1. Baseline patient characteristics (n = 76)
Characteristic N (%) or mean ± SD
Age (years) 62 ± 10
Male 60 (79%)




Current smoking 21 (28%)
History of smoking 23 (30%)




Calcium channel blockers 22 (29%)
Beta-blockers 62 (82%)
Statins 67 (88%)
Dual anti-platelets 34 (45%)
Long-acting nitrates 17  (22%)
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Characteristic N (%) or mean ± SD
Cardiac symptoms
Stable angina 43 (57%)
Free of symptoms 17 (22%)
Dyspnea 13 (17%)





SD, standard deviation; CAD, coronary artery disease; RCA, right coronary 
artery; LAD, left anterior descending; Cx, circumflex; MI, myocardial 
infarction; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft surgery
Table 2. CTO and collateral characteristics
Characteristic N (%) 
Stump cap morphology 21 (28%)
Proximal cap bifurcation 32 (42%)
Microchannel 15 (20%)
≥ 20mm length 35 (46%)
Calcification 41 (54%)
Bending (> 45⁰) 12 (16%)

















Hemodynamic conditions during PET
The hemodynamic conditions during baseline and hyperemia PET are summarized in table 3. Heart 
rate and rate pressure product increased from baseline to hyperemia (both p < 0.001). Systolic blood 
pressure and mean arterial pressure were significantly lower during hyperemia as compared to 
baseline PET (p < 0.01 and p = 0.04, respectively). 
Table 3. Hemodynamic conditions during PET at baseline and hyperemia
Parameter Baseline Hyperemia p- value
Heart rate (bpm) 63 ± 8   81 ± 10   p < 0.001
Systolic blood pressure (mmHg) 123 ± 23 117 ± 20 p < 0.01
Diastolic blood pressure (mmHg) 64 ± 9   63 ± 11 p = 0.31
Mean arterial pressure (mmHg)   84 ± 12   81 ± 13 p = 0.04
Rate-pressure product 7861 ± 2027 9505 ± 2167   p < 0.001
PET, positron emission tomography; bpm, beats per minute
Baseline myocardial blood flow
Global MBF was 0.95 ± 0.22 mL∙min-1∙g-1, whereas MBF of the target area during baseline was 
significantly lower as compared to the remote area (0.89 ± 0.25 vs. 0.98 ± 0.23 mL∙min-1∙g-1, p < 0.001). 
A high J-CTO score (≥ 3) resulted in a more reduced baseline perfusion (p < 0.01), whilst baseline 
perfusion was comparable for different CC scores and Rentrop grades (table 4). An example of severely 
impaired baseline perfusion in the presence of angiographically well-developed collateral arteries is 
illustrated in figure 1.
Table 4. Perfusion in relation to CTO characteristics
Characteristic Baseline MBF Hyperemic MBF CFR RFR
CTO arteries
RCA (n=52) 0.91 ± 0.25 1.37 ± 0.38 1.62 ± 0.59 0.55 ± 0.12
LAD (n=15) 0.85 ± 0.25 1.21 ± 0.33 1.75 ± 1.39 0.47 ± 0.15
CX (n=9) 0.88 ± 0.23 1.57 ± 0.31 1.89 ± 0.55 0.56 ± 0.13
p-value p = 0.70 p = 0.07 p = 0.59 p = 0.10
J-CTO score
0-1 (n=36) 0.97 ± 0.24µ 1.50 ± 0.39†§ 1.63 ± 0.60 0.55 ± 0.14
2 (n=25) 0.86 ± 0.25 1.28 ± 0.28 1.59 ± 0.56 0.55 ± 0.12
≥ 3( n=15) 0.75 ± 0.20 1.20 ± 0.35 1.91 ± 1.39 0.47 ± 0.11
p-value p < 0.01 p < 0.01 p = 0.45 p = 0.10
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Characteristic Baseline MBF Hyperemic MBF CFR RFR
CC score
0 (n=7) 0.87 ± 0.23 1.40 ± 0.36 1.67 ± 0.43 0.57 ± 0.13
1 (n=13) 0.94 ± 0.20 1.37 ± 0.44 1.53 ± 0.65 0.50 ± 0.15
2 (n=56) 0.88 ± 0.26 1.36 ± 0.36 1.70 ± 0.87 0.54 ± 0.13
p-value p = 0.73 p = 0.97 p = 0.79 p = 0.44
Rentrop grade
0-1( n=3) 0.87 ± 0.31 1.38 ± 0.45 1.75 ± 0.80 0.46 ± 0.09
2 (n=19) 0.94 ± 0.21 1.38 ± 0.39 1.51 ± 0.47 0.56 ± 0.14
3 (n=54) 0.87 ± 0.26 1.37 ± 0.37 1.67 ± 0.80 0.54 ± 0.13
p-value p = 0.56 p = 0.98 p = 0.61 p = 0.38
µ p < 0.01 vs. J-CTO ≥ 3; † p < 0.05 vs. J-CTO 2; § p = 0.02 vs. J-CTO ≥ 3
CTO, chronic total occlusion; standard deviation; MBF, myocardial blood flow; CFR, coronary flow reserve; RFR, 
relative flow reserve; RCA, right coronary artery; LAD, left anterior descending artery; CX, circumflex artery; 
J-CTO, Japanese chronic total occlusion; CC, collateral connection; Intergroup significance was determined with 
ANOVA and a posthoc Bonferroni for localizing the source of the difference.
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Figure 1. Illustrati on of a pati ent with severe reduced perfusion of the anterior wall during baseline PET in the 
territory of a CTO LAD. Even the presence of excellent epicardial collaterals (A) and complete retrograde fi lling 
of the CTO vessel (B) does not guarantee suffi  cient myocardial perfusion during resti ng conditi ons (C and D). PET, 
positron emission tomography; CTO, chronic total occlusion; LAD, left  descending artery.
Hyperemic myocardial blood fl ow 
During hyperemia, mean MBF was signifi cantly lower for target than remote myocardial area (1.37 ± 
0.37 vs. 2.63 ± 0.71 mL∙min-1∙g-1, p < 0.001, respecti vely). Relati ve fl ow reserve during hyperemia was 
on average 0.54 ± 0.13, and 73 (96%) pati ents demonstrated a signifi cantly impaired RFR (≤ 0.75). Four 
(5%) pati ents did not show any or only limited ischemic burden (0-1 myocardial segments), whilst 72 
(95%) pati ents displayed moderate (2-4 myocardial segments, n=38 (50%) to severe (> 4 myocardial 
segments, n=34 (45%)) ischemic burden. Pati ents with only 0-1 segments of perfusion defect were all 
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in the J-CTO group 0-1, showed a CC score ranging from 0-2 and a Rentrop grade 2 or 3. A J-CTO score 
of 0-1 resulted in a less pronounced target perfusion impairment as compared to J-CTO ≥ 2 (fi gure 2). 
Figure 2. Illustrati on hyperemic MBF in relati on to CTO-vessel (A), J-CTO score (B), CC score (C), and Rentrop 
grade (D). Hyperemic MBF was comparable among diff erent CTO vessels, CC score, and Rentrop grade. However, 
hyperemic MBF was signifi cantly lower for a J-CTO score ≥ 2 as compared to J-CTO 0-1. MBF, myocardial blood 
fl ow; J-CTO, Japanese chronic total occlusion; CC, collateral connecti on; other abbreviati ons as in fi gure 1.
Hyperemic perfusion was not related to higher CC score and Rentrop grade (Table 4). Figure 3 illustrates 
the lack of associati on between collateral arteries and myocardial perfusion of the downstream CTO 
area. Hyperemic perfusion of the target area of asymptomati c pati ents did not diff er from symptomati c 
pati ents (1.36 ± 0.37 vs. 1.37 ± 0.37 mL∙min-1∙g-1, p = 0.96, respecti vely). Univariate analysis showed 
that age, J-CTO score, CTO calcifi cati on, and the presence of a microchannel had a signifi cant impact 
on hyperemic MBF of the downstream CTO territory, whilst multi variate analysis specifi ed that only 
CTO calcifi cati on and the presence of a microchannel were independently related to hyperemic MBF 
of the CTO territory (table 5).
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Figure 3. Four scenarios displaying the lacking relati onship between the collateral state and stress myocardial 
perfusion. Panel A shows well-developed collaterals from LAD to RCA, preventi ng signifi cant myocardial ischemia. 
Panel B illustrates that even without well-developed collaterals the myocardium during stress is not ischemic 
per see. An example of good visual collaterals with limited functi onal capacity resulti ng in myocardial ischemia 
during vasodilatati on stress PET is displayed in panel C. The fourth scenario (D) demonstrates a pati ent with stress 
perfusion impairment on PET in the absence of well-developed collaterals. RCA, right coronary artery; other 
abbreviati ons as fi gure 1.
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Table 5. Results of univariate and multivariate linear regression analysis of hyperemic MBF and CFR 









β p-value β p-value β p-value β p-value
Age (years) -0.01 0.07   -0.01 0.49  
Gender (male) -0.16 0.12   0.37 0.10  
Body Mass Index -0.01 0.32   -0.02 0.33  
Hypertension 0.07 0.41   -0.02 0.90  
Hypercholesterolemia 0.01 0.68   0.00 0.97  
Smoking -0.07 0.39   -0.13 0.49  
Family history CAD -0.04 0.67   -0.22 0.24  
Diabetes -0.03 0.75   -0.35 0.12  
J-CTO score -0.09 0.02   0.08 0.35  
Calcification -0.25 < 0.01 -0.25 < 0.01 -0.11 0.55  
Microchannel 0.18 0.09 0.18 0.08 0.05 0.85  
CTO length (>20mm) -0.02 0.78   0.03 0.86  
CC core -0.02 0.80   0.06 0.68  
Rentrop grade -0.02 0.83   0.11 0.51  
MBF, myocardial blood flow; CFR, coronary flow reserve; CAD, coronary artery disease; J-CTO, Japanese chronic 
total occlusion; CTO, chronic total occlusion; CC, collateral connection 
Coronary flow reserve
Mean CFR of target area was significantly lower compared to the mean CFR of remote area (1.67 ± 
0.80 vs. 2.79 ± 0.84, p <0.001). Only 7 (9%) patients displayed a preserved CFR of ≥ 2.50 in the target 
area. Coronary steal (CFR < 1.0) of the target area was observed in 10 (13%) patients. Univariate 
analysis did not identify any predictors for differences in CFR of the CTO territory (table 5).
DISCUSSION
The present study was conducted to evaluate the extent of PET perfusion deficits in presence of a 
documented CTO. Results indicate that the vast majority of patients demonstrate severe perfusion 
impairment on cardiac PET independent of CC score and Rentrop grade in the co-existence of viable 
myocardium.
CTO characteristics
Well-developed collateral arteries preserve left ventricular function in the manifestation of a 
coronary occlusion.(22) In the present cohort of CTO patients with a preserved LVEF, predominantly 
well-developed collateral arteries were observed. Almost all patients displayed a CC score ≥1 and 
Rentrop grade ≥2, which is in line with previous studies in patients without prior Q-wave myocardial 
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infarction.(15;16) However, intracoronary flow and pressure measurements allow for a more accurate 
estimation of the functional capacity of the collateral circulation than coronary angiography.(23) 
These invasive measurements have demonstrated the inability of the collateral arteries to comply 
with increased oxygen demand, which is confirmed by the present data.(16;24) Also, van der Hoeven 
et al. showed that when using invasive pressure measurements, the mean collateral flow index 
(CFI) in CTO patients is only 0.39, pointing at limited functional collateral capacity in the majority of 
patients, albeit with a large heterogeneity.(25) Interestingly, baseline and hyperemic perfusion were 
significantly lower in patients with unfavorable occlusion characteristics as expressed by higher J-CTO. 
It could be hypothesized that a high J-CTO represents more pronounced CAD, which is correlated with 
increased myocardial perfusion impairment. In addition, collateral supply to the CTO territory could 
be hampered by obstructive or diffuse disease of the donor vessels. Two-vessel disease was observed 
in seventeen patients (22%) in the present study, possibly altering the hyperemic perfusion of the 
downstream CTO territory. However, there was no significant difference in hyperemic perfusion of 
the downstream CTO as well as remote area between patients with single-vessel CTO and two-vessel 
disease (data not shown, p=0.42 and p=0.20, respectively).
Baseline perfusion
Baseline PET of the present study showed that myocardial perfusion was reduced in the downstream 
CTO area during resting conditions. This finding was not completely unexpected since multiple studies 
have observed, with invasive pressure interrogation, that invasive CFI was < 0.8 in the majority of CTO 
patients.(24;25) Given the wide variation of perfusion demand during resting conditions, these results 
do not imply that those patients are in a continuous ischemic state. However, it may emphasize the 
limited functional reserve of the microvasculature in collateral-depending myocardium or represent 
downregulation of flow as an early sign of hibernation.(26) 
Hyperemic myocardial perfusion 
Multiple studies have shown that hyperemic invasive fractional flow reserve of CTOs is severely reduced, 
and that hyperemic Doppler flow distal to the CTO is impaired in a significant proportion of patients (> 
90%).(15;16;24) Also, studies using SPECT showed extensive relative stress perfusion deficits.(27;28) 
However, actual quantitative myocardial flow data of CTO-patients is lacking. The present study 
demonstrated a severely compromised hyperemic myocardial perfusion of the downstream CTO area, 
and a reduction of almost 50% as compared to remote perfusion. (29;30) Furthermore, 96% of the 
patients displayed a perfusion target to remote perfusion difference ≥ 25% (RFR ≤ 0.75). This would 
be comparable with a fractional flow reserve ≤ 0.75 in the co-existence of completely normal remote 
perfusion(31), although, the presence of a CTO is associated with a lower FFR of the contralateral 
vessel due to donor collateral supply.(16;32) This suggest that remote perfusion in CTO patients is an 
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unsuitable reference standard for RFR calculation as it would underestimate the relative perfusion 
impairment. 
In addition to the prevalence and severity of perfusion impairment, CTO patients with large ischemic 
burden have a worse cardiovascular outcome compared to those with small ischemic burden.(33) 
Oxygen labeled water ([15O]H2O), used as cardiac PET tracer in the current study, is freely diffusible 
in perfusable tissue only and thereby excludes areas of scar. The defect size on ([15O]H2O PET should 
therefore solely represent the ischemic burden, which is predictive for myocardial infarction(12). 
Furthermore, Safley et al. identified an ischemic extent of 12.5% at nuclear imaging as an optimal cut-
off to select patients who will be likely to have significant ischemia reduction after PCI of a CTO.(28) 
According to the standardized 17-segment model of the American Heart Association, two myocardial 
segments equals 12% of the myocardium.(21) In the present study seventy-two (95%) patients 
revealed ≥ 2 ischemic myocardial segments, and could be considered for revascularization. However, 
Simonsen J.A. et al. showed that the benefit of revascularization is more marked in patients with a 
LVEF <50%, suggesting that LVEF should also be included in the decision making process(34). 
Coronary flow reserve
Werner et al. reported coronary steal during hyperemic Doppler flow measurements in one-third of 
patients with a CTO.(16) In the present study, myocardial steal (i.e. CFR < 1.0) was only observed in 
a small subset (13%) of patients.(35) In case of antegrade blood flow, flow of the epicardial vessel 
will be distributed to the myocardium distal to the location of the Doppler flow wire. Under these 
circumstances, the Doppler flow wire will detect representative flow velocity to the downstream 
myocardial territory. However, if flow originates from the distal end of the vessel, as with collateral 
flow, a significant proportion of the blood flow could be disseminated to the myocardium before 
arriving at the Doppler flow wire. This phenomenon could hamper the accuracy of Doppler flow 
measurements distal of a CTO, especially during hyperemia as microvascular resistance is minimized.
Limitations
Results should not be generalized to completely different patients groups (i. e. heart failure), 
particularly since some degree of patient selection bias is present when using clinical populations. 
Furthermore, patients with small vessel CTOs may not even be considered for CTO PCI and are 
missing from this analysis. Also, capacity of the collateral circulation was only graded by angiographic 
scoring rather than using invasively measured CFI. Last, the present study did not analyze response to 
revascularization, therefore, it remains debatable if ≥ 2 ischemic myocardial segments are sufficient to 




The vast majority of CTO patients with a preserved LVEF showed significant perfusion impairment, 
even in the presence of angiographically well-developed collateral arteries. These results suggest 
that collateral function during increased blood flow demand in viable myocardium is predominantly 
insufficient and that revascularization should be considered. Given the large perfusion deficits in 
this patient population, PET might prove as valuable surrogate endpoint in future clinical trials to 
determine the effects of mechanical or pharmacological (re)vascularization.
IMPACT ON DAILY PRACTICE
The results suggests that additional ischemia testing prior to revascularization of a CTO should be 
questioned, since the proportion of patients with PET-defined stress perfusion deficits is exceptionally 
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CONDENSED ABSTARCT
The present study investigated the effects of successful CTO PCI on absolute myocardial blood flow 
and functional recovery in a patient population with documented ischemia and viability. The vast 
majority of CTO patients successfully treated with CTO PCI showed a significant improvement in stress 
MBF and a reduction in ischemic zone >3 myocardial segments. In addition, there was a minor but 
significant improvement in LVEF of 1.1%, which was not related to restoration of stress MBF. These 
results suggest that patients should be selected based on the presence of viable myocardium and 
ischemia rather than anatomical CTO characteristics.
ABSTRACT
Aims: The aim of the present study was to investigate the effects of successful CTO PCI on absolute 
myocardial blood flow (MBF) and functional recovery.
Methods and Results: Patients with a documented CTO were prospectively examined for ischemia 
and viability with H2
15O positron emission tomography (PET) and late gadolinium enhancement cardiac 
magnetic resonance imaging (LGE-CMR). Sixty-nine consecutive patients, in whom PCI was successful, 
underwent follow-up PET and CMR after approximately 12 weeks to evaluate potential improvement 
of MBF as well as systolic function.
After PCI, stress MBF in the CTO area increased from 1.22±0.36 to 2.40±0.90mL∙min-1∙g-1 (p<0.001), 
whilst stress MBF in the remote area also increased significantly between baseline and follow-up 
PET (2.58±0.68 to 2.77±0.77mL∙min-1∙g-1, p=0.01). The ratio of stress MBF between CTO and remote 
area was 0.49±0.13 at baseline and increased to 0.87±0.24 at follow-up (p<0.001). MBF defect size of 
the CTO area decreased from 5.12±1.69 to 1.91±1.75 myocardial segments after PCI (p<0.001). Left 
ventricular ejection fraction significantly increased (46.4±11.0 vs. 47.5±11.4%, p=0.01) at follow-up.
Conclusions: The vast majority of CTO patients with documented ischemia and viability showed 
significant improvement in stress MBF and a reduction of ischemic burden after successful 




Chronic total occlusions (CTO) are observed in up to 30% of patients with known or suspected coronary 
artery disease. However, percutaneous coronary intervention (PCI) is attempted in only 10-30% of 
these patients. 1 The reluctance of physicians towards referral for CTO PCI is based on historically low 
success rates and the notion that patients may not benefit as collateral flow is assumed to be sufficient 
to prevent ischemia or that myocardium subtended by the occluded artery is likely to be non-viable.1-4 
Consequently, non-invasive ischemia and viability testing are advocated to guide revascularization of 
CTOs in a more judicious manner.3 An ischemic burden of 12.5% of myocardium at nuclear imaging 
has been identified as optimal cut-off to select patients who will be likely to have significant ischemia 
reduction after CTO PCI.5 In addition, recovery of dysfunctional myocardium after CTO PCI can be 
anticipated in the presence of myocardial viability prior to revascularization.6 Nowadays, success 
rates for CTO PCI have been raised to over 90% with dual arterial access, improvement in guidewire 
technology, and implementation of dissection and re-entry strategies.7 Without historical technical 
barriers for CTO PCI, focus should be directed to select patients most likely to benefit from percutaneous 
revascularization, defined as a decrease of symptoms, improvement of left ventricular function (LVF), 
or significant reduction of ischemic burden. The aim of the present study was to investigate the effects 
of successful CTO PCI on absolute myocardial perfusion and functional recovery.
METHODS
Study design and participants
The study population consisted of prospectively recruited patients with a documented CTO of a 
native coronary artery evaluated with late gadolinium enhancement cardiac magnetic resonance 
imaging (LGE-CMR) and [15O]H2O positron emission tomography (PET) to detect myocardial viability 
and ischemia respectively. Patients were scheduled for LGE-CMR and PET at least twelve weeks 
after successful percutaneous revascularization to evaluate the impact of the procedure on LVF and 
ischemic burden. Exclusion criteria were symptomatic asthma, pregnancy, high degree AV-block, and 
three-vessel disease. The study was approved by the institutional Medical Ethics Review Committee 
and patients provided written informed consent. 
Angiographic CTO characteristics
Dual arterial coronary angiograms were evaluated by two experienced CTO operators (PK & AN). Pre-
interventional angiographic CTO- and collateral characteristics, procedural strategy, and procedural 
outcome were scored according to the following criteria. A CTO was defined as a complete occlusion 
with TIMI flow grade 0. Collateral pathways were identified as ipsilateral bridging, epicardial, and/or 
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septal. Collateral connection score was gra-ded as no visible connection (CC0), thread-like connection 
(CC1), or small branch like connection (CC2).8 Collateral flow was scored based on epicardial filling of 
the occluded artery consistent with the Rentrop and Cohen classification, and the primary retrograde 
filling pattern was used to identify the dominant collateral pathway.9 Angiographic CTO morphology 
was assessed according to the J-CTO score.10 Procedural success was defined as <30% diameter 
stenosis and TIMI flow grade III. Recanalization was achieved either by antegrade wire escalation 
(AWE), antegrade dissection and re-entry (ADR), retrograde wire escalation (RWE), or retrograde 
dissection and re-entry (RDR).7 
Positron emission tomography
PET studies using [15O]H2O were performed as described previously.
11  Briefly, a dynamic emission scan 
was performed at rest followed by an identical scan during administration of intravenous adenosine 
(140µ∙kg-1∙min-1). The ratio of stress MBF to rest MBF was defined as coronary flow reserve (CFR), and 
relative flow reserve (RFR) was calculated as the ratio of stress MBF of the downstream myocardial 
area of a CTO to stress MBF of a normal reference vascular territory (remote). A remote area was 
defined as a minimum of four adjacent myocardial segments supplied by a non-obstructive vessel with 
the highest stress MBF values. Defect size was defined as total of segments in the downstream CTO 
territory with an RFR ≤0.75. 
CMR imaging protocol
CMR was performed on a 1.5-Tesla scanner (Avanto, Siemens, Erlangen, Germany) before and 12 
weeks after PCI of CTO. Functional imaging was performed using a ECG-gated, balanced steady-state 
free precession sequence in four-, three-, and two- chamber long-axis and short-axis orientations 
during mild expiration (typical parameters: TR/TE 3.2/1.5ms, flip angle ~75°, voxel size 1.4×1.4x5.0 
mm, temporal resolution 35x50ms). CMR data were assessed by two experienced observers who were 
blinded to the time point of CMR examinations (baseline/follow-up) and clinical data. Left ventricle 
(LV) end diastolic volume (EDV), LV end systolic volume (ESV), and LV ejection fraction (LVEF) were 
calculated using endocardial and epicardial borders. Segmental systolic wall thickening (SWT) was 
defined as the percentage difference between the end diastolic wall thickness and the end systolic 
wall thickness. Dysfunctional myocardium was defined as a segment with <45% SWT. Late gadolinium 
enhancement images were acquired 10-15 minutes after intravenous administration of a bolus of 
0.15mmol/kg Gd-DOTA. Viable myocardium was defined as myocardium without or with ≤50% extent 
of hyperenhancement. Baseline ECGs of all patients were assessed for the presence of pathological 




Continuous variables are presented as mean values ± standard deviation (SD), whereas categorical 
variables are expressed as actual numbers. Continuous variables of paired data were compared 
with the paired sample t-test whereas comparisons between groups were performed using the two 
independent sample t-test, unless stated otherwise. Paired non-normal data were analysed with the 
Wilcoxon signed rank test where appropriate. Associations were evaluated using Pearson’s correlation 
analysis for normally distributed data or Spearman’s correlation analysis for non-normal distributed 
data. Differences in change of CTO MBF and LVF predicted by given variables were estimated by linear 
regression analysis. Each variable was first modeled separately. All variables that were significant with 
univariate analyses were entered simultaneously in a multivariate regression analyses model. A level 
of p < 0.05 was considered significant. Statistical analyses were performed using SPSS software (IBM 
SPSS Statistics 20.0, Chicago, IL).
RESULTS
Patient population
Out of 116 potential eligible patients, sixty-nine consecutive patients (63±10 years, 86% male) 
analyzed with cardiac PET and CMR prior and at least 12 weeks after successful CTO PCI were included 
for analysis (figure 1). Patient characteristics are shown in table 1. Duration from PCI to follow-up 
imaging was 99 (96-110) days. The majority of patients were treated with PCI for the CTO-vessel only 
(n=59, 86%), whilst ten (14%) patients were additionally treated with PCI for a non-occlusive lesion of 
a non-CTO coronary artery. Angiographical and procedural characteristics are listed in table 2 and 3.
Table 1. Baseline patient characteristics (n=69)
Characteristic N (%) or mean ± SD
Age (years) 63±10
Male 59 (86%)




Current smoking 20 (29%)
History of smoking 22 (32%)
Family history CAD 31 (45%)
Diabetes 11 (16%)
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Characteristic N (%) or mean ± SD
Medication
Aspirin 63 (91%)
Calcium channel blockers 16 (23%)
Beta-blockers 53 (77%)
Statins 53 (77%)
Dual anti-platelets 46 (67%)
Long-acting nitrates 18 (26%)
Cardiac symptoms
Stable angina 41 (59%)
Free of symptoms 12 (17%)
Dyspnea 16 (23%)
SD, standard deviation; CAD, coronary artery disease
Figure 1. Patient and imaging flow chart displaying the selection procedure for follow-up imaging. 
CMR, cardiac magnetic resonance imaging; PET, positron emission tomography; PCI, percutaneous 
coronary intervention; CTO, chronic total occlusion; ICD, implantable cardioverter defibrillator
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Blunt cap morphology 21 (30%)
≥ 20mm length 29 (42%)
Calcification 40 (58%)
Bending (> 45⁰) 13 (19%)





CTO, chronic total occlusion; RCA, right coronary artery; LAD, left anterior 
descending; CX, circumflex; mm, millimeters; J-CTO, Japanese chronic 
total  
occlusion score






















ADR   8 (12%)
RWE  5 (7%)
RDR 21 (30%)
CC, collateral connection; AWE, antegrade wire escalation; ADR, antegrade  
dissection and re-entry; RWE, retrograde wire escalation; RDR, retrograde  
dissection and re-entry; PCI, percutaneous coronary intervention
Myocardial blood flow
Results of PET perfusion before and after CTO PCI are shown in table 4. MBF during rest and stress 
at baseline were significantly lower in the CTO territory as compared with remote (both p<0.001). 
After PCI, MBF during stress increased with 1.18±0.79 and 0.19±0.58mL∙min-1∙g-1 in CTO and remote 
territories, respectively (figure 2). The increase in remote stress MBF persisted after exclusion of 
patients with additional non-CTO vessel PCI (n=59, 2.64±0.70 vs. 2.81±0.81mL∙min-1∙g-1, p=0.04). Mean 
CFR of the CTO area was significantly lower compared with CFR remote at baseline (p<0.001), and 
resolved after PCI (p=0.62, table 4). Uni- and multivariate analysis showed that baseline remote stress 
MBF and baseline LVEF were independently related to change in stress MBF of the CTO territory (table 
5).
Table 4. Myocardial blood flow of remote and CTO area pre- and post CTO PCI
 Baseline Follow-up p-value
CTO MBF rest (mL∙min-1∙g-1) 0.82±0.24 0.82±0.27 1.00
Remote MBF rest  (mL∙min-1∙g-1) 0.99±0.27 0.95±0.27 <0.05
p-value <0.001 <0.001
CTO MBF stress (mL∙min-1∙g-1) 1.22±0.36 2.40±0.90 <0.001
Remote MBF stress  (mL∙min-1∙g-1) 2.58±0.68 2.77±0.77 0.01
p-value <0.001 <0.001
CTO CFR  1.62±0.78 3.13±1.42 <0.001
Remote CFR 2.75±0.93 3.05±0.99 0.001
p-value <0.001 0.62
RFR 0.49±0.13 0.87±0.24 <0.001
Defect size (segments) 5.12±1.69 1.91±1.75 <0.001
CTO, chronic total occlusion; PCI, percutaneous coronary intervention; PET, positron emission tomography; mL, 




Figure 2. Stress MBF of the CTO territory, stress MBF of the remote territory, and RFR increased signifi cantly 
between baseline and follow-up PET. MBF, myocardial blood fl ow; RFR, relati ve fl ow reserve: other abbreviati ons 
as in fi gure 1.
Table 5. Results of uni- and multi variate linear regression analyses of CTO stress MBF recovery and LVF 
improvement









β p-value β p-value β p-value β p-value
Age (years) 0.01 0.91 na  -0.16 0.19 na 
Remote stress MBF 0.27 0.03 0.24 0.04 -0.06 0.64 na 
CTO stress MBF 0.09 0.48 na  0.02 0.88 na 
Baseline LVEF (%) 0.32 0.01 0.30 0.01 -0.09 0.44 na 
Baseline CTO SWT (%) 0.18 0.14 na  -0.06 0.60 na 
CTO scar (%) -0.03 0.83 na  -0.02 0.85 na 
CTO vessel LAD 0.12 0.31 na  0.01 0.92 na 
CTO vessel RCA -0.10 0.44 na  -0.06 0.61 na 
CTO vessel CX -0.04 0.77 na  0.09 0.43 na 
AWE 0.15 0.22 na  -0.10 0.43 na 
RWE -0.06 0.61 na  0.12 0.33 na 
ADR 0.05 0.69 na  -0.06 0.61 na 
RDR -0.16 0.19 na  0.08 0.50 na 
CTO, chronic total occlusion; MBF, myocardial blood fl ow; LVEF, left  ventricular ejecti on fracti on; SWT, segmental 
systolic wall thickening; LAD, left  anterior descending; RCA, right coronary artery; CX, circumfl ex; AWE, antergrade 
wire escalati on; RWE, retrograde wire escalati on; ADR, antegrade dissecti on and re-entry; RDR, retrograde 
dissecti on and re-entry 
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Relative flow reserve and defect size
RFR of the CTO territory at baseline was, on average, 0.49±0.13 and increased to 0.87±0.24 after 
CTO PCI (figure 2). There was a significant reduction in defect size after PCI (5.12±1.69 vs. 1.91±1.75 
myocardial segments, p<0.001, table 4).
Left ventricular function and volume
Mean LVEDV as well as mean LVESV decreased from baseline to follow-up CMR (p=0.03 and p<0.01, 
respectively, table 6, figure 3). LVEF increased, on average, with 1.1±4.1% after CTO PCI (p=0.01). 
SWT of viable segments (n=287, 26%) increased from 27.2±13.2 to 37.1±21.7% (p<0.001). Mean SWT 
of the CTO territory, including segments without wall motion abnormalities and segments without 
viability, did not significantly improve at follow-up CMR (p=0.18, table 6). Correlation of LGE extent 
with LVEF and SWT of the CTO territory is illustrated in figure 4. Univariate analysis did not identify 
any predictors for change in LVEF after PCI (table 5). Patients with pathological Q-waves in the CTO 
territory on baseline ECG (n=13, 19%) showed significantly more LGE in the CTO myocardial area (mean 
[IQR]: 13.8[7.1;31.2] vs. 3.2[0;10.5]%, p=0.002) and a lower baseline LVEF (37.9±9.8 vs. 48.3±10.4%, 
p=0.002) as compared with patients with non-Q-wave ECGs. No significant improvement in LVEF was 
observed among patients with pathological Q-waves in the area corresponding with the treated CTO 
(n=13, 37.9±9.8 vs. 38.2±11.8%, p=0.83).
Table 6. Left ventricular function and volumes
All patients (n=69)  Baseline Follow-up p-value
LVEDV (mL) 199±64 193±61 0.03
LVESV (mL)  112±60 106±59 <0.01
LVEF (%) 46.4±11.0 47.5±11.4 0.01
LV stroke volume (mL) 87±20 87±19 0.66
SWT CTO area (%) 53.8±22.4 56.4±25.4 0.18
LVEDV, left ventricular end diastolic volume; mL, milliliter; LVESV, left ventricular end systolic volume; LVEF, 




Figure 3. Left  ventricular volumes and functi on between baseline and follow-up CMR imaging. 
Figure 4. Relati onship of LVEF (A) and change in LVEF with LV scar (B). Panel C shows CTO SWT in relati on to scar 
in the CTO area, whilst panel D illustrates that there is no correlati on between change of segmental systolic wall 
thickening and scar in the CTO area at follow-up. LV, left  ventricle; SWT, segmental systolic wall thickening; other 
abbreviati ons as in fi gure 1, 3.
240
Relati on between myocardial perfusion and functi on
Figure 5 displays the moderate relati onship of baseline stress MBF with LGE extent and regional wall 
thickening as well as the absent relati onship of stress MBF change with LGE extent and change of 
regional wall thickening in the CTO territory at follow-up. An example of a pati ent with normalizati on 
of stress MBF and a signifi cant improvement in LVEF due to CTO PCI is illustrated in fi gure 6 (panel 
A, B), whilst the majority of pati ents did not show a signifi cant increase of LVEF, although stress MBF 
normalized (Figure 6, panel C, D).
Figure 5. Relati onship of CTO stress MBF with CTO scar (A) and segmental systolic wall thickening of the CTO 
territory (B). Panel C illustrates that there is no correlati on between change in CTO stress MBF and scar of the 
CTO territory, whilst panel D shows the lack of a relati onship between change in CTO stress MBF and change in 
segmental systolic wall thickening of the CTO territory at follow-up. Abbreviati ons as in fi gure 1, 2, and 4.
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Figure 6. Panel A shows a pati ent with a proximal CTO RCA (fi rst arrow) and septal collateral fi lling from the 
LAD to distal RCA (panel A, second arrow). On PET perfusion there is a clear perfusion defect of the inferior and 
inferio-septal wall (third arrow) and CMR end diastolic and end systolic cine images revealed hypokinesia of the 
infero-septal wall (fourth arrow). Aft er successful percutaneous revascularizati on (panel B), stress MBF on PET 
normalized and the LVEF increased due to improved infero-septal wall moti on. Panel C illustrates a pati ent with a 
CTO RCA (fi rst arrow: proximal cap) and clear perfusion defect on stress PET (panel C, third arrow) in the presence 
of very well developed collaterals (panel C, second arrow). End diastolic and end systolic cine-CMR showed a 
moderately reduced LVEF (panel C, right images). This pati ent was successfully treated with PCI with a good 
angiographic result. Stress MBF normalized, but LVEF did not improve three months aft er CTO PCI. RCA, right 
coronary artery; LAD, left  anterior descending artery; other abbreviati ons as in fi gure 1, 2, 3.
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DISCUSSION
The present prospectively conducted study evaluated the recovery of MBF and LVF after successful 
percutaneous revascularization of a CTO in a patient population with documented ischemia and 
viability. The main results demonstrated that stress MBF increased substantially, resulting in a decrease 
in the pre-procedural perfusion defect size of more than 3 myocardial segments in the vast majority 
of cases. In contrast, there was only a minor improvement in LVEF of 1.1%, which was not related to 
restoration of stress MBF.
Patient selection
The present study population consisted of patients with stable angina, dyspnea, as well as asymptomatic 
patients. Yet, all included patients were evaluated using LGE-CMR and perfusion PET to assure the 
presence of viable myocardium and ischemia before referral for CTO PCI. This strategy has previously 
been suggested to legitimately select patients eligible for revascularization.3, 6 The present results 
highlight that such a diagnostic workup provides a patient selection where a significant reduction in 
ischemic burden can be anticipated after PCI, without a profound impact on LV function.
Myocardial blood flow
Stress MBF in the myocardial CTO area prior to PCI was severely impaired, which was illustrated by 
a significantly compromised CFR and an absolute stress MBF reduction of about 50%, as compared 
with normally perfused myocardium within the same patient (remote). This is in line with previous 
studies, where a high prevalence of inducible perfusion deficits was observed in patients with a CTO.2, 
5 The presence of a CTO together with a perfusion deficit is a significant independent predictor for 
major adverse cardiac events.12, 13 On top of a marked increase in absolute myocardial perfusion, 
a profound reduction in defect size was observed after PCI in the present study. According to the 
standardized 17-segment model of the American Heart Association, three segments equals 17,5% of 
the myocardium, and should be classified as prognostically relevant.12, 14 Multivariate analysis identified 
that preserved remote vasodilator response as well as preservation of LVEF acted as independent 
predictors for recovery of stress MBF after PCI. 
Interestingly, remote stress MBF also increased significantly. Collateralization to the distal CTO vessel 
keeps the myocardium viable, but, extracts flow from the donor myocardium Itself. Upon restoration 
of antegrade flow to the previous CTO territory, the collateral flow regresses virtually instantaneously 
thereby augmenting a hyperemic response to the donor artery. This phenomenon has previously been 




Previous studies using left ventricular angiography have shown mainly favorable results regarding LVF 
after revascularization of high grade stenosis as well as CTOs in the circumstance of persisting patent 
vessels.16-18 Contrary, more recent studies investigating the recovery of LVEF after CTO PCI using CMR 
imaging demonstrated conflicting results.6, 19, 20 Discrepancies between these studies are probably 
related to the method of LVF assessment, patient population characteristics, a predominantly 
retrospective study design, and relatively small sample sizes. The present study was conducted 
prospectively, selected patients on the presence of viable myocardium over the full range of baseline 
LVF, and is the largest in this subject group. There was no significant improvement of SWT in the 
CTO territory after successful CTO PCI, but a significant slight increase in LVEF combined with some 
extent of reverse remodeling was observed at three months follow-up. Pujadas S. et al. observed that 
EDV increased 6 month after a failed procedure, suggesting negative LV remodeling over time in the 
presence of a persisting CTO.19 Therefore, it could be hypothesized that the process of negative LV 
remodeling would progress if a CTO would be left untouched.  
As expected, baseline LVEF was significantly related to the extent of LV scar, yet, functional recovery 
(LVEF and SWT) was not. By selecting only viable but dysfunctional myocardial segments, however, a 
significant improvement in SWT was observed. These findings are in line with previous results exploring 
the relationship between viability and functional recovery after revascularization.21 Myocardial 
dysfunction is a prerequisite for the ability to show functional recovery due to reperfusion. Functional 
recovery is, therefore, an unsuitable surrogate for revascularization benefit when baseline LVEF is 
preserved, and the effect of revascularization in the present study may be underestimated. On the 
other hand, no significant improvement in LVEF was observed in the few patients (n=13) with previous 
Q-wave myocardial infarction in the CTO territory, suggesting that pathological Q-waves may be a 
robust marker for the absence of viability and thus limited functional benefit from revascularization 
in CTO patients. Though, the sample size of the present study may be insufficient to draw definite 
conclusions on these findings. Interestingly, univariate analysis did not identify any predictors of 
LVEF recovery. This is in contrast to the results of a study by Werner et al. and the Total Occlusion 
Study of Canada (TOSCA) that revealed that baseline LV dysfunction was an independent predictor for 
improvement in LVEF after revascularization of CTOs.22, 23  Though, the absolute increase in LVEF in the 
TOSCA was very comparable with the results of the present study. Moreover, there was no correlation 
between improvement of stress MBF and functional recovery. This suggests that, in the presence of 
mainly viable tissue, reduced myocardial function is predominantly provoked by myocardial damage 
(scar) rather than repetitive ischemia. 
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Limitations
Imaging at follow-up was not performed in patients after a failed procedure. Therefore, it remains 
unclear what the effect of a failed procedure would have been on MBF and LVEF. The risks of a CTO 
procedure should be included in the decision making process for CTO PCI. In addition, the present 
study did not incorporate assessment of potential recurrent luminal narrowing or occlusion at the 
time of follow-up imaging. This may have resulted in an underestimation of LVF improvement since 
continued vessel patency is a major determinant for functional recovery. Moreover, CMR imaging was 
performed approximately three months after revascularization; however, an ongoing improvement 
in LVF can be observed in up to three years after revascularization of CTOs. 24 The short follow-up 
period could have hampered the magnitude of regional and global recovery of LVF after CTO PCI. 
Furthermore, the proportion of LAD CTO lesions in the present study was relatively low as compared 
with previous studies.6, 20, 23 The LAD normally comprises a large extent of the LV myocardial mass and a 
more profound impact on LVEF may have been observed in case of evenly distribution of CTOs among 
the three major coronary arteries. 
CONCLUSION
The vast majority of CTO patients selected based on the presence of ischemia and viable myocardium 
showed a significant improvement in stress MBF and a reduction in ischemic zone >3 myocardial 
segments after successful percutaneous revascularization. Re-opening a CTO improved LVEF only 
slightly however could potentially protect from negative LV remodeling. These results, combined with 
recently reported high success rates for CTO PCI, suggest that patients should be selected based on the 
presence of viable myocardium and ischemia rather than anatomical CTO characteristics.
IMPACT ON DAILY PRACTICE
Evidence regarding patient benefit of CTO PCI is lacking. The present study showed that there is a 
considerable decrease of ischemic burden and slight significant increase in LVEF after successful CTO 
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ABSTRACT
Objective: To determine the impact of right ventricular side branch (RVB) occlusion, during 
percutaneous coronary interventions (PCI) of chronic total occlusions (CTO) of the right coronary 
artery (RCA), on right ventricular (RV) function.
Background: Developments in PCI techniques have expanded CTO PCI feasibility. However, the 
utilization of dissection and re-entry techniques and extensive stent implantation increases the risk of 
coronary side branch occlusion.
Methods: Fifty-four patients (80% male, 63±10 years) evaluated with cardiac magnetic resonance 
imaging (CMR) prior and three months after successful CTO PCI RCA (median: 99 days, IQR: 92-105 
days) were included. Right ventricular end-diastolic volume (RVEDV), end-systolic volume (RVESV), 
and ejection fraction (RVEF) were quantified on CMR images. Occurrence of RVB occlusion and/or RVB 
recruitment was assessed using procedural angiograms.
Results: RVB occlusion was observed in 12 patients (22%), while RVB recruitment occurred in seven 
patients (13%). Overall, RVEF was comparable between baseline and follow-up (53.8 ± 5.8 vs. 53.9 ± 
5.8%, p=0.95). RVB occlusion was not associated with a significant change in RVEDV or RVEF (156.9 
± 36.3 vs. 162.1 ± 35.5mL, p=0.30 and 54.2 ± 3.9 vs. 52.7 ± 4.4%, p=0.19, respectively), however a 
trend was observed for an increase of RVESV (72.5 ± 20.0 vs. 77.4 ± 20.7mL, p=0.05) at follow-up. RVB 
recruitment did not result in a significant improvement of RVEF (55.4 ± 4.6 vs. 56.1 ± 5.3%, p=0.75).
Conclusion: RVB occlusion was not associated with a significant decreased RVEF at follow-up, although 




Chronic total occlusions (CTO), defined as complete discontinuation of true lumen antegrade coronary 
blood flow (TIMI flow 0) for a duration of three months or longer, are observed in approximately 
20% of patients undergoing invasive coronary angiography. [1-3] Patients with a CTO are less likely 
to be treated with revascularization as compared with patients with non-occlusive coronary artery 
disease (CAD). For CTO patients who are referred for revascularization, only one-third is treated with 
percutaneous coronary intervention (PCI). [3] However, implementation of dissection and re-entry 
techniques have expanded CTO PCI feasibility and success rates have risen to over 90% in dedicated 
CTO centers. [4-6] Still, CTO PCI remains a laborious procedure in which iatrogenic injury, due to 
dissection and re-entry techniques and stent implantation over a relatively long coronary tract, may 
occur. [7,8] Concomitant myocardial injury is commonly tolerated as tradeoff for procedural success, 
however periprocedural myocardial infarction is associated with an increased long-term mortality. 
[9] Particularly right ventricular side branches (RVB) are regularly subject to iatrogenic occlusion and 
related right ventricular (RV) myocardial injury, since the majority of CTOs are located in the right 
coronary artery (RCA) (>50%). [2,10-12] The importance of a well-functioning right ventricle has been 
demonstrated in previous studies, which reported RV function to be an important prognostic factor 
in patients with pulmonary hypertension and chronic heart failure. [13-15] Moreover, in the setting 
of myocardial infarction, a decreased right ventricular ejection fraction (RVEF) is an independent 
predictor of mortality. [16] To date, no studies have investigated the incidence and impact of RVB 
occlusion on RV function in the current CTO PCI era. The aim of the present study was to investigate 
the effect of CTO PCI RCA and associated RVB occlusion on RV volumes and function, as assessed by 
cardiac magnetic resonance imaging (CMR) before and three months after successful CTO PCI RCA.   
METHODS
Study design and participants
All patients with a CTO considered for percutaneous revascularization at the VU University Medical 
Center are analyzed in a dedicated screening and treatment program and a prospective database of 
all patients is maintained. All consecutive patients between January 2013 and April 2016 with a CTO 
of the RCA that were analyzed with CMR prior and three months after successful CTO PCI RCA, were 
included in the study. As part of a clinical dedicated CTO program, follow-up CMR after successful 
CTO PCI was performed routinely and independently from symptoms. All patients provided written 
informed consent and the study was approved by the institutional ethics committee. 
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Angiographic CTO characteristics
Two experienced CTO operators (PK and AN) assessed all dual arterial invasive coronary angiograms to 
determine angiographic CTO- and RCA side branch characteristics. A CTO was defined as an occlusion 
on invasive coronary angiography with no true lumen antegrade flow (TIMI Flow 0). [1] Angiographic 
CTO morphology was evaluated in accordance with the J-CTO score. [17] Collateral connection 
score was scored as; no visible connection (CC0), thread-like connection (CC1), or small branch like 
connection (CC2), and the extent of collateral flow was graded according to the Rentrop and Cohen 
classification. [18,19] A RVB was defined as a side branch of the RCA supplying the RV territory on 
invasive coronary angiography originating from proximal, mid, or distal RCA. All side branches from 
the right posterolateral or right posterior descending artery were not considered as RVB. Diameter 
and TIMI flow of all RVBs were assessed on the first and last angiographic images of the procedure. A 
RVB with a diameter ≥ 1mm and antegrade filling pattern ≥ TIMI flow grade II was deemed clinically 
significant. [20] In case of post-procedural RVB occlusion (figure 1), the etiology (i.e. dissection/stent 
implant) for side branch occlusion was documented. Development of a pre-procedural occluded or 
non-significant RVB (<1 mm) into a RVB with a diameter (≥ 1mm) and TIMI flow ≥ II after PCI, was 
defined as RVB recruitment (figure 1). Coronary recanalization was performed either by antegrade 
wire escalation (AWE), antegrade dissection and re-entry (ADR), retrograde wire escalation (RWE), or 
retrograde dissection and re-entry (RDR). Procedural success was defined as <30% diameter stenosis 
and TIMI flow grade III. 
CMR protocol and image analysis
CMR was performed on a 1.5-Tesla scanner (Avanto, Siemens, Erlangen, Germany) before and 
approximately 12 weeks after CTO PCI RCA. Functional imaging was performed using an ECG-gated, 
balanced steady-state free precession sequence in four-, three-, and two- chamber long-axis and 
short-axis orientations during mild expiration (typical parameters: TR/TE 3.2/1.5 ms, flip angle ~75°, 
voxel size 1.4×1.4x5.0 mm, temporal resolution 3550 ms). 
Cardiac magnetic resonance analysis was performed using dedicated software (qMass v7.6, Medis, 
Leiden, the Netherlands). CMR images were assessed by two experienced observers (PD and SB) who 
were blinded to the time point of CMR examinations (baseline versus follow-up) and clinical data. Right 
ventricle endocardial borders were manually delineated on end diastolic and end systolic cine short-
axis images (Figure 2). [21,22] Right ventricular end diastolic volume (RVEDV), right ventricular end 
systolic volume (RVESV), and RVEF were automatically calculated according to endocardial borders. 
[21,22]   
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Figure 1. Invasive coronary angiography of two CTO PCI procedures illustrati ng right ventricular side branch loss 
and gain. Panel A shows a completely occluded RCA with one clinically signifi cant RVB. The CTO was successfully 
crossed using a RDR technique, the concomitant dissecti on plane resulted in occlusion of the RVB (B). Panel C 
displays a CTO RCA of a pati ent with no clinically signifi cant RVBs. However, the restorati on of antegrade blood 
fl ow aft er CTO PCI using AWE resulted in recruitment of a RVB (D). PCI; percutaneous coronary interventi on, CTO; 
chronic total occlusion, RCA; right coronary artery, RVB; right ventricular branch, RDR; retrograde dissecti on re-
entry, AWE; antegrade wire escalati on.         
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Figure 2. Cine short-axis CMR images. To determine right ventricular functi on prior and aft er CTO PCI, right 
ventricle endocardial borders were manually delineated on end diastolic (A) and end systolic (B) cine short-axis 
images. CMR; cardiac magneti c resonance imaging. other abbreviati ons as fi gure 1.        
Stati sti cal analyses
Conti nuous variables are presented as mean values ± standard deviati on (SD), whereas categorical 
variables are expressed as actual numbers with percentages. Conti nuous variables of paired data 
were compared with the paired sample t-test or Wilcoxon test, depending on the distributi on patt ern, 
whereas diff erences between multi ple groups were compared with the One-Way ANOVA test for 
normally distributed data and with the Kruskall Wallis test if there was a non-normal distributi on. A 
level of p < 0.05 was considered signifi cant. Stati sti cal analyses were performed using SPSS soft ware 
(IBM SPSS Stati sti cs 22.0, Chicago, IL).
RESULTS
Pati ent populati on
Seventy-nine pati ents who underwent CMR imaging prior to successful CTO PCI RCA between January 
2013 and April 2016 were retrospecti vely identi fi ed. Of these, 55 consecuti ve pati ents with CMR 
imaging aft er successful percutaneous treatment of a CTO RCA were included for analysis, whilst 
24 pati ents had refused a follow-up CMR. There were no adverse cardiac events registered during 
11
255 
follow up. One patient was excluded for analysis due to insufficient CMR quality to be able to assess 
RV function accurately. Fifty-four patients (63 ± 10 years) included in the present study underwent 
CMR imaging 39 days (interquartile range (IQR): 22-62 days) prior and three months after CTO PCI 
(median days; 99, IQR: 92-105). Patients characteristics are presented in table 1. CTO characteristics 
and collateral function are shown in table 2. J-CTO scores were equally distributed among the 54 CTO 
lesions with 10% being scored as easy (0), 37% as intermediate (1), 28% as difficult (2), and 25% as very 
difficult (≥ 3). The majority of patients showed well-functioning collaterals with a CC score of 2 (88%) 
and a Rentrop grade 3 (88%) on invasive coronary angiography. 
Table 1. Baseline patients characteristics 
Characteristics n (%) or mean ± SD
Male 43 (80)
Age (years) 63 ± 10
BMI 27.3 ± 3.4
CAD risk factors




History of smoking 16 (30)
Diabetes mellitus 10 (19)
Medication
Beta blockers 43 (80)
Anticoagulant 2   (4)
Antiplatelet therapy 47 (87)
Long working nitrates 16 (30)








5   (9)
n; number, SD; standard deviation, BMI; body mass index, CAD; coronary artery disease, PCI; percutaneous 
coronary intervention, CABG; coronary artery bypass grafting. 
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Table 2. CTO characteristics and collateral function 
Characteristics n (%)
Calcification 34 (63)
Length ≥20 mm 27 (50)
Bending 15 (28)
Stump cap 10 (19)
Re-attempt 11 (20)
J-CTO score 
Easy (0) 5   (10)
Intermediate (1) 20 (37)
Difficult (2) 15 (28)
Very difficult (≥3) 14 (25)
CC score
0 3   (6)
1 3   (6)
2 48 (88)
Rentrop grade
1 1   (2)
2 5   (10)
3 48 (88)
Successful intervention method 
AWE 22 (41)
ADR 6   (11)
RWE 5   (9)
RDR 21 (39)
CTO; chronic total occlusion, n; number, J-CTO; Japanese-chronic total occlusion, CC; collateral connection score, 
AWE; antegrade wiring escalation, ADR; antegrade dissection re-entry, RWE; retrograde wire escalation, RDR; 
retrograde dissection re-entry.
The presence of RVBs and procedural characteristics 
The presence of significant RVBs prior to intervention ranged from zero to three (median: 1, IQR: 1-2) 
per patient (table 3). Successful procedural strategies and strategy distribution among different J-CTO 
scores are presented in figure 3. Twenty-eight (52%) CTOs were successfully treated with an antegrade 
approach (AWE; 41%, ADR; 11%), in 26 (48%) patients a retrograde approach (RWE; 9%, RDR; 39%) 
resulted in successful recanalization of the CTO. Dissection and re-entry techniques were utilized in 
25 (46%) procedures. Retrograde dissection and re-entry was the preferred interventional technique 
among high J-CTO scores, lesions with low J-CTO scores were predominantly successfully crossed using 
AWE (figure 3). In the majority of the treated patients, CTO PCI did not result in RVB occlusion or 
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recruitment (n=37, 68%). Procedural RVB occlusion was observed in 12 patients (22%), in none of 
these patients more than one clinically significant RVB was lost (table 3). Right ventricular branch 
occlusion occurred primarily during a retrograde technique (n=7, 58%), and was caused by coronary 
dissection or stent implantation (n=7, 58% and n=5, 42%, respectively). Recruitment of eight RVBs was 
observed after successful CTO PCI among seven (13%) patients (table 3). Procedural RVB occlusion and 
concurrent RVB recruitment occurred in two patients (4%). Recruitment of a RVB was solely observed 
after successful true-to-true wiring (AWE; 86%, RWE; 14%). 
Table 3. Number of right ventricular branches pre- and post-PCI.
Pre PCI RVB occlusion RVB PVR Post PCI
n (%) n n n (%)
RVBs per patient (n)
0 5 (9) 0         3* 8 (15)
1 29 (54) 6 4 26 (48)
2 18 (33) 5 1 19 (35)
3 2 (4) 1 0 1 (2)
Total RVBs 71 12 8 67
*= In one patient two RVBs exhibited positive vessel remodeling. 
PCI; percutaneous coronary intervention, RVB; right ventricular side branch, PVR; positive vessel remodeling, n; 
number. 
Figure 3. Distribution of successful interventional strategy among J-CTO scores. In 28 (52%) of the procedures an 
antegrade approach was successful (AWE; 41%, ADR; 11%), In the other 26 (48%) patients a retrograde approach 
resulted in successful CTO revascularization (RWE; 9%, RDR; 39%). Retrograde dissection and re-entry was the 
preferred interventional technique among the higher J-CTO scores, whereas lesions with low J-CTO scores were 
primarily crossed using AWE. J-CTO; Japanese-chronic total occlusion, ADR; antegrade dissection re-entry, RWE; 
retrograde wire escalation, other abbreviations as figure 1.  
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Right ventricular function and volume parameters 
Mean values of RV volumes and RVEF prior and after CTO PCI are shown in table 4. There were no 
significant differences in mean RVEDV, RVESV, and RVEF between baseline and follow-up CMR in 
patients without RVB occlusion or RVB recruitment (table 4). A trend in an increase in RVESV among 
patient with periprocedural RVB occlusion (baseline vs. follow-up; 72.5 ± 20.0 vs. 77.4 ± 20.7mL, 
p=0.05) was observed. Right ventricular EDV and RVEF were not significantly different between 
baseline and follow-up CMR among patients with a periprocedural RVB occlusion (table 4). In patients 
with procedural RVB occlusion and no concurrent recruitment of another RVB (n=10), mean RVEDV, 
RVESV, and RVEF did not significantly change three months after successful CTO PCI (161.2 ± 37.4 vs. 
163.8 ± 37.6mL, p=0.63; 76.1 ± 19.8 vs. 79.8 ± 20.6mL, p=0.12; 53.1 ± 3.2 vs. 51.6 ± 3.2%, p=0.18, 
respectively). There were no significant differences observed between baseline and follow-
up within patients with RVB occlusion of vessels >2.0mm (n=5) for RVEDV, RVESV, and 
RVEF (148.6 ± 21.7 vs. 158.2 ± 23.2mL, p=0.33, 68.6 ± 16.1 vs. 73.6 ± 18.3mL, p=0.42, 54.2 ± 5.5 
vs. 54.0 ± 5.8%, p=0.94, respectively). Figure 4 illustrates that the presence and quantity of clinical 
significant RVBs at baseline and follow-up were not related to RVEF.







RVEDV (mL) 154.1 ± 38.8 153.7 ± 38.2 0.86
RVESV (mL) 71.4 ± 22.4 71.8 ± 22.7 0.82
RVEF (%) 53.8 ± 5.8 53.9 ± 5.8 0.95
No RVB occlusion or PVR (n=37)
RVEDV (mL) 152.7 ± 39.3 149.5 ± 38.6 0.30
RVESV (mL) 71.2 ± 23.2 69.9 ± 23.9 0.53
RVEF (%) 53.5 ± 6.4 54.0 ± 6.3 0.48
RVB occlusion (n=12)
RVEDV (mL) 156.9 ± 36.3 162.1 ± 35.5 0.28
RVESV (mL) 72.5 ± 20.0 77.4 ± 20.7 0.05
RVEF (%) 54.2 ± 3.9 52.7 ± 4.4 0.19
Only RVB PVR (n=5)
RVEDV (mL) 157.5 ± 48.2 164.5 ± 43,5 0.14 
RVESV (mL) 71.0 ± 26.4 72.0 ± 19,9 0.85
RVEF (%) 55.4 ± 4.6 56.1 ± 5.3 0.75
SD; standard deviation, RVEDV; right ventricular end-diastolic volume, RVESV; right ventricular end-systolic 




Figure 4. Relation between presence and quantity of right ventricular branches and RVEF. The number of 
clinically significant RVBs per patient before PCI was not related with baseline RVEF (A) nor was the number of 
RVBs after the procedure related with RVEF at follow-up (B). RVEF; right ventricular ejection fraction, other 
abbreviations as figure 1 and 3. 
DISCUSSION
The present study was conducted to evaluate the impact of RVB occlusion during percutaneous 
revascularization of CTO RCA on RV function. The main results indicate that RVB occlusion occurred in 
22% of procedures either due to dissection and re-entry techniques or coronary stent implantation, 
however, no significant impact of RVB occlusion on RVEF was identified. Though, a trend of an increase 
in RVESV among patients with periprocedural RVB occlusion was observed. Recruitment of a RVB 
occurred exclusively during successful true-to-true wiring procedures, and did not increase RVEF 
significantly. 
Side branch occlusion mechanism and incidence
The Japanese-CTO score has been developed to predict antegrade true-to-true guidewire crossing 
within 30 minutes and is a generally accepted CTO complexity grading tool. [17] Previous studies 
have illustrated that percutaneous dissection and re-entry strategies are more frequently utilized in 
case of high complexity CTOs. [23,24] However, by using the subintimal space to cross a coronary 
occlusion, side branches originating from the dissection plane will be exposed to a high risk of 
occlusion. Furthermore, the subintimal dissection space subsequently serves as a newly formed 
coronary lumen and disrupted intimal fragments may be pressed to the contralateral vessel wall 
during stent implantation. This technique thereby jeopardizes the continuity of coronary side branches 
originating from the dissection plane as well as the contralateral vessel wall. Limiting the dissection 
burden with dedicated dissection and re-entry techniques and supplies (CrossBoss and Stingray) is 
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therefore desired, and may lead to favorable outcomes. [25,26] Previous studies investigating side 
branch occlusion during CTO PCI are scarce and aimed predominantly at periprocedural myocardial 
injury rather than myocardial function. [20,27]  Additionally, RVB occlusion is generally considered of 
limited clinical value as compared with loss of branches supplying the left ventricle. However, CTOs are 
predominantly located in the RCA and the incidence and consequences of RVB loss remains unknown. 
The results of the present study showed RVB occlusion in 22% of the procedures. Right ventricular 
branch occlusion occurred due to coronary dissection (58%) or stent implantation (42%), and was 
predominantly observed during (retrograde) dissection and re-entry techniques. Interestingly, the 
present study demonstrated a notable uniformity with previous results of studies investigating side-
branch loss during CTO PCI. [20,27]  Nguyen-Trong P.J. et al investigated the incidence of side-branch 
occlusion and its association with adverse clinical outcomes among 109 consecutive CTO procedures. 
Side branch loss occurred in 25.7%, was predominantly RCA-related (69%), and was mainly caused 
by dissection and re-entry techniques or stenting over a side branch (50 and 43%, respectively). [20] 
On the other hand, revascularization of a CTO may also reinstate or improve antegrade flow of a pre-
procedural small or occluded side branch. In the present study recanalization of the RCA resulted in 
side recruitment in 7 (13%) patients. Epicardial blood pressure distal to a CTO is dependent on the 
limited, albeit with large heterogeneity, functional collateral capacity, whereas low epicardial perfusion 
pressure will result in regression of coronary vessels and side branches. [28] Inversely, a rising epicardial 
pressure is the driving force for vessel growth, and reinstatement of normal epicardial pressure by CTO 
revascularization will almost immediately result in enlargement of vessel and side branch dimensions. 
[29] Interestingly, recruitment of a RVB occurred exclusively in patients revascularized using successful 
true-to-true wiring techniques. This may indicate that dissection and re-entry revascularization 
techniques interfere with the probability of RVB recruitment during recanalization of a CTO.
Right ventricular function
As already alluded to, iatrogenic injury to RVBs during CTO PCI RCA is frequently tolerated as compromise 
to reinstate antegrade coronary flow of the RCA itself. The consequences of RVB loss on RV function 
have not yet been investigated even though RV dysfunction is a recognized independent predictor of 
mortality and cardiac events. [16,30,31] Ozkan et al. investigated RV function of 41 patients one month 
after successful percutaneous recanalization of a CTO RCA, utilizing echocardiography with tissue 
Doppler imaging and two dimensional speckle tracking echocardiography (2DSTE). Tissue Doppler 
imaging derived isovolumic acceleration and 2DSTE derived global longitudinal strain and systolic 
strain rate values showed improvement in RV function after successful CTO PCI. [32] However, no data 
was presented regarding RVB loss, or change in RVEF due to the limitations of RV echocardiography. 
The present study is the first to assess RV function prior to and after CTO PCI RCA using the gold 
standard imaging technique, and in relation to RVB occlusion. The validity of RV function and volume 
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assessment with CMR has been previously established in the variety of healthy volunteers, patients 
with heart failure, and patients with ventricular hypertrophy. [33] Although, RVB occlusion occurred in 
a relatively large proportion of patients, no significant impact on RV function was detected. However, 
a trend toward an increase in RVESV in patients with periprocedural RVB loss was observed, suggesting 
that RVB occlusion could lead to RV dilatation. Preservation of the RVEF among these patients can 
be explained by a non-significant increase of RVEDV. Interestingly, the majority (63%) of patients 
showed no or only one clinically significant RVB prior to PCI, suggesting that one or more RVBs were 
severely affected by CAD at baseline. However, RVEF at baseline was generally normal and was not 
related to the presence and number of clinically relevant RVBs. Although somewhat speculative, this 
may indicate that RVEF is not evidently reduced by preprocedural RVB disease and that RVB loss may 
be less important as compared with loss of side branches supplying the left ventricle. In addition, 
RV perfusion during normal conditions is relatively low and can probably be maintained sufficiently 
by collateral flow, whilst the retrograde collateral pathway from the left coronary artery to the RCA 
regularly involves RVBs. [29] Noteworthy, the existence of these retrograde filling pathways will 
undoubtedly define the tolerance to periprocedural side branch occlusion and protect the myocardium 
against infarction.
Limitations
The present study has some limitations. The study was performed retrospectively which could have 
introduced a selection bias based on mandatory pre- and postprocedural CMR imaging. However, this 
selection bias should be relatively limited since all patients with successful CTO PCI were routinely 
referred for follow-up CMR imaging. Still, patient refusal for CMR is not uncommon and could have 
altered the outcomes of the present study. Also, only patients with successful CTO PCI were included 
although the results of the present study could have been more comprehensive interpreted if a control 
group was included. Unfortunately, this data was not available. The small sample size in the present 
study may hamper the probability to achieve significant difference between patient groups with or 
without RVB loss. Still, the absolute difference in RV function among patients with occlusion of a RVB 
seems of relatively limited clinical significance. Lastly, RV perfusion at follow-up may be restored by 
temporal recruitment of collaterals to the periprocedural occluded RVB.
CONCLUSION 
Right ventricular side branch occlusion occurred relatively frequent after CTO PCI RCA and was related 
to dissection and re-entry techniques or stent implantation. Although periprocedural occlusion of a 
significant RVB was not associated with a significant decreased right ventricular ejection fraction at 
three months follow-up, the results suggested a minor increase of RVESV.
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The aim of this thesis was to (1) further optimize non-invasive detection of hemodynamically 
significant coronary artery disease (CAD) with coronary computed tomography angiography (CCTA) and 
myocardial perfusion imaging (MPI) and to examine (2) the effect of implantation of the bioresorbable 
vascular scaffold (BVS) and (3) chronic total occlusion percutaneous coronary intervention (CTO PCI).
Introduction and outline of the thesis
CCTA is an excellent diagnostic tool to rule out significant CAD in patients with low to intermediate 
pretest likelihood of obstructive CAD. Beyond luminal stenosis severity, current generation CT 
technologies possess sufficient spatial and temporal resolution to enable quantitative assessment of 
plaque volume, morphology and composition, which may aid in predicting significant CAD. 
MPI evaluates the consequences of a potential coronary stenosis on myocardial perfusion rather than 
identifying coronary atherosclerosis itself. MPI is therefore an appropriate technique to diagnose 
hemodynamically significant CAD and guide referral to the catheterization laboratory for PCI. 
After PCI, long-term restenosis is a regularly observed complication with need for subsequent 
revascularization or occurrence of an acute myocardial infarction. A potential solution for the long-
term risk of in-stent restenosis or thrombosis is implantation of a BVS. Due to complete resorption of 
this scaffold, a renewed natural vessel wall develops, potentially reinstalling a normal physiology and 
avoiding long-term complications. Also, there is potentially restored perceptibility for physiological 
triggers resulting in vasodilation in case of more oxygen demand. However, this relatively bulky device 
may increase short-term risk for stent thrombosis within the resorption period.
The last decades, there has been a growing interest in complex percutaneous revascularization, such 
as CTO PCI. A CTO has been the ultimate challenge for the interventional cardiologist with traditionally 
low success of percutaneous revascularization. However, nowadays success rates have increased to 
95% in dedicated centers using the complete arsenal of materials and techniques. Yet, it remains 
currently unknown if revascularization leads to improved patient outcome.
Part I Detection of significant coronary artery disease
In Chapter 1 the results are described of a study evaluating the incremental value of transluminal 
attenuation gradient (TAG) over luminal stenosis grading alone. TAG is defined as the contrast 
opacification gradient along the length of a coronary artery on CCTA. The hypothesis was that in 
presence of significant stenosis the decline of contrast delivery (opacification) would be higher as 
compared with stenosis with no or little hemodynamic consequences. Therefore, the goal was to 
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increase the predictive value of CCTA for hemodynamically significant CAD by adding TAG to stenosis 
severity measurements. In this study, eighty-five patients with intermediate probability of CAD were 
prospectively included. All patients underwent step-and-shoot 256-slice CCTA. TAG analysis was 
performed followed by invasive coronary angiography in conjunction with fractional flow reserve 
(FFR) measurements of all major coronary branches. Two correction models were applied based on 
either dephasing of contrast delivery by relating coronary density to corresponding descending aortic 
opacification (TAG-CCO) or exclusion of calcified coronary segments (TAG-ExC). The results showed a 
nearly perfect sensitivity and moderate specificity for conventional stenosis grading. Opposed to the 
hypothesis of this study, addition of TAG, TAG-ExC or TAG-COO did not improve specificity of CCTA 
for assessment of the hemodynamic consequences of a coronary stenosis. These observations are 
not entirely unanticipated from a theoretical point of view. A fall in contrast opacification beyond 
a stenosis reflects impaired resting flow whereas multiple studies have clearly demonstrated that 
resting flow remains stable till the point of subtotal coronary occlusion. Therefore, TAG appears to be 
most suitable to detect subtotal occlusions with TIMI flow rates < 3 or total occlusions with a collateral 
circulation rather than significant intermediate stenosis. 
The study reported in Chapter 2 aimed to assess the diagnostic accuracy of relative flow reserve (RFR) 
with quantitative PET in comparison with absolute myocardial blood flow (MBF) for the prediction of 
invasive FFR. RFR is defined as the ratio of hyperemic MBF in a stenotic myocardial area to hyperemic 
MBF in a normal perfused area. Invasive FFR reflects the hyperemic pressure gradient across a 
specific epicardial lesion. It has to be noted, however, that the pressure gradient is dependent on the 
hyperemic response of the vessel distal to a stenosis. In vessels with a more pronounced response to 
an adenosine challenge, the pressure will drop more at the level of the stenosis than in the vessel in 
which the hyperemic response is blunted. Hyperemic MBF is a composite measurement of an entire 
single coronary vascular bed affected by an epicardial stenosis as well as microvascular resistance. 
In case of poor microvascular function, MBF becomes abnormal even without obstructive epicardial 
disease. Consequently, disconcordance between FFR and hyperemic perfusion with PET can frequently 
be observed due to differences in underlying physiological processes. Therefore, this study sought to 
assess if RFR would outperform hyperemic MBF for the prediction of significant CAD determined by 
FFR. In 92 patients with single or two vessel disease, the correlation between RFR and invasive FFR was 
moderate (r = 0.54, p<0.01). ROC curve analysis showed an area under the curve of 0.82 for RFR, which 
was not significantly higher compared with hyperemic MBF and coronary flow reserve (CFR, 0.76, 
p=0.32 and 0.72, p=0.08, respectively). This study suggests that RFR calculation with quantitative PET 
is feasible. However, in this relatively small sample size, a clear improvement of diagnostic accuracy 
over hyperemic MBF or CFR was not observed.
Although CCTA displays good agreement with stenosis on invasive coronary angiography, the relatively 
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poor predictive value for ischemia using stenosis severity alone derived from either invasive or 
noninvasive angiography is well established. Next to coronary stenosis severity, atherosclerotic plaque 
burden and morphology may also affect myocardial perfusion. Chapter 3 explores the impact of CT 
derived atherosclerotic plaque characteristics on both myocardial perfusion as assessed with PET as 
well as invasive FFR. This study showed that positive remodeling and noncalcified plaque volume 
are associated with detrimental downstream hyperemic myocardial perfusion and invasive FFR, 
independent from lesion severity. Apparently, hemodynamics is not only affected by luminal stenosis, 
but also by other geometric variables such as plaque length, volume or morphology. Nonetheless, 
the additional value of these adverse plaque characteristics over luminal stenosis as predictors of 
ischemia within this study was limited.  In chapter 4 the main results of the ‘’Stress Myocardial 
Perfusion Imaging versus Coronary Computed Tomographic Angiography for Diagnosis of Invasive 
Vessel-Specific Ischemia: Predictive Modeling Results from the Computed TomogRaphic Evaluation 
of Atherosclerotic DEtermiNants of Myocardial IsChEmia (CREDENCE) Trial‘’ are reported. The aim 
of this trial was to derive, validate, and compare an optimized CCTA with MPI assessment for the 
prediction of functionally significant CAD, determined as vessel-specific ischemia by invasive FFR. 
Although comparative findings are available from prior diagnostic accuracy trials, these test findings 
are generally summed as dichotomous measures, used anatomic stenosis severity as the comparator, 
and did not include the entirety of risk-based markers available from noninvasive imaging tests. The 
CREDENCE trial is a prospective, multicenter diagnostic derivation-validation controlled clinical trial 
recruiting 612 stable patients from 2014-2017. Enrolled patients underwent CCTA and MPI (PET-, 
SPECT-, or MRI perfusion imaging) as index tests followed by invasive coronary angiography with FFR 
measurements in 3 epicardial coronary arteries, as the reference test within 60 days. Predictors for 
myocardial perfusion imaging were summed rest score and summed difference score within specific 
vascular territories. The area under the ROC curve did not significantly change by stepwise addition 
of left ventricular ejection fraction or exercise ECG findings on top of summed rest score and summed 
difference score. Significant atherosclerotic plaque predictors included the number of lesions with 
≥30% diameter stenosis, percent non-calcified atheroma volume, lumen volume, and the number of 
lesions with high-risk plaque. With regard to the primary endpoint comparing the AUC by modality, 
the results revealed that an optimized CCTA model was superior to the overall MPI model for the 
diagnosis of vessel-specific ischemia (AUC 0.81 (95% Confidence Intervals [CI]: 0.78-0.84) vs. 0.67 
(95% CI: 0.63-0.71), p<0.001). These results extend prior findings (as reported in chapter 4) revealing 
that various qualitative and quantitative CCTA-derived atherosclerotic plaque characteristics were 
highly predictive of vessel-specific ischemia. These findings suggest that the incorporation of whole 
vessel quantification of epicardial coronary atherosclerosis provides a more comprehensive view of 
the underlying disease burden and myocardial ischemia as compared to examination of a given focal 
stenosis alone. These quantitative CCTA analyses are currently not fully automated and therefore 
time-consuming, which may hamper widespread clinical adoption at present.
269 
Part II Bioresorbable vascular scaffold
Chapter 5 and 6 describe the interim and final results of the Impact of Vascular Reparative Therapy 
on Vasomotor Function and Myocardial Perfusion: A Randomized [15O]2O PET/CT Study (VANISH). 
The VANISH-trial was a prospective, single-blind, randomized, two-group, single-center clinical 
trial including 60 patients with de novo flow-limiting single-vessel CAD without biochemical signs 
of myocardial infarction and with a normal left ventricular function (≥50%). These patients were 
randomized to the implantation of BVS vs. metal drug-eluting stent (DES) in a one-to-one fashion 
and subsequently followed for three years to assess the effect of scaffold resorption on MBF during 
hyperemia and cold pressor testing (CPT). CPT is the gold standard to assess coronary artery vasomotor 
function in response to sympathetic stimulation. As mentioned before, it has been hypothesized 
that released from the intracoronary “cage”, the originally stented coronary segment may become 
responsive to physiological stimuli with revival of normal vasomotor functions. The interim analysis 
at 1 month follow-up revealed no differences in PET-derived absolute myocardial perfusion during 
hyperemia and CPT between BVS-treated patients as compared to DES-treated patients. Interestingly, 
CFR was attenuated in BVS-treated patients, although still within the normal range. However, the ratio 
of target CFR to remote CFR (in non-treated area subtended by non-obstructive coronary artery in the 
same patient) did not differ between both treatment arms, indicating a homogeneously attenuated 
global CFR in the BVS treatment arm. This potential global effect of BVS on CFR, is so far unexplained 
and requires further research. At three year follow-up, 59 (98%), 56 (93%), and 51 (85%) patients 
successfully completed one-month, two-year, and three-year follow-up PET imaging, respectively. No 
culprit vessel events were registered during follow-up time. The primary study endpoint (i.e. interaction 
between device type and myocardial perfusion over time) was non-significant for hyperemic MBF, 
CPT, and CFR, indicating that there were no beneficial effects observed due to BVS resorption during 
hyperemia or endothelium-dependent vasodilation by CPT. These findings signify no clinical benefit 
with regard to myocardial perfusion and do not support the use of BVS over DES, notwithstanding that 
long-term (>3 year) benefit may still exist.
Part III Chronic total occlusion percutaneous coronary intervention
In chapter 7, the value of imaging with PET and CCTA is discussed for the diagnostic work-up of patients 
with a CTO. CTO PCI is challenging and traditionally accompanied by lower success rates and higher 
complication rates as compared with regular PCI for non-occlusive lesions. Success rates decrease with 
increased level of lesion complexity. However, advances in guide wire technology and implementation 
of dissection and re-entry techniques have enabled success rates exceeding 95%. Therefore, it is of 
utmost importance to prepare and consider all potential recanalization routes and accompanied risks 
before starting the procedure. CCTA may be of interest to prepare for CTO intervention since it allows 
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for detailed three-dimensional illustration of coronary CTOs and assessment of lesion morphology. 
These findings could guide the operator to a specific strategy. Still, patient selection for CTO PCI should 
be focused on anticipated patient benefit in terms of health status and long-term prognosis rather 
than coronary anatomic complexity. Once the diagnosis of a CTO has been established, information 
pertaining LV function is mandatory. Normal regional LV function of myocardium subtended by the 
CTO by definition excludes non-viable myocardium. The decision to proceed to a revascularization 
procedure is then merely based on the presence and extent of ischemia or symptoms. Without 
documented ischemia, such a procedure is futile and even hazardous. On the other hand, when 
patients exhibit extensive regional wall motion abnormalities in the affected vascular territory, we 
recommend that the diagnostic work-up is being focused on myocardial viability rather than ischemia. 
Within this review a diagnostic decision scheme is proposed. It also discussed the angiographic 
predictors of procedural success. In the following chapter 8, clinical presentation and characteristics 
of patients with a CTO as well as current high standard revascularization techniques in dedicated CTO 
PCI are discussed. Patients with a CTO are older, more frequently male, and have a relatively high 
prevalence of cardiac risk factors as compared with patients with non-occlusive CAD. Approximately 
one out of four patients with a CTO do not experience symptoms. The lack of symptoms may be due 
to the presence of collateral circulation combined with reduced daily physical activity or autonomic 
neuropathy in diabetic patients, whom are strongly represented in the CTO patient population. In 
symptomatic CTO patients, typical cardiac chest pain may be less prominent than shortness of breath 
or atypical symptoms. CTOs are diagnosed in 16-18.4% of patients with CAD, however CTO PCI 
represents only 5-10% of the total PCI volume. This may be due to the traditionally higher complication 
and lower success rates. To establish high success rates for CTO PCI, preparation and strategy selection 
is key. Double arterial access, use of a micro catheter, and careful assessment of the angiographic 
characteristics such as (1) proximal cap morphology, (2) CTO lesion length, (3) Distal landing zone, 
and (4) interventional collaterals, is strongly advised since it facilitates appropriate strategy selection. 
Chapter 9 aimed to explore the prevalence of ischemia in a clinical population presented with a CTO 
and a preserved left ventricular ejection fraction. This population consisted of 76 patients with (un)
stable angina (61%), dyspnea (17%) and even no symptoms (22%). All patients were evaluated with 
PET perfusion to assess quantitative MBF. The reduction in hyperemic MBF was on average 46%, and 
73 (96%) patients demonstrated a significantly impaired hyperemic MBF (≤75% of patient specific 
normal values). Moreover, the Rentrop grade (scoring for retrograde epicardial filling) was excellent in 
96% of patients. These results indicate that in a clinical consecutive cohort of patients with a CTO and a 
preserved left ventricular function, the vast majority have significantly impaired myocardial perfusion 
even in the presence of angiographically well-developed collateral arteries.
In chapter 10 the effects of successful percutaneous coronary intervention of chronic total occlusions 
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on myocardial perfusion and left ventricular function was assessed. The hypothesis was that in 
presence of large ischemic burden at nuclear imaging patients will be likely to have significant ischemia 
reduction after CTO PCI. In addition, recovery of dysfunctional myocardium after CTO PCI may be 
anticipated in the presence of myocardial viability prior to revascularization. In this study 69 patients, 
with a documented CTO of a native coronary artery evaluated with late gadolinium enhancement 
cardiac magnetic resonance imaging (LGE-CMR) and quantitative PET to detect myocardial viability 
and ischemia respectively, were prospectively recruited. LGE-CMR and PET were performed at least 
twelve weeks after successful percutaneous revascularization to evaluate the impact of the procedure 
on left ventricular function and ischemic burden. The main results showed that hyperemic MBF 
increased substantially, resulting in a fall in the pre-procedural perfusion defect size of more than 3 
myocardial segments in the vast majority of cases. In contrast, there was only a minor improvement 
in left ventricular ejection fraction of 1.1%, which was not related to restoration of hyperemic MBF. 
These results suggest that revascularization should be considered in patients with a documented CTO 
in case of significant ischemic burden and viable myocardial tissue, even though randomized evidence 
regarding patient benefit of CTO PCI is currently lacking.
Chapter 11 aimed to assess the consequences of per procedural right ventricular side branch (RVB) 
occlusion on right ventricular function. The introduction and adoption of dissection and re-entry 
techniques for CTO PCI in combination with extensive stent implantation increases the risk of coronary 
side branch occlusion. In addition, the RVB occlusion is considered a low price to pay for restoration 
of flow through the right coronary artery itself. However, the impact on right ventricular function 
has never been investigated. In a clinical population of 54 patients with CTO PCI of an occluded right 
coronary artery and LGE-CMR prior and after the procedure, RVB occlusion occurred in 12 patients 
(22%). RVB occlusion was not associated with a significant change in right ventricular end diastolic 
volume or right ventricular ejection fraction, however a trend was observed for an increase of right 
ventricular end systolic volume RVESV (72.5 ± 20.0 vs. 77.4 ± 20.7mL, p=0.05) at follow-up. These 
results indicate that there may be detrimental effects of RVB occlusion, however these consequences 
seem to be relatively small. 
CONCLUSIONS
Several main conclusions can be drawn from this thesis. First, angiographic characteristics such as 
volumetric measures as well as morphological aspects of atherosclerosis as assessed by CCTA are 
of interest when considering the hemodynamic consequences of atherosclerosis. These findings add 
to luminal stenosis grading alone and aid in increasing the diagnostic accuracy of CCTA to predict 
hemodynamically significant CAD determined by invasive FFR. 
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Second, implantation of the BVS is feasible however no benefit with regard to myocardial perfusion 
is observed during hyperemia or cold pressor testing. These findings do not support the use of BVS 
instead of metallic DES, especially since large randomized trials have illustrated that there is an 
increased risk in scaffold thrombosis during the first three years. Still, long-term outcome (>3 years) 
has yet to become available. 
Third, the vast majority of patients with a CTO have significantly impaired myocardial perfusion with 
great effect of successful CTO PCI on recovery of myocardial perfusion and decrease of ischemic 
burden. Patient selection for CTO PCI should be based on expected patient benefit rather than lesion 
complexity.
FUTURE PERSPECTIVES
The abovementioned conclusions suggest the importance of conducting further studies. First, Part I 
contains 2 studies  (Chapter 1 and 2) aiming to increase the diagnostic value of CCTA and PET, however 
with a negative outcome. It is very important that we continue trying to limit false-positive and false-
negative test results to refrain from unnecessary additional diagnostic testing or treatment. Aside 
from investigating additional indices retrieved from current non-invasive imaging test, the unending 
developments in technology and scan resolution will result in ongoing availability of new information. 
Chapter 3 and 4 are great examples showing that with this newly available information we are a step 
closer to accurately assess pathophysiological processes and disease burden. These chapters showed 
that employment of these findings might aid in identifying hemodynamically significant CAD. Therefore, 
diagnostic comparative studies in the future will need to incorporate the entirety of information from 
diagnostic scans rather than conventional dichotomous grading only. Technology is developing and 
investigators need to consider how these improvements in image quality could be incorporated in 
clinical studies and practice. In the future we will not be grading CCTA based on stenosis severity alone 
but plaque burden and morphology should be integrated in our desicion making.
In part II the VANISH-trial is presented and discussed. In general, the BVS has not met the high 
expectations and BVS in its current form will not be used in clinical practice. Still, long-term follow-up 
of some large scaled studies will determine wheter the concept of a disappearing coronary stent may 
remain interesting for the future. The negative results are probably related to its ‘’bulky’’ design and 
future improvements in scaffold design, delivery and resorption cannot be ruled out. More importantly, 
future studies with resorbable coronary stents should be employed carfully to warrant patient safety.
Part III clearly illustrated that patients with a CTO have significantly impaired myocardial perfusion 
and if the lesion is successfully revascularized the myocardial perfusion increases substantially. These 
patients should therefore not be treated medically only just because the lesion may be complex to 
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revascularize. There is more and more interest among interventional cardiologist to treat these lesions 
percutaneously. This interest is expanding the volume of dedicated and well-experienced operators 
as well as materials and interventional strategies. This has led to high success rates for CTO PCI in 
many centers paving the way for large-scaled adoption of CTO PCI. Unfortunately, no evidence of 
reductions in major adverse cardiac events from randomized clinical trials is currently available and 
will hopefully become available soon. These kind of randomized strudies are tough to perform due to 






Het doel van dit proefschrift was om (1) niet-invasieve detectie van hemodynamisch significant 
coronairlijden verder te optimaliseren met coronaire CT angiografie (CCTA) en myocardiale perfusie-
beeldvorming (myocardial perfusion imaging, MPI) en om het effect van (2) implantatie van de 
bioresorbeerbare coronaire stent (bioresorbable vascular scaffold, BVS) en (3) percutane coronaire 
interventie van chronische totale occlusies (CTO PCI) te onderzoeken.
Inleiding en opzet van het proefschrift
CCTA is een uitstekend diagnostisch middel om significant coronairlijden uit te sluiten bij patiënten 
met een lage tot gemiddelde vooraf kans op obstructief coronairlijden. Naast de mogelijkheid om 
nauwkeurig de mate van een luminale stenose te beoordelen, heeft de huidige generatie CT-scans 
voldoende resolutie om atherosclerotisch volume, -morfologie en -samenstelling te bepalen en 
kwantificeren. Deze gegevens zouden kunnen helpen bij het voorspellen van hemodynamisch 
significant coronairlijden.
MPI meet juist de gevolgen van een coronaire stenose op de perfusie (doorbloeding) van de hartspier 
in tegenstelling tot het aantonen van de coronaire atherosclerose zelf. Daarom is MPI een geschikte 
techniek om het hemodynamisch belang van een potentieel coronaire stenose te bepalen en op basis 
hiervan te verwijzen voor revascularisatie.
Na PCI bestaat er een langdurige kans op in-stent restenose of trombose, een complicatie waarbij er 
soms noodzaak tot het verrichten van re-PCI (of bypass chirurgie) is of zelfs een acuut myocardinfarct 
kan optreden. De BVS is een potentiele oplossing om het risico op lange termijn van in-stent restenose 
of trombose te vermijden. Als gevolg van de resorptie van deze resorbeerbare stent ontstaat er een 
nieuwe natuurlijke vaatwand, die mogelijk een meer normale fysiologische omstandigheid creëert 
en daardoor complicaties op de lange termijn vermijdt. Tevens zou het mogelijk zijn dat met het 
resorberen van de stent het bloedvat de mogelijkheid herwint om op fysiologische triggers te reageren 
met vaatverwijding. Deze resorbeerbare stent is echter relatief star en dik waarbij het risico van 
stenttrombose op korte termijn (gedurende de resorptie) juist verhoogd blijkt.
De laatste decennia is er een toenemende interesse voor complexe percutane revascularisatie, 
zoals CTO PCI. Een CTO is de ultieme uitdaging voor de interventie cardioloog waarbij er traditioneel 
lage succespercentages voor percutane revascularisatie werden bereikt. Tegenwoordig zijn de 
slagingspercentages van deze procedure echter gestegen naar 95% indien verricht in gespecialiseerde 
centra die het volledige arsenaal aan materialen en technieken gebruiken. Toch is het momenteel nog 
onbekend of revascularisatie daadwerkelijk leidt tot een verbeterde uitkomst voor de patiënt.
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Deel I Detectie van significant coronairlijden
In hoofdstuk 1 worden de resultaten beschreven van een studie met als doel de toegevoegde waarde 
van de transluminale contrast gradiënt (transluminal attenuation gradient, TAG) aan de reguliere 
beoordeling van stenosegraad te onderzoeken. TAG is gedefinieerd als de gradiënt van contrastdensiteit 
over de lengte van een coronair op CCTA. De hypothese was dat in aanwezigheid van een significante 
stenose de afname van contrastdensiteit groter zou zijn in vergelijking met geen of nauwelijks 
aanwezigheid van een stenose. Daarom was het doel om de voorspellende waarde van CCTA voor 
hemodynamisch significant coronairlijden te verbeteren door TAG toe te voegen aan stenosegraad. 
In deze studie werden vijfentachtig patiënten met een gemiddeld risico op obstructief coronairlijden 
geïncludeerd. Alle patiënten ondergingen step-and-shoot 256-slice CCTA. TAG werd geanalyseerd 
waarna een invasieve coronaire angiografie inclusief coronaire drukmetingen (fractional flow reserve, 
FFR)  metingen van alle belangrijke coronaire takken werd verricht. Twee correctiemodellen werden 
toegepast door ofwel te corrigeren voor de constrastfase verschillen binnen de coronaire meting (TAG-
CCO) of door uitsluiting van gecalcificeerde coronaire segmenten (TAG-ExC). De resultaten toonden een 
bijna perfecte sensitiviteit en redelijke specificiteit voor reguliere beoordeling van de stenosegraad. 
Echter, in tegenstelling tot de hypothese van deze studie verbeterde de specificiteit van CCTA niet 
door de toevoeging van TAG, TAG-ExC of TAG-COO voor het beoordelen van de hemodynamische 
gevolgen van een coronaire stenose. Vanuit theoretisch oogpunt zijn deze waarnemingen niet geheel 
onverwacht. Een daling van de contrast densiteit voorbij een stenose weerspiegelt een verminderde 
doorbloeding tijdens rust, terwijl meerdere onderzoeken duidelijk hebben aangetoond dat de 
doorbloeding tijdens rust stabiel blijft tot het punt van subtotale coronaire occlusie. Daarom lijkt TAG 
het meest geschikt om subtotale occlusies te detecteren met TIMI-flow (invasief bepaalde contrast 
stroomsnelheden) <3 of totale occlusies met een collaterale circulatie in plaats van een significante 
intermediaire stenose.
De studie gerapporteerd in hoofdstuk 2 was gericht op het beoordelen van de diagnostische 
nauwkeurigheid van relatieve perfusie van het myocard (relative flow reserve, RFR) met kwantitatieve 
PET in vergelijking met absolute perfusie van het myocard voor de voorspelling van invasief gemeten 
FFR. RFR is gedefinieerd als de ratio van hyperemische perfusie in een stenotisch gebied van het 
myocard tot hyperemische perfusie in een normaal niet-obstructief gebied van het myocard. Invasief 
gemeten FFR weerspiegelt de hyperemische drukgradiënt over een specifieke epicardiale stenose. Er 
moet echter worden opgemerkt dat de drukgradiënt afhankelijk is van de hyperemische reactie van 
het vat distaal van de stenose. In bloedvaten met een meer uitgesproken reactie op een adenosine 
(gebruikt om hyperemie te bereiken), zal de druk meer dalen op het niveau van de stenose dan in 
bloedvaten waarin de hyperemische respons is afgezwakt. Hyperemische perfusie is een samengestelde 
meting van het coronaire vaatbed evenals microvasculaire weerstand in het myocard zelf. In het geval 
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van een slechte microvasculaire functie kan perfusie zelfs zonder obstructieve epicardiale stenose 
abnormaal worden. Hierdoor kan een verschil tussen FFR en hyperemische perfusie met PET worden 
waargenomen vanwege verschillen in onderliggende fysiologische processen. Om deze reden werd 
in deze studie onderzocht of RFR een betere voorspelling van significant coronairlijden (bepaald door 
FFR)  zou geven in vergelijking met hyperemische perfusie. Bij 92 patiënten met een stenose in één of 
twee van de drie coronairen was de correlatie tussen RFR en invasieve FFR matig (r = 0,54, p <0,01). 
ROC-curve-analyse toonde een oppervlakte onder de curve van 0,82 voor RFR. Dit was niet significant 
hoger dan het oppervlakte onder de curve van hyperemische perfusie en coronaire flow reserve (ratio 
tussen hyperemische en rust perfusie, CFR; 0,76, p = 0,32 en 0,72, p = 0,08, respectievelijk). Deze 
studie suggereert dat RFR-berekening met kwantitatieve PET mogelijk is maar dat in deze relatief 
kleine studie er geen duidelijke verbetering van de diagnostische nauwkeurigheid werd waargenomen 
in vergelijking met hyperemische perfusie of CFR.
Hoewel stenose gemeten met CCTA een goede overeenkomst vertoont met stenose op invasieve 
coronair angiografie, is de relatief slechte voorspellende waarde van stenosegraad voor ischemie 
van het myocard goed bewezen. Naast de ernst van de coronaire stenose, wordt de perfusie van 
het myocard mogelijk ook beïnvloed door het atherosclerotisch volume en morfologie. Hoofdstuk 3 
onderzoekt de invloed van CT-afgeleide atherosclerotische eigenschappen op de doorbloeding van het 
myocard gemeten met zowel PET en invasieve FFR. Deze studie toonde aan dat positief remodelleren 
(atherosclerotische groei buiten het lumen) en niet-gecalcificeerde atherosclerose geassocieerd zijn 
met nadelige hyperemische perfusie van het myocard en invasieve FFR. Deze bevindingen waren 
onafhankelijk van de ernst van de stenose. Blijkbaar wordt de hemodynamiek niet alleen beïnvloed 
door luminale stenose, maar ook door andere (geometrische) variabelen zoals atherosclerotische 
lengte, volume of morfologie. Desalniettemin was de toegevoegde waarde van deze ongunstige 
atherosclerotische eigenschappen ten opzichte van luminale stenose als voorspellers voor ischemie 
binnen dit onderzoek beperkt. In hoofdstuk 4 worden de belangrijkste resultaten van de ’’Stress 
Myocardial Perfusion Imaging versus Coronary Computed Tomographic Angiography for Diagnosis 
of Invasive Vessel-Specific Ischemia: Predictive Modeling Results from the Computed TomogRaphic 
Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia (CREDENCE) Trial’’ gerapporteerd. 
Het doel van dit onderzoek was om een  geoptimaliseerde beoordeling van CCTA te creëren, 
valideren en te vergelijken met een geoptimaliseerde beoordeling van MPI voor de voorspelling van 
hemodynamisch significant coronairlijden, gedefinieerd als een afwijkende invasieve FFR. Hoewel 
resultaten van vergelijkende diagnostische studies beschikbaar zijn, gebruikten deze studies alleen 
de ernst van de anatomische stenose als de uitkomst en worden de bevindingen over het algemeen 
samengevat als dichotome uitkomsten. De CREDENCE-studie is een prospectieve, multicenter 
diagnostische derivatie-validatie klinische studie waarbij 612 stabiele patiënten werden geïncludeerd 
tussen 2014-2017. Zowel CCTA als MPI (PET-, SPECT- of MRI-cardiale perfusie beeldvorming) werden 
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als diagnostische tests verricht bij alle geïncludeerde patiënten waarna binnen 60 dagen een invasieve 
coronair angiografie met FFR-metingen in alle drie epicardiale coronairen als referentietest werd 
verricht. Voorspellers voor een afwijkende referentie test voor MPI waren score van afwijkende 
rust perfusie en de score van het verschil tussen de score tijdens hyperemie en rust (verschilscore) 
binnen de specifieke vasculaire myocardiale gebieden. Het oppervlakte onder de ROC-curve (AUC) 
veranderde niet significant door stapsgewijze toevoeging van linker ventrikel ejectiefractie of ECG-
bevindingen bovenop de rustscore en verschilscore. Significante voorspelers voor een abnormale 
referentietest voor CCTA waren het aantal laesies met stenose met een diameter van ≥30%, het 
percentage niet-gecalcificeerd atheroma-volume, het volume van het lumen van de coronair en het 
aantal laesies met hoog-risico atherosclerotische eigenschappen. Wat betreft het primaire eindpunt 
van de studie, de geoptimaliseerde oppervlakte onder de ROC-curve per modaliteit, toonden de 
resultaten dat een geoptimaliseerd CCTA-model superieur is ten opzichte van het MPI-model voor 
de diagnose van ischemie (AUC 0,81 (95% betrouwbaarheidsintervallen [CI]: 0,78-0,84) ) versus 0,67 
(95% BI: 0,63-0,71), p <0,001). Deze resultaten vormen een uitbreiding van eerdere bevindingen (zoals 
gerapporteerd in hoofdstuk 4) en onthullen dat verschillende kwalitatieve en kwantitatieve CCTA-
afgeleide atherosclerotische plaque-eigenschappen zeer voorspellend zijn voor myocardiale ischemie. 
Deze bevindingen suggereren dat de incorporatie van zowel stenosegraad als de eigenschappen van 
epicardiale coronaire atherosclerose een vollediger beeld geeft van de ziekte en myocardiale ischemie 
vergeleken met bepaling van een de ernst van een focale stenose alleen. Deze kwantitatieve CCTA-
analyses zijn momenteel niet volledig geautomatiseerd en zijn daarom tijdrovend, dit kan momenteel 
een brede toepassing in de klinisch praktijk  belemmeren.
Deel II Bioresorbable vascular scaffold
Hoofdstuk 5 en 6 beschrijven de tussentijdse en definitieve resultaten van ‘’the Impact of Vascular 
Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized [15O]2O PET/CT 
Study’’ (VANISH). De VANISH-studie was een prospectieve, single-blind, gerandomiseerde, twee-groep, 
single-center klinische studie met 60 patiënten met de nieuw obstructief coronairlijden van één coronair 
zonder biochemische tekenen van een myocardinfarct en met een normale linkerventrikelfunctie ( 
≥50%). Deze patiënten werden één-op-één gerandomiseerd naar de implantatie van BVS versus een 
metalen drug eluting stent (DES) en vervolgens drie jaar gevolgd om het effect van BVS op perfusie 
te beoordelen tijdens hyperemie en koude test (cold pressor test, CPT). CPT is de gouden standaard 
om de vasomotorische functie van de coronair te beoordelen in reactie op sympathische stimulatie. 
Zoals eerder vermeld, is de hypothese dat bevrijd van de intravasculaire “kooi”, het oorspronkelijk 
van stent voorziene coronaire segment weer kan reageren op fysiologische stimuli met herstel van 
normale vasomotorische functies. De tussentijdse analyse na 1 maand onthulde geen verschillen van 
de absolute myocardiale perfusie tijdens hyperemie en CPT tussen de met BVS en DES behandelde 
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patiënten. Interessant is dat CFR lager was bij met BVS behandelde patiënten, hoewel nog steeds 
binnen normale grenzen. De ratio van CFR van het behandelde gebied ten opzichte van de CFR in een 
niet behandeld (normaal) gebied verschilde echter niet tussen beide behandelarmen, wat wijst op 
een homogeen verlaagde globale CFR in de BVS-behandelarm. Dit potentiële globale effect van BVS 
op CFR is tot nu toe onverklaard en vereist verder onderzoek. Na drie jaar voltooiden 59 (98%), 56 
(93%) en 51 (85%) patiënten met succes respectievelijk het een maand, twee jaar en drie jaar controle 
moment inclusief PET-beeldvorming. Tijdens de drie jaar studieperiode werden geen cardiale events 
geregistreerd. Het primaire studie-eindpunt (de interactie tussen de geplaatste stent en myocardiale 
perfusie over de tijd) was niet significant voor hyperemische perfusie, CPT en CFR. Dit betekent dat 
er geen gunstige effecten werden waargenomen als gevolg van BVS-resorptie tijdens hyperemie 
of endotheel-afhankelijke vasodilatatie door CPT. Hieruit volgt dat er geen klinisch voordeel is met 
betrekking tot perfusie van het myocard en deze gegevens ondersteunen het gebruik van BVS daarom 
momenteel niet, ondanks het feit dat er nog steeds een voordeel op lange termijn (> 3 jaar) zou 
kunnen bestaan.
Deel III Chronische totale occlusie percutane coronaire interventie
In hoofdstuk 7 wordt de waarde van beeldvorming met PET en CCTA besproken voor het diagnostische 
proces van patiënten met een CTO. CTO PCI is uitdagend en gaat traditioneel gepaard met lagere 
slagingspercentages en een hogere complicatiekans in vergelijking met reguliere PCI voor niet-
occlusieve laesies. Succespercentages nemen af  met toenemende complexiteit van coronaire laesies. 
Dankzij de vooruitgang in materiaal en de implementatie van dissectie- en re-entry technieken is 
het succespercentage gestegen naar 95%. Daarom is het van het groot belang om alle mogelijke 
rekanalisatie opties en bijbehorende risico’s in overweging te nemen voordat de procedure wordt 
gestart. CCTA kan van belang zijn bij het voorbereiden op CTO-interventie omdat het een gedetailleerde 
driedimensionale weergave van coronaire CTO’s en beoordeling van de morfologie van de occlusie 
mogelijk maakt. Deze bevindingen kunnen de interventie cardioloog naar een specifieke strategie 
leiden. Toch moet de patiëntselectie voor CTO PCI gericht zijn op de te verwachte afname in ziektelast 
voor de patiënt in termen van gezondheidstoestand en prognose op de lange termijn in plaats van 
op coronaire anatomische complexiteit. Nadat de diagnose van een CTO is vastgesteld, is informatie 
over de linker ventrikel functie essentieel. Een normale regionale linker ventrikelfunctie in het gebied 
van de CTO sluit per definitie niet-vitaal myocard uit. De beslissing om een revascularisatie procedure 
uit te voeren zou in dat geval gebaseerd moeten zijn op de aanwezigheid en omvang van ischemie 
of symptomen. Zonder gedocumenteerde ischemie is een dergelijke procedure zinloos en zelfs 
gevaarlijk. Aan de andere kant, wanneer patiënten uitgebreide regionale wandbewegingsstoornissen 
vertonen in het CTO gebied, raden we aan dat de diagnostische voorbereiding is gericht op vitaliteit 
van het myocard in plaats van ischemie. Binnen dit review wordt een diagnostisch beslissingsschema 
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voorgesteld. Tevens vermeldt dit hoofdstuk de angiografische voorspellers van procedureel succes. 
In hoofdstuk 8 worden de klinische presentatie en de kenmerken van patiënten met een CTO en de 
huidige revascularisatie strategieën voor specifiek CTO PCI besproken. Patiënten met een CTO zijn 
ouder, vaker man en hebben een relatief hoge prevalentie van cardiale risicofactoren in vergelijking 
met patiënten met niet-occlusieve coronairlijden. Ongeveer een op de vier patiënten met een CTO 
ervaart geen symptomen. De afwezigheid van symptomen kan mogelijk worden verklaart door de 
aanwezigheid van collaterale circulatie in combinatie met verminderde dagelijkse fysieke activiteit 
of autonome neuropathie bij diabetespatiënten, die sterk vertegenwoordigd zijn in de CTO-
patiëntpopulatie. Bij symptomatische CTO-patiënten kan typische angina pectoris minder uitgesproken 
zijn dan kortademigheid of atypische symptomen. CTO’s worden gediagnosticeerd bij 16-18,4% van 
de patiënten met coronairlijden, maar CTO PCI vertegenwoordigt slechts 5-10% van het totale PCI-
volume. Dit kan te wijten zijn aan de traditioneel hogere complicaties- en lagere slagingspercentages. 
Om hoge slagingspercentages voor CTO PCI te waarborgen zijn een goede procedure voorbereiding 
en strategiekeuze van cruciaal belang. Dubbele arteriële toegang, gebruik van een microkatheter en 
zorgvuldige beoordeling van de angiografische kenmerken zoals (1) morfologie van het proximale deel 
van de occlusie, (2) occlusielengte, (3) distale kwaliteit van de coronair en (4) collateralen geschikt voor 
interventie, worden sterk geadviseerd omdat het de juiste selectie van de strategie mogelijk maakt.
Hoofdstuk 9 was bedoeld om de prevalentie van ischemie te onderzoeken in een klinische populatie 
met een CTO en een normale linker ventrikelfunctie. Deze populatie bestond uit 76 patiënten met 
(in)stabiele angina pectoris (61%), dyspneu (17%) en geen symptomen (22%). Alle patiënten werden 
geëvalueerd met PET-perfusie om kwantitatieve perfusie te beoordelen. De gemiddelde afname 
van hyperemische perfusie was gemiddeld 46%, en 73 (96%) patiënten vertoonden een significant 
verminderde hyperemische perfusie (≤75% van patiënt specifieke normaalwaarden). Bovendien 
was de Rentrop-score (score voor retrograde epicardiale vulling van het gebied achter de occlusie) 
uitstekend bij 96% van de patiënten. Deze resultaten geven aan dat in een klinisch cohort van patiënten 
met een CTO en een behouden linker ventrikelfunctie de overgrote meerderheid een aanzienlijk 
verlaagde perfusie van het myocard heeft, zelfs in aanwezigheid van angiografisch goed ontwikkelde 
collaterale circulatie.
In hoofdstuk 10 werden de effecten van succesvolle percutane coronaire interventie van chronische 
totale occlusies op myocardperfusie en linkerventrikelfunctie onderzocht. De hypothese was dat in 
aanwezigheid van een groot ischemisch gebied op nucleaire beeldvorming CTO PCI zal resulteren in 
een significante ischemiereductie. Bovendien kan door CTO PCI herstel van linker ventrikel functie 
worden verwacht indien er sprake is van vitaliteit en disfunctie van het myocard in het gebied van 
de CTO. In deze studie werden 69 patiënten, met een gedocumenteerde CTO en beeldvorming 
met cardiale MRI met gadolinium aankleuring in late fase (LGE-CMR) en kwantitatieve PET om 
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respectievelijk vitaliteit en ischemie te detecteren, prospectief geïncludeerd. Ten minste twaalf weken 
na succesvolle percutane revascularisatie werd de LGE-CMR en PET herhaald om het effect van de 
procedure op de linker ventrikelfunctie en ischemie te evalueren. De belangrijkste resultaten toonden 
aan dat hyperemische perfusie aanzienlijk toenam, resulterend in een daling van de pre-procedurele 
grootte het perfusie defect van meer dan 3 myocardiale segmenten in de overgrote meerderheid 
van de patiënten. Daarentegen was er slechts een kleine verbetering in linker ventrikel ejectiefractie 
van 1,1%, welke niet gerelateerd was aan het herstel van hyperemische perfusie. Deze resultaten 
suggereren dat revascularisatie moet worden overwogen bij patiënten met een gedocumenteerde 
CTO in geval van significant ischemie en vitaal myocard, hoewel gerandomiseerd bewijs met betrekking 
tot een verbeterde prognose door CTO PCI momenteel ontbreekt.
Hoofdstuk 11 was bedoeld om de gevolgen van procedurele occlusie van een zijtak van de rechter 
coronairarterie naar de rechter ventrikel (right ventricular branch, RVB) te onderzoeken. Het 
gebruik van dissectie- en re-entry technieken voor CTO PCI in combinatie met uitgebreide stent 
implantatie verhoogt het risico op een occlusie van een coronaire zijtak. Bovendien wordt de RVB-
occlusie beschouwd als een acceptabele opoffering voor herstel van de bloedstroom door de rechter 
kransslagader zelf. Het gevolg op het functioneren de rechter ventrikel is echter nooit onderzocht. 
In een klinische populatie van 54 patiënten met CTO PCI en LGE-CMR voor en na de procedure trad 
RVB-occlusie op bij 12 patiënten (22%). RVB-occlusie was niet geassocieerd met een significante 
verandering in het eind diastolische volume van de rechter ventrikel of rechter ventrikel ejectiefractie. 
Echter werd er wel een trend waargenomen voor een toename van het eind systolische volume van de 
rechter ventrikel (72,5 ± 20,0 versus 77,4 ± 20,7 ml, p = 0,05 ) bij follow-up. Deze resultaten geven aan 
dat er nadelige effecten kunnen zijn van RVB-occlusie, maar de gevolgen relatief beperkt lijken te zijn.
CONCLUSIES
Uit dit proefschrift kunnen verschillende hoofdconclusies worden getrokken. Ten eerste zijn 
angiografische kenmerken op CCTA zoals volumetrische metingen en morfologische aspecten van 
atherosclerose van belang bij het beoordelen van de hemodynamische gevolgen van atherosclerose. 
Deze bevindingen dragen bij aan het verhogen van de diagnostische nauwkeurigheid van CCTA om 
hemodynamisch significant coronairlijden te voorspellen. 
Ten tweede is implantatie van de BVS mogelijk, maar er wordt geen voordeel gevonden met betrekking 
tot perfusie van het myocard tijdens hyperemie of endotheel afhankelijk vasodilatatie. Deze 
bevindingen ondersteunen het gebruik van de BVS in plaats van metalen DES niet, mede vanwege de 
combinatie met uitkomsten van grote gerandomiseerde onderzoeken waarbij er een verhoogd risico 
is op trombose gedurende de eerste drie jaar is vastgesteld. 
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Ten derde heeft de overgrote meerderheid van patiënten met een CTO een aanzienlijk aangetaste 
perfusie van het myocard waarbij er een groot effect van revascularisatie op het herstel van de perfusie 
kan worden verwacht. De effecten op het herstel van linker ventrikel functie lijken minder evident.
TOEKOMSTPERSPECTIEVEN
De bovengenoemde conclusies wijzen op het belang van verder onderzoek. Ten eerste bevat deel 
I twee onderzoeken (hoofdstuk 1 en 2) met als doel de diagnostische waarde van CCTA en PET te 
verbeteren, echter met een negatief resultaat. Het is heel belangrijk dat we blijven proberen om fout-
positieve en fout-negatieve testresultaten te beperken om onnodige aanvullende diagnostische testen 
of behandelingen te voorkomen. Afgezien van het onderzoeken van aanvullende afgeleiden die zijn 
verkregen uit de huidige beeldvromende techniek, zullen de eindeloze ontwikkelingen in technologie 
en scanresolutie resulteren in voortdurende beschikbaarheid van nieuwe informatie. Hoofdstuk 3 en 
4 zijn indrukwekkende voorbeelden die aantonen dat we met deze nieuw beschikbare mogelijkheden 
een stap dichterbij komen om pathofysiologische processen nauwkeurig niet-invasief te beoordelen. 
Uit deze hoofdstukken bleek dat het gebruik van deze bevindingen kan helpen bij het identificeren van 
hemodynamisch significant coronairlijden. Daarom zullen diagnostische vergelijkende onderzoeken 
in de toekomst alle informatie uit diagnostische scans moeten worden opgenomen in plaats van 
alleen conventionele dichotome beoordeling. Technologie ontwikkelt zich en onderzoekers moeten 
bedenken hoe deze verbeteringen in de beeldkwaliteit kunnen worden opgenomen in klinische studies 
en praktijk. In de toekomst zullen we CCTA niet alleen beoordelen op basis van de ernst van de stenose, 
maar volumetrische metingen en morfologie moeten worden geïntegreerd in onze besluitvorming. 
In deel II wordt de VANISH-trial gepresenteerd en besproken. Over het algemeen heeft de BVS niet 
aan de hoge verwachtingen voldaan en zal BVS in zijn huidige vorm niet in de klinische praktijk worden 
gebruikt. Toch zullen de resultaten van langdurige follow-up van enkele grootschalige onderzoeken 
bepalen of het concept van een oplosbare coronaire stent interessant kan blijven voor de toekomst. De 
negatieve resultaten zijn waarschijnlijk gerelateerd aan het ‘’omvangrijke’’ en starre ontwerp waarbij 
toekomstige verbeteringen in het ontwerp van een oplosbare stent niet kunnen worden uitgesloten. 
Het zal vooral belangrijk zijn toekomstige studies met resorbeerbare coronaire stents voorzichtig uit te 
voeren om de veiligheid van de patiënten te waarborgen.
In deel III is beschreven dat patiënten met een CTO een aanzienlijk aangetaste perfusie van het 
myocard hebben en dat dit kan herstellen door het verrichten van een PCI van de CTO. Deze patiënten 
moeten daarom niet alleen medicamenteus behandeld worden omdat revascularizatie van de laesie 
complex is. Er is steeds meer interesse onder interventiecardiologen om deze laesies percutaan te 
behandelen. Deze interesse heeft ervoor gezorgd dat er steeds meer toegewijde en goed ervaren 
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interventiecardiologen zijn, evenals gespecialiseerde materialen en technieken. Dit heeft geleid tot 
hoge slagingspercentages voor CTO PCI in gespecialiseerde centra. Helaas is er op dit moment geen 
gerandomiseerd bewijs voor reducties in belangrijke ongewenste cardiale gebeurtenissen en hopelijk 
zullen deze binnenkort beschikbaar komen. Dit soort gerandomiseerde studies zijn echter moeilijk uit 
te voeren vanwege selectie van patiënten waarbij revascularizatie niet de voorkeur heeft en een hoge 
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Supplemental table 1. Univariable and multivariable analysis of plaque characteristics for coronary flow reserve 
using [15O]H2O PET
Univariable analysis Analysis corrected for 
luminal stenosis
Multivariable analysis using 
forward selection
Plaque characteristics Coefficient (95% CI) P-value Coefficient (95% CI) P-value Coefficient (95% CI) P-value
Quantitative plaque characteristics
Luminal stenosis - - - <0.001*
   No stenosis 0
(reference)
- - - 0
(reference)
-
   0 – 50% stenosis -0.002
(-0.056, 0.051)
0.930 - - 0.007
(-0.045, 0.060)
0.783
   50 – 70% stenosis -0.084
(-0.139, -0.030)
0.002* - - -0.057
(-0.111, -0.003)
0.039*
   > 70% stenosis -0.203
(-0.259, -0.146)
<0.001* - - -0.145
(-0.205, -0.086)
<0.001*

























































































Quantitative plaque burden and morphology related to FFR CI = confidence interval; * indicate significant 
coefficients for P < 0.05
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Supplemental table 2: CT characteristics according to concordant and discordant PET derived stress MBF and 
invasive FFR.
CT characteristics Total Stress  
MBF+ FFR+   
(n = 119)
Stress  
MBF– FFR+  
(n = 38)
Stress  
MBF+ FFR–  
(n = 96)
Stress  





   No stenosis 195 (32) 0 (0) a 1 (3) a 31 (32) b 157 (46) b <0.001
   0 – 50% stenosis 112 (18) 6 (5) a 4 (11) a,b 19 (20) b 79 (23) b <0.001
   50 – 70% stenosis 149 (24) 27 (23) a,b 17 (45) b 28 (29) a,b 71 (21) a <0.001
   > 70% stenosis 154 (25) 86 (72) a 16 (42) b 18 (19) c 33 (10) c <0.001
Plaque length [mm] 26 ± 28 55 ± 28 a 41 ± 19 b 29 ± 30 c 14 ± 19 d <0.001
Plaque volume [mm3] 162 ± 224 380 ± 297 a 250 ± 173 b 174 ± 221 b 75 ± 122 c <0.001
Noncalcified plaque 
volume [mm3]
52 ± 118 145 ± 218 a 83 ± 90 b 43 ± 66 b,c 20 ± 39 c <0.001
Calcified plaque volume 
[mm3]
110 ± 152 235 ± 179 a 167 ± 122 b 130 ± 172 b 56 ± 100 c <0.001
Lumen area [mm2] 3.2 ± 2.4 1.2 ± 1.0 a 1.7 ± 1.2 a 3.7 ± 2.3 b 4.0 ± 2.3 b <0.001
Wall area [mm2] 5.3 ± 5.1 9.3 ± 5.5 a 7.5 ± 3.7 a,b 5.4 ± 4.9 b 3.6 ± 4.2 c <0.001
Plaque burden [%] 55 ± 40 92 ± 14 a 84 ± 19 a 53 ± 39 b 39 ± 38 c <0.001
Noncalcified plaque 113 (19) 38 (32) a 12 (32) a 22 (23) a 38 (11) b <0.001
Partially calcified plaque 272 (45) 104 (87) a 26 (68) b 42 (44) b 97 (29) c <0.001
Calcified plaque 266 (44) 75 (63) a 26 (68) a 46 (48) a,b 114 (34) b <0.001
Low attenuation plaque 76 (13) 41 (35) a 14 (37) a 6 (6) b 13 (4) b <0.001
Positive remodeling 68 (11) 39 (33) a 11 (29) a 5 (5) b 12 (4) b <0.001
Spotty calcification 35 (6) 20 (17) a 3 (8) a,b 2 (2) b 8 (2) b <0.001
Napkin ring sign 22 (4) 14 (12) a 2 (5) a,b 2 (2) b 3 (1) b <0.001
Each letter denotes a subset of PET MBF and FFR discordancy categories whose proportions do not differ 
significantly from each other at the 0.05 level.
CT = computed tomography; FFR = fractional flow reserve; MBF = myocardial blood flow; PET = positron emission 
tomography
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Supplemental table 3: CT characteristics according to concordant and discordant PET derived stress MBF and 
CFR.
CT characteristics Total Stress  
MBF+ CFR+ (n 
= 164)
Stress  











   No stenosis 195 (32) 22 (13) a 9 (39) b,c 11 (20) a,c 153 (43) b < 0.001
   0 – 50% stenosis 112 (18) 15 (9) a 6 (26) a,b 10 (18) a,b 79 (22) b < 0.001
   50 – 70% stenosis 149 (24) 41 (25) a 3 (13) a 17 (31) a 85 (24) a < 0.001
   > 70% stenosis 154 (25) 86 (52) a 5 (22) b,c 17 (31) c 43 (12) b < 0.001
Plaque length [mm] 26 ± 28 44 ± 32 a 26 ± 29 b 38 ± 32 a,b 16 ± 20 b < 0.001
Plaque volume [mm3] 162 ± 224 299 ± 297 a 142 ± 189 b 228 ± 238 a,b 88 ± 136 b < 0.001
Noncalcified plaque 
volume [mm3]
52 ± 118 111 ± 192 a 27 ± 36 b 58 ± 92 b 25 ± 51 b < 0.001
Calcified plaque volume 
[mm3]
110 ± 152 188 ± 183 a 114 ± 162 a,b 170 ± 185 a 63 ± 106 b < 0.001
Lumen area [mm2] 3.2 ± 2.4 2.0 ± 2.0 a 3.2 ± 2.1 a, b 3.3 ± 2.4 b 3.8 ± 2.3 b < 0.001
Wall area [mm2] 5.3 ± 5.1 7.8 ± 5.8 a 3.9 ± 3.8 b,c 6.6 ± 4.7 a,c 4.0 ± 4.4 b < 0.001
Plaque burden [%] 55 ± 40 77 ± 34 a 47 ± 40 b 66 ± 35 a,b 43 ± 39 b < 0.001
Noncalcified plaque 113 (19) 44 (27) a 4 (17) a,b 17 (31) a 46 (13) b < 0.001
Partially calcified plaque 272 (45) 113 (69) a 8 (35) b,c 32 (58) a,c 113 (31) b < 0.001
Calcified plaque 266 (44) 94 (57) a 9 (39) a,b 29 (53) a,b 128 (36) b < 0.001
Low attenuation plaque 76 (13) 41 (25) a 2 (9) a,b 7 (13) a,b 25 (7) b < 0.001
Positive remodeling 68 (11) 38 (23) a 0 (0) a,b 6 (11) a,b 24 (7) b < 0.001
Spotty calcification 35 (6) 20 (12) a 0 (0) a,b 2 (4) a,b 10 (3) b < 0.001
Napkin ring sign 22 (4) 13 (8) a 0 (0) a,b 3 (6) a,b 5 (1) b < 0.001
Each letter denotes a subset of PET MBF and CFR discordancy categories whose proportions do not differ 
significantly from each other at the 0.05 level.
CT = computed tomography; CFR = coronary flow reserve; MBF = myocardial blood flow; PET = positron emission 
tomography
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Supplemental fi gure 1. The quanti tati ve relati onship between coronary fl ow reserve and fracti onal fl ow reserve
Supplemental fi gure 2. The quanti tati ve relati onship between PET derived hyperemic myocardial blood fl ow and 
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e-Table 1. Clinical Characteristics of Stable Chest Pain Patients Enrolled in the CREDENCE Trial. All measures are 







Age, years (mean±SD) 64±10 64±10 0.685
Female Sex (%) 29% 31% 0.561
Body Mass Index, in kg/m2 (mean±SD) 26±4 26±4 0.870
Race (%)   
    Black or African 2% 3% 0.632
    Asian 71% 70%
    American Indian or Alaskan Native 0.3% 0%
    White 27% 26%
Cardiovascular Risk Factors (%)
    Hypertension 64% 65% 0.913
    Dyslipidemia 44% 56% 0.003
    Diabetes 31% 30% 0.766
    Family History of CAD* 20% 20% 0.968
    Current Smoker or History of Smoking                                                    ≤1 year 17% 22% 0.143
Symptoms (%)**
    Typical or Atypical Angina 54% 64%
0.015    Non-Cardiac Chest Pain 13% 11%
    Heart Failure Symptoms 1% 0%
    No symptoms with Abnormal Diagnostic Test 32% 24%
*Family history of CAD was defined as a first-degree relative with a history of coronary artery disease (CAD) age 
<55 years (male) or age <65 years (female). **Symptom frequency does not sum to 100%; 5 patients did not have 
symptoms or a prior abnormal test recorded on their case report form. 
e-Table 2. Findings from Invasive Coronary Angiography Including Obstructive Coronary Artery Disease and 
Invasive FFR Measurements from the CREDENCE Trial. All measures are calculated as mean±standard deviation 
(SD) or %, as noted. 
Invasive Coronary Angiography Findings












QCA-Measured Maximum Diameter 
Stenosis (mean±SD) 37.4%±27.5% 27.0%±30.3% 21.6%±28.9% 28.8%±29.6%
% with Diameter Stenosis 
    ≥50%









% with ≥50%Stenosis in Proximal 
Segment
13% 8% 7% 10%
FFR ≤0.80 or >90% stenosis (%) 44% 18% 17% 27%
Abbreviations: QCA: Quantitative coronary angiography, FFR: Fractional flow reserve.
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e-Table 3. Multivariable Generalized Linear Mixed Model* Based on Rest/Stress MPI Measurements by Vascular 
Territory Estimating Vessel-Specific Invasive FFR ≤0.80 from the CREDENCE Trial. This final model was based on 
variables included in the final MPI model from Figure 2.
 Model Parameters for Per-Vessel Odds Ratio 
(95% Confidence Interval) Χ2 p value
SRS, per % Myocardium




SDS, per % Myocardium




*Rest and post-stress LVEF and exertional ST depression ≥1.0 mm were not statistically significant and not entered 
into the final multivariable model.
Abbreviations: SRS: Summed rest score, SDS: Summed difference score or the % ischemic myocardium.
e-Table 4. Receiver Operating Characteristics Curve Analysis with Calculation of the Area Under the Curve (AUC) 
for Subgroups of Women, Men and by Age <65 and ≥65 years
AUC for CCTA AUC for MPI p value
Women 0.88 0.73 <0.001
Men 0.83 0.66 <0.001
Age <65 years 0.83 0.68 <0.001
Age ≥65 years 0.86 0.68 <0.001






























































e-Figure 2: Per-vessel Predicted Probability of Invasive FFR ≤0.80 for CCTA Variables from the Multi variable 
Logisti c Regression Model (See Table 3).
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e-Figure 3: Pr-vessel Predicted Probability of Invasive FFR ≤0.80 for MPIVariables from the Multi variable Logisti c 












































Appendix C. Inclusion and Exclusion Criteria
Inclusion criteria
1. Age >18 years
2. Scheduled to undergo clinically-indicated non-emergent invasive coronary angiography 
Exclusion criteria
1. Known CAD before index testing (myocardial infarction, percutaneous coronary intervention, or 
coronary artery bypass graft surgery)
2. Hemodynamic instability
3. Inability to provide written informed consent
4. Concomitant participation in another clinical trial in which subject is subject to investigational 
drug or device
5. Pregnant state 
6. Contraindication to iodinated contrast due to prior near-fatal anaphylactic reaction (laryngospasm, 
bronchospasm, cardiorespiratory collapse, or equivalent) 
7. Serum creatinine ≥1.7 mg/dl or Glomerular Filtration Rate <30 ml/min
8. Baseline irregular heart rhythm (e.g., atrial fibrillation, etc.)
9. Heart rate ≥100 beats per minute
10. Systolic blood pressure ≤90 mm Hg
11. Contraindications to β blockers or nitroglycerin or adenosine
12. BMI >40 kg/m2
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Appendix D. Study Organization
Executive Steering Committee: 
•	 James K. Min, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, NY, USA)
•	 Leslee J. Shaw, PhD (Department of Radiology, NewYork-Presbyterian Hospital and Weill 
Cornell Medicine, New York, NY, USA)
•	 Subha Raman, MD (Ohio State University, Columbus, OH, USA)
•	 Gianluca Pontone, MD, PhD (Department of Clinical Sciences and Community Health, 
University of Milan, Centro Cardiologico Monzino, IRCCS Milan, Italy)
•	 Daniele Andreini, MD (Department of Clinical Sciences and Community Health, University 
of Milan, Centro Cardiologico Monzino, IRCCS Milan, Italy)
•	 Jonathon Leipsic, MD (Department of Medicine and Radiology, University of British 
Columbia, Vancouver, BC, Canada)
The Executive Steering Committee, a group of physicians and/or professionals with expertise in 
Myocardial perfusion imaging, coronary computed tomography angiography, invasive coronary 
angiography, clinical research, statistics, and coronary intervention, provided direction and oversight 
of the CREDENCE trial. The Executive Steering Committee was tasked with oversight of the trial design 
and conduct of the study, analysis of data and publication of results. To contribute to enhancing the 
integrity of the trial, the Executive Steering Committee was allowed to formulate recommendations 
relating to selection/recruitment of participants, their management, improving adherence to protocol-
specified regimens, and the procedures for data management and quality control. The Executive 
Steering Committee approved the final analysis design.
Data and Safety Monitoring Board: 
•	 Aloke Finn, MD (Division of Cardiology, Emory University School of Medicine, Atlanta, GA)
•	 Arshed A. Quyyumi, MD (Emory Clinical Cardiovascular Research Institute, Emory University 
School of Medicine, Atlanta, GA) 
•	 Farouc A. Jaffer, MD, PhD (Massachusetts General Hospital and Harvard Medical School, 
Boston, Massachusetts) 
•	 Todd C. Villines, MD (Department of Medicine, Walter Reed Medical Center, Washington, 
DC).
Clinical Events Committee: 
•	 Erica C. Jones, MD (Clinical Cardiologist; Dalio Institute of Cardiovascular Imaging, 
Department of Radiology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New 
York, NY) 
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•	 Robert J. Kim, MD (Clinical Cardiologist; Dalio Institute of Cardiovascular Imaging, Department 
of Radiology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Aeshita Dwivedi, MD (Clinical Cardiologist; Dalio Institute of Cardiovascular Imaging, 
Department of Radiology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New 
York, NY)
Clinical and Data Coordinating Center: 
•	 Leslee J. Shaw, PhD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Fay Y. Lin, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, NewYork-
Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Wijnand J. Stuijfzand, MD (Dalio Institute of Cardiovascular Imaging, Department of 
Radiology, NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Alexander van Rosendael, MD (Dalio Institute of Cardiovascular Imaging, Department 
of Radiology, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY; 
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands)
•	 Inge van den Hoogen, MD (Dalio Institute of Cardiovascular Imaging, Department of 
Radiology, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY; 
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands)
•	 Umberto Gianni, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY; Department of 
Molecular Medicine, Section of Cardiology, University of Pavia, Pavia, Italy)
•	 James K. Min, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
NewYork-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Rich Ferraro, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, New 
York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Amanda M. Su, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY)
•	 Mahn-Won Park, MD (Dalio Institute of Cardiovascular Imaging, Department of Radiology, 
New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY; Department of 
Cardiology, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon, Korea)
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Appendix E. Participating Sites and Enrolling Investigators 
Site Investigators Site Name
Hyuk-Jae Chang, PhD, MD Severance Cardiovascular Hospital, Yonsei University Health System, 
Seoul, Korea
Jung Hyun Choi, MD PhD Pusan National University Hospital, Busan, South Korea
Hyung-Bok Park, MD Division of Cardiology, Department of Internal Medicine, International St. 
Mary’s Hospital, Catholic Kwandong University, Incheon, South Korea
Joon Hyung Doh, MD Division of Cardiology, Inje University Ilsan Paik Hospital, South Korea
Ae-Young Her, MD Kangwon National University Hospital, Chuncheon, South Korea
Bon-Kwon Koo, MD PhD Department of Cardiology, Seoul National University College of Medicine, 
Seoul, South Korea
Chang-Wook Nam, MD PhD Dongsan Medical Center, Keimyung University College of Medicine, Taegu, 
South Korea
Sang-Hoon Shin, MD National Health Insurance Service Ilsan Hospital, South Korea
Jason Cole, MD Cardiology Associates of Mobile, Inc; Mobile, AL
Alessia Gimelli, MD 
Dante Chiappino, MD
Fondazione Toscana / CNR Gabriele Monasterio, Pisa, Italy
Muhammad Akram Khan, 
MD|Venkaa Chilakapati, MD 
Ahmed Ladak, MD 
Irfan Ullah, MD
Cardiac Center of Texas, McKinney, TX
Ryo Nakazato, MD 
Hiroyumi Niinuma, MD
St. Luke’s International Hospital, Tokyo, Japan
Faisal Nabi, MD Houston Methodist Hospital, Houston, TX
Randall Thompson, MD St Luke’s Hospital of Kansas City, Kansas City, MO
U. Joseph Schoepf, MD 
Daniel Sternberg, MD
Medical University of South Carolina - Heart and Vascular Center, 
Charleston, SC
Bin Lu, MD State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National 
Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences 
and Peking Union Medical, Beijing, China
James Jang, MD Kaiser Permanente, San Jose, CA
Paul Knaapen, PhD, MD VU University Medical Center, Amsterdam, the Netherlands
Christopher Rowan, MD Renown Institute for Heart and Vascular Health, Reno, NV
Michael Ridner, MD Heart Center Research, LLC; Huntsville, AL
Erick Avelar, MD Oconee Heart and Vascular Center - St Mary’s Medical Group, Athens, GA
Atizazul Mansoor, MD PinnacleHealth Cardiovascular Institute, Harrisburg, PA
Andrejs Erglis, MD Pauls Stradins Clinical University Hospital, Riga, Latvia
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Appendix F. Imaging Methods
Coronary Computed Tomographic Angiography Acquisition and Quality Assurance
Coronary computed tomography angiography was performed using a single- or dual source CT scanner 
with at least 64 detector rows and a detector row width of ≤ 75 mm, with multiple vendors, using 
prospective or retrospective gating. In total, 114 (18.63%) CT scanners were General Electric, 16 
(2.61%) Philips, 285 (46.57%) Siemens, 197 (32.19%) Toshiba and 0 (0.00%) other. As pre-treatment, 
278 (60.04%) patients were administered beta-blockers and 418 (90.09%) patients nitroglycerin, heart 
rate was <65 BPM in 393 (67.64%) patients. Tube current (mA), tube voltage (kV), dose-length product 
and contrast dose were recorded by individual sites. Site-submitted DICOM files were transmitted to 
the CCTA imaging core laboratory.
The core laboratory independent level III-experienced readers performed quantitative and qualitative 
measurements on a per-segment and per-lesion level, using semi-automated plaque analysis software 
(MEDIS QAngio CT Research Edition v3.1.4.1, Medis Medical Imaging Systems, Leiden, the Netherlands), 
with reconstructions at the smallest slice thickness (e.g., ~500 µm)1,2. Standard displays (e.g., width 
740 HU, level 220 HU) were adjusted by contrast level of the aorta. The existence of coronary plaque 
was defined as >1mm2 within or adjacent to the lumen that can be discriminated from surrounding 
pericardial tissue, epicardial fat, or lumen; and identified in >2 planes3. Core laboratory readers were 
blinded to clinical data and all other test results. 
Per-Segment Analysis
Coronary segments according to the 18-segment SCCT model were qualitatively evaluated for the 
categorical stenosis severity of CAD by the segmental severity score (CCTA-SSS)4-6. The location (i.e. 
proximal, mid, and distal) of the most sever lesion was recorded. Scans were assessed for non-
evaluable segments due to: 1611 (15.48%) segments <2 mm, 326 (3.13%) segments anatomically not 
existing, 406 (3.90%) segments with artifacts, 46 (0.44%) segments with CTO, 14 (0.14%) segments 
with PCI or CABG, 18 (0.17%) segments with file error or pair out, 17 (0.16%) segments with no image.
Quantitative segmental analysis was performed for vessel length, vessel-, plaque-, and lumen volumes, 
and mean plaque burden. Mean plaque burden was defined as total plaque volume divided by total 
vessel volume multiplied by 100 (%)7-9. Vessel-, plaque, and lumen volumes were normalized for vessel 
length by dividing the volume by the length of measured segment. Plaque composition volumes 
were determined using Hounsfield Unit (HU) thresholds including: 1) calcified plaque (HU>350), 2) 
fibrous plaque (HU 131-350), 3) fibrofatty plaque (HU 31-130), and 4) necrotic core (HU -30-30)1,2. 
Proportion of plaque composition within the total plaque volume was calculated as ratio of the plaque 
composition to total plaque volume.
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Per-Lesion Basis 
Lesions, which were allocated to the segment containing the minimal lumen diameter (MLD), were 
qualitatively and quantitatively evaluated for the following characteristics: 1) plaque composition as 
predominantly non-calcified (<30% calcified), mixed (30-70%), and calcified (>70% calcified), 2) low 
attenuation plaque (LAP) defined by HU<30; 3) positive remodeling (PR), defined by remodeling index 
≥1.1, 4) spotty calcification (SC) defined as ≤3mm calcification in any direction within the lesion, 5) 
napkin-ring sign (NRS), defined as a central low attenuation with a circumferential greater attenuated 
region of a non-calcified plaque, 6) bifurcation within 5mm of the lesion, and 7) tortuosity, defined as 
a >90-degree bend or three 45-90 degree curves were found using a 3-point angle within the lesion 
9-14. High-risk plaque (HRP) was defined as the presence of ≥2 features including PR, LAP, or SC within 
a coronary lesion. 
Lesions were also analyzed quantitatively for plaque length, total plaque volume and plaque 
composition volumes, as described in the per-segment analysis. Minimal and mean luminal diameters, 
minimal lumen area, plaque area, plaque area components, minimal and maximal plaque thickness, 
and plaque burden were determined in the maximal stenotic cross section of the lesion. Diameter 
stenosis and area stenosis were calculated using a normal cross-section within 5 mmm proximal to 
the lesion as reference15. The remodeling index was quantitatively calculated using the within lesion 
peak vessel area in comparison to the area of the vessel from 5 mm proximal until 5 mm distal to the 
lesion10. A quantitative remodeling ≥1.1 was considered abnormal. 
Segmental data was summed to per-vessel and per patient values according to the segmentation of 
the SCCT4. Diffuseness of atherosclerosis was calculated as a % of the summed length of coronary 
lesions divided by the total vessel lengths. For vessels and patients without lesions, diameter stenosis 
of the worst lesion was set to 0%, whilst for vessels or patients containing a total obstruction the 
diameter stenosis of the worst lesion was assigned 100%. 
Myocardial Perfusion Imaging Analysis
For SPECT and PET imaging utilized scanner vendors were: 114 (22.35%) General Electric, 194 
(38.04%) Philips, 90 (17.65%) Siemens, 2 (0.39%) Toshiba and 111 (21.72%) other. For SPECT, the 
following radiopharmaceuticals were used: 361 (77.30%) scans with Tc-99m and 3 (0.64%) scans with 
Thallium-201/Tc-99m. For PET, 35 (83.33%) scans were with Rubidium-82 and 7 (16.67%) scans with 
N13-Ammonia. For SPECT and PET combined, 92 (18.04%) scans were exercise and 419 (82.00%) scans 
were vasodilator stress. The core laboratory for SPECT and PET semi-quantitatively graded both rest 
and stress scans during a consensus meeting with three experienced MPI readers. Perfusion in each 
of the 17-segment AHA/ACC model was graded semi-quantitatively as normal (0), equivocal/mild 
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reduction (1), moderate reduction (2), severe reduction (3), or absent uptake (4), and segmental scores 
were summed for rest (summed rest score, SRS) and stress scans (summed stress score, SSS)16. The 
summed difference score (SDS) was defined as the sum of the segmental difference between stress and 
rest. Segmental scores were summed to per-vessel territory and per-patient values according to the 
standardized segmentation (Figure A1)16. Percent myocardium defect size was then calculated for SRS, 
SSS, and SDS. To calculate percent myocardium, SRS, SSS, and SDS were multiplied by 100 (%) divided 
by 68 (maximal defect score; 17 segments with worst score of 4). Subsequently, the left ventricular 
ejection fraction (LVEF) and post stress wall-motion abnormalities (WMA) were reported if available. 
Additional exercise ECG findings and high-risk scan features (HRSF) such as transient ischemic dilation 
(TID), ≥5% fall in LVEF post stress, and increased lung uptake were taken into account. 
CMR imaging was performed using the following scanner vendors: 1 (0.99%) General Electric, 6 
(5.94%) Philips, 93 (92.08%) Siemens, 1 (0.99%) Toshiba and 0 (0.00%) other. For CMR, 96 (95.05%) 
of scans performed using vasodilator stress: 96 (95.05%) scans with adenosine, 0 (0.00%) scans with 
regadenoson, 0 (0.00%) scans with dipyridamole, 4 (3.96%) scans with dobutamine. In 1 (0.99%) 
patient, stress imaging was not performed. Furthermore, 99 (98%) scans had a diagnostic image 
quality. For CMR perfusion, core laboratory expert readers assessed rest and stress perfusion images 
on a per segment basis according to 16 (precluding apex) of the 17-segment AHA/ACC model16. 
Segmental perfusion was graded semi-quantitatively as normal (0) or abnormal (1), and segmental 
scores were summed for rest (summed rest score, SRS) and stress scans (summed stress score, SSS)17,18. 
The summed difference score (SDS) was defined as the sum of the segmental difference between 
stress and rest. Similarly to SPECT/PET, segmental scores were summed to per-vessel territory and per-
patient values according to the standardized segmentation (Figure A1). Percent myocardium defect 
size was calculated for SRS, SSS, and SDS. To calculate percent myocardium defect size, SRS, SSS, and 
SDS were multiplied by 100 (%) divided by 16 (maximal defect score; 16 segments with worst score of 
1). In addition, resting LVEF, LV dysfunction, and the presence and location of WMAs were reported.
Invasive Coronary Angiography and Fractional Flow Reserve Interpretation
Dedicated core laboratories performed blinded quantitative coronary angiography (QCA) in two 
orthogonal views on a per lesion basis of every lesion visually ≥30% DS in vessels with a reference vessel 
diameter ≥2.00mm. All FFR tracings were interpreted and graded as reliable as continuous, reliable as 
dichotomous, or unreliable by an independent blinded core laboratory reader. Vessels with QCA ≤40 
or ≥90% DS without FFR interrogation were deemed normal or significant, respectively. For vessels 
with FFR, an FFR threshold of ≤0.80 was graded as significant, whilst an FFR >0.80 was considered 
normal. Subsequently, reference standard adjudication was performed during a consensus meeting, 
to assure FFR correspondence with all lesions >40% DS on QCA. For vessels containing a lesion of 40-
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90% DS without a distally performed FFR, the reference standard was graded as undetermined. These 
vessels were excluded from the analysis (Manuscript Figure 1). 
Fracti onal Flow Reserve by Computed Tomography (FFR-CT) Interpretati on
FFR-CT analyses were performed in a single center (HeartFlow, Inc., Redwood City, CA), and alignment 
to QCT performed by blinded readers (AR, UG). Vessels with QCT ≤25 or ≥99% stenosis severity by 
QCT were deemed normal or signifi cant, respecti vely. Vessels with QCT >25% stenosis were assigned 
the FFR-CT value co-localized to the segment of maximal diameter stenosis. For vessels with FFR-CT, 
an FFR-CT threshold of ≤0.80 was graded as signifi cant, whilst an FFR >0.80 was considered normal. 
Vessels with missing FFRCT were handled using missing indicator analysis. 
 Figure F1. Myocardial Segmentati on According to Vascular Territory
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Appendix G. Core Laboratory Principal Investigators
Coronary Computed Tomographic Angiography: 
• Hyuk-Jae Chang, MD, PhD, Severance Cardiovascular Hospital, Seoul, Korea
Myocardial Perfusion Imaging:
Single Photon Emission Computed Tomography / Positron Emission Tomography
• Paul Knaapen, MD, PhD, Roel S. Driessen, MD, Amsterdam University Medical Center, location VU 
University Medical Center, Amsterdam, The Netherlands
Cardiac Magnetic Resonance Perfusion Imaging
• Gianluca Pontone, MD, PhD, Centro Cardiologico Monzino, IRCCS, Milan, Italy
Invasive Coronary Angiography / Quantitative Coronary Angiography
• Paul Knaapen, MD, PhD, Michiel J. Bom, MD, Amsterdam University Medical Center, location VU 
University Medical Center, Amsterdam, The Netherlands 
• Hyuk-Jae Chang, MD, PhD, Severance Cardiovascular Hospital, Seoul, Korea
• Philippe Genereux, MD, Cardiovascular Research Foundation, New York, USA
Invasive Fractional Flow Reserve
• Paul Knaapen, MD, PhD, Guus A. De Waard, MD, Amsterdam University Medical Center, location 
VU University Medical Center, Amsterdam, The Netherlands 
Computed Tomography Derived Franctional Flow Reserve (FFR-CT)
• Chris Zarins, MD, HeartFlow, Redwood City, CA, USA
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Appendix H. Radiation exposure
Coronary computed tomography angiography
For CCTA, the effective dose in millisieverts (mSv) was estimated using the dose-length product (DLP, 
mGy*cm) with a conversion coefficient of 0.014 mSv/(mGy*cm).19 
Single Photon Emission Computed Tomography and Positron Emission Tomography
For SPECT and PET, the effective dose was established using the radiopharmaceutical dose for rest and 
stress imaging in MegaBequerel (MBq) with radiopharmaceutical specific conversion factors for rest 
and stress imaging separately (mSv/MBq).
Table. SPECT and PET radiopharmaceutical conversion factors
Radiopharmaceutical Conversion factor rest per MBq Conversion factor stress per MBq
SPECT20
Tc-99m Sestamibi 0.0092 0.0078





Table. Effective dose and reference value per modality and reference values
Dose within study in mSv
Mean ± SD
CCTA (≥ 64 slice)21 6.07 ± 4.79
SPECT20 13.56 ± 4.99
PET21 3.62 ± 1.07
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kindness, enthusiasm, and knowledge have inspired me deeply. I have been lucky to meet you and I 
owe you many thanks for the opportunities you have given me.
Alle co-auteurs wil ik bedanken voor hun waardevolle feedback en voor de prettige 
samenwerking. Dear co-authors, thank you very much for your contribution to my papers.
Speciale dank aan alle artsen, het interventie planbureau, laboranten en verpleegkundigen 
binnen het AUMC, locatie VUmc, voor jullie continue inbreng en steun aan de onderzoeken.
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Beste Paul Teunissen, jou wil ik bedanken aangezien jij een grote rol hebt gespeeld door mij aan te 
dragen als promovendus. Verder hebben wij ontzettend veel aan elkaar gehad zowel op medisch 
wetenschappelijke als vriendschappelijke basis. Ik heb enorm genoten van jou als collega.
Ibrahim, jij bent een groot voorbeeld voor mij geweest gedurende met name de eerste jaren van mijn 
promotie. Ik heb ontzettend veel van jou geleerd. Mede door jou, en de reeds vervaardigde data voor ik 
begon, is dit proefschrift tot stand gekomen. 
Kamergenoten, Mischa, Roel, Nina, Gladys en Stefan (Paul en Ibrahim) – wat een geniale tijd heb ik 
met jullie mogen beleven. Wij hebben een bijzonder goede klik en jullie hebben mij enorm gemotiveerd 
gedurende mijn promotie. Naast perioden van hard werken wisten wij met elkaar ook een hele leuk tijd 
te creëren. Voor mij zal deze band met jullie altijd speciaal blijven. 
Beste Stefan (Schumacher), ik heb de eer mogen hebben om jou in te werken als mijn opvolger. Jij gaf 
weer een nieuwe positieve flow op de werkvloer. Ik heb aan jou veel gehad, en ik mag mij gelukkig 
prijzen met jou als mijn toekomstig collega. 
Overige collega’s, Guus, Maurits, Monique, Henk, Raquel, Hendrik-Jan, Jailen, Luc, Sebastiaan, Stefan 
(biesbroek), Alwin, Michiel, Anne-Lotte, Marthe, Mark, Matthijs Rahana en de anderen met wie ik 
maar kort heb samengewerkt, ook jullie wil ik bedanken voor de fantastische tijd. Een unieke groep 
met veel publicaties en plezier.
Familie en vrienden, bedankt voor het luisterende oor in moeilijkere tijden en het zorgen voor een 
juiste balans tussen werk en privé.
Roel en Mischa, mijn paranimfen, wat een voorrecht om jullie aan mijn zijde te hebben tijdens de 
promotieceremonie. Jullie hebben zoveel bijgedragen aan mijn promotie dat ik er trots op ben dat jullie 
deze functie willen invullen.
Lieve mama, jij bent mijn rots in de branding. Jij hebt mij altijd de vrijheid gegeven mijn eigen weg te 
kiezen. Jouw vertrouwen heeft heel veel voor mij betekend en zonder jouw basis was dit proefschrift 
niet tot stand gekomen. 
Lieve pappa, ik heb jouw aanwezigheid en ondersteuning altijd gevoeld ondanks dat jij er fysiek niet 
meer was. Wat had ik dit alles graag met je gedeeld. Jij hebt voor mij alles mogelijk gemaakt, ik ben je 
eeuwig dankbaar en mis je nog iedere dag.
Laurien, wat ben jij een fantastische vrouw. Jij bent er altijd voor mij geweest met je liefde en steun. 
Vooral door jou hebben wij een ongelooflijke tijd gehad in New York. Het is uniek dat wij zo goed 
collega’s, vrienden en partners van elkaar kunnen zijn. Jouw vertrouwen in mij is met geen woorden te 
beschrijven waarvoor heel veel dank.
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